

Variable	Variable Order	Type	MaxLength	Table	Item
acary1_f	3074	NUM	8	4	o
acary2_f	3090	NUM	8	4	o
acary3_f	3106	NUM	8	4	o
acary4_f	3122	NUM	8	4	o
acarz_f	3062	NUM	8	4	o
acarz_n	3335	NUM	8	4	o
acarz_s	3305	NUM	8	4	o
acarz_u	3365	NUM	8	4	o
acdry1_f	3073	NUM	8	4	o
acdry2_f	3089	NUM	8	4	o
acdry3_f	3105	NUM	8	4	o
acdry4_f	3121	NUM	8	4	o
acdrz_f	3061	NUM	8	4	o
acdrz_n	3334	NUM	8	4	o
acdrz_s	3304	NUM	8	4	o
acdrz_u	3364	NUM	8	4	o
achfy1_f	3072	NUM	8	4	o
achfy2_f	3088	NUM	8	4	o
achfy3_f	3104	NUM	8	4	o
achfy4_f	3120	NUM	8	4	o
achfz_f	3060	NUM	8	4	o
achfz_n	3333	NUM	8	4	o
achfz_s	3303	NUM	8	4	o
achfz_u	3363	NUM	8	4	o
age1y1_f	143	NUM	8	1	c
age1y2_f	174	NUM	8	1	c
age1y3_f	205	NUM	8	1	c
age1y4_f	236	NUM	8	1	c
age1y4_n	296	NUM	8	1	c
age1y4_s	265	NUM	8	1	c
age1y4_u	327	NUM	8	1	c
age2y1_f	144	NUM	8	1	c
age2y2_f	175	NUM	8	1	c
age2y3_f	206	NUM	8	1	c
age2y4_f	237	NUM	8	1	c
age2y4_n	297	NUM	8	1	c
age2y4_s	266	NUM	8	1	c
age2y4_u	328	NUM	8	1	c
age3y1_f	145	NUM	8	1	c
age3y2_f	176	NUM	8	1	c
age3y3_f	207	NUM	8	1	c
age3y4_f	238	NUM	8	1	c
age3y4_n	298	NUM	8	1	c

age3y4_s	267	NUM	8	1	c
age3y4_u	329	NUM	8	1	c
agemy1_f	2416	NUM	8	2	b
agemy2_f	2482	NUM	8	2	b
agemy3_f	2548	NUM	8	2	b
agemy4_f	2614	NUM	8	2	b
agemy4_n	2746	NUM	8	2	b
agemy4_s	2680	NUM	8	2	b
agemy4_u	2812	NUM	8	2	b
agey1_f	141	NUM	8	1	b
agey2_f	172	NUM	8	1	b
agey3_f	203	NUM	8	1	b
agey4_f	234	NUM	8	1	b
agey4_n	295	NUM	8	1	b
agey4_s	264	NUM	8	1	b
agey4_u	326	NUM	8	1	b
alcomy1_f	2388	NUM	8	2	w
alcomy2_f	2454	NUM	8	2	w
alcomy3_f	2520	NUM	8	2	w
alcomy4_f	2586	NUM	8	2	w
alcomy4_n	2718	NUM	8	2	w
alcomy4_s	2652	NUM	8	2	w
alcomy4_u	2784	NUM	8	2	w
allcnty1_f	1552	NUM	8	DATA	
allcnty2_f	1584	NUM	8	DATA	
allcnty3_f	1616	NUM	8	DATA	
allcnty4_f	817	NUM	8	13	l
allcnty4m_n	848	NUM	8	13	l
allcnty4m_s	839	NUM	8	13	l
allcnty4m_u	857	NUM	8	13	l
allmcDeaq1_f	11	NUM	8	C1	4
allmcDeaq2_f	22	NUM	8	C1	4
allmcDeaq3_f	33	NUM	8	C1	4
allmcDeaq4_f	44	NUM	8	C1	4
allmcDeay3_f	99	NUM	8	C1	4
allmcEcovDeaPq1_f	13	NUM	8	C1	5
allmcEcovDeaPq2_f	24	NUM	8	C1	5
allmcEcovDeaPq3_f	35	NUM	8	C1	5
allmcEcovDeaPq4_f	46	NUM	8	C1	5
allmcEcovDeaPq4_n	126	NUM	8	C1	5
allmcEcovDeaPq4_s	118	NUM	8	C1	5
allmcEcovDeaPq4_u	134	NUM	8	C1	5
allmcEcovDeaPy3_f	101	NUM	8	C1	5
allmcEcovDeaq1_f	12	NUM	8	C1	5

allmcEcovDeaq2_f	23	NUM	8	C1	5
allmcEcovDeaq3_f	34	NUM	8	C1	5
allmcEcovDeaq4_f	45	NUM	8	C1	5
allmcEcovDeay3_f	100	NUM	8	C1	5
allmcEcovHosPq1_f	16	NUM	8	C1	7
allmcEcovHosPq2_f	27	NUM	8	C1	7
allmcEcovHosPq3_f	38	NUM	8	C1	7
allmcEcovHosPq4_f	49	NUM	8	C1	7
allmcEcovHosPq4_n	127	NUM	8	C1	7
allmcEcovHosPq4_s	119	NUM	8	C1	7
allmcEcovHosPq4_u	135	NUM	8	C1	7
allmcEcovHosPy3_f	104	NUM	8	C1	7
allmcEcovHosq1_f	15	NUM	8	C1	7
allmcEcovHosq2_f	26	NUM	8	C1	7
allmcEcovHosq3_f	37	NUM	8	C1	7
allmcEcovHosq4_f	48	NUM	8	C1	7
allmcEcovHosy3_f	103	NUM	8	C1	7
allmcEcovpatPq1_f	10	NUM	8	C1	2
allmcEcovpatPq2_f	21	NUM	8	C1	2
allmcEcovpatPq3_f	32	NUM	8	C1	2
allmcEcovpatPq4_f	43	NUM	8	C1	2
allmcEcovpatPq4_n	125	NUM	8	C1	2
allmcEcovpatPq4_s	117	NUM	8	C1	2
allmcEcovpatPq4_u	133	NUM	8	C1	2
allmcEcovpatPy3_f	98	NUM	8	C1	2
allmcEcovpatq1_f	9	NUM	8	C1	2
allmcEcovpatq2_f	20	NUM	8	C1	2
allmcEcovpatq3_f	31	NUM	8	C1	2
allmcEcovpatq4_f	42	NUM	8	C1	2
allmcEcovpaty3_f	97	NUM	8	C1	2
allmcFcovpatPq1_f	8	NUM	8	C1	3
allmcFcovpatPq2_f	19	NUM	8	C1	3
allmcFcovpatPq3_f	30	NUM	8	C1	3
allmcFcovpatPq4_f	41	NUM	8	C1	3
allmcFcovpatPq4_n	124	NUM	8	C1	3
allmcFcovpatPq4_s	116	NUM	8	C1	3
allmcFcovpatPq4_u	132	NUM	8	C1	3
allmcFcovpatPy3_f	96	NUM	8	C1	3
allmcFcovpatq1_f	7	NUM	8	C1	3
allmcFcovpatq2_f	18	NUM	8	C1	3
allmcFcovpatq3_f	29	NUM	8	C1	3
allmcFcovpatq4_f	40	NUM	8	C1	3
allmcFcovpaty3_f	95	NUM	8	C1	3
allmcHosq1_f	14	NUM	8	C1	6

allmcHosq2_f	25	NUM	8	C1	6
allmcHosq3_f	36	NUM	8	C1	6
allmcHosq4_f	47	NUM	8	C1	6
allmcHosy3_f	102	NUM	8	C1	6
allmcpatq1_f	6	NUM	8	C1	1
allmcpatq2_f	17	NUM	8	C1	1
allmcpatq3_f	28	NUM	8	C1	1
allmcpatq4_f	39	NUM	8	C1	1
allmcpaty3_f	94	NUM	8	C1	1
ambumy1_f	2398	NUM	8	2	w
ambumy2_f	2464	NUM	8	2	w
ambumy3_f	2530	NUM	8	2	w
ambumy4_f	2596	NUM	8	2	w
ambumy4_n	2728	NUM	8	2	w
ambumy4_s	2662	NUM	8	2	w
ambumy4_u	2794	NUM	8	2	w
ashdmy1_f	2389	NUM	8	2	w
ashdmy2_f	2455	NUM	8	2	w
ashdmy3_f	2521	NUM	8	2	w
ashdmy4_f	2587	NUM	8	2	w
ashdmy4_n	2719	NUM	8	2	w
ashdmy4_s	2653	NUM	8	2	w
ashdmy4_u	2785	NUM	8	2	w
asianmy1_f	2407	NUM	8	2	d
asianmy2_f	2473	NUM	8	2	d
asianmy3_f	2539	NUM	8	2	d
asianmy4_f	2605	NUM	8	2	d
asianmy4_n	2737	NUM	8	2	d
asianmy4_s	2671	NUM	8	2	d
asianmy4_u	2803	NUM	8	2	d
avfpresentmy1_f	2448	NUM	8	2	m
avfpresentmy2_f	2514	NUM	8	2	m
avfpresentmy3_f	2580	NUM	8	2	m
avfpresentmy4_f	2646	NUM	8	2	m
avfpresentmy4_n	2778	NUM	8	2	m
avfpresentmy4_s	2712	NUM	8	2	m
avfpresentmy4_u	2845	NUM	8	2	m
blackmy1_f	2405	NUM	8	2	d
blackmy2_f	2471	NUM	8	2	d
blackmy3_f	2537	NUM	8	2	d
blackmy4_f	2603	NUM	8	2	d
blackmy4_n	2735	NUM	8	2	d
blackmy4_s	2669	NUM	8	2	d
blackmy4_u	2801	NUM	8	2	d

bmifmy1_f	2453	NUM	8	2	h
bmifmy2_f	2519	NUM	8	2	h
bmifmy3_f	2585	NUM	8	2	h
bmifmy4_f	2651	NUM	8	2	h
bmifmy4_n	2780	NUM	8	2	h
bmifmy4_s	2714	NUM	8	2	h
bmifmy4_u	2847	NUM	8	2	h
bmimmy1_f	2452	NUM	8	2	h
bmimmy2_f	2518	NUM	8	2	h
bmimmy3_f	2584	NUM	8	2	h
bmimmy4_f	2650	NUM	8	2	h
bmimmy4_n	2779	NUM	8	2	h
bmimmy4_s	2713	NUM	8	2	h
bmimmy4_u	2846	NUM	8	2	h
cadallty1_f	3392	NUM	8	5	c
cadallty2_f	3400	NUM	8	5	c
cadallty3_f	3408	NUM	8	5	c
cadallty4_f	3416	NUM	8	5	c
cadalltz_f	3387	NUM	8	5	c
cadalltzm_n	3442	NUM	8	5	c
cadalltzm_s	3433	NUM	8	5	c
cadalltzm_u	3451	NUM	8	5	c
canmy1_f	2391	NUM	8	2	w
canmy2_f	2457	NUM	8	2	w
canmy3_f	2523	NUM	8	2	w
canmy4_f	2589	NUM	8	2	w
canmy4_n	2721	NUM	8	2	w
canmy4_s	2655	NUM	8	2	w
canmy4_u	2787	NUM	8	2	w
cardy1_f	2868	NUM	8	3	f
cardy2_f	2878	NUM	8	3	f
cardy3_f	2888	NUM	8	3	f
cardy4_f	2898	NUM	8	3	f
cardz_f	2859	NUM	8	3	f
cardz_n	3018	NUM	8	3	f
cardz_s	2999	NUM	8	3	f
cardz_u	3037	NUM	8	3	f
cempmy1_f	2409	NUM	8	2	i
cempmy2_f	2475	NUM	8	2	i
cempmy3_f	2541	NUM	8	2	i
cempmy4_f	2607	NUM	8	2	i
cempmy4_n	2739	NUM	8	2	i
cempmy4_s	2673	NUM	8	2	i
cempmy4_u	2805	NUM	8	2	i

cfc_f	827	NUM	8	13	t
cfc_N	855	NUM	8	13	t
cfc_S	846	NUM	8	13	t
cfc_U	864	NUM	8	13	t
CHAINNAM	829	CHAR	100	13	a
chfmy1_f	2392	NUM	8	2	w
chfmy2_f	2458	NUM	8	2	w
chfmy3_f	2524	NUM	8	2	w
chfmy4_f	2590	NUM	8	2	w
chfmy4_n	2722	NUM	8	2	w
chfmy4_s	2656	NUM	8	2	w
chfmy4_u	2788	NUM	8	2	w
chichdy1_f	3144	NUM	8	4	g
chichdy2_f	3147	NUM	8	4	g
chichdy3_f	3150	NUM	8	4	g
chichdy4_f	3153	NUM	8	4	g
chichdz_f	3156	NUM	8	4	g
chichedy1_f	3184	NUM	8	4	w
chichedy2_f	3187	NUM	8	4	w
chichedy3_f	3190	NUM	8	4	w
chichedy4_f	3193	NUM	8	4	w
chichedz_f	3196	NUM	8	4	w
chichtay1_f	3129	NUM	8	4	m
chichtay2_f	3132	NUM	8	4	m
chichtay3_f	3135	NUM	8	4	m
chichtay4_f	3138	NUM	8	4	m
chichtaz_f	3141	NUM	8	4	m
chimy1_f	2902	NUM	8	3	j
chimy2_f	2905	NUM	8	3	j
chimy3_f	2908	NUM	8	3	j
chimy4_f	2911	NUM	8	3	j
chimz_f	2914	NUM	8	3	j
chitfy1_f	3955	NUM	8	8	o
chitfy2_f	3958	NUM	8	8	o
chitfy3_f	3961	NUM	8	8	o
chitfy4_f	3964	NUM	8	8	o
chitz_f	3423	NUM	8	5	j
clmalcomy1_f	645	NUM	8	12	b
clmalcomy2_f	670	NUM	8	12	b
clmalcomy3_f	695	NUM	8	12	b
clmalcomy4_f	720	NUM	8	12	b
clmalcomy4_n	770	NUM	8	12	b
clmalcomy4_s	745	NUM	8	12	b
clmalcomy4_u	795	NUM	8	12	b

clmanemy1_f	643	NUM	8	12	b
clmanemy2_f	668	NUM	8	12	b
clmanemy3_f	693	NUM	8	12	b
clmanemy4_f	718	NUM	8	12	b
clmanemy4_n	768	NUM	8	12	b
clmanemy4_s	743	NUM	8	12	b
clmanemy4_u	793	NUM	8	12	b
clmcamy1_f	647	NUM	8	12	b
clmcamy2_f	672	NUM	8	12	b
clmcamy3_f	697	NUM	8	12	b
clmcamy4_f	722	NUM	8	12	b
clmcamy4_n	772	NUM	8	12	b
clmcamy4_s	747	NUM	8	12	b
clmcamy4_u	797	NUM	8	12	b
clmcanmy1_f	646	NUM	8	12	b
clmcanmy2_f	671	NUM	8	12	b
clmcanmy3_f	696	NUM	8	12	b
clmcanmy4_f	721	NUM	8	12	b
clmcanmy4_n	771	NUM	8	12	b
clmcanmy4_s	746	NUM	8	12	b
clmcanmy4_u	796	NUM	8	12	b
clmcdmy1_f	648	NUM	8	12	b
clmcdmy2_f	673	NUM	8	12	b
clmcdmy3_f	698	NUM	8	12	b
clmcdmy4_f	723	NUM	8	12	b
clmcdmy4_n	773	NUM	8	12	b
clmcdmy4_s	748	NUM	8	12	b
clmcdmy4_u	798	NUM	8	12	b
clmchfmy1_f	651	NUM	8	12	b
clmchfmy2_f	676	NUM	8	12	b
clmchfmy3_f	701	NUM	8	12	b
clmchfmy4_f	726	NUM	8	12	b
clmchfmy4_n	776	NUM	8	12	b
clmchfmy4_s	751	NUM	8	12	b
clmchfmy4_u	801	NUM	8	12	b
clmcntcomy1_f	666	NUM	8	12	c
clmcntcomy2_f	691	NUM	8	12	c
clmcntcomy3_f	716	NUM	8	12	c
clmcntcomy4_f	741	NUM	8	12	c
clmcntcomy4_n	788	NUM	8	12	c
clmcntcomy4_s	763	NUM	8	12	c
clmcntcomy4_u	813	NUM	8	12	c
clmcopdmy1_f	650	NUM	8	12	b
clmcopdmy2_f	675	NUM	8	12	b

clmcopdmy3_f	700	NUM	8	12	b
clmcopdmy4_f	725	NUM	8	12	b
clmcopdmy4_n	775	NUM	8	12	b
clmcopdmy4_s	750	NUM	8	12	b
clmcopdmy4_u	800	NUM	8	12	b
clmcvdmy1_f	649	NUM	8	12	b
clmcvdmy2_f	674	NUM	8	12	b
clmcvdmy3_f	699	NUM	8	12	b
clmcvdmy4_f	724	NUM	8	12	b
clmcvdmy4_n	774	NUM	8	12	b
clmcvdmy4_s	749	NUM	8	12	b
clmcvdmy4_u	799	NUM	8	12	b
clmdiabmy1_f	652	NUM	8	12	b
clmdiabmy2_f	677	NUM	8	12	b
clmdiabmy3_f	702	NUM	8	12	b
clmdiabmy4_f	727	NUM	8	12	b
clmdiabmy4_n	777	NUM	8	12	b
clmdiabmy4_s	752	NUM	8	12	b
clmdiabmy4_u	802	NUM	8	12	b
clmdrugmy1_f	653	NUM	8	12	b
clmdrugmy2_f	678	NUM	8	12	b
clmdrugmy3_f	703	NUM	8	12	b
clmdrugmy4_f	728	NUM	8	12	b
clmdrugmy4_n	778	NUM	8	12	b
clmdrugmy4_s	753	NUM	8	12	b
clmdrugmy4_u	803	NUM	8	12	b
clmgtbmy1_f	654	NUM	8	12	b
clmgtbmy2_f	679	NUM	8	12	b
clmgtbmy3_f	704	NUM	8	12	b
clmgtbmy4_f	729	NUM	8	12	b
clmgtbmy4_n	779	NUM	8	12	b
clmgtbmy4_s	754	NUM	8	12	b
clmgtbmy4_u	804	NUM	8	12	b
clmhpbmy1_f	655	NUM	8	12	b
clmhpbmy2_f	680	NUM	8	12	b
clmhpbmy3_f	705	NUM	8	12	b
clmhpbmy4_f	730	NUM	8	12	b
clmhpbmy4_n	780	NUM	8	12	b
clmhpbmy4_s	755	NUM	8	12	b
clmhpbmy4_u	805	NUM	8	12	b
clmhpothmy1_f	656	NUM	8	12	b
clmhpothmy2_f	681	NUM	8	12	b
clmhpothmy3_f	706	NUM	8	12	b
clmhpothmy4_f	731	NUM	8	12	b



clmhepothmy4_n	781	NUM	8	12	b
clmhepothmy4_s	756	NUM	8	12	b
clmhepothmy4_u	806	NUM	8	12	b
clmhivaidmy1_f	644	NUM	8	12	b
clmhivaidmy2_f	669	NUM	8	12	b
clmhivaidmy3_f	694	NUM	8	12	b
clmhivaidmy4_f	719	NUM	8	12	b
clmhivaidmy4_n	769	NUM	8	12	b
clmhivaidmy4_s	744	NUM	8	12	b
clmhivaidmy4_u	794	NUM	8	12	b
clmhypthymy1_f	657	NUM	8	12	b
clmhypthymy2_f	682	NUM	8	12	b
clmhypthymy3_f	707	NUM	8	12	b
clmhypthymy4_f	732	NUM	8	12	b
clmhypthymy4_n	782	NUM	8	12	b
clmhypthymy4_s	757	NUM	8	12	b
clmhypthymy4_u	807	NUM	8	12	b
clmihdmy1_f	660	NUM	8	12	b
clmihdmy2_f	685	NUM	8	12	b
clmihdmy3_f	710	NUM	8	12	b
clmihdmy4_f	735	NUM	8	12	b
clmihdmy4_n	784	NUM	8	12	b
clmihdmy4_s	759	NUM	8	12	b
clmihdmy4_u	809	NUM	8	12	b
clminfmy1_f	658	NUM	8	12	b
clminfmy2_f	683	NUM	8	12	b
clminfmy3_f	708	NUM	8	12	b
clminfmy4_f	733	NUM	8	12	b
clminfmy4_n	783	NUM	8	12	b
clminfmy4_s	758	NUM	8	12	b
clminfmy4_u	808	NUM	8	12	b
clminfvamy1_f	659	NUM	8	12	b
clminfvamy2_f	684	NUM	8	12	b
clminfvamy3_f	709	NUM	8	12	b
clminfvamy4_f	734	NUM	8	12	b
clminfvamy4_n	789	NUM	8	12	b
clminfvamy4_s	764	NUM	8	12	b
clminfvamy4_u	814	NUM	8	12	b
clmmimy1_f	661	NUM	8	12	b
clmmimy2_f	686	NUM	8	12	b
clmmimy3_f	711	NUM	8	12	b
clmmimy4_f	736	NUM	8	12	b
clmmimy4_n	785	NUM	8	12	b
clmmimy4_s	760	NUM	8	12	b

clmmimy4_u	810	NUM	8	12	b
clmmstinfmy1_f	664	NUM	8	12	b
clmmstinfmy2_f	689	NUM	8	12	b
clmmstinfmy3_f	714	NUM	8	12	b
clmmstinfmy4_f	739	NUM	8	12	b
clmmstinfmy4_n	790	NUM	8	12	b
clmmstinfmy4_s	765	NUM	8	12	b
clmmstinfmy4_u	815	NUM	8	12	b
clmpnemy1_f	663	NUM	8	12	b
clmpnemy2_f	688	NUM	8	12	b
clmpnemy3_f	713	NUM	8	12	b
clmpnemy4_f	738	NUM	8	12	b
clmpnemy4_n	787	NUM	8	12	b
clmpnemy4_s	762	NUM	8	12	b
clmpnemy4_u	812	NUM	8	12	b
clmpvdmy1_f	662	NUM	8	12	b
clmpvdmy2_f	687	NUM	8	12	b
clmpvdmy3_f	712	NUM	8	12	b
clmpvdmy4_f	737	NUM	8	12	b
clmpvdmy4_n	786	NUM	8	12	b
clmpvdmy4_s	761	NUM	8	12	b
clmpvdmy4_u	811	NUM	8	12	b
clmtbmy1_f	665	NUM	8	12	b
clmtbmy2_f	690	NUM	8	12	b
clmtbmy3_f	715	NUM	8	12	b
clmtbmy4_f	740	NUM	8	12	b
clmtbmy4_n	791	NUM	8	12	b
clmtbmy4_s	766	NUM	8	12	b
clmtbmy4_u	816	NUM	8	12	b
clochdy1_f	3145	NUM	8	4	g
clochdy2_f	3148	NUM	8	4	g
clochdy3_f	3151	NUM	8	4	g
clochdy4_f	3154	NUM	8	4	g
clochdz_f	3157	NUM	8	4	g
clochedy1_f	3185	NUM	8	4	w
clochedy2_f	3188	NUM	8	4	w
clochedy3_f	3191	NUM	8	4	w
clochedy4_f	3194	NUM	8	4	w
clochedz_f	3197	NUM	8	4	w
clochtay1_f	3130	NUM	8	4	m
clochtay2_f	3133	NUM	8	4	m
clochtay3_f	3136	NUM	8	4	m
clochtay4_f	3139	NUM	8	4	m
clochtaz_f	3142	NUM	8	4	m

clomy1_f	2903	NUM	8	3	j
clomy2_f	2906	NUM	8	3	j
clomy3_f	2909	NUM	8	3	j
clomy4_f	2912	NUM	8	3	j
clomz_f	2915	NUM	8	3	j
clotfy1_f	3956	NUM	8	8	o
clotfy2_f	3959	NUM	8	8	o
clotfy3_f	3962	NUM	8	8	o
clotfy4_f	3965	NUM	8	8	o
clotz_f	3424	NUM	8	5	j
cntcomy1_f	2421	NUM	8	2	x
cntcomy2_f	2487	NUM	8	2	x
cntcomy3_f	2553	NUM	8	2	x
cntcomy4_f	2619	NUM	8	2	x
cntcomy4_n	2751	NUM	8	2	x
cntcomy4_s	2685	NUM	8	2	x
cntcomy4_u	2817	NUM	8	2	x
compl_cond	826	NUM	8	13	s
copdmy1_f	2400	NUM	8	2	w
copdmy2_f	2466	NUM	8	2	w
copdmy3_f	2532	NUM	8	2	w
copdmy4_f	2598	NUM	8	2	w
copdmy4_n	2730	NUM	8	2	w
copdmy4_s	2664	NUM	8	2	w
copdmy4_u	2796	NUM	8	2	w
creamy1_f	2418	NUM	8	2	p
creamy2_f	2484	NUM	8	2	p
creamy3_f	2550	NUM	8	2	p
creamy4_f	2616	NUM	8	2	p
creamy4_n	2748	NUM	8	2	p
creamy4_s	2682	NUM	8	2	p
creamy4_u	2814	NUM	8	2	p
cvamy1_f	2393	NUM	8	2	w
cvamy2_f	2459	NUM	8	2	w
cvamy3_f	2525	NUM	8	2	w
cvamy4_f	2591	NUM	8	2	w
cvamy4_n	2723	NUM	8	2	w
cvamy4_s	2657	NUM	8	2	w
cvamy4_u	2789	NUM	8	2	w
CW_HEMOSTATNS	831	NUM	8	13	d
CW_OWNER_F	830	CHAR	1	13	b
CWavgPy1_f	367	NUM	8	10	c
CWavgPy2_f	388	NUM	8	10	c
CWavgPy3_f	409	NUM	8	10	c

CWavgPy4_f	430	NUM	8	10	c
CWavgPy4_n	468	NUM	8	10	c
CWavgPy4_s	447	NUM	8	10	c
CWavgPy4_u	489	NUM	8	10	c
CWavgUnCay1_f	364	NUM	8	10	e
CWavgUnCay2_f	385	NUM	8	10	e
CWavgUnCay3_f	406	NUM	8	10	e
CWavgUnCay4_f	427	NUM	8	10	e
CWavgUnCay4_n	467	NUM	8	10	e
CWavgUnCay4_s	446	NUM	8	10	e
CWavgUnCay4_u	488	NUM	8	10	e
CWhcptdenomy1_f	375	NUM	8	DATA	
CWhcptdenomy2_f	396	NUM	8	DATA	
CWhcptdenomy3_f	417	NUM	8	DATA	
CWhcptdenomy4_f	438	NUM	8	DATA	
CWhcptdenomy4m_n	481	NUM	8	DATA	
CWhcptdenomy4m_s	460	NUM	8	DATA	
CWhcptdenomy4m_u	502	NUM	8	DATA	
CWhcptmthdenomy1_f	376	NUM	8	DATA	
CWhcptmthdenomy2_f	397	NUM	8	DATA	
CWhcptmthdenomy3_f	418	NUM	8	DATA	
CWhcptmthdenomy4_f	439	NUM	8	DATA	
CWhcptmthdenomy4m_n	482	NUM	8	DATA	
CWhcptmthdenomy4m_s	461	NUM	8	DATA	
CWhcptmthdenomy4m_u	503	NUM	8	DATA	
CWhdalb1y1_f	4038	NUM	8	9	d
CWhdalb1y2_f	4061	NUM	8	9	d
CWhdalb1y3_f	4084	NUM	8	9	d
CWhdalb1y4_f	4107	NUM	8	9	d
CWhdalb1y4_n	4211	NUM	8	9	d
CWhdalb1y4_s	4176	NUM	8	9	d
CWhdalb1y4_u	4246	NUM	8	9	d
CWhdalb2y1_f	4039	NUM	8	9	d
CWhdalb2y2_f	4062	NUM	8	9	d
CWhdalb2y3_f	4085	NUM	8	9	d
CWhdalb2y4_f	4108	NUM	8	9	d
CWhdalb2y4_n	4212	NUM	8	9	d
CWhdalb2y4_s	4177	NUM	8	9	d
CWhdalb2y4_u	4247	NUM	8	9	d
CWhdalb3y1_f	4040	NUM	8	9	d
CWhdalb3y2_f	4063	NUM	8	9	d
CWhdalb3y3_f	4086	NUM	8	9	d
CWhdalb3y4_f	4109	NUM	8	9	d
CWhdalb3y4_n	4213	NUM	8	9	d

CWhdalb3y4_s	4178	NUM	8	9	d
CWhdalb3y4_u	4248	NUM	8	9	d
CWhdalb4y1_f	4041	NUM	8	9	d
CWhdalb4y2_f	4064	NUM	8	9	d
CWhdalb4y3_f	4087	NUM	8	9	d
CWhdalb4y4_f	4110	NUM	8	9	d
CWhdalb4y4_n	4214	NUM	8	9	d
CWhdalb4y4_s	4179	NUM	8	9	d
CWhdalb4y4_u	4249	NUM	8	9	d
CWhdalb5y1_f	4042	NUM	8	9	d
CWhdalb5y2_f	4065	NUM	8	9	d
CWhdalb5y3_f	4088	NUM	8	9	d
CWhdalb5y4_f	4111	NUM	8	9	d
CWhdalb5y4_n	4215	NUM	8	9	d
CWhdalb5y4_s	4180	NUM	8	9	d
CWhdalb5y4_u	4250	NUM	8	9	d
CWhdalblt4y1_f	4043	NUM	8	9	e
CWhdalblt4y2_f	4066	NUM	8	9	e
CWhdalblt4y3_f	4089	NUM	8	9	e
CWhdalblt4y4_f	4112	NUM	8	9	e
CWhdalblt4y4_n	4216	NUM	8	9	e
CWhdalblt4y4_s	4181	NUM	8	9	e
CWhdalblt4y4_u	4251	NUM	8	9	e
CWhdalby1_f	4037	NUM	8	9	c
CWhdalby2_f	4060	NUM	8	9	c
CWhdalby3_f	4083	NUM	8	9	c
CWhdalby4_f	4106	NUM	8	9	c
CWhdalby4_n	4210	NUM	8	9	c
CWhdalby4_s	4175	NUM	8	9	c
CWhdalby4_u	4245	NUM	8	9	c
CWhdavgHGBy1_f	3864	NUM	8	8	c
CWhdavgHGBy2_f	3873	NUM	8	8	c
CWhdavgHGBy3_f	3882	NUM	8	8	c
CWhdavgHGBy4_f	3891	NUM	8	8	c
CWhdavgHGBy4_n	3989	NUM	8	8	c
CWhdavgHGBy4_s	3966	NUM	8	8	c
CWhdavgHGBy4_u	4012	NUM	8	8	c
CWhdavgktvy1_f	4149	NUM	8	9	j
CWhdavgktvy2_f	4156	NUM	8	9	j
CWhdavgktvy3_f	4163	NUM	8	9	j
CWhdavgktvy4_f	4170	NUM	8	9	j
CWhdavgktvy4_n	4238	NUM	8	9	j
CWhdavgktvy4_s	4203	NUM	8	9	j
CWhdavgktvy4_u	4273	NUM	8	9	j

CWhdavgufry1_f	4044	NUM	8	9	f
CWhdavgufry2_f	4067	NUM	8	9	f
CWhdavgufry3_f	4090	NUM	8	9	f
CWhdavgufry4_f	4113	NUM	8	9	f
CWhdavgufry4_n	4217	NUM	8	9	f
CWhdavgufry4_s	4182	NUM	8	9	f
CWhdavgufry4_u	4252	NUM	8	9	f
CWhddenomy1_f	4035	NUM	8	9	a
CWhddenomy2_f	4058	NUM	8	9	a
CWhddenomy3_f	4081	NUM	8	9	a
CWhddenomy4_f	4104	NUM	8	9	a
CWhddenomy4m_n	4229	NUM	8	9	a
CWhddenomy4m_s	4194	NUM	8	9	a
CWhddenomy4m_u	4264	NUM	8	9	a
CWhdesarxy1_f	3870	NUM	8	8	d
CWhdesarxy2_f	3879	NUM	8	8	d
CWhdesarxy3_f	3888	NUM	8	8	d
CWhdesarxy4_f	3897	NUM	8	8	d
CWhdesarxy4_n	3995	NUM	8	8	d
CWhdesarxy4_s	3972	NUM	8	8	d
CWhdesarxy4_u	4018	NUM	8	8	d
CWhdhgb1y1_f	3865	NUM	8	8	d
CWhdhgb1y2_f	3874	NUM	8	8	d
CWhdhgb1y3_f	3883	NUM	8	8	d
CWhdhgb1y4_f	3892	NUM	8	8	d
CWhdhgb1y4_n	3990	NUM	8	8	d
CWhdhgb1y4_s	3967	NUM	8	8	d
CWhdhgb1y4_u	4013	NUM	8	8	d
CWhdhgb2y1_f	3866	NUM	8	8	d
CWhdhgb2y2_f	3875	NUM	8	8	d
CWhdhgb2y3_f	3884	NUM	8	8	d
CWhdhgb2y4_f	3893	NUM	8	8	d
CWhdhgb2y4_n	3991	NUM	8	8	d
CWhdhgb2y4_s	3968	NUM	8	8	d
CWhdhgb2y4_u	4014	NUM	8	8	d
CWhdhgb3y1_f	3867	NUM	8	8	d
CWhdhgb3y2_f	3876	NUM	8	8	d
CWhdhgb3y3_f	3885	NUM	8	8	d
CWhdhgb3y4_f	3894	NUM	8	8	d
CWhdhgb3y4_n	3992	NUM	8	8	d
CWhdhgb3y4_s	3969	NUM	8	8	d
CWhdhgb3y4_u	4015	NUM	8	8	d
CWhdhgb4y1_f	3868	NUM	8	8	d
CWhdhgb4y2_f	3877	NUM	8	8	d

CWhdhgb4y3_f	3886	NUM	8	8	d
CWhdhgb4y4_f	3895	NUM	8	8	d
CWhdhgb4y4_n	3993	NUM	8	8	d
CWhdhgb4y4_s	3970	NUM	8	8	d
CWhdhgb4y4_u	4016	NUM	8	8	d
CWhdhgb5y1_f	3869	NUM	8	8	d
CWhdhgb5y2_f	3878	NUM	8	8	d
CWhdhgb5y3_f	3887	NUM	8	8	d
CWhdhgb5y4_f	3896	NUM	8	8	d
CWhdhgb5y4_n	3994	NUM	8	8	d
CWhdhgb5y4_s	3971	NUM	8	8	d
CWhdhgb5y4_u	4017	NUM	8	8	d
CWhdktv1y1_f	4150	NUM	8	9	k
CWhdktv1y2_f	4157	NUM	8	9	k
CWhdktv1y3_f	4164	NUM	8	9	k
CWhdktv1y4_f	4171	NUM	8	9	k
CWhdktv1y4_n	4239	NUM	8	9	k
CWhdktv1y4_s	4204	NUM	8	9	k
CWhdktv1y4_u	4274	NUM	8	9	k
CWhdktv2y1_f	4151	NUM	8	9	k
CWhdktv2y2_f	4158	NUM	8	9	k
CWhdktv2y3_f	4165	NUM	8	9	k
CWhdktv2y4_f	4172	NUM	8	9	k
CWhdktv2y4_n	4240	NUM	8	9	k
CWhdktv2y4_s	4205	NUM	8	9	k
CWhdktv2y4_u	4275	NUM	8	9	k
CWhdktv3y1_f	4152	NUM	8	9	k
CWhdktv3y2_f	4159	NUM	8	9	k
CWhdktv3y3_f	4166	NUM	8	9	k
CWhdktv3y4_f	4173	NUM	8	9	k
CWhdktv3y4_n	4241	NUM	8	9	k
CWhdktv3y4_s	4206	NUM	8	9	k
CWhdktv3y4_u	4276	NUM	8	9	k
CWhdktv4y1_f	4153	NUM	8	9	k
CWhdktv4y2_f	4160	NUM	8	9	k
CWhdktv4y3_f	4167	NUM	8	9	k
CWhdktv4y4_f	4174	NUM	8	9	k
CWhdktv4y4_n	4242	NUM	8	9	k
CWhdktv4y4_s	4207	NUM	8	9	k
CWhdktv4y4_u	4277	NUM	8	9	k
CWhdktvptmthy1_f	4148	NUM	8	9	i
CWhdktvptmthy2_f	4155	NUM	8	9	i
CWhdktvptmthy3_f	4162	NUM	8	9	i
CWhdktvptmthy4_f	4169	NUM	8	9	i

CWhdktvptmthy4m_N	4244	NUM	8	9	i
CWhdktvptmthy4m_S	4209	NUM	8	9	i
CWhdktvptmthy4m_U	4279	NUM	8	9	i
cwhdktvptsy1_f	4147	NUM	8	9	h
cwhdktvptsy2_f	4154	NUM	8	9	h
cwhdktvptsy3_f	4161	NUM	8	9	h
cwhdktvptsy4_f	4168	NUM	8	9	h
CWhdktvptsy4m_N	4243	NUM	8	9	h
CWhdktvptsy4m_S	4208	NUM	8	9	h
CWhdktvptsy4m_U	4278	NUM	8	9	h
CWhdmthdenomy1_f	4036	NUM	8	9	b
CWhdmthdenomy2_f	4059	NUM	8	9	b
CWhdmthdenomy3_f	4082	NUM	8	9	b
CWhdmthdenomy4_f	4105	NUM	8	9	b
CWhdmthdenomy4m_n	4230	NUM	8	9	b
CWhdmthdenomy4m_s	4195	NUM	8	9	b
CWhdmthdenomy4m_u	4265	NUM	8	9	b
CWhdptdenomy1_f	3862	NUM	8	8	a
CWhdptdenomy2_f	3871	NUM	8	8	a
CWhdptdenomy3_f	3880	NUM	8	8	a
CWhdptdenomy4_f	3889	NUM	8	8	a
CWhdptdenomy4m_n	4003	NUM	8	8	a
CWhdptdenomy4m_s	3980	NUM	8	8	a
CWhdptdenomy4m_u	4026	NUM	8	8	a
CWhdptmthdenomy1_f	3863	NUM	8	8	b
CWhdptmthdenomy2_f	3872	NUM	8	8	b
CWhdptmthdenomy3_f	3881	NUM	8	8	b
CWhdptmthdenomy4_f	3890	NUM	8	8	b
CWhdptmthdenomy4m_n	4004	NUM	8	8	b
CWhdptmthdenomy4m_s	3981	NUM	8	8	b
CWhdptmthdenomy4m_u	4027	NUM	8	8	b
CWhdufr1y1_f	4045	NUM	8	9	g
CWhdufr1y2_f	4068	NUM	8	9	g
CWhdufr1y3_f	4091	NUM	8	9	g
CWhdufr1y4_f	4114	NUM	8	9	g
CWhdufr1y4_n	4218	NUM	8	9	g
CWhdufr1y4_s	4183	NUM	8	9	g
CWhdufr1y4_u	4253	NUM	8	9	g
CWhdufr2y1_f	4046	NUM	8	9	g
CWhdufr2y2_f	4069	NUM	8	9	g
CWhdufr2y3_f	4092	NUM	8	9	g
CWhdufr2y4_f	4115	NUM	8	9	g
CWhdufr2y4_n	4219	NUM	8	9	g
CWhdufr2y4_s	4184	NUM	8	9	g



CWhdufr2y4_u	4254	NUM	8	9	g
CWhdufrgt20y1_f	4048	NUM	8	9	g
CWhdufrgt20y2_f	4071	NUM	8	9	g
CWhdufrgt20y3_f	4094	NUM	8	9	g
CWhdufrgt20y4_f	4117	NUM	8	9	g
CWhdufrgt20y4_n	4221	NUM	8	9	g
CWhdufrgt20y4_s	4186	NUM	8	9	g
CWhdufrgt20y4_u	4256	NUM	8	9	g
CWhdufrmissy1_f	4047	NUM	8	9	g
CWhdufrmissy2_f	4070	NUM	8	9	g
CWhdufrmissy3_f	4093	NUM	8	9	g
CWhdufrmissy4_f	4116	NUM	8	9	g
CWhdufrmissy4_n	4220	NUM	8	9	g
CWhdufrmissy4_s	4185	NUM	8	9	g
CWhdufrmissy4_u	4255	NUM	8	9	g
CWP1y1_f	368	NUM	8	10	d
CWP1y2_f	389	NUM	8	10	d
CWP1y3_f	410	NUM	8	10	d
CWP1y4_f	431	NUM	8	10	d
CWP1y4_n	469	NUM	8	10	d
CWP1y4_s	448	NUM	8	10	d
CWP1y4_u	490	NUM	8	10	d
CWP2y1_f	369	NUM	8	10	d
CWP2y2_f	390	NUM	8	10	d
CWP2y3_f	411	NUM	8	10	d
CWP2y4_f	432	NUM	8	10	d
CWP2y4_n	470	NUM	8	10	d
CWP2y4_s	449	NUM	8	10	d
CWP2y4_u	491	NUM	8	10	d
CWP3y1_f	370	NUM	8	10	d
CWP3y2_f	391	NUM	8	10	d
CWP3y3_f	412	NUM	8	10	d
CWP3y4_f	433	NUM	8	10	d
CWP3y4_n	471	NUM	8	10	d
CWP3y4_s	450	NUM	8	10	d
CWP3y4_u	492	NUM	8	10	d
CWP4y1_f	371	NUM	8	10	d
CWP4y2_f	392	NUM	8	10	d
CWP4y3_f	413	NUM	8	10	d
CWP4y4_f	434	NUM	8	10	d
CWP4y4_n	472	NUM	8	10	d
CWP4y4_s	451	NUM	8	10	d
CWP4y4_u	493	NUM	8	10	d
CWP5y1_f	372	NUM	8	10	d

CWP5y2_f	393	NUM	8	10	d
CWP5y3_f	414	NUM	8	10	d
CWP5y4_f	435	NUM	8	10	d
CWP5y4_n	473	NUM	8	10	d
CWP5y4_s	452	NUM	8	10	d
CWP5y4_u	494	NUM	8	10	d
CWpdalb1y1_f	4052	NUM	8	9	q
CWpdalb1y2_f	4075	NUM	8	9	q
CWpdalb1y3_f	4098	NUM	8	9	q
CWpdalb1y4_f	4121	NUM	8	9	q
CWpdalb1y4_n	4223	NUM	8	9	q
CWpdalb1y4_s	4188	NUM	8	9	q
CWpdalb1y4_u	4258	NUM	8	9	q
CWpdalb2y1_f	4053	NUM	8	9	q
CWpdalb2y2_f	4076	NUM	8	9	q
CWpdalb2y3_f	4099	NUM	8	9	q
CWpdalb2y4_f	4122	NUM	8	9	q
CWpdalb2y4_n	4224	NUM	8	9	q
CWpdalb2y4_s	4189	NUM	8	9	q
CWpdalb2y4_u	4259	NUM	8	9	q
CWpdalb3y1_f	4054	NUM	8	9	q
CWpdalb3y2_f	4077	NUM	8	9	q
CWpdalb3y3_f	4100	NUM	8	9	q
CWpdalb3y4_f	4123	NUM	8	9	q
CWpdalb3y4_n	4225	NUM	8	9	q
CWpdalb3y4_s	4190	NUM	8	9	q
CWpdalb3y4_u	4260	NUM	8	9	q
CWpdalb4y1_f	4055	NUM	8	9	q
CWpdalb4y2_f	4078	NUM	8	9	q
CWpdalb4y3_f	4101	NUM	8	9	q
CWpdalb4y4_f	4124	NUM	8	9	q
CWpdalb4y4_n	4226	NUM	8	9	q
CWpdalb4y4_s	4191	NUM	8	9	q
CWpdalb4y4_u	4261	NUM	8	9	q
CWpdalb5y1_f	4056	NUM	8	9	q
CWpdalb5y2_f	4079	NUM	8	9	q
CWpdalb5y3_f	4102	NUM	8	9	q
CWpdalb5y4_f	4125	NUM	8	9	q
CWpdalb5y4_n	4227	NUM	8	9	q
CWpdalb5y4_s	4192	NUM	8	9	q
CWpdalb5y4_u	4262	NUM	8	9	q
CWpdalb1t4y1_f	4057	NUM	8	9	r
CWpdalb1t4y2_f	4080	NUM	8	9	r
CWpdalb1t4y3_f	4103	NUM	8	9	r

CWpdalblt4y4_f	4126	NUM	8	9	r
CWpdalblt4y4_n	4228	NUM	8	9	r
CWpdalblt4y4_s	4193	NUM	8	9	r
CWpdalblt4y4_u	4263	NUM	8	9	r
CWpdalby1_f	4051	NUM	8	9	p
CWpdalby2_f	4074	NUM	8	9	p
CWpdalby3_f	4097	NUM	8	9	p
CWpdalby4_f	4120	NUM	8	9	p
CWpdalby4_n	4222	NUM	8	9	p
CWpdalby4_s	4187	NUM	8	9	p
CWpdalby4_u	4257	NUM	8	9	p
CWpdavgHGBy1_f	3900	NUM	8	8	h
CWpdavgHGBy2_f	3909	NUM	8	8	h
CWpdavgHGBy3_f	3918	NUM	8	8	h
CWpdavgHGBy4_f	3927	NUM	8	8	h
CWpdavgHGBy4_n	3996	NUM	8	8	h
CWpdavgHGBy4_s	3973	NUM	8	8	h
CWpdavgHGBy4_u	4019	NUM	8	8	h
CWpdavgkctvy1_f	4127	NUM	8	9	n
CWpdavgkctvy2_f	4132	NUM	8	9	n
CWpdavgkctvy3_f	4137	NUM	8	9	n
CWpdavgkctvy4_f	4142	NUM	8	9	n
CWpdavgkctvy4_n	4233	NUM	8	9	n
CWpdavgkctvy4_s	4198	NUM	8	9	n
CWpdavgkctvy4_u	4268	NUM	8	9	n
CWpddenomy1_f	4049	NUM	8	9	l
CWpddenomy2_f	4072	NUM	8	9	l
CWpddenomy3_f	4095	NUM	8	9	l
CWpddenomy4_f	4118	NUM	8	9	l
CWpddenomy4m_n	4231	NUM	8	9	l
CWpddenomy4m_s	4196	NUM	8	9	l
CWpddenomy4m_u	4266	NUM	8	9	l
CWpdesarxy1_f	3906	NUM	8	8	j
CWpdesarxy2_f	3915	NUM	8	8	j
CWpdesarxy3_f	3924	NUM	8	8	j
CWpdesarxy4_f	3933	NUM	8	8	j
CWpdesarxy4_n	4002	NUM	8	8	j
CWpdesarxy4_s	3979	NUM	8	8	j
CWpdesarxy4_u	4025	NUM	8	8	j
CWpdhgb1y1_f	3901	NUM	8	8	i
CWpdhgb1y2_f	3910	NUM	8	8	i
CWpdhgb1y3_f	3919	NUM	8	8	i
CWpdhgb1y4_f	3928	NUM	8	8	i
CWpdhgb1y4_n	3997	NUM	8	8	i

CWpdhgb1y4_s	3974	NUM	8	8	i
CWpdhgb1y4_u	4020	NUM	8	8	i
CWpdhgb2y1_f	3902	NUM	8	8	i
CWpdhgb2y2_f	3911	NUM	8	8	i
CWpdhgb2y3_f	3920	NUM	8	8	i
CWpdhgb2y4_f	3929	NUM	8	8	i
CWpdhgb2y4_n	3998	NUM	8	8	i
CWpdhgb2y4_s	3975	NUM	8	8	i
CWpdhgb2y4_u	4021	NUM	8	8	i
CWpdhgb3y1_f	3903	NUM	8	8	i
CWpdhgb3y2_f	3912	NUM	8	8	i
CWpdhgb3y3_f	3921	NUM	8	8	i
CWpdhgb3y4_f	3930	NUM	8	8	i
CWpdhgb3y4_n	3999	NUM	8	8	i
CWpdhgb3y4_s	3976	NUM	8	8	i
CWpdhgb3y4_u	4022	NUM	8	8	i
CWpdhgb4y1_f	3904	NUM	8	8	i
CWpdhgb4y2_f	3913	NUM	8	8	i
CWpdhgb4y3_f	3922	NUM	8	8	i
CWpdhgb4y4_f	3931	NUM	8	8	i
CWpdhgb4y4_n	4000	NUM	8	8	i
CWpdhgb4y4_s	3977	NUM	8	8	i
CWpdhgb4y4_u	4023	NUM	8	8	i
CWpdhgb5y1_f	3905	NUM	8	8	i
CWpdhgb5y2_f	3914	NUM	8	8	i
CWpdhgb5y3_f	3923	NUM	8	8	i
CWpdhgb5y4_f	3932	NUM	8	8	i
CWpdhgb5y4_n	4001	NUM	8	8	i
CWpdhgb5y4_s	3978	NUM	8	8	i
CWpdhgb5y4_u	4024	NUM	8	8	i
CWpdktv1y1_f	4128	NUM	8	9	o
CWpdktv1y2_f	4133	NUM	8	9	o
CWpdktv1y3_f	4138	NUM	8	9	o
CWpdktv1y4_f	4143	NUM	8	9	o
CWpdktv1y4_n	4234	NUM	8	9	o
CWpdktv1y4_s	4199	NUM	8	9	o
CWpdktv1y4_u	4269	NUM	8	9	o
CWpdktv2y1_f	4129	NUM	8	9	o
CWpdktv2y2_f	4134	NUM	8	9	o
CWpdktv2y3_f	4139	NUM	8	9	o
CWpdktv2y4_f	4144	NUM	8	9	o
CWpdktv2y4_n	4235	NUM	8	9	o
CWpdktv2y4_s	4200	NUM	8	9	o
CWpdktv2y4_u	4270	NUM	8	9	o

CWpdktv3y1_f	4130	NUM	8	9	o
CWpdktv3y2_f	4135	NUM	8	9	o
CWpdktv3y3_f	4140	NUM	8	9	o
CWpdktv3y4_f	4145	NUM	8	9	o
CWpdktv3y4_n	4236	NUM	8	9	o
CWpdktv3y4_s	4201	NUM	8	9	o
CWpdktv3y4_u	4271	NUM	8	9	o
CWpdktv4y1_f	4131	NUM	8	9	o
CWpdktv4y2_f	4136	NUM	8	9	o
CWpdktv4y3_f	4141	NUM	8	9	o
CWpdktv4y4_f	4146	NUM	8	9	o
CWpdktv4y4_n	4237	NUM	8	9	o
CWpdktv4y4_s	4202	NUM	8	9	o
CWpdktv4y4_u	4272	NUM	8	9	o
CWpdmthdenomy1_f	4050	NUM	8	9	m
CWpdmthdenomy2_f	4073	NUM	8	9	m
CWpdmthdenomy3_f	4096	NUM	8	9	m
CWpdmthdenomy4_f	4119	NUM	8	9	m
CWpdmthdenomy4m_n	4232	NUM	8	9	m
CWpdmthdenomy4m_s	4197	NUM	8	9	m
CWpdmthdenomy4m_u	4267	NUM	8	9	m
CWpdptdenomy1_f	3898	NUM	8	8	f
CWpdptdenomy2_f	3907	NUM	8	8	f
CWpdptdenomy3_f	3916	NUM	8	8	f
CWpdptdenomy4_f	3925	NUM	8	8	f
CWpdptdenomy4m_n	4005	NUM	8	8	f
CWpdptdenomy4m_s	3982	NUM	8	8	f
CWpdptdenomy4m_u	4028	NUM	8	8	f
CWpdptmthdenomy1_f	3899	NUM	8	8	g
CWpdptmthdenomy2_f	3908	NUM	8	8	g
CWpdptmthdenomy3_f	3917	NUM	8	8	g
CWpdptmthdenomy4_f	3926	NUM	8	8	g
CWpdptmthdenomy4m_n	4006	NUM	8	8	g
CWpdptmthdenomy4m_s	3983	NUM	8	8	g
CWpdptmthdenomy4m_u	4029	NUM	8	8	g
CWPmissy1_f	373	NUM	8	10	d
CWPmissy2_f	394	NUM	8	10	d
CWPmissy3_f	415	NUM	8	10	d
CWPmissy4_f	436	NUM	8	10	d
CWPmissy4_n	474	NUM	8	10	d
CWPmissy4_s	453	NUM	8	10	d
CWPmissy4_u	495	NUM	8	10	d
CWPOoRy1_f	374	NUM	8	10	d
CWPOoRy2_f	395	NUM	8	10	d

CWPOoRy3_f	416	NUM	8	10	d
CWPOoRy4_f	437	NUM	8	10	d
CWPOoRy4_n	475	NUM	8	10	d
CWPOoRy4_s	454	NUM	8	10	d
CWPOoRy4_u	496	NUM	8	10	d
CWptdenomy1_f	357	NUM	8	10	a
CWptdenomy2_f	378	NUM	8	10	a
CWptdenomy3_f	399	NUM	8	10	a
CWptdenomy4_f	420	NUM	8	10	a
CWptdenomy4m_n	477	NUM	8	10	a
CWptdenomy4m_s	456	NUM	8	10	a
CWptdenomy4m_u	498	NUM	8	10	a
CWptmthdenomy1_f	358	NUM	8	10	b
CWptmthdenomy2_f	379	NUM	8	10	b
CWptmthdenomy3_f	400	NUM	8	10	b
CWptmthdenomy4_f	421	NUM	8	10	b
CWptmthdenomy4m_n	478	NUM	8	10	b
CWptmthdenomy4m_s	457	NUM	8	10	b
CWptmthdenomy4m_u	499	NUM	8	10	b
CWunCa1y1_f	359	NUM	8	10	f
CWunCa1y2_f	380	NUM	8	10	f
CWunCa1y3_f	401	NUM	8	10	f
CWunCa1y4_f	422	NUM	8	10	f
CWunCa1y4_n	462	NUM	8	10	f
CWunCa1y4_s	441	NUM	8	10	f
CWunCa1y4_u	483	NUM	8	10	f
CWunCa2y1_f	360	NUM	8	10	f
CWunCa2y2_f	381	NUM	8	10	f
CWunCa2y3_f	402	NUM	8	10	f
CWunCa2y4_f	423	NUM	8	10	f
CWunCa2y4_n	463	NUM	8	10	f
CWunCa2y4_s	442	NUM	8	10	f
CWunCa2y4_u	484	NUM	8	10	f
CWunCa3y1_f	361	NUM	8	10	f
CWunCa3y2_f	382	NUM	8	10	f
CWunCa3y3_f	403	NUM	8	10	f
CWunCa3y4_f	424	NUM	8	10	f
CWunCa3y4_n	464	NUM	8	10	f
CWunCa3y4_s	443	NUM	8	10	f
CWunCa3y4_u	485	NUM	8	10	f
CWunCagt102y1_f	377	NUM	8	10	g
CWunCagt102y2_f	398	NUM	8	10	g
CWunCagt102y3_f	419	NUM	8	10	g
CWunCagt102y4_f	440	NUM	8	10	g

CWunCagt102y4_n	476	NUM	8	10	g
CWunCagt102y4_s	455	NUM	8	10	g
CWunCagt102y4_u	497	NUM	8	10	g
CWunCamissy1_f	362	NUM	8	10	f
CWunCamissy2_f	383	NUM	8	10	f
CWunCamissy3_f	404	NUM	8	10	f
CWunCamissy4_f	425	NUM	8	10	f
CWunCamissy4_n	465	NUM	8	10	f
CWunCamissy4_s	444	NUM	8	10	f
CWunCamissy4_u	486	NUM	8	10	f
CWunCaOoRy1_f	363	NUM	8	10	f
CWunCaOoRy2_f	384	NUM	8	10	f
CWunCaOoRy3_f	405	NUM	8	10	f
CWunCaOoRy4_f	426	NUM	8	10	f
CWunCaOoRy4_n	466	NUM	8	10	f
CWunCaOoRy4_s	445	NUM	8	10	f
CWunCaOoRy4_u	487	NUM	8	10	f
dbprimy1_f	2411	NUM	8	2	f
dbprimy2_f	2477	NUM	8	2	f
dbprimy3_f	2543	NUM	8	2	f
dbprimy4_f	2609	NUM	8	2	f
dbprimy4_n	2741	NUM	8	2	f
dbprimy4_s	2675	NUM	8	2	f
dbprimy4_u	2807	NUM	8	2	f
deay1_f	2863	NUM	8	3	c
deay2_f	2873	NUM	8	3	c
deay3_f	2883	NUM	8	3	c
deay4_f	2893	NUM	8	3	c
deaz_f	2852	NUM	8	3	c
deazm_n	3012	NUM	8	3	c
deazm_s	2993	NUM	8	3	c
deazm_u	3031	NUM	8	3	c
DFR_First_certdate	838	NUM	8	13	c
DFR_PROVNAME	2	CHAR	200	ID	
diabimy1_f	2394	NUM	8	2	w
diabimy2_f	2460	NUM	8	2	w
diabimy3_f	2526	NUM	8	2	w
diabimy4_f	2592	NUM	8	2	w
diabimy4_n	2724	NUM	8	2	w
diabimy4_s	2658	NUM	8	2	w
diabimy4_u	2790	NUM	8	2	w
diabmy1_f	2395	NUM	8	2	w
diabmy2_f	2461	NUM	8	2	w
diabmy3_f	2527	NUM	8	2	w

diabmy4_f	2593	NUM	8	2	w
diabmy4_n	2725	NUM	8	2	w
diabmy4_s	2659	NUM	8	2	w
diabmy4_u	2791	NUM	8	2	w
dietFTy1_f	1574	NUM	8	DATA	
dietFTy2_f	1606	NUM	8	DATA	
dietFTy3_f	1638	NUM	8	DATA	
dietFTy4_f	1665	NUM	8	DATA	
dietFTy4m_n	1731	NUM	8	DATA	
dietFTy4m_s	1697	NUM	8	DATA	
dietFTy4m_u	1765	NUM	8	DATA	
dietPTy1_f	1575	NUM	8	DATA	
dietPTy2_f	1607	NUM	8	DATA	
dietPTy3_f	1639	NUM	8	DATA	
dietPTy4_f	1666	NUM	8	DATA	
dietPTy4m_n	1735	NUM	8	DATA	
dietPTy4m_s	1701	NUM	8	DATA	
dietPTy4m_u	1769	NUM	8	DATA	
dis1y1_f	146	NUM	8	1	g
dis1y2_f	177	NUM	8	1	g
dis1y3_f	208	NUM	8	1	g
dis1y4_f	239	NUM	8	1	g
dis1y4_n	299	NUM	8	1	g
dis1y4_s	268	NUM	8	1	g
dis1y4_u	330	NUM	8	1	g
dis2y1_f	147	NUM	8	1	g
dis2y2_f	178	NUM	8	1	g
dis2y3_f	209	NUM	8	1	g
dis2y4_f	240	NUM	8	1	g
dis2y4_n	300	NUM	8	1	g
dis2y4_s	269	NUM	8	1	g
dis2y4_u	331	NUM	8	1	g
dis3y1_f	148	NUM	8	1	g
dis3y2_f	179	NUM	8	1	g
dis3y3_f	210	NUM	8	1	g
dis3y4_f	241	NUM	8	1	g
dis3y4_n	301	NUM	8	1	g
dis3y4_s	270	NUM	8	1	g
dis3y4_u	332	NUM	8	1	g
dis4y1_f	149	NUM	8	1	g
dis4y2_f	180	NUM	8	1	g
dis4y3_f	211	NUM	8	1	g
dis4y4_f	242	NUM	8	1	g
dis4y4_n	302	NUM	8	1	g



dis4y4_s	271	NUM	8	1	g
dis4y4_u	333	NUM	8	1	g
dis5y1_f	150	NUM	8	1	g
dis5y2_f	181	NUM	8	1	g
dis5y3_f	212	NUM	8	1	g
dis5y4_f	243	NUM	8	1	g
dis5y4_n	303	NUM	8	1	g
dis5y4_s	272	NUM	8	1	g
dis5y4_u	334	NUM	8	1	g
drugmy1_f	2396	NUM	8	2	w
drugmy2_f	2462	NUM	8	2	w
drugmy3_f	2528	NUM	8	2	w
drugmy4_f	2594	NUM	8	2	w
drugmy4_n	2726	NUM	8	2	w
drugmy4_s	2660	NUM	8	2	w
drugmy4_u	2792	NUM	8	2	w
dudy1_f	2864	NUM	8	3	g
dudy2_f	2874	NUM	8	3	g
dudy3_f	2884	NUM	8	3	g
dudy4_f	2894	NUM	8	3	g
dudz_f	2855	NUM	8	3	g
dudzm_n	3014	NUM	8	3	g
dudzm_s	2995	NUM	8	3	g
dudzm_u	3033	NUM	8	3	g
dyy1_f	2862	NUM	8	3	b
dyy2_f	2872	NUM	8	3	b
dyy3_f	2882	NUM	8	3	b
dyy4_f	2892	NUM	8	3	b
dyz_f	2854	NUM	8	3	b
dyzm_n	3011	NUM	8	3	b
dyzm_s	2992	NUM	8	3	b
dyzm_u	3030	NUM	8	3	b
ed30expy1_f	3204	NUM	8	4	z
ed30expy2_f	3211	NUM	8	4	z
ed30expy3_f	3218	NUM	8	4	z
ed30expy4_f	3225	NUM	8	4	z
ed30expz_f	3232	NUM	8	4	z
ed30expzm_n	3339	NUM	8	4	z
ed30expzm_s	3309	NUM	8	4	z
ed30expzm_u	3369	NUM	8	4	z
ed30indexy1_f	3198	NUM	8	4	x
ed30indexy2_f	3205	NUM	8	4	x
ed30indexy3_f	3212	NUM	8	4	x
ed30indexy4_f	3219	NUM	8	4	x

ed30indexz_f	3226	NUM	8	4	x
ed30indexzm_n	3337	NUM	8	4	x
ed30indexzm_s	3307	NUM	8	4	x
ed30indexzm_u	3367	NUM	8	4	x
ed30lcly1_f	3201	NUM	8	4	ac
ed30lcly2_f	3208	NUM	8	4	ac
ed30lcly3_f	3215	NUM	8	4	ac
ed30lcly4_f	3222	NUM	8	4	ac
ed30lclz_f	3229	NUM	8	4	ac
ed30obsy1_f	3199	NUM	8	4	y
ed30obsy2_f	3206	NUM	8	4	y
ed30obsy3_f	3213	NUM	8	4	y
ed30obsy4_f	3220	NUM	8	4	y
ed30obsz_f	3227	NUM	8	4	y
ed30obszm_n	3338	NUM	8	4	y
ed30obszm_s	3308	NUM	8	4	y
ed30obszm_u	3368	NUM	8	4	y
ed30py1_f	3203	NUM	8	4	ab
ed30py2_f	3210	NUM	8	4	ab
ed30py3_f	3217	NUM	8	4	ab
ed30py4_f	3224	NUM	8	4	ab
ed30pz_f	3231	NUM	8	4	ab
ed30uclly1_f	3202	NUM	8	4	ac
ed30uclly2_f	3209	NUM	8	4	ac
ed30uclly3_f	3216	NUM	8	4	ac
ed30uclly4_f	3223	NUM	8	4	ac
ed30uclz_f	3230	NUM	8	4	ac
ed30y1_f	3200	NUM	8	4	aa
ed30y2_f	3207	NUM	8	4	aa
ed30y3_f	3214	NUM	8	4	aa
ed30y4_f	3221	NUM	8	4	aa
ed30z_f	3228	NUM	8	4	aa
ed30z_n	3340	NUM	8	4	aa
ed30z_s	3310	NUM	8	4	aa
ed30z_u	3370	NUM	8	4	aa
edyr1_f	3166	NUM	8	DATA	
edyr2_f	3171	NUM	8	DATA	
edyr3_f	3176	NUM	8	DATA	
edyr4_f	3181	NUM	8	DATA	
edyrz_f	3160	NUM	8	DATA	
edyrz_n	3349	NUM	8	DATA	
edyrz_s	3319	NUM	8	DATA	
edyrz_u	3379	NUM	8	DATA	
edyrzm_n	3348	NUM	8	DATA	

edyrzm_s	3318	NUM	8	DATA	
edyrzm_u	3378	NUM	8	DATA	
eFVy1_f	3651	NUM	8	7	a
eFVy2_f	3679	NUM	8	7	a
eFVy3_f	3707	NUM	8	7	a
eFVy4_f	3735	NUM	8	7	a
eFVy4m_n	3826	NUM	8	7	a
eFVy4m_s	3797	NUM	8	7	a
eFVy4m_u	3860	NUM	8	7	a
employedy1_f	1582	NUM	8	DATA	
employedy2_f	1614	NUM	8	DATA	
employedy3_f	1646	NUM	8	DATA	
employedy4_f	1671	NUM	8	DATA	
employedy4_n	1739	NUM	8	DATA	
employedy4_s	1705	NUM	8	DATA	
employedy4_u	1773	NUM	8	DATA	
endcnty1_f	1553	NUM	8	DATA	
endcnty2_f	1585	NUM	8	DATA	
endcnty3_f	1617	NUM	8	DATA	
endcnty4_f	818	NUM	8	13	o
endcnty4m_n	849	NUM	8	13	o
endcnty4m_s	840	NUM	8	13	o
endcnty4m_u	858	NUM	8	13	o
eth1y1_f	156	NUM	8	1	f
eth1y2_f	187	NUM	8	1	f
eth1y3_f	218	NUM	8	1	f
eth1y4_f	249	NUM	8	1	f
eth1y4_n	314	NUM	8	1	f
eth1y4_s	283	NUM	8	1	f
eth1y4_u	345	NUM	8	1	f
eth2y1_f	157	NUM	8	1	f
eth2y2_f	188	NUM	8	1	f
eth2y3_f	219	NUM	8	1	f
eth2y4_f	250	NUM	8	1	f
eth2y4_n	315	NUM	8	1	f
eth2y4_s	284	NUM	8	1	f
eth2y4_u	346	NUM	8	1	f
eth3y1_f	158	NUM	8	1	f
eth3y2_f	189	NUM	8	1	f
eth3y3_f	220	NUM	8	1	f
eth3y4_f	251	NUM	8	1	f
eth3y4_n	316	NUM	8	1	f
eth3y4_s	285	NUM	8	1	f
eth3y4_u	347	NUM	8	1	f

ethmy1_f	2403	NUM	8	2	e
ethmy2_f	2469	NUM	8	2	e
ethmy3_f	2535	NUM	8	2	e
ethmy4_f	2601	NUM	8	2	e
ethmy4_n	2733	NUM	8	2	e
ethmy4_s	2667	NUM	8	2	e
ethmy4_u	2799	NUM	8	2	e
exdy1_f	2865	NUM	8	3	d
exdy2_f	2875	NUM	8	3	d
exdy3_f	2885	NUM	8	3	d
exdy4_f	2895	NUM	8	3	d
exdz_f	2853	NUM	8	3	d
exdzm_n	3013	NUM	8	3	d
exdzm_s	2994	NUM	8	3	d
exdzm_u	3032	NUM	8	3	d
exedy1_f	3164	NUM	8	4	t
exedy2_f	3169	NUM	8	4	t
exedy3_f	3174	NUM	8	4	t
exedy4_f	3179	NUM	8	4	t
exedz_f	3159	NUM	8	4	t
exedzm_n	3347	NUM	8	4	t
exedzm_s	3317	NUM	8	4	t
exedzm_u	3377	NUM	8	4	t
exhdy1_f	3069	NUM	8	4	d
exhdy2_f	3085	NUM	8	4	d
exhdy3_f	3101	NUM	8	4	d
exhdy4_f	3117	NUM	8	4	d
exhdz_f	3052	NUM	8	4	d
exhdzm_n	3325	NUM	8	4	d
exhdzm_s	3295	NUM	8	4	d
exhdzm_u	3355	NUM	8	4	d
extfy1_f	3937	NUM	8	8	n
extfy2_f	3942	NUM	8	8	n
extfy3_f	3947	NUM	8	8	n
extfy4_f	3952	NUM	8	8	n
extfy4m_n	4010	NUM	8	8	n
extfy4m_s	3987	NUM	8	8	n
extfy4m_u	4033	NUM	8	8	n
extxy1_f	3397	NUM	8	5	g
extxy2_f	3405	NUM	8	5	g
extxy3_f	3413	NUM	8	5	g
extxy4_f	3421	NUM	8	5	g
extxz_f	3383	NUM	8	5	g
extxzm_n	3444	NUM	8	5	g

extxzm_s	3435	NUM	8	5	g
extxzm_u	3453	NUM	8	5	g
exty1_f	3068	NUM	8	4	j
exty2_f	3084	NUM	8	4	j
exty3_f	3100	NUM	8	4	j
exty4_f	3116	NUM	8	4	j
extz_f	3050	NUM	8	4	j
extzm_n	3323	NUM	8	4	j
extzm_s	3293	NUM	8	4	j
extzm_u	3353	NUM	8	4	j
femmy1_f	2415	NUM	8	2	c
femmy2_f	2481	NUM	8	2	c
femmy3_f	2547	NUM	8	2	c
femmy4_f	2613	NUM	8	2	c
femmy4_n	2745	NUM	8	2	c
femmy4_s	2679	NUM	8	2	c
femmy4_u	2811	NUM	8	2	c
FV1839hy1_f	3660	NUM	8	7	h
FV1839hy2_f	3688	NUM	8	7	h
FV1839hy3_f	3716	NUM	8	7	h
FV1839hy4_f	3744	NUM	8	7	h
FV1839hy4_n	3811	NUM	8	7	h
FV1839hy4_s	3782	NUM	8	7	h
FV1839hy4_u	3845	NUM	8	7	h
FV4064hy1_f	3661	NUM	8	7	h
FV4064hy2_f	3689	NUM	8	7	h
FV4064hy3_f	3717	NUM	8	7	h
FV4064hy4_f	3745	NUM	8	7	h
FV4064hy4_n	3812	NUM	8	7	h
FV4064hy4_s	3783	NUM	8	7	h
FV4064hy4_u	3846	NUM	8	7	h
FV6574hy1_f	3662	NUM	8	7	h
FV6574hy2_f	3690	NUM	8	7	h
FV6574hy3_f	3718	NUM	8	7	h
FV6574hy4_f	3746	NUM	8	7	h
FV6574hy4_n	3813	NUM	8	7	h
FV6574hy4_s	3784	NUM	8	7	h
FV6574hy4_u	3847	NUM	8	7	h
FV75uphy1_f	3663	NUM	8	7	h
FV75uphy2_f	3691	NUM	8	7	h
FV75uphy3_f	3719	NUM	8	7	h
FV75uphy4_f	3747	NUM	8	7	h
FV75uphy4_n	3814	NUM	8	7	h
FV75uphy4_s	3785	NUM	8	7	h

FV75uphy4_u	3848	NUM	8	7	h
FVashy1_f	3666	NUM	8	7	h
FVashy2_f	3694	NUM	8	7	h
FVashy3_f	3722	NUM	8	7	h
FVashy4_f	3750	NUM	8	7	h
FVashy4_n	3817	NUM	8	7	h
FVashy4_s	3788	NUM	8	7	h
FVashy4_u	3851	NUM	8	7	h
FVblkhy1_f	3670	NUM	8	7	h
FVblkhy2_f	3698	NUM	8	7	h
FVblkhy3_f	3726	NUM	8	7	h
FVblkhy4_f	3754	NUM	8	7	h
FVblkhy4_n	3821	NUM	8	7	h
FVblkhy4_s	3792	NUM	8	7	h
FVblkhy4_u	3855	NUM	8	7	h
FVdeclinedfy1_f	3676	NUM	8	7	e
FVdeclinedfy2_f	3704	NUM	8	7	e
FVdeclinedfy3_f	3732	NUM	8	7	e
FVdeclinedfy3_n	3800	NUM	8	7	e
FVdeclinedfy3_s	3771	NUM	8	7	e
FVdeclinedfy3_u	3834	NUM	8	7	e
FVdualhy1_f	3656	NUM	8	7	h
FVdualhy2_f	3684	NUM	8	7	h
FVdualhy3_f	3712	NUM	8	7	h
FVdualhy4_f	3740	NUM	8	7	h
FVdualhy4_n	3807	NUM	8	7	h
FVdualhy4_s	3778	NUM	8	7	h
FVdualhy4_u	3841	NUM	8	7	h
FVfemhy1_f	3665	NUM	8	7	h
FVfemhy2_f	3693	NUM	8	7	h
FVfemhy3_f	3721	NUM	8	7	h
FVfemhy4_f	3749	NUM	8	7	h
FVfemhy4_n	3816	NUM	8	7	h
FVfemhy4_s	3787	NUM	8	7	h
FVfemhy4_u	3850	NUM	8	7	h
FVfy1_f	3675	NUM	8	7	c
FVfy1_u	3829	NUM	8	7	Foot
FVfy2_f	3703	NUM	8	7	c
FVfy2_u	3831	NUM	8	7	Foot
FVfy3_f	3731	NUM	8	7	c
FVfy3_n	3799	NUM	8	7	c
FVfy3_s	3770	NUM	8	7	c
FVfy3_u	3833	NUM	8	7	c
FVhisphy1_f	3671	NUM	8	7	h

FVhisphy2_f	3699	NUM	8	7	h
FVhisphy3_f	3727	NUM	8	7	h
FVhisphy4_f	3755	NUM	8	7	h
FVhisphy4_n	3822	NUM	8	7	h
FVhisphy4_s	3793	NUM	8	7	h
FVhisphy4_u	3856	NUM	8	7	h
FVhy1_f	3652	NUM	8	7	f
FVhy1_u	3828	NUM	8	7	Foot
FVhy2_f	3680	NUM	8	7	f
FVhy2_u	3830	NUM	8	7	Foot
FVhy3_f	3708	NUM	8	7	f
FVhy3_u	3832	NUM	8	7	Foot
FVhy4_f	3736	NUM	8	7	f
FVhy4_n	3803	NUM	8	7	f
FVhy4_s	3774	NUM	8	7	f
FVhy4_u	3837	NUM	8	7	f
FVlt18hy1_f	3659	NUM	8	7	h
FVlt18hy2_f	3687	NUM	8	7	h
FVlt18hy3_f	3715	NUM	8	7	h
FVlt18hy4_f	3743	NUM	8	7	h
FVlt18hy4_n	3810	NUM	8	7	h
FVlt18hy4_s	3781	NUM	8	7	h
FVlt18hy4_u	3844	NUM	8	7	h
FVmahy1_f	3654	NUM	8	7	h
FVmahy2_f	3682	NUM	8	7	h
FVmahy3_f	3710	NUM	8	7	h
FVmahy4_f	3738	NUM	8	7	h
FVmahy4_n	3805	NUM	8	7	h
FVmahy4_s	3776	NUM	8	7	h
FVmahy4_u	3839	NUM	8	7	h
FVmalehy1_f	3664	NUM	8	7	h
FVmalehy2_f	3692	NUM	8	7	h
FVmalehy3_f	3720	NUM	8	7	h
FVmalehy4_f	3748	NUM	8	7	h
FVmalehy4_n	3815	NUM	8	7	h
FVmalehy4_s	3786	NUM	8	7	h
FVmalehy4_u	3849	NUM	8	7	h
FVmcarehy1_f	3653	NUM	8	7	h
FVmcarehy2_f	3681	NUM	8	7	h
FVmcarehy3_f	3709	NUM	8	7	h
FVmcarehy4_f	3737	NUM	8	7	h
FVmcarehy4_n	3804	NUM	8	7	h
FVmcarehy4_s	3775	NUM	8	7	h
FVmcarehy4_u	3838	NUM	8	7	h

FVmpphy1_f	3655	NUM	8	7	h
FVmpphy2_f	3683	NUM	8	7	h
FVmpphy3_f	3711	NUM	8	7	h
FVmpphy4_f	3739	NUM	8	7	h
FVmpphy4_n	3806	NUM	8	7	h
FVmpphy4_s	3777	NUM	8	7	h
FVmpphy4_u	3840	NUM	8	7	h
FVmsphy1_f	3657	NUM	8	7	h
FVmsphy2_f	3685	NUM	8	7	h
FVmsphy3_f	3713	NUM	8	7	h
FVmsphy4_f	3741	NUM	8	7	h
FVmsphy4_n	3808	NUM	8	7	h
FVmsphy4_s	3779	NUM	8	7	h
FVmsphy4_u	3842	NUM	8	7	h
FVnahy1_f	3667	NUM	8	7	h
FVnahy2_f	3695	NUM	8	7	h
FVnahy3_f	3723	NUM	8	7	h
FVnahy4_f	3751	NUM	8	7	h
FVnahy4_n	3818	NUM	8	7	h
FVnahy4_s	3789	NUM	8	7	h
FVnahy4_u	3852	NUM	8	7	h
FVnonmcarehy1_f	3658	NUM	8	7	h
FVnonmcarehy2_f	3686	NUM	8	7	h
FVnonmcarehy3_f	3714	NUM	8	7	h
FVnonmcarehy4_f	3742	NUM	8	7	h
FVnonmcarehy4_n	3809	NUM	8	7	h
FVnonmcarehy4_s	3780	NUM	8	7	h
FVnonmcarehy4_u	3843	NUM	8	7	h
FVothersnfy1_f	3678	NUM	8	7	e
FVothersnfy2_f	3706	NUM	8	7	e
FVothersnfy3_f	3734	NUM	8	7	e
FVothersnfy3_n	3802	NUM	8	7	e
FVothersnfy3_s	3773	NUM	8	7	e
FVothersnfy3_u	3836	NUM	8	7	e
FVovndfy1_f	3677	NUM	8	7	e
FVovndfy2_f	3705	NUM	8	7	e
FVovndfy3_f	3733	NUM	8	7	e
FVovndfy3_n	3801	NUM	8	7	e
FVovndfy3_s	3772	NUM	8	7	e
FVovndfy3_u	3835	NUM	8	7	e
FVrothhy1_f	3669	NUM	8	7	h
FVrothhy2_f	3697	NUM	8	7	h
FVrothhy3_f	3725	NUM	8	7	h
FVrothhy4_f	3753	NUM	8	7	h



FVrothhy4_n	3820	NUM	8	7	h
FVrothhy4_s	3791	NUM	8	7	h
FVrothhy4_u	3854	NUM	8	7	h
FVVCat1hy1_f	3672	NUM	8	7	h
FVVCat1hy2_f	3700	NUM	8	7	h
FVVCat1hy3_f	3728	NUM	8	7	h
FVVCat1hy4_f	3756	NUM	8	7	h
FVVCat1hy4_n	3823	NUM	8	7	h
FVVCat1hy4_s	3794	NUM	8	7	h
FVVCat1hy4_u	3857	NUM	8	7	h
FVVCat2hy1_f	3673	NUM	8	7	h
FVVCat2hy2_f	3701	NUM	8	7	h
FVVCat2hy3_f	3729	NUM	8	7	h
FVVCat2hy4_f	3757	NUM	8	7	h
FVVCat2hy4_n	3824	NUM	8	7	h
FVVCat2hy4_s	3795	NUM	8	7	h
FVVCat2hy4_u	3858	NUM	8	7	h
FVVCat3hy1_f	3674	NUM	8	7	h
FVVCat3hy2_f	3702	NUM	8	7	h
FVVCat3hy3_f	3730	NUM	8	7	h
FVVCat3hy4_f	3758	NUM	8	7	h
FVVCat3hy4_n	3825	NUM	8	7	h
FVVCat3hy4_s	3796	NUM	8	7	h
FVVCat3hy4_u	3859	NUM	8	7	h
FVwhhy1_f	3668	NUM	8	7	h
FVwhhy2_f	3696	NUM	8	7	h
FVwhhy3_f	3724	NUM	8	7	h
FVwhhy4_f	3752	NUM	8	7	h
FVwhhy4_n	3819	NUM	8	7	h
FVwhhy4_s	3790	NUM	8	7	h
FVwhhy4_u	3853	NUM	8	7	h
fycardiacy1_f	2943	NUM	8	3	q
fycardiacy2_f	2952	NUM	8	3	q
fycardiacy3_f	2961	NUM	8	3	q
fycardiacz_f	2935	NUM	8	3	q
fycardiacz_n	3027	NUM	8	3	q
fycardiacz_s	3008	NUM	8	3	q
fycardiacz_u	3046	NUM	8	3	q
fychimy1_f	2917	NUM	8	3	t
fychimy2_f	2920	NUM	8	3	t
fychimy3_f	2923	NUM	8	3	t
fychimz_f	2926	NUM	8	3	t
fyclomy1_f	2918	NUM	8	3	t
fyclomy2_f	2921	NUM	8	3	t

fyclomy3_f	2924	NUM	8	3	t
fyclomz_f	2927	NUM	8	3	t
fydeay1_f	2939	NUM	8	3	n
fydeay2_f	2948	NUM	8	3	n
fydeay3_f	2957	NUM	8	3	n
fydeaz_f	2930	NUM	8	3	n
fydeazm_n	3022	NUM	8	3	n
fydeazm_s	3003	NUM	8	3	n
fydeazm_u	3041	NUM	8	3	n
fydyy1_f	2938	NUM	8	3	m
fydyy2_f	2947	NUM	8	3	m
fydyy3_f	2956	NUM	8	3	m
fydyz_f	2929	NUM	8	3	m
fydym_n	3021	NUM	8	3	m
fydym_s	3002	NUM	8	3	m
fydym_u	3040	NUM	8	3	m
fyexdy1_f	2940	NUM	8	3	o
fyexdy2_f	2949	NUM	8	3	o
fyexdy3_f	2958	NUM	8	3	o
fyexdz_f	2931	NUM	8	3	o
fyexdm_n	3023	NUM	8	3	o
fyexdm_s	3004	NUM	8	3	o
fyexdm_u	3042	NUM	8	3	o
fyinfy1_f	2942	NUM	8	3	q
fyinfy2_f	2951	NUM	8	3	q
fyinfy3_f	2960	NUM	8	3	q
fyinfz_f	2934	NUM	8	3	q
fyinfz_n	3026	NUM	8	3	q
fyinfz_s	3007	NUM	8	3	q
fyinfz_u	3045	NUM	8	3	q
fylivy1_f	2944	NUM	8	3	q
fylivy2_f	2953	NUM	8	3	q
fylivy3_f	2962	NUM	8	3	q
fylivz_f	2936	NUM	8	3	q
fylivz_n	3028	NUM	8	3	q
fylivz_s	3009	NUM	8	3	q
fylivz_u	3047	NUM	8	3	q
fynmy1_f	2937	NUM	8	3	l
fynmy2_f	2946	NUM	8	3	l
fynmy3_f	2955	NUM	8	3	l
fynmz_f	2928	NUM	8	3	l
fynmzm_n	3020	NUM	8	3	l
fynmzm_s	3001	NUM	8	3	l
fynmzm_u	3039	NUM	8	3	l

fypmy1_f	2916	NUM	8	3	s
fypmy2_f	2919	NUM	8	3	s
fypmy3_f	2922	NUM	8	3	s
fypmz_f	2925	NUM	8	3	s
fysmry1_f	2945	NUM	8	3	r
fysmry2_f	2954	NUM	8	3	r
fysmry3_f	2963	NUM	8	3	r
fysmrz_f	2932	NUM	8	3	r
fysmrz_n	3024	NUM	8	3	r
fysmrz_s	3005	NUM	8	3	r
fysmrz_u	3043	NUM	8	3	r
fywity1_f	2941	NUM	8	3	p
fywity2_f	2950	NUM	8	3	p
fywity3_f	2959	NUM	8	3	p
fywitz_f	2933	NUM	8	3	p
fywitz_n	3025	NUM	8	3	p
fywitz_s	3006	NUM	8	3	p
fywitz_u	3044	NUM	8	3	p
gfrmy1_f	2420	NUM	8	2	q
gfrmy2_f	2486	NUM	8	2	q
gfrmy3_f	2552	NUM	8	2	q
gfrmy4_f	2618	NUM	8	2	q
gfrmy4_n	2750	NUM	8	2	q
gfrmy4_s	2684	NUM	8	2	q
gfrmy4_u	2816	NUM	8	2	q
gnprimy1_f	2412	NUM	8	2	f
gnprimy2_f	2478	NUM	8	2	f
gnprimy3_f	2544	NUM	8	2	f
gnprimy4_f	2610	NUM	8	2	f
gnprimy4_n	2742	NUM	8	2	f
gnprimy4_s	2676	NUM	8	2	f
gnprimy4_u	2808	NUM	8	2	f
hdy1_f	3067	NUM	8	4	c
hdy2_f	3083	NUM	8	4	c
hdy3_f	3099	NUM	8	4	c
hdy4_f	3115	NUM	8	4	c
hdy1_f	3066	NUM	8	4	b
hdy2_f	3082	NUM	8	4	b
hdy3_f	3098	NUM	8	4	b
hdy4_f	3114	NUM	8	4	b
hdyz_f	3053	NUM	8	4	b
hdyzm_n	3326	NUM	8	4	b
hdyzm_s	3296	NUM	8	4	b
hdyzm_u	3356	NUM	8	4	b

hdz_f	3051	NUM	8	4	c
hdzm_n	3324	NUM	8	4	c
hdzm_s	3294	NUM	8	4	c
hdzm_u	3354	NUM	8	4	c
hedy1_f	3163	NUM	8	4	s
hedy2_f	3168	NUM	8	4	s
hedy3_f	3173	NUM	8	4	s
hedy4_f	3178	NUM	8	4	s
hedz_f	3158	NUM	8	4	s
hedzm_n	3346	NUM	8	4	s
hedzm_s	3316	NUM	8	4	s
hedzm_u	3376	NUM	8	4	s
hemomy1_f	2450	NUM	8	2	k
hemomy2_f	2516	NUM	8	2	k
hemomy3_f	2582	NUM	8	2	k
hemomy4_f	2648	NUM	8	2	k
hemomy4m_n	2782	NUM	8	2	k
hemomy4m_s	2716	NUM	8	2	k
hemomy4m_u	2849	NUM	8	2	k
hgmy1_f	2419	NUM	8	2	n
hgmy2_f	2485	NUM	8	2	n
hgmy3_f	2551	NUM	8	2	n
hgmy4_f	2617	NUM	8	2	n
hgmy4_n	2749	NUM	8	2	n
hgmy4_s	2683	NUM	8	2	n
hgmy4_u	2815	NUM	8	2	n
htay1_f	3065	NUM	8	4	i
htay2_f	3081	NUM	8	4	i
htay3_f	3097	NUM	8	4	i
htay4_f	3113	NUM	8	4	i
htaz_f	3049	NUM	8	4	i
htazm_n	3322	NUM	8	4	i
htazm_s	3292	NUM	8	4	i
htazm_u	3352	NUM	8	4	i
htprimy1_f	2413	NUM	8	2	f
htprimy2_f	2479	NUM	8	2	f
htprimy3_f	2545	NUM	8	2	f
htprimy4_f	2611	NUM	8	2	f
htprimy4_n	2743	NUM	8	2	f
htprimy4_s	2677	NUM	8	2	f
htprimy4_u	2809	NUM	8	2	f
hxhtmy1_f	2397	NUM	8	2	w
hxhtmy2_f	2463	NUM	8	2	w
hxhtmy3_f	2529	NUM	8	2	w

hxhtmy4_f	2595	NUM	8	2	w
hxhtmy4_n	2727	NUM	8	2	w
hxhtmy4_s	2661	NUM	8	2	w
hxhtmy4_u	2793	NUM	8	2	w
ihcapdy1_f	1564	NUM	8	DATA	
ihcapdy2_f	1596	NUM	8	DATA	
ihcapdy3_f	1628	NUM	8	DATA	
ihcapdy4_f	1658	NUM	8	DATA	
ihcapdy4m_n	1726	NUM	8	DATA	
ihcapdy4m_s	1692	NUM	8	DATA	
ihcapdy4m_u	1760	NUM	8	DATA	
ihccpdy1_f	1565	NUM	8	DATA	
ihccpdy2_f	1597	NUM	8	DATA	
ihccpdy3_f	1629	NUM	8	DATA	
ihccpdy4_f	1659	NUM	8	DATA	
ihccpdy4m_n	1727	NUM	8	DATA	
ihccpdy4m_s	1693	NUM	8	DATA	
ihccpdy4m_u	1761	NUM	8	DATA	
ihdy1_f	511	NUM	8	11	h
ihdy2_f	524	NUM	8	11	h
ihdy3_f	537	NUM	8	11	h
ihdy4_f	550	NUM	8	11	h
ihdy4m_n	617	NUM	8	11	h
ihdy4m_s	600	NUM	8	11	h
ihdy4m_u	634	NUM	8	11	h
ihfreqy1_f	1561	NUM	8	DATA	
ihfreqy2_f	1593	NUM	8	DATA	
ihfreqy3_f	1625	NUM	8	DATA	
ihfreqy4_f	1655	NUM	8	DATA	
ihfreqy4m_n	1723	NUM	8	DATA	
ihfreqy4m_s	1689	NUM	8	DATA	
ihfreqy4m_u	1757	NUM	8	DATA	
ihhemy1_f	1560	NUM	8	DATA	
ihhemy2_f	1592	NUM	8	DATA	
ihhemy3_f	1624	NUM	8	DATA	
ihhemy4_f	1654	NUM	8	DATA	
ihhemy4m_n	1722	NUM	8	DATA	
ihhemy4m_s	1688	NUM	8	DATA	
ihhemy4m_u	1756	NUM	8	DATA	
ihnonfreqy1_f	1562	NUM	8	DATA	
ihnonfreqy2_f	1594	NUM	8	DATA	
ihnonfreqy3_f	1626	NUM	8	DATA	
ihnonfreqy4_f	1656	NUM	8	DATA	
ihnonfreqy4m_n	1724	NUM	8	DATA	

ihnonfreqy4m_s	1690	NUM	8	DATA	
ihnonfreqy4m_u	1758	NUM	8	DATA	
ihothy1_f	1563	NUM	8	DATA	
ihothy2_f	1595	NUM	8	DATA	
ihothy3_f	1627	NUM	8	DATA	
ihothy4_f	1657	NUM	8	DATA	
ihothy4m_n	1725	NUM	8	DATA	
ihothy4m_s	1691	NUM	8	DATA	
ihothy4m_u	1759	NUM	8	DATA	
incpery1_f	1579	NUM	8	DATA	
incpery2_f	1611	NUM	8	DATA	
incpery3_f	1643	NUM	8	DATA	
incpery4_f	1670	NUM	8	DATA	
incpery4_n	1738	NUM	8	DATA	
incpery4_s	1704	NUM	8	DATA	
incpery4_u	1772	NUM	8	DATA	
indexmy4_n	3342	NUM	8	4	ad
indexmy4_s	3312	NUM	8	4	ad
indexmy4_u	3372	NUM	8	4	ad
indexy1_f	3233	NUM	8	4	ad
indexy2_f	3240	NUM	8	4	ad
indexy3_f	3247	NUM	8	4	ad
indexy4_f	3254	NUM	8	4	ad
infy1_f	2867	NUM	8	3	f
infy2_f	2877	NUM	8	3	f
infy3_f	2887	NUM	8	3	f
infy4_f	2897	NUM	8	3	f
infz_f	2858	NUM	8	3	f
infz_n	3017	NUM	8	3	f
infz_s	2998	NUM	8	3	f
infz_u	3036	NUM	8	3	f
insempmy1_f	2428	NUM	8	2	g
insempmy2_f	2494	NUM	8	2	g
insempmy3_f	2560	NUM	8	2	g
insempmy4_f	2626	NUM	8	2	g
insempmy4_n	2758	NUM	8	2	g
insempmy4_s	2692	NUM	8	2	g
insempmy4_u	2824	NUM	8	2	g
insmdcdmy1_f	2426	NUM	8	2	g
insmdcdmy2_f	2492	NUM	8	2	g
insmdcdmy3_f	2558	NUM	8	2	g
insmdcdmy4_f	2624	NUM	8	2	g
insmdcdmy4_n	2756	NUM	8	2	g
insmdcdmy4_s	2690	NUM	8	2	g

insmdcdmy4_u	2822	NUM	8	2	g
insmdcrcdmy1_f	2427	NUM	8	2	g
insmdcrcdmy2_f	2493	NUM	8	2	g
insmdcrcdmy3_f	2559	NUM	8	2	g
insmdcrcdmy4_f	2625	NUM	8	2	g
insmdcrcdmy4_n	2757	NUM	8	2	g
insmdcrcdmy4_s	2691	NUM	8	2	g
insmdcrcdmy4_u	2823	NUM	8	2	g
insmdcrmy1_f	2425	NUM	8	2	g
insmdcrmy2_f	2491	NUM	8	2	g
insmdcrmy3_f	2557	NUM	8	2	g
insmdcrmy4_f	2623	NUM	8	2	g
insmdcrmy4_n	2755	NUM	8	2	g
insmdcrmy4_s	2689	NUM	8	2	g
insmdcrmy4_u	2821	NUM	8	2	g
insmdcromy1_f	2430	NUM	8	2	g
insmdcromy2_f	2496	NUM	8	2	g
insmdcromy3_f	2562	NUM	8	2	g
insmdcromy4_f	2628	NUM	8	2	g
insmdcromy4_n	2760	NUM	8	2	g
insmdcromy4_s	2694	NUM	8	2	g
insmdcromy4_u	2826	NUM	8	2	g
insmedomy1_f	2431	NUM	8	2	g
insmedomy2_f	2497	NUM	8	2	g
insmedomy3_f	2563	NUM	8	2	g
insmedomy4_f	2629	NUM	8	2	g
insmedomy4_n	2761	NUM	8	2	g
insmedomy4_s	2695	NUM	8	2	g
insmedomy4_u	2827	NUM	8	2	g
insnonemy1_f	2429	NUM	8	2	g
insnonemy2_f	2495	NUM	8	2	g
insnonemy3_f	2561	NUM	8	2	g
insnonemy4_f	2627	NUM	8	2	g
insnonemy4_n	2759	NUM	8	2	g
insnonemy4_s	2693	NUM	8	2	g
insnonemy4_u	2825	NUM	8	2	g
ipedy1_f	3079	NUM	8	4	r
ipedy2_f	3095	NUM	8	4	r
ipedy3_f	3111	NUM	8	4	r
ipedy4_f	3127	NUM	8	4	r
ipedz_f	3063	NUM	8	4	r
ipedz_n	3336	NUM	8	4	r
ipedz_s	3306	NUM	8	4	r
ipedz_u	3366	NUM	8	4	r

iucapdy1_f	1558	NUM	8	DATA	
iucapdy2_f	1590	NUM	8	DATA	
iucapdy3_f	1622	NUM	8	DATA	
iucapdy4_f	1652	NUM	8	DATA	
iucapdy4m_n	1720	NUM	8	DATA	
iucapdy4m_s	1686	NUM	8	DATA	
iucapdy4m_u	1754	NUM	8	DATA	
iuccpdy1_f	1559	NUM	8	DATA	
iuccpdy2_f	1591	NUM	8	DATA	
iuccpdy3_f	1623	NUM	8	DATA	
iuccpdy4_f	1653	NUM	8	DATA	
iuccpdy4m_n	1721	NUM	8	DATA	
iuccpdy4m_s	1687	NUM	8	DATA	
iuccpdy4m_u	1755	NUM	8	DATA	
iufreqy1_f	1555	NUM	8	DATA	
iufreqy2_f	1587	NUM	8	DATA	
iufreqy3_f	1619	NUM	8	DATA	
iufreqy4_f	1649	NUM	8	DATA	
iufreqy4m_n	1717	NUM	8	DATA	
iufreqy4m_s	1683	NUM	8	DATA	
iufreqy4m_u	1751	NUM	8	DATA	
ihemy1_f	1554	NUM	8	DATA	
ihemy2_f	1586	NUM	8	DATA	
ihemy3_f	1618	NUM	8	DATA	
ihemy4_f	1648	NUM	8	DATA	
ihemy4m_n	1716	NUM	8	DATA	
ihemy4m_s	1682	NUM	8	DATA	
ihemy4m_u	1750	NUM	8	DATA	
iunonfreqy1_f	1556	NUM	8	DATA	
iunonfreqy2_f	1588	NUM	8	DATA	
iunonfreqy3_f	1620	NUM	8	DATA	
iunonfreqy4_f	1650	NUM	8	DATA	
iunonfreqy4m_n	1718	NUM	8	DATA	
iunonfreqy4m_s	1684	NUM	8	DATA	
iunonfreqy4m_u	1752	NUM	8	DATA	
iuothy1_f	1557	NUM	8	DATA	
iuothy2_f	1589	NUM	8	DATA	
iuothy3_f	1621	NUM	8	DATA	
iuothy4_f	1651	NUM	8	DATA	
iuothy4m_n	1719	NUM	8	DATA	
iuothy4m_s	1685	NUM	8	DATA	
iuothy4m_u	1753	NUM	8	DATA	
leny1_f	3077	NUM	8	4	q
leny2_f	3093	NUM	8	4	q



leny3_f	3109	NUM	8	4	q
leny4_f	3125	NUM	8	4	q
lenz_f	3056	NUM	8	4	q
lenz_n	3329	NUM	8	4	q
lenz_s	3299	NUM	8	4	q
lenz_u	3359	NUM	8	4	q
liveallty1_f	3393	NUM	8	5	c
liveallty2_f	3401	NUM	8	5	c
liveallty3_f	3409	NUM	8	5	c
liveallty4_f	3417	NUM	8	5	c
livealltz_f	3388	NUM	8	5	c
livealltzm_n	3443	NUM	8	5	c
livealltzm_s	3434	NUM	8	5	c
livealltzm_u	3452	NUM	8	5	c
livery1_f	2869	NUM	8	3	f
livery2_f	2879	NUM	8	3	f
livery3_f	2889	NUM	8	3	f
livery4_f	2899	NUM	8	3	f
livz_f	2860	NUM	8	3	f
livz_n	3019	NUM	8	3	f
livz_s	3000	NUM	8	3	f
livz_u	3038	NUM	8	3	f
LTC_f	866	CHAR	3	13	j
LTC_modal_f	867	CHAR	1	13	k
ltsy1_f	510	NUM	8	11	g
ltsy2_f	523	NUM	8	11	g
ltsy3_f	536	NUM	8	11	g
ltsy4_f	549	NUM	8	11	g
ltsy4_n	609	NUM	8	11	g
ltsy4_s	592	NUM	8	11	g
ltsy4_u	626	NUM	8	11	g
medicarey1_f	1566	NUM	8	DATA	
medicarey2_f	1598	NUM	8	DATA	
medicarey3_f	1630	NUM	8	DATA	
medicarey4_f	819	NUM	8	13	p
medicarey4_n	852	NUM	8	13	p
medicarey4_s	843	NUM	8	13	p
medicarey4_u	861	NUM	8	13	p
medpendy1_f	1567	NUM	8	DATA	
medpendy2_f	1599	NUM	8	DATA	
medpendy3_f	1631	NUM	8	DATA	
medpendy4_f	820	NUM	8	13	p
medpendy4_n	853	NUM	8	13	p
medpendy4_s	844	NUM	8	13	p

medpendy4_u	862	NUM	8	13	p
medrsnfy1_f	3766	NUM	8	7	b
medrsnfy2_f	3767	NUM	8	7	b
medrsnfy3_f	3768	NUM	8	7	b
medrsnfy4_f	3769	NUM	8	7	b
medrsnfy4m_N	3827	NUM	8	DATA	
medrsnfy4m_S	3798	NUM	8	DATA	
medrsnfy4m_U	3861	NUM	8	DATA	
mefavfmy1_f	2444	NUM	8	2	l
mefavfmy2_f	2510	NUM	8	2	l
mefavfmy3_f	2576	NUM	8	2	l
mefavfmy4_f	2642	NUM	8	2	l
mefavfmy4_n	2774	NUM	8	2	l
mefavfmy4_s	2708	NUM	8	2	l
mefavfmy4_u	2841	NUM	8	2	l
mefcathmy1_f	2446	NUM	8	2	l
mefcathmy2_f	2512	NUM	8	2	l
mefcathmy3_f	2578	NUM	8	2	l
mefcathmy4_f	2644	NUM	8	2	l
mefcathmy4_n	2776	NUM	8	2	l
mefcathmy4_s	2710	NUM	8	2	l
mefcathmy4_u	2843	NUM	8	2	l
mefgraftmy1_f	2445	NUM	8	2	l
mefgraftmy2_f	2511	NUM	8	2	l
mefgraftmy3_f	2577	NUM	8	2	l
mefgraftmy4_f	2643	NUM	8	2	l
mefgraftmy4_n	2775	NUM	8	2	l
mefgraftmy4_s	2709	NUM	8	2	l
mefgraftmy4_u	2842	NUM	8	2	l
mefoumaccessmy1_f	2447	NUM	8	2	l
mefoumaccessmy2_f	2513	NUM	8	2	l
mefoumaccessmy3_f	2579	NUM	8	2	l
mefoumaccessmy4_f	2645	NUM	8	2	l
mefoumaccessmy4_n	2777	NUM	8	2	l
mefoumaccessmy4_s	2711	NUM	8	2	l
mefoumaccessmy4_u	2844	NUM	8	2	l
miiy1_f	3070	NUM	8	4	o
miiy2_f	3086	NUM	8	4	o
miiy3_f	3102	NUM	8	4	o
miiy4_f	3118	NUM	8	4	o
miiz_f	3058	NUM	8	4	o
miiz_n	3331	NUM	8	4	o
miiz_s	3301	NUM	8	4	o
miiz_u	3361	NUM	8	4	o

modal_f	868	CHAR	1	13	e
modcapdy1_f	168	NUM	8	1	k
modcapdy2_f	199	NUM	8	1	k
modcapdy3_f	230	NUM	8	1	k
modcapdy4_f	261	NUM	8	1	k
modcapdy4_n	322	NUM	8	1	k
modcapdy4_s	291	NUM	8	1	k
modcapdy4_u	353	NUM	8	1	k
modccpdy1_f	169	NUM	8	1	k
modccpdy2_f	200	NUM	8	1	k
modccpdy3_f	231	NUM	8	1	k
modccpdy4_f	262	NUM	8	1	k
modccpdy4_n	323	NUM	8	1	k
modccpdy4_s	292	NUM	8	1	k
modccpdy4_u	354	NUM	8	1	k
modhdy1_f	166	NUM	8	1	k
modhdy2_f	197	NUM	8	1	k
modhdy3_f	228	NUM	8	1	k
modhdy4_f	259	NUM	8	1	k
modhdy4_n	320	NUM	8	1	k
modhdy4_s	289	NUM	8	1	k
modhdy4_u	351	NUM	8	1	k
modhhdy1_f	167	NUM	8	1	k
modhhdy2_f	198	NUM	8	1	k
modhhdy3_f	229	NUM	8	1	k
modhhdy4_f	260	NUM	8	1	k
modhhdy4_n	321	NUM	8	1	k
modhhdy4_s	290	NUM	8	1	k
modhhdy4_u	352	NUM	8	1	k
modothry1_f	170	NUM	8	1	k
modothry2_f	201	NUM	8	1	k
modothry3_f	232	NUM	8	1	k
modothry4_f	263	NUM	8	1	k
modothry4_n	324	NUM	8	1	k
modothry4_s	293	NUM	8	1	k
modothry4_u	355	NUM	8	1	k
nativmy1_f	2406	NUM	8	2	d
nativmy2_f	2472	NUM	8	2	d
nativmy3_f	2538	NUM	8	2	d
nativmy4_f	2604	NUM	8	2	d
nativmy4_n	2736	NUM	8	2	d
nativmy4_s	2670	NUM	8	2	d
nativmy4_u	2802	NUM	8	2	d
ncmy1_f	642	NUM	8	12	a

ncmy2_f	667	NUM	8	12	a
ncmy3_f	692	NUM	8	12	a
ncmy4_f	717	NUM	8	12	a
ncmy4m_n	767	NUM	8	12	a
ncmy4m_s	742	NUM	8	12	a
ncmy4m_u	792	NUM	8	12	a
nepnomy1_f	2433	NUM	8	2	s
nepnomy2_f	2499	NUM	8	2	s
nepnomy3_f	2565	NUM	8	2	s
nepnomy4_f	2631	NUM	8	2	s
nepnomy4_n	2763	NUM	8	2	s
nepnomy4_s	2697	NUM	8	2	s
nepnomy4_u	2829	NUM	8	2	s
nephunkmissmy1_f	2437	NUM	8	2	s
nephunkmissmy2_f	2503	NUM	8	2	s
nephunkmissmy3_f	2569	NUM	8	2	s
nephunkmissmy4_f	2635	NUM	8	2	s
nephunkmissmy4_n	2767	NUM	8	2	s
nephunkmissmy4_s	2701	NUM	8	2	s
nephunkmissmy4_u	2834	NUM	8	2	s
nephy12my1_f	2436	NUM	8	2	s
nephy12my2_f	2502	NUM	8	2	s
nephy12my3_f	2568	NUM	8	2	s
nephy12my4_f	2634	NUM	8	2	s
nephy12my4_n	2766	NUM	8	2	s
nephy12my4_s	2700	NUM	8	2	s
nephy12my4_u	2832	NUM	8	2	s
nephy612my1_f	2435	NUM	8	2	s
nephy612my2_f	2501	NUM	8	2	s
nephy612my3_f	2567	NUM	8	2	s
nephy612my4_f	2633	NUM	8	2	s
nephy612my4_n	2765	NUM	8	2	s
nephy612my4_s	2699	NUM	8	2	s
nephy612my4_u	2831	NUM	8	2	s
nephy6my1_f	2434	NUM	8	2	s
nephy6my2_f	2500	NUM	8	2	s
nephy6my3_f	2566	NUM	8	2	s
nephy6my4_f	2632	NUM	8	2	s
nephy6my4_n	2764	NUM	8	2	s
nephy6my4_s	2698	NUM	8	2	s
nephy6my4_u	2830	NUM	8	2	s
nephyunkmy4_u	2833	NUM	8	2	Foot
NETWORK	5	CHAR	2	ID	
nh_acary1_f	1865	NUM	8	15	4o

nh_acary2_f	1899	NUM	8	15	4o
nh_acary3_f	1933	NUM	8	15	4o
nh_acary4_f	1967	NUM	8	15	4o
nh_acary4_n	2255	NUM	8	15	4o
nh_acary4_s	2180	NUM	8	15	4o
nh_acary4_u	2330	NUM	8	15	4o
nh_acdry1_f	1864	NUM	8	15	4o
nh_acdry2_f	1898	NUM	8	15	4o
nh_acdry3_f	1932	NUM	8	15	4o
nh_acdry4_f	1966	NUM	8	15	4o
nh_acdry4_n	2254	NUM	8	15	4o
nh_acdry4_s	2179	NUM	8	15	4o
nh_acdry4_u	2329	NUM	8	15	4o
nh_achfy1_f	1863	NUM	8	15	4o
nh_achfy2_f	1897	NUM	8	15	4o
nh_achfy3_f	1931	NUM	8	15	4o
nh_achfy4_f	1965	NUM	8	15	4o
nh_achfy4_n	2253	NUM	8	15	4o
nh_achfy4_s	2178	NUM	8	15	4o
nh_achfy4_u	2328	NUM	8	15	4o
nh_age1y1_f	1983	NUM	8	15	1c
nh_age1y2_f	2011	NUM	8	15	1c
nh_age1y3_f	2039	NUM	8	15	1c
nh_age1y4_f	2067	NUM	8	15	1c
nh_age1y4_n	2271	NUM	8	15	1c
nh_age1y4_s	2196	NUM	8	15	1c
nh_age1y4_u	2346	NUM	8	15	1c
nh_age2y1_f	1984	NUM	8	15	1c
nh_age2y2_f	2012	NUM	8	15	1c
nh_age2y3_f	2040	NUM	8	15	1c
nh_age2y4_f	2068	NUM	8	15	1c
nh_age2y4_n	2272	NUM	8	15	1c
nh_age2y4_s	2197	NUM	8	15	1c
nh_age2y4_u	2347	NUM	8	15	1c
nh_age3y1_f	1985	NUM	8	15	1c
nh_age3y2_f	2013	NUM	8	15	1c
nh_age3y3_f	2041	NUM	8	15	1c
nh_age3y4_f	2069	NUM	8	15	1c
nh_age3y4_n	2273	NUM	8	15	1c
nh_age3y4_s	2198	NUM	8	15	1c
nh_age3y4_u	2348	NUM	8	15	1c
nh_allmdcrmy1_f	2097	NUM	8	15	2g
nh_allmdcrmy2_f	2114	NUM	8	15	2g
nh_allmdcrmy3_f	2131	NUM	8	15	2g

nh_allmdcrmy4_f	2148	NUM	8	15	2g
nh_allmdcrmy4_n	2298	NUM	8	15	2g
nh_allmdcrmy4_s	2223	NUM	8	15	2g
nh_allmdcrmy4_u	2373	NUM	8	15	2g
nh_avfpresentmy1_f	2105	NUM	8	15	2m
nh_avfpresentmy2_f	2122	NUM	8	15	2m
nh_avfpresentmy3_f	2139	NUM	8	15	2m
nh_avfpresentmy4_f	2156	NUM	8	15	2m
nh_avfpresentmy4_n	2306	NUM	8	15	2m
nh_avfpresentmy4_s	2231	NUM	8	15	2m
nh_avfpresentmy4_u	2381	NUM	8	15	2m
nh_clmcamy1_f	1874	NUM	8	15	12b
nh_clmcamy2_f	1908	NUM	8	15	12b
nh_clmcamy3_f	1942	NUM	8	15	12b
nh_clmcamy4_f	1976	NUM	8	15	12b
nh_clmcamy4_n	2264	NUM	8	15	12b
nh_clmcamy4_s	2189	NUM	8	15	12b
nh_clmcamy4_u	2339	NUM	8	15	12b
nh_clmcdmy1_f	1875	NUM	8	15	12b
nh_clmcdmy2_f	1909	NUM	8	15	12b
nh_clmcdmy3_f	1943	NUM	8	15	12b
nh_clmcdmy4_f	1977	NUM	8	15	12b
nh_clmcdmy4_n	2265	NUM	8	15	12b
nh_clmcdmy4_s	2190	NUM	8	15	12b
nh_clmcdmy4_u	2340	NUM	8	15	12b
nh_clmchfmy1_f	1877	NUM	8	15	12b
nh_clmchfmy2_f	1911	NUM	8	15	12b
nh_clmchfmy3_f	1945	NUM	8	15	12b
nh_clmchfmy4_f	1979	NUM	8	15	12b
nh_clmchfmy4_n	2267	NUM	8	15	12b
nh_clmchfmy4_s	2192	NUM	8	15	12b
nh_clmchfmy4_u	2342	NUM	8	15	12b
nh_clmcvdmy1_f	1876	NUM	8	15	12b
nh_clmcvdmy2_f	1910	NUM	8	15	12b
nh_clmcvdmy3_f	1944	NUM	8	15	12b
nh_clmcvdmy4_f	1978	NUM	8	15	12b
nh_clmcvdmy4_n	2266	NUM	8	15	12b
nh_clmcvdmy4_s	2191	NUM	8	15	12b
nh_clmcvdmy4_u	2341	NUM	8	15	12b
nh_clmhpbmy1_f	1868	NUM	8	15	12b
nh_clmhpbmy2_f	1902	NUM	8	15	12b
nh_clmhpbmy3_f	1936	NUM	8	15	12b
nh_clmhpbmy4_f	1970	NUM	8	15	12b
nh_clmhpbmy4_n	2258	NUM	8	15	12b

nh_clmhepbmy4_s	2183	NUM	8	15	12b
nh_clmhepbmy4_u	2333	NUM	8	15	12b
nh_clmhemothmy1_f	1869	NUM	8	15	12b
nh_clmhemothmy2_f	1903	NUM	8	15	12b
nh_clmhemothmy3_f	1937	NUM	8	15	12b
nh_clmhemothmy4_f	1971	NUM	8	15	12b
nh_clmhemothmy4_n	2259	NUM	8	15	12b
nh_clmhemothmy4_s	2184	NUM	8	15	12b
nh_clmhemothmy4_u	2334	NUM	8	15	12b
nh_clmhivaidmy1_f	1866	NUM	8	15	12b
nh_clmhivaidmy2_f	1900	NUM	8	15	12b
nh_clmhivaidmy3_f	1934	NUM	8	15	12b
nh_clmhivaidmy4_f	1968	NUM	8	15	12b
nh_clmhivaidmy4_n	2256	NUM	8	15	12b
nh_clmhivaidmy4_s	2181	NUM	8	15	12b
nh_clmhivaidmy4_u	2331	NUM	8	15	12b
nh_clmihdmy1_f	1878	NUM	8	15	12b
nh_clmihdmy2_f	1912	NUM	8	15	12b
nh_clmihdmy3_f	1946	NUM	8	15	12b
nh_clmihdmy4_f	1980	NUM	8	15	12b
nh_clmihdmy4_n	2268	NUM	8	15	12b
nh_clmihdmy4_s	2193	NUM	8	15	12b
nh_clmihdmy4_u	2343	NUM	8	15	12b
nh_clminfmy1_f	1873	NUM	8	15	12b
nh_clminfmy2_f	1907	NUM	8	15	12b
nh_clminfmy3_f	1941	NUM	8	15	12b
nh_clminfmy4_f	1975	NUM	8	15	12b
nh_clminfmy4_n	2263	NUM	8	15	12b
nh_clminfmy4_s	2188	NUM	8	15	12b
nh_clminfmy4_u	2338	NUM	8	15	12b
nh_clminfvamy1_f	1867	NUM	8	15	12b
nh_clminfvamy2_f	1901	NUM	8	15	12b
nh_clminfvamy3_f	1935	NUM	8	15	12b
nh_clminfvamy4_f	1969	NUM	8	15	12b
nh_clminfvamy4_n	2257	NUM	8	15	12b
nh_clminfvamy4_s	2182	NUM	8	15	12b
nh_clminfvamy4_u	2332	NUM	8	15	12b
nh_clmmimy1_f	1879	NUM	8	15	12b
nh_clmmimy2_f	1913	NUM	8	15	12b
nh_clmmimy3_f	1947	NUM	8	15	12b
nh_clmmimy4_f	1981	NUM	8	15	12b
nh_clmmimy4_n	2269	NUM	8	15	12b
nh_clmmimy4_s	2194	NUM	8	15	12b
nh_clmmimy4_u	2344	NUM	8	15	12b

nh_clmmstinfmy1_f	1870	NUM	8	15	12b
nh_clmmstinfmy2_f	1904	NUM	8	15	12b
nh_clmmstinfmy3_f	1938	NUM	8	15	12b
nh_clmmstinfmy4_f	1972	NUM	8	15	12b
nh_clmmstinfmy4_n	2260	NUM	8	15	12b
nh_clmmstinfmy4_s	2185	NUM	8	15	12b
nh_clmmstinfmy4_u	2335	NUM	8	15	12b
nh_clmpnemy1_f	1871	NUM	8	15	12b
nh_clmpnemy2_f	1905	NUM	8	15	12b
nh_clmpnemy3_f	1939	NUM	8	15	12b
nh_clmpnemy4_f	1973	NUM	8	15	12b
nh_clmpnemy4_n	2261	NUM	8	15	12b
nh_clmpnemy4_s	2186	NUM	8	15	12b
nh_clmpnemy4_u	2336	NUM	8	15	12b
nh_clmpvdmy1_f	1880	NUM	8	15	12b
nh_clmpvdmy2_f	1914	NUM	8	15	12b
nh_clmpvdmy3_f	1948	NUM	8	15	12b
nh_clmpvdmy4_f	1982	NUM	8	15	12b
nh_clmpvdmy4_n	2270	NUM	8	15	12b
nh_clmpvdmy4_s	2195	NUM	8	15	12b
nh_clmpvdmy4_u	2345	NUM	8	15	12b
nh_clmtbmy1_f	1872	NUM	8	15	12b
nh_clmtbmy2_f	1906	NUM	8	15	12b
nh_clmtbmy3_f	1940	NUM	8	15	12b
nh_clmtbmy4_f	1974	NUM	8	15	12b
nh_clmtbmy4_n	2262	NUM	8	15	12b
nh_clmtbmy4_s	2187	NUM	8	15	12b
nh_clmtbmy4_u	2337	NUM	8	15	12b
nh_CWhddenomy1_f	1791	NUM	8	15	9a
nh_CWhddenomy2_f	1794	NUM	8	15	9a
nh_CWhddenomy3_f	1797	NUM	8	15	9a
nh_CWhddenomy4_f	1800	NUM	8	15	9a
nh_CWhdesarxy1_f	1818	NUM	8	15	8e
nh_CWhdesarxy2_f	1822	NUM	8	15	8e
nh_CWhdesarxy3_f	1826	NUM	8	15	8e
nh_CWhdesarxy4_f	1830	NUM	8	15	8e
nh_CWhdesarxy4_n	2243	NUM	8	15	8e
nh_CWhdesarxy4_s	2168	NUM	8	15	8e
nh_CWhdesarxy4_u	2318	NUM	8	15	8e
nh_CWhdhgb1y1_f	1817	NUM	8	15	8d
nh_CWhdhgb1y2_f	1821	NUM	8	15	8d
nh_CWhdhgb1y3_f	1825	NUM	8	15	8d
nh_CWhdhgb1y4_f	1829	NUM	8	15	8d
nh_CWhdhgb1y4_n	2242	NUM	8	15	8d



nh_CWhdhgb1y4_s	2167	NUM	8	15	8d
nh_CWhdhgb1y4_u	2317	NUM	8	15	8d
nh_CWhdktv1y1_f	1793	NUM	8	15	9k
nh_CWhdktv1y2_f	1796	NUM	8	15	9k
nh_CWhdktv1y3_f	1799	NUM	8	15	9k
nh_CWhdktv1y4_f	1802	NUM	8	15	9k
nh_CWhdktv1y4_n	2240	NUM	8	15	9k
nh_CWhdktv1y4_s	2165	NUM	8	15	9k
nh_CWhdktv1y4_u	2315	NUM	8	15	9k
nh_CWhdmthdenomy1_f	1792	NUM	8	15	9b
nh_CWhdmthdenomy2_f	1795	NUM	8	15	9b
nh_CWhdmthdenomy3_f	1798	NUM	8	15	9b
nh_CWhdmthdenomy4_f	1801	NUM	8	15	9b
nh_CWhdptdenomy1_f	1815	NUM	8	15	8a
nh_CWhdptdenomy2_f	1819	NUM	8	15	8a
nh_CWhdptdenomy3_f	1823	NUM	8	15	8a
nh_CWhdptdenomy4_f	1827	NUM	8	15	8a
nh_CWhdptmthdenomy1_f	1816	NUM	8	15	8b
nh_CWhdptmthdenomy2_f	1820	NUM	8	15	8b
nh_CWhdptmthdenomy3_f	1824	NUM	8	15	8b
nh_CWhdptmthdenomy4_f	1828	NUM	8	15	8b
nh_CWpddenomy1_f	1803	NUM	8	15	9l
nh_CWpddenomy2_f	1806	NUM	8	15	9l
nh_CWpddenomy3_f	1809	NUM	8	15	9l
nh_CWpddenomy4_f	1812	NUM	8	15	9l
nh_CWpdesarxy1_f	1834	NUM	8	15	8j
nh_CWpdesarxy2_f	1838	NUM	8	15	8j
nh_CWpdesarxy3_f	1842	NUM	8	15	8j
nh_CWpdesarxy4_f	1846	NUM	8	15	8j
nh_CWpdesarxy4_n	2245	NUM	8	15	8j
nh_CWpdesarxy4_s	2170	NUM	8	15	8j
nh_CWpdesarxy4_u	2320	NUM	8	15	8j
nh_CWpdhgb1y1_f	1833	NUM	8	15	8i
nh_CWpdhgb1y2_f	1837	NUM	8	15	8i
nh_CWpdhgb1y3_f	1841	NUM	8	15	8i
nh_CWpdhgb1y4_f	1845	NUM	8	15	8i
nh_CWpdhgb1y4_n	2244	NUM	8	15	8i
nh_CWpdhgb1y4_s	2169	NUM	8	15	8i
nh_CWpdhgb1y4_u	2319	NUM	8	15	8i
nh_CWpdktv1y1_f	1805	NUM	8	15	9o
nh_CWpdktv1y2_f	1808	NUM	8	15	9o
nh_CWpdktv1y3_f	1811	NUM	8	15	9o
nh_CWpdktv1y4_f	1814	NUM	8	15	9o
nh_CWpdktv1y4_n	2241	NUM	8	15	9o

nh_CWpdktv1y4_s	2166	NUM	8	15	9o
nh_CWpdktv1y4_u	2316	NUM	8	15	9o
nh_CWpdmthdenomy1_f	1804	NUM	8	15	9m
nh_CWpdmthdenomy2_f	1807	NUM	8	15	9m
nh_CWpdmthdenomy3_f	1810	NUM	8	15	9m
nh_CWpdmthdenomy4_f	1813	NUM	8	15	9m
nh_CWpdptdenomy1_f	1831	NUM	8	15	8f
nh_CWpdptdenomy2_f	1835	NUM	8	15	8f
nh_CWpdptdenomy3_f	1839	NUM	8	15	8f
nh_CWpdptdenomy4_f	1843	NUM	8	15	8f
nh_CWpdptmthdenomy1_f	1832	NUM	8	15	8g
nh_CWpdptmthdenomy2_f	1836	NUM	8	15	8g
nh_CWpdptmthdenomy3_f	1840	NUM	8	15	8g
nh_CWpdptmthdenomy4_f	1844	NUM	8	15	8g
nh_deay1_f	1849	NUM	8	15	3c
nh_deay2_f	1883	NUM	8	15	3c
nh_deay3_f	1917	NUM	8	15	3c
nh_deay4_f	1951	NUM	8	15	3c
nh_dis1y1_f	1986	NUM	8	15	1g
nh_dis1y2_f	2014	NUM	8	15	1g
nh_dis1y3_f	2042	NUM	8	15	1g
nh_dis1y4_f	2070	NUM	8	15	1g
nh_dis1y4_n	2274	NUM	8	15	1g
nh_dis1y4_s	2199	NUM	8	15	1g
nh_dis1y4_u	2349	NUM	8	15	1g
nh_dis2y1_f	1987	NUM	8	15	1g
nh_dis2y2_f	2015	NUM	8	15	1g
nh_dis2y3_f	2043	NUM	8	15	1g
nh_dis2y4_f	2071	NUM	8	15	1g
nh_dis2y4_n	2275	NUM	8	15	1g
nh_dis2y4_s	2200	NUM	8	15	1g
nh_dis2y4_u	2350	NUM	8	15	1g
nh_dis3y1_f	1988	NUM	8	15	1g
nh_dis3y2_f	2016	NUM	8	15	1g
nh_dis3y3_f	2044	NUM	8	15	1g
nh_dis3y4_f	2072	NUM	8	15	1g
nh_dis3y4_n	2276	NUM	8	15	1g
nh_dis3y4_s	2201	NUM	8	15	1g
nh_dis3y4_u	2351	NUM	8	15	1g
nh_dis4y1_f	1989	NUM	8	15	1g
nh_dis4y2_f	2017	NUM	8	15	1g
nh_dis4y3_f	2045	NUM	8	15	1g
nh_dis4y4_f	2073	NUM	8	15	1g
nh_dis4y4_n	2277	NUM	8	15	1g

nh_dis4y4_s	2202	NUM	8	15	1g
nh_dis4y4_u	2352	NUM	8	15	1g
nh_dis5y1_f	1990	NUM	8	15	1g
nh_dis5y2_f	2018	NUM	8	15	1g
nh_dis5y3_f	2046	NUM	8	15	1g
nh_dis5y4_f	2074	NUM	8	15	1g
nh_dis5y4_n	2278	NUM	8	15	1g
nh_dis5y4_s	2203	NUM	8	15	1g
nh_dis5y4_u	2353	NUM	8	15	1g
nh_dyy1_f	1848	NUM	8	15	3b
nh_dyy2_f	1882	NUM	8	15	3b
nh_dyy3_f	1916	NUM	8	15	3b
nh_dyy4_f	1950	NUM	8	15	3b
nh_eth1y1_f	1996	NUM	8	15	1f
nh_eth1y2_f	2024	NUM	8	15	1f
nh_eth1y3_f	2052	NUM	8	15	1f
nh_eth1y4_f	2080	NUM	8	15	1f
nh_eth1y4_n	2284	NUM	8	15	1f
nh_eth1y4_s	2209	NUM	8	15	1f
nh_eth1y4_u	2359	NUM	8	15	1f
nh_eth2y1_f	1997	NUM	8	15	1f
nh_eth2y2_f	2025	NUM	8	15	1f
nh_eth2y3_f	2053	NUM	8	15	1f
nh_eth2y4_f	2081	NUM	8	15	1f
nh_eth2y4_n	2285	NUM	8	15	1f
nh_eth2y4_s	2210	NUM	8	15	1f
nh_eth2y4_u	2360	NUM	8	15	1f
nh_eth3y1_f	1998	NUM	8	15	1f
nh_eth3y2_f	2026	NUM	8	15	1f
nh_eth3y3_f	2054	NUM	8	15	1f
nh_eth3y4_f	2082	NUM	8	15	1f
nh_eth3y4_n	2286	NUM	8	15	1f
nh_eth3y4_s	2211	NUM	8	15	1f
nh_eth3y4_u	2361	NUM	8	15	1f
nh_exdy1_f	1850	NUM	8	15	3d
nh_exdy2_f	1884	NUM	8	15	3d
nh_exdy3_f	1918	NUM	8	15	3d
nh_exdy4_f	1952	NUM	8	15	3d
nh_exty1_f	1854	NUM	8	15	4j
nh_exty2_f	1888	NUM	8	15	4j
nh_exty3_f	1922	NUM	8	15	4j
nh_exty4_f	1956	NUM	8	15	4j
nh_hdy1_f	1852	NUM	8	15	4b
nh_hdy2_f	1886	NUM	8	15	4b

nh_hdyy3_f	1920	NUM	8	15	4b
nh_hdyy4_f	1954	NUM	8	15	4b
nh_hemomy1_f	2096	NUM	8	15	2k
nh_hemomy2_f	2113	NUM	8	15	2k
nh_hemomy3_f	2130	NUM	8	15	2k
nh_hemomy4_f	2147	NUM	8	15	2k
nh_htay1_f	1853	NUM	8	15	4i
nh_htay2_f	1887	NUM	8	15	4i
nh_htay3_f	1921	NUM	8	15	4i
nh_htay4_f	1955	NUM	8	15	4i
nh_insempmy1_f	2099	NUM	8	15	2g
nh_insempmy2_f	2116	NUM	8	15	2g
nh_insempmy3_f	2133	NUM	8	15	2g
nh_insempmy4_f	2150	NUM	8	15	2g
nh_insempmy4_n	2300	NUM	8	15	2g
nh_insempmy4_s	2225	NUM	8	15	2g
nh_insempmy4_u	2375	NUM	8	15	2g
nh_insmcdmy1_f	2098	NUM	8	15	2g
nh_insmcdmy2_f	2115	NUM	8	15	2g
nh_insmcdmy3_f	2132	NUM	8	15	2g
nh_insmcdmy4_f	2149	NUM	8	15	2g
nh_insmcdmy4_n	2299	NUM	8	15	2g
nh_insmcdmy4_s	2224	NUM	8	15	2g
nh_insmcdmy4_u	2374	NUM	8	15	2g
nh_insnonthmy1_f	2100	NUM	8	15	2g
nh_insnonthmy2_f	2117	NUM	8	15	2g
nh_insnonthmy3_f	2134	NUM	8	15	2g
nh_insnonthmy4_f	2151	NUM	8	15	2g
nh_insnonthmy4_n	2301	NUM	8	15	2g
nh_insnonthmy4_s	2226	NUM	8	15	2g
nh_insnonthmy4_u	2376	NUM	8	15	2g
nh_ltcy1_f	1778	NUM	8	15	11g
nh_ltcy2_f	1782	NUM	8	15	11g
nh_ltcy3_f	1786	NUM	8	15	11g
nh_ltcy4_f	1790	NUM	8	15	11g
nh_ltcy4_n	2239	NUM	8	15	11g
nh_ltcy4_s	2164	NUM	8	15	11g
nh_ltcy4_u	2314	NUM	8	15	11g
nh_mcDeaq1_f	55	NUM	8	C2	4
nh_mcDeaq2_f	66	NUM	8	C2	4
nh_mcDeaq3_f	77	NUM	8	C2	4
nh_mcDeaq4_f	88	NUM	8	C2	4
nh_mcDeay3_f	110	NUM	8	C2	4
nh_mcEcovDeaPq1_f	57	NUM	8	C2	5

nh_mcEcovDeaPq2_f	68	NUM	8	C2	5
nh_mcEcovDeaPq3_f	79	NUM	8	C2	5
nh_mcEcovDeaPq4_f	90	NUM	8	C2	5
nh_mcEcovDeaPq4_n	130	NUM	8	C2	5
nh_mcEcovDeaPq4_s	122	NUM	8	C2	5
nh_mcEcovDeaPq4_u	138	NUM	8	C2	5
nh_mcEcovDeaPy3_f	112	NUM	8	C2	5
nh_mcEcovDeaq1_f	56	NUM	8	C2	5
nh_mcEcovDeaq2_f	67	NUM	8	C2	5
nh_mcEcovDeaq3_f	78	NUM	8	C2	5
nh_mcEcovDeaq4_f	89	NUM	8	C2	5
nh_mcEcovDeay3_f	111	NUM	8	C2	5
nh_mcEcovHosPq1_f	60	NUM	8	C2	7
nh_mcEcovHosPq2_f	71	NUM	8	C2	7
nh_mcEcovHosPq3_f	82	NUM	8	C2	7
nh_mcEcovHosPq4_f	93	NUM	8	C2	7
nh_mcEcovHosPq4_n	131	NUM	8	C2	7
nh_mcEcovHosPq4_s	123	NUM	8	C2	7
nh_mcEcovHosPq4_u	139	NUM	8	C2	7
nh_mcEcovHosPy3_f	115	NUM	8	C2	7
nh_mcEcovHosq1_f	59	NUM	8	C2	7
nh_mcEcovHosq2_f	70	NUM	8	C2	7
nh_mcEcovHosq3_f	81	NUM	8	C2	7
nh_mcEcovHosq4_f	92	NUM	8	C2	7
nh_mcEcovHosy3_f	114	NUM	8	C2	7
nh_mcEcovpatPq1_f	54	NUM	8	C2	2
nh_mcEcovpatPq2_f	65	NUM	8	C2	2
nh_mcEcovpatPq3_f	76	NUM	8	C2	2
nh_mcEcovpatPq4_f	87	NUM	8	C2	2
nh_mcEcovpatPq4_n	129	NUM	8	C2	2
nh_mcEcovpatPq4_s	121	NUM	8	C2	2
nh_mcEcovpatPq4_u	137	NUM	8	C2	2
nh_mcEcovpatPy3_f	109	NUM	8	C2	2
nh_mcEcovpatq1_f	53	NUM	8	C2	2
nh_mcEcovpatq2_f	64	NUM	8	C2	2
nh_mcEcovpatq3_f	75	NUM	8	C2	2
nh_mcEcovpatq4_f	86	NUM	8	C2	2
nh_mcEcovpaty3_f	108	NUM	8	C2	2
nh_mcFcovpatPq1_f	52	NUM	8	C2	3
nh_mcFcovpatPq2_f	63	NUM	8	C2	3
nh_mcFcovpatPq3_f	74	NUM	8	C2	3
nh_mcFcovpatPq4_f	85	NUM	8	C2	3
nh_mcFcovpatPq4_n	128	NUM	8	C2	3
nh_mcFcovpatPq4_s	120	NUM	8	C2	3

nh_mcFcovpatPq4_u	136	NUM	8	C2	3
nh_mcFcovpatPy3_f	107	NUM	8	C2	3
nh_mcFcovpatq1_f	51	NUM	8	C2	3
nh_mcFcovpatq2_f	62	NUM	8	C2	3
nh_mcFcovpatq3_f	73	NUM	8	C2	3
nh_mcFcovpatq4_f	84	NUM	8	C2	3
nh_mcFcovpaty3_f	106	NUM	8	C2	3
nh_mcHosq1_f	58	NUM	8	C2	6
nh_mcHosq2_f	69	NUM	8	C2	6
nh_mcHosq3_f	80	NUM	8	C2	6
nh_mcHosq4_f	91	NUM	8	C2	6
nh_mchHosy3_f	113	NUM	8	C2	6
nh_mcpatq1_f	50	NUM	8	C2	1
nh_mcpatq2_f	61	NUM	8	C2	1
nh_mcpatq3_f	72	NUM	8	C2	1
nh_mcpatq4_f	83	NUM	8	C2	1
nh_mcpaty3_f	105	NUM	8	C2	1
nh_mefavfmy1_f	2101	NUM	8	15	2
nh_mefavfmy2_f	2118	NUM	8	15	2
nh_mefavfmy3_f	2135	NUM	8	15	2
nh_mefavfmy4_f	2152	NUM	8	15	2
nh_mefavfmy4_n	2302	NUM	8	15	2
nh_mefavfmy4_s	2227	NUM	8	15	2
nh_mefavfmy4_u	2377	NUM	8	15	2
nh_mefcathmy1_f	2103	NUM	8	15	2
nh_mefcathmy2_f	2120	NUM	8	15	2
nh_mefcathmy3_f	2137	NUM	8	15	2
nh_mefcathmy4_f	2154	NUM	8	15	2
nh_mefcathmy4_n	2304	NUM	8	15	2
nh_mefcathmy4_s	2229	NUM	8	15	2
nh_mefcathmy4_u	2379	NUM	8	15	2
nh_mefgraftmy1_f	2102	NUM	8	15	2
nh_mefgraftmy2_f	2119	NUM	8	15	2
nh_mefgraftmy3_f	2136	NUM	8	15	2
nh_mefgraftmy4_f	2153	NUM	8	15	2
nh_mefgraftmy4_n	2303	NUM	8	15	2
nh_mefgraftmy4_s	2228	NUM	8	15	2
nh_mefgraftmy4_u	2378	NUM	8	15	2
nh_mefoumaccessmy1_f	2104	NUM	8	15	2
nh_mefoumaccessmy2_f	2121	NUM	8	15	2
nh_mefoumaccessmy3_f	2138	NUM	8	15	2
nh_mefoumaccessmy4_f	2155	NUM	8	15	2
nh_mefoumaccessmy4_n	2305	NUM	8	15	2
nh_mefoumaccessmy4_s	2230	NUM	8	15	2

nh_mefoumaccessmy4_u	2380	NUM	8	15	2l
nh_miiy1_f	1862	NUM	8	15	4o
nh_miiy2_f	1896	NUM	8	15	4o
nh_miiy3_f	1930	NUM	8	15	4o
nh_miiy4_f	1964	NUM	8	15	4o
nh_miiy4_n	2252	NUM	8	15	4o
nh_miiy4_s	2177	NUM	8	15	4o
nh_miiy4_u	2327	NUM	8	15	4o
nh_modcapdy1_f	2007	NUM	8	15	1k
nh_modcapdy2_f	2035	NUM	8	15	1k
nh_modcapdy3_f	2063	NUM	8	15	1k
nh_modcapdy4_f	2091	NUM	8	15	1k
nh_modcapdy4_n	2295	NUM	8	15	1k
nh_modcapdy4_s	2220	NUM	8	15	1k
nh_modcapdy4_u	2370	NUM	8	15	1k
nh_modccpdy1_f	2008	NUM	8	15	1k
nh_modccpdy2_f	2036	NUM	8	15	1k
nh_modccpdy3_f	2064	NUM	8	15	1k
nh_modccpdy4_f	2092	NUM	8	15	1k
nh_modccpdy4_n	2296	NUM	8	15	1k
nh_modccpdy4_s	2221	NUM	8	15	1k
nh_modccpdy4_u	2371	NUM	8	15	1k
nh_modhdy1_f	2005	NUM	8	15	1k
nh_modhdy2_f	2033	NUM	8	15	1k
nh_modhdy3_f	2061	NUM	8	15	1k
nh_modhdy4_f	2089	NUM	8	15	1k
nh_modhdy4_n	2293	NUM	8	15	1k
nh_modhdy4_s	2218	NUM	8	15	1k
nh_modhdy4_u	2368	NUM	8	15	1k
nh_modhhd1_f	2006	NUM	8	15	1k
nh_modhhd2_f	2034	NUM	8	15	1k
nh_modhhd3_f	2062	NUM	8	15	1k
nh_modhhd4_f	2090	NUM	8	15	1k
nh_modhhd4_n	2294	NUM	8	15	1k
nh_modhhd4_s	2219	NUM	8	15	1k
nh_modhhd4_u	2369	NUM	8	15	1k
nh_modothy1_f	2009	NUM	8	15	1k
nh_modothy2_f	2037	NUM	8	15	1k
nh_modothy3_f	2065	NUM	8	15	1k
nh_modothy4_f	2093	NUM	8	15	1k
nh_modothy4_n	2297	NUM	8	15	1k
nh_modothy4_s	2222	NUM	8	15	1k
nh_modothy4_u	2372	NUM	8	15	1k
nh_ncmy1_f	1855	NUM	8	15	12a

nh_ncmy2_f	1889	NUM	8	15	12a
nh_ncmy3_f	1923	NUM	8	15	12a
nh_ncmy4_f	1957	NUM	8	15	12a
nh_nepnomy1_f	2106	NUM	8	15	2s
nh_nepnomy2_f	2123	NUM	8	15	2s
nh_nepnomy3_f	2140	NUM	8	15	2s
nh_nepnomy4_f	2157	NUM	8	15	2s
nh_nepnomy4_n	2307	NUM	8	15	2s
nh_nepnomy4_s	2232	NUM	8	15	2s
nh_nepnomy4_u	2382	NUM	8	15	2s
nh_nephunkmissmy1_f	2110	NUM	8	15	2s
nh_nephunkmissmy2_f	2127	NUM	8	15	2s
nh_nephunkmissmy3_f	2144	NUM	8	15	2s
nh_nephunkmissmy4_f	2161	NUM	8	15	2s
nh_nephunkmissmy4_n	2311	NUM	8	15	2s
nh_nephunkmissmy4_s	2236	NUM	8	15	2s
nh_nephunkmissmy4_u	2386	NUM	8	15	2s
nh_nephy12my1_f	2109	NUM	8	15	2s
nh_nephy12my2_f	2126	NUM	8	15	2s
nh_nephy12my3_f	2143	NUM	8	15	2s
nh_nephy12my4_f	2160	NUM	8	15	2s
nh_nephy12my4_n	2310	NUM	8	15	2s
nh_nephy12my4_s	2235	NUM	8	15	2s
nh_nephy12my4_u	2385	NUM	8	15	2s
nh_nephy612my1_f	2108	NUM	8	15	2s
nh_nephy612my2_f	2125	NUM	8	15	2s
nh_nephy612my3_f	2142	NUM	8	15	2s
nh_nephy612my4_f	2159	NUM	8	15	2s
nh_nephy612my4_n	2309	NUM	8	15	2s
nh_nephy612my4_s	2234	NUM	8	15	2s
nh_nephy612my4_u	2384	NUM	8	15	2s
nh_nephy6my1_f	2107	NUM	8	15	2s
nh_nephy6my2_f	2124	NUM	8	15	2s
nh_nephy6my3_f	2141	NUM	8	15	2s
nh_nephy6my4_f	2158	NUM	8	15	2s
nh_nephy6my4_n	2308	NUM	8	15	2s
nh_nephy6my4_s	2233	NUM	8	15	2s
nh_nephy6my4_u	2383	NUM	8	15	2s
nh_nmy1_f	2095	NUM	8	15	2a
nh_nmy2_f	2112	NUM	8	15	2a
nh_nmy3_f	2129	NUM	8	15	2a
nh_nmy4_f	2146	NUM	8	15	2a
nh_obdry1_f	1856	NUM	8	15	3c/1
nh_obdry2_f	1890	NUM	8	15	3c/1



nh_obdry3_f	1924	NUM	8	15	3c/1
nh_obdry4_f	1958	NUM	8	15	3c/1
nh_obdry4_n	2246	NUM	8	15	3c/1
nh_obdry4_s	2171	NUM	8	15	3c/1
nh_obdry4_u	2321	NUM	8	15	3c/1
nh_obhtry1_f	1859	NUM	8	15	4i/1
nh_obhtry2_f	1893	NUM	8	15	4i/1
nh_obhtry3_f	1927	NUM	8	15	4i/1
nh_obhtry4_f	1961	NUM	8	15	4i/1
nh_obhtry4_n	2249	NUM	8	15	4i/1
nh_obhtry4_s	2174	NUM	8	15	4i/1
nh_obhtry4_u	2324	NUM	8	15	4i/1
nh_pahy1_f	2010	NUM	8	15	1a
nh_pahy2_f	2038	NUM	8	15	1a
nh_pahy3_f	2066	NUM	8	15	1a
nh_pahy4_f	2094	NUM	8	15	1a
nh_phdvapty1_f	1775	NUM	8	15	11a
nh_phdvapty2_f	1779	NUM	8	15	11a
nh_phdvapty3_f	1783	NUM	8	15	11a
nh_phdvapty4_f	1787	NUM	8	15	11a
nh_phdy1_f	1776	NUM	8	15	11b
nh_phdy2_f	1780	NUM	8	15	11b
nh_phdy3_f	1784	NUM	8	15	11b
nh_phdy4_f	1788	NUM	8	15	11b
nh_ppavfy1_f	1777	NUM	8	15	11c
nh_ppavfy2_f	1781	NUM	8	15	11c
nh_ppavfy3_f	1785	NUM	8	15	11c
nh_ppavfy4_f	1789	NUM	8	15	11c
nh_ppavfy4_n	2238	NUM	8	15	11c
nh_ppavfy4_s	2163	NUM	8	15	11c
nh_ppavfy4_u	2313	NUM	8	15	11c
nh_ptinfyfy1_f	2111	NUM	8	15	2t
nh_ptinfyfy2_f	2128	NUM	8	15	2t
nh_ptinfyfy3_f	2145	NUM	8	15	2t
nh_ptinfyfy4_f	2162	NUM	8	15	2t
nh_ptinfyfy4_n	2312	NUM	8	15	2t
nh_ptinfyfy4_s	2237	NUM	8	15	2t
nh_ptinfyfy4_u	2387	NUM	8	15	2t
nh_rac1y1_f	1991	NUM	8	15	1e
nh_rac1y2_f	2019	NUM	8	15	1e
nh_rac1y3_f	2047	NUM	8	15	1e
nh_rac1y4_f	2075	NUM	8	15	1e
nh_rac1y4_n	2279	NUM	8	15	1e
nh_rac1y4_s	2204	NUM	8	15	1e

nh_rac1y4_u	2354	NUM	8	15	1e
nh_rac2y1_f	1992	NUM	8	15	1e
nh_rac2y2_f	2020	NUM	8	15	1e
nh_rac2y3_f	2048	NUM	8	15	1e
nh_rac2y4_f	2076	NUM	8	15	1e
nh_rac2y4_n	2280	NUM	8	15	1e
nh_rac2y4_s	2205	NUM	8	15	1e
nh_rac2y4_u	2355	NUM	8	15	1e
nh_rac3y1_f	1993	NUM	8	15	1e
nh_rac3y2_f	2021	NUM	8	15	1e
nh_rac3y3_f	2049	NUM	8	15	1e
nh_rac3y4_f	2077	NUM	8	15	1e
nh_rac3y4_n	2281	NUM	8	15	1e
nh_rac3y4_s	2206	NUM	8	15	1e
nh_rac3y4_u	2356	NUM	8	15	1e
nh_rac4y1_f	1994	NUM	8	15	1e
nh_rac4y2_f	2022	NUM	8	15	1e
nh_rac4y3_f	2050	NUM	8	15	1e
nh_rac4y4_f	2078	NUM	8	15	1e
nh_rac4y4_n	2282	NUM	8	15	1e
nh_rac4y4_s	2207	NUM	8	15	1e
nh_rac4y4_u	2357	NUM	8	15	1e
nh_rac5y1_f	1995	NUM	8	15	1e
nh_rac5y2_f	2023	NUM	8	15	1e
nh_rac5y3_f	2051	NUM	8	15	1e
nh_rac5y4_f	2079	NUM	8	15	1e
nh_rac5y4_n	2283	NUM	8	15	1e
nh_rac5y4_s	2208	NUM	8	15	1e
nh_rac5y4_u	2358	NUM	8	15	1e
nh_rdshy1_f	1851	NUM	8	15	4a
nh_rdshy2_f	1885	NUM	8	15	4a
nh_rdshy3_f	1919	NUM	8	15	4a
nh_rdshy4_f	1953	NUM	8	15	4a
nh_rdsmy1_f	1847	NUM	8	15	3a
nh_rdsmy2_f	1881	NUM	8	15	3a
nh_rdsmy3_f	1915	NUM	8	15	3a
nh_rdsmy4_f	1949	NUM	8	15	3a
nh_sepiy1_f	1861	NUM	8	15	4o
nh_sepiy2_f	1895	NUM	8	15	4o
nh_sepiy3_f	1929	NUM	8	15	4o
nh_sepiy4_f	1963	NUM	8	15	4o
nh_sepiy4_n	2251	NUM	8	15	4o
nh_sepiy4_s	2176	NUM	8	15	4o
nh_sepiy4_u	2326	NUM	8	15	4o

nh_sexy1_f	2004	NUM	8	15	1d
nh_sexy2_f	2032	NUM	8	15	1d
nh_sexy3_f	2060	NUM	8	15	1d
nh_sexy4_f	2088	NUM	8	15	1d
nh_sexy4_n	2292	NUM	8	15	1d
nh_sexy4_s	2217	NUM	8	15	1d
nh_sexy4_u	2367	NUM	8	15	1d
nh_shrty1_f	1860	NUM	8	15	4k
nh_shrty2_f	1894	NUM	8	15	4k
nh_shrty3_f	1928	NUM	8	15	4k
nh_shrty4_f	1962	NUM	8	15	4k
nh_shrty4_n	2250	NUM	8	15	4k
nh_shrty4_s	2175	NUM	8	15	4k
nh_shrty4_u	2325	NUM	8	15	4k
nh_smry1_f	1857	NUM	8	15	3h
nh_smry2_f	1891	NUM	8	15	3h
nh_smry3_f	1925	NUM	8	15	3h
nh_smry4_f	1959	NUM	8	15	3h
nh_smry4_n	2247	NUM	8	15	3h
nh_smry4_s	2172	NUM	8	15	3h
nh_smry4_u	2322	NUM	8	15	3h
nh_vin1y1_f	1999	NUM	8	15	1i
nh_vin1y2_f	2027	NUM	8	15	1i
nh_vin1y3_f	2055	NUM	8	15	1i
nh_vin1y4_f	2083	NUM	8	15	1i
nh_vin1y4_n	2287	NUM	8	15	1i
nh_vin1y4_s	2212	NUM	8	15	1i
nh_vin1y4_u	2362	NUM	8	15	1i
nh_vin2y1_f	2000	NUM	8	15	1i
nh_vin2y2_f	2028	NUM	8	15	1i
nh_vin2y3_f	2056	NUM	8	15	1i
nh_vin2y4_f	2084	NUM	8	15	1i
nh_vin2y4_n	2288	NUM	8	15	1i
nh_vin2y4_s	2213	NUM	8	15	1i
nh_vin2y4_u	2363	NUM	8	15	1i
nh_vin3y1_f	2001	NUM	8	15	1i
nh_vin3y2_f	2029	NUM	8	15	1i
nh_vin3y3_f	2057	NUM	8	15	1i
nh_vin3y4_f	2085	NUM	8	15	1i
nh_vin3y4_n	2289	NUM	8	15	1i
nh_vin3y4_s	2214	NUM	8	15	1i
nh_vin3y4_u	2364	NUM	8	15	1i
nh_vin4y1_f	2002	NUM	8	15	1i
nh_vin4y2_f	2030	NUM	8	15	1i

nh_vin4y3_f	2058	NUM	8	15	1i
nh_vin4y4_f	2086	NUM	8	15	1i
nh_vin4y4_n	2290	NUM	8	15	1i
nh_vin4y4_s	2215	NUM	8	15	1i
nh_vin4y4_u	2365	NUM	8	15	1i
nh_vin5y1_f	2003	NUM	8	15	1i
nh_vin5y2_f	2031	NUM	8	15	1i
nh_vin5y3_f	2059	NUM	8	15	1i
nh_vin5y4_f	2087	NUM	8	15	1i
nh_vin5y4_n	2291	NUM	8	15	1i
nh_vin5y4_s	2216	NUM	8	15	1i
nh_vin5y4_u	2366	NUM	8	15	1i
nh_wity1_f	1858	NUM	8	15	3e
nh_wity2_f	1892	NUM	8	15	3e
nh_wity3_f	1926	NUM	8	15	3e
nh_wity4_f	1960	NUM	8	15	3e
nh_wity4_n	2248	NUM	8	15	3e
nh_wity4_s	2173	NUM	8	15	3e
nh_wity4_u	2323	NUM	8	15	3e
nmy1_f	2451	NUM	8	2	a
nmy2_f	2517	NUM	8	2	a
nmy3_f	2583	NUM	8	2	a
nmy4_f	2649	NUM	8	2	a
nmy4m_n	2783	NUM	8	2	a
nmy4m_s	2717	NUM	8	2	a
nmy4m_u	2850	NUM	8	2	a
nonmedy1_f	1568	NUM	8	DATA	
nonmedy2_f	1600	NUM	8	DATA	
nonmedy3_f	1632	NUM	8	DATA	
nonmedy4_f	821	NUM	8	13	p
nonmedy4_n	854	NUM	8	13	p
nonmedy4_s	845	NUM	8	13	p
nonmedy4_u	863	NUM	8	13	p
NPI	832	CHAR	10	13	i
nrshomey1_f	165	NUM	8	1	j
nrshomey2_f	196	NUM	8	1	j
nrshomey3_f	227	NUM	8	1	j
nrshomey4_f	258	NUM	8	1	j
nrshomey4_n	318	NUM	8	1	j
nrshomey4_s	287	NUM	8	1	j
nrshomey4_u	349	NUM	8	1	j
nurseFTy1_f	1570	NUM	8	DATA	
nurseFTy2_f	1602	NUM	8	DATA	
nurseFTy3_f	1634	NUM	8	DATA	

nurseFTy4_f	1661	NUM	8	DATA	
nurseFTy4m_n	1729	NUM	8	DATA	
nurseFTy4m_s	1695	NUM	8	DATA	
nurseFTy4m_u	1763	NUM	8	DATA	
nursePTy1_f	1571	NUM	8	DATA	
nursePTy2_f	1603	NUM	8	DATA	
nursePTy3_f	1635	NUM	8	DATA	
nursePTy4_f	1662	NUM	8	DATA	
nursePTy4m_n	1733	NUM	8	DATA	
nursePTy4m_s	1699	NUM	8	DATA	
nursePTy4m_u	1767	NUM	8	DATA	
omprimary1_f	2414	NUM	8	2	f
omprimary2_f	2480	NUM	8	2	f
omprimary3_f	2546	NUM	8	2	f
omprimary4_f	2612	NUM	8	2	f
omprimary4_n	2744	NUM	8	2	f
omprimary4_s	2678	NUM	8	2	f
omprimary4_u	2810	NUM	8	2	f
oney1_f	3078	NUM	8	4	p
oney2_f	3094	NUM	8	4	p
oney3_f	3110	NUM	8	4	p
oney4_f	3126	NUM	8	4	p
onez_f	3057	NUM	8	4	p
onez_n	3330	NUM	8	4	p
onez_s	3300	NUM	8	4	p
onez_u	3360	NUM	8	4	p
othcarmy1_f	2390	NUM	8	2	w
othcarmy2_f	2456	NUM	8	2	w
othcarmy3_f	2522	NUM	8	2	w
othcarmy4_f	2588	NUM	8	2	w
othcarmy4_n	2720	NUM	8	2	w
othcarmy4_s	2654	NUM	8	2	w
othcarmy4_u	2786	NUM	8	2	w
p_age1y1_f	880	NUM	8	14	1c
p_age1y2_f	922	NUM	8	14	1c
p_age1y3_f	964	NUM	8	14	1c
p_age1y4_f	1006	NUM	8	14	1c
p_age1y4_n	1362	NUM	8	14	1c
p_age1y4_s	1285	NUM	8	14	1c
p_age1y4_u	1439	NUM	8	14	1c
p_age2y1_f	881	NUM	8	14	1c
p_age2y2_f	923	NUM	8	14	1c
p_age2y3_f	965	NUM	8	14	1c
p_age2y4_f	1007	NUM	8	14	1c

p_age2y4_n	1363	NUM	8	14	1c
p_age2y4_s	1286	NUM	8	14	1c
p_age2y4_u	1440	NUM	8	14	1c
p_age3y1_f	882	NUM	8	14	1c
p_age3y2_f	924	NUM	8	14	1c
p_age3y3_f	966	NUM	8	14	1c
p_age3y4_f	1008	NUM	8	14	1c
p_age3y4_n	1364	NUM	8	14	1c
p_age3y4_s	1287	NUM	8	14	1c
p_age3y4_u	1441	NUM	8	14	1c
p_age4y1_f	883	NUM	8	14	1c
p_age4y2_f	925	NUM	8	14	1c
p_age4y3_f	967	NUM	8	14	1c
p_age4y4_f	1009	NUM	8	14	1c
p_age4y4_n	1365	NUM	8	14	1c
p_age4y4_s	1288	NUM	8	14	1c
p_age4y4_u	1442	NUM	8	14	1c
p_allmdcrmy1_f	1037	NUM	8	14	2g
p_allmdcrmy2_f	1054	NUM	8	14	2g
p_allmdcrmy3_f	1071	NUM	8	14	2g
p_allmdcrmy4_f	1088	NUM	8	14	2g
p_allmdcrmy4_n	1393	NUM	8	14	2g
p_allmdcrmy4_s	1316	NUM	8	14	2g
p_allmdcrmy4_u	1470	NUM	8	14	2g
p_avfpresentmy1_f	1051	NUM	8	14	2m
p_avfpresentmy2_f	1068	NUM	8	14	2m
p_avfpresentmy3_f	1085	NUM	8	14	2m
p_avfpresentmy4_f	1102	NUM	8	14	2m
p_avfpresentmy4_n	1407	NUM	8	14	2m
p_avfpresentmy4_s	1330	NUM	8	14	2m
p_avfpresentmy4_u	1484	NUM	8	14	2m
p_CWhdalb1y1_f	1208	NUM	8	14	9d
p_CWhdalb1y2_f	1224	NUM	8	14	9d
p_CWhdalb1y3_f	1240	NUM	8	14	9d
p_CWhdalb1y4_f	1256	NUM	8	14	9d
p_CWhdalb1y4_n	1426	NUM	8	14	9d
p_CWhdalb1y4_s	1349	NUM	8	14	9d
p_CWhdalb1y4_u	1503	NUM	8	14	9d
p_CWhdalb2y1_f	1209	NUM	8	14	9d
p_CWhdalb2y2_f	1225	NUM	8	14	9d
p_CWhdalb2y3_f	1241	NUM	8	14	9d
p_CWhdalb2y4_f	1257	NUM	8	14	9d
p_CWhdalb2y4_n	1427	NUM	8	14	9d
p_CWhdalb2y4_s	1350	NUM	8	14	9d

p_CWhdalb2y4_u	1504	NUM	8	14	9d
p_CWhdalb3y1_f	1210	NUM	8	14	9d
p_CWhdalb3y2_f	1226	NUM	8	14	9d
p_CWhdalb3y3_f	1242	NUM	8	14	9d
p_CWhdalb3y4_f	1258	NUM	8	14	9d
p_CWhdalb3y4_n	1428	NUM	8	14	9d
p_CWhdalb3y4_s	1351	NUM	8	14	9d
p_CWhdalb3y4_u	1505	NUM	8	14	9d
p_CWhdalb4y1_f	1211	NUM	8	14	9d
p_CWhdalb4y2_f	1227	NUM	8	14	9d
p_CWhdalb4y3_f	1243	NUM	8	14	9d
p_CWhdalb4y4_f	1259	NUM	8	14	9d
p_CWhdalb4y4_n	1429	NUM	8	14	9d
p_CWhdalb4y4_s	1352	NUM	8	14	9d
p_CWhdalb4y4_u	1506	NUM	8	14	9d
p_CWhdalb5y1_f	1212	NUM	8	14	9d
p_CWhdalb5y2_f	1228	NUM	8	14	9d
p_CWhdalb5y3_f	1244	NUM	8	14	9d
p_CWhdalb5y4_f	1260	NUM	8	14	9d
p_CWhdalb5y4_n	1430	NUM	8	14	9d
p_CWhdalb5y4_s	1353	NUM	8	14	9d
p_CWhdalb5y4_u	1507	NUM	8	14	9d
p_CWhdalby1_f	1207	NUM	8	14	9c
p_CWhdalby2_f	1223	NUM	8	14	9c
p_CWhdalby3_f	1239	NUM	8	14	9c
p_CWhdalby4_f	1255	NUM	8	14	9c
p_CWhdalby4_n	1425	NUM	8	14	9c
p_CWhdalby4_s	1348	NUM	8	14	9c
p_CWhdalby4_u	1502	NUM	8	14	9c
p_CWhdavgHGBBy1_f	1143	NUM	8	14	8c
p_CWhdavgHGBBy2_f	1151	NUM	8	14	8c
p_CWhdavgHGBBy3_f	1159	NUM	8	14	8c
p_CWhdavgHGBBy4_f	1167	NUM	8	14	8c
p_CWhdavgHGBBy4_n	1413	NUM	8	14	8c
p_CWhdavgHGBBy4_s	1336	NUM	8	14	8c
p_CWhdavgHGBBy4_u	1490	NUM	8	14	8c
p_CWhddenomy1_f	1205	NUM	8	14	9a
p_CWhddenomy2_f	1221	NUM	8	14	9a
p_CWhddenomy3_f	1237	NUM	8	14	9a
p_CWhddenomy4_f	1253	NUM	8	14	9a
p_CWhdhgb1y1_f	1144	NUM	8	14	8d
p_CWhdhgb1y2_f	1152	NUM	8	14	8d
p_CWhdhgb1y3_f	1160	NUM	8	14	8d
p_CWhdhgb1y4_f	1168	NUM	8	14	8d

p_CWhdhgb1y4_n	1414	NUM	8	14	8d
p_CWhdhgb1y4_s	1337	NUM	8	14	8d
p_CWhdhgb1y4_u	1491	NUM	8	14	8d
p_CWhdhgb2y1_f	1145	NUM	8	14	8d
p_CWhdhgb2y2_f	1153	NUM	8	14	8d
p_CWhdhgb2y3_f	1161	NUM	8	14	8d
p_CWhdhgb2y4_f	1169	NUM	8	14	8d
p_CWhdhgb2y4_n	1415	NUM	8	14	8d
p_CWhdhgb2y4_s	1338	NUM	8	14	8d
p_CWhdhgb2y4_u	1492	NUM	8	14	8d
p_CWhdhgb3y1_f	1146	NUM	8	14	8d
p_CWhdhgb3y2_f	1154	NUM	8	14	8d
p_CWhdhgb3y3_f	1162	NUM	8	14	8d
p_CWhdhgb3y4_f	1170	NUM	8	14	8d
p_CWhdhgb3y4_n	1416	NUM	8	14	8d
p_CWhdhgb3y4_s	1339	NUM	8	14	8d
p_CWhdhgb3y4_u	1493	NUM	8	14	8d
p_CWhdhgb4y1_f	1147	NUM	8	14	8d
p_CWhdhgb4y2_f	1155	NUM	8	14	8d
p_CWhdhgb4y3_f	1163	NUM	8	14	8d
p_CWhdhgb4y4_f	1171	NUM	8	14	8d
p_CWhdhgb4y4_n	1417	NUM	8	14	8d
p_CWhdhgb4y4_s	1340	NUM	8	14	8d
p_CWhdhgb4y4_u	1494	NUM	8	14	8d
p_CWhdhgb5y1_f	1148	NUM	8	14	8d
p_CWhdhgb5y2_f	1156	NUM	8	14	8d
p_CWhdhgb5y3_f	1164	NUM	8	14	8d
p_CWhdhgb5y4_f	1172	NUM	8	14	8d
p_CWhdhgb5y4_n	1418	NUM	8	14	8d
p_CWhdhgb5y4_s	1341	NUM	8	14	8d
p_CWhdhgb5y4_u	1495	NUM	8	14	8d
p_CWhdktvge12y1_f	1275	NUM	8	14	9j
p_CWhdktvge12y2_f	1278	NUM	8	14	9j
p_CWhdktvge12y3_f	1281	NUM	8	14	9j
p_CWhdktvge12y4_f	1284	NUM	8	14	9j
p_CWhdktvge12y4_n	1438	NUM	8	14	9j
p_CWhdktvge12y4_s	1361	NUM	8	14	9j
p_CWhdktvge12y4_u	1515	NUM	8	14	9j
p_CWhdktvpmy1_f	1274	NUM	8	14	9h
p_CWhdktvpmy2_f	1277	NUM	8	14	9h
p_CWhdktvpmy3_f	1280	NUM	8	14	9h
p_CWhdktvpmy4_f	1283	NUM	8	14	9h
p_CWhdktvptsy1_f	1273	NUM	8	14	9g
p_CWhdktvptsy2_f	1276	NUM	8	14	9g



p_CWhdktvptsy3_f	1279	NUM	8	14	9g
p_CWhdktvptsy4_f	1282	NUM	8	14	9g
p_CWhdmthdenomy1_f	1206	NUM	8	14	9b
p_CWhdmthdenomy2_f	1222	NUM	8	14	9b
p_CWhdmthdenomy3_f	1238	NUM	8	14	9b
p_CWhdmthdenomy4_f	1254	NUM	8	14	9b
p_CWhdptdenomy1_f	1141	NUM	8	14	8a
p_CWhdptdenomy2_f	1149	NUM	8	14	8a
p_CWhdptdenomy3_f	1157	NUM	8	14	8a
p_CWhdptdenomy4_f	1165	NUM	8	14	8a
p_CWhdptmthdenomy1_f	1142	NUM	8	14	8b
p_CWhdptmthdenomy2_f	1150	NUM	8	14	8b
p_CWhdptmthdenomy3_f	1158	NUM	8	14	8b
p_CWhdptmthdenomy4_f	1166	NUM	8	14	8b
p_CWpdalb1y1_f	1216	NUM	8	14	9p
p_CWpdalb1y2_f	1232	NUM	8	14	9p
p_CWpdalb1y3_f	1248	NUM	8	14	9p
p_CWpdalb1y4_f	1264	NUM	8	14	9p
p_CWpdalb1y4_n	1432	NUM	8	14	9p
p_CWpdalb1y4_s	1355	NUM	8	14	9p
p_CWpdalb1y4_u	1509	NUM	8	14	9p
p_CWpdalb2y1_f	1217	NUM	8	14	9p
p_CWpdalb2y2_f	1233	NUM	8	14	9p
p_CWpdalb2y3_f	1249	NUM	8	14	9p
p_CWpdalb2y4_f	1265	NUM	8	14	9p
p_CWpdalb2y4_n	1433	NUM	8	14	9p
p_CWpdalb2y4_s	1356	NUM	8	14	9p
p_CWpdalb2y4_u	1510	NUM	8	14	9p
p_CWpdalb3y1_f	1218	NUM	8	14	9p
p_CWpdalb3y2_f	1234	NUM	8	14	9p
p_CWpdalb3y3_f	1250	NUM	8	14	9p
p_CWpdalb3y4_f	1266	NUM	8	14	9p
p_CWpdalb3y4_n	1434	NUM	8	14	9p
p_CWpdalb3y4_s	1357	NUM	8	14	9p
p_CWpdalb3y4_u	1511	NUM	8	14	9p
p_CWpdalb4y1_f	1219	NUM	8	14	9p
p_CWpdalb4y2_f	1235	NUM	8	14	9p
p_CWpdalb4y3_f	1251	NUM	8	14	9p
p_CWpdalb4y4_f	1267	NUM	8	14	9p
p_CWpdalb4y4_n	1435	NUM	8	14	9p
p_CWpdalb4y4_s	1358	NUM	8	14	9p
p_CWpdalb4y4_u	1512	NUM	8	14	9p
p_CWpdalb5y1_f	1220	NUM	8	14	9p
p_CWpdalb5y2_f	1236	NUM	8	14	9p

p_CWpdalb5y3_f	1252	NUM	8	14	9p
p_CWpdalb5y4_f	1268	NUM	8	14	9p
p_CWpdalb5y4_n	1436	NUM	8	14	9p
p_CWpdalb5y4_s	1359	NUM	8	14	9p
p_CWpdalb5y4_u	1513	NUM	8	14	9p
p_CWpdalby1_f	1215	NUM	8	14	9o
p_CWpdalby2_f	1231	NUM	8	14	9o
p_CWpdalby3_f	1247	NUM	8	14	9o
p_CWpdalby4_f	1263	NUM	8	14	9o
p_CWpdalby4_n	1431	NUM	8	14	9o
p_CWpdalby4_s	1354	NUM	8	14	9o
p_CWpdalby4_u	1508	NUM	8	14	9o
p_CWpdavgHGBBy1_f	1175	NUM	8	14	8h
p_CWpdavgHGBBy2_f	1183	NUM	8	14	8h
p_CWpdavgHGBBy3_f	1191	NUM	8	14	8h
p_CWpdavgHGBBy4_f	1199	NUM	8	14	8h
p_CWpdavgHGBBy4_n	1419	NUM	8	14	8h
p_CWpdavgHGBBy4_s	1342	NUM	8	14	8h
p_CWpdavgHGBBy4_u	1496	NUM	8	14	8h
p_CWpddenomy1_f	1213	NUM	8	14	9k
p_CWpddenomy2_f	1229	NUM	8	14	9k
p_CWpddenomy3_f	1245	NUM	8	14	9k
p_CWpddenomy4_f	1261	NUM	8	14	9k
p_CWpdhgb1y1_f	1176	NUM	8	14	8i
p_CWpdhgb1y2_f	1184	NUM	8	14	8i
p_CWpdhgb1y3_f	1192	NUM	8	14	8i
p_CWpdhgb1y4_f	1200	NUM	8	14	8i
p_CWpdhgb1y4_n	1420	NUM	8	14	8i
p_CWpdhgb1y4_s	1343	NUM	8	14	8i
p_CWpdhgb1y4_u	1497	NUM	8	14	8i
p_CWpdhgb2y1_f	1177	NUM	8	14	8i
p_CWpdhgb2y2_f	1185	NUM	8	14	8i
p_CWpdhgb2y3_f	1193	NUM	8	14	8i
p_CWpdhgb2y4_f	1201	NUM	8	14	8i
p_CWpdhgb2y4_n	1421	NUM	8	14	8i
p_CWpdhgb2y4_s	1344	NUM	8	14	8i
p_CWpdhgb2y4_u	1498	NUM	8	14	8i
p_CWpdhgb3y1_f	1178	NUM	8	14	8i
p_CWpdhgb3y2_f	1186	NUM	8	14	8i
p_CWpdhgb3y3_f	1194	NUM	8	14	8i
p_CWpdhgb3y4_f	1202	NUM	8	14	8i
p_CWpdhgb3y4_n	1422	NUM	8	14	8i
p_CWpdhgb3y4_s	1345	NUM	8	14	8i
p_CWpdhgb3y4_u	1499	NUM	8	14	8i

p_CWpdhgb4y1_f	1179	NUM	8	14	8i
p_CWpdhgb4y2_f	1187	NUM	8	14	8i
p_CWpdhgb4y3_f	1195	NUM	8	14	8i
p_CWpdhgb4y4_f	1203	NUM	8	14	8i
p_CWpdhgb4y4_n	1423	NUM	8	14	8i
p_CWpdhgb4y4_s	1346	NUM	8	14	8i
p_CWpdhgb4y4_u	1500	NUM	8	14	8i
p_CWpdhgb5y1_f	1180	NUM	8	14	8i
p_CWpdhgb5y2_f	1188	NUM	8	14	8i
p_CWpdhgb5y3_f	1196	NUM	8	14	8i
p_CWpdhgb5y4_f	1204	NUM	8	14	8i
p_CWpdhgb5y4_n	1424	NUM	8	14	8i
p_CWpdhgb5y4_s	1347	NUM	8	14	8i
p_CWpdhgb5y4_u	1501	NUM	8	14	8i
p_CWpdktvge18y1_f	1269	NUM	8	14	9n
p_CWpdktvge18y2_f	1270	NUM	8	14	9n
p_CWpdktvge18y3_f	1271	NUM	8	14	9n
p_CWpdktvge18y4_f	1272	NUM	8	14	9n
p_CWpdktvge18y4_n	1437	NUM	8	14	9n
p_CWpdktvge18y4_s	1360	NUM	8	14	9n
p_CWpdktvge18y4_u	1514	NUM	8	14	9n
p_CWpdmthdenomy1_f	1214	NUM	8	14	9l
p_CWpdmthdenomy2_f	1230	NUM	8	14	9l
p_CWpdmthdenomy3_f	1246	NUM	8	14	9l
p_CWpdmthdenomy4_f	1262	NUM	8	14	9l
p_CWpdptdenomy1_f	1173	NUM	8	14	8f
p_CWpdptdenomy2_f	1181	NUM	8	14	8f
p_CWpdptdenomy3_f	1189	NUM	8	14	8f
p_CWpdptdenomy4_f	1197	NUM	8	14	8f
p_CWpdptmthdenomy1_f	1174	NUM	8	14	8g
p_CWpdptmthdenomy2_f	1182	NUM	8	14	8g
p_CWpdptmthdenomy3_f	1190	NUM	8	14	8g
p_CWpdptmthdenomy4_f	1198	NUM	8	14	8g
p_deay1_f	872	NUM	8	14	3c
p_deay2_f	914	NUM	8	14	3c
p_deay3_f	956	NUM	8	14	3c
p_deay4_f	998	NUM	8	14	3c
p_dis1y1_f	884	NUM	8	14	1g
p_dis1y2_f	926	NUM	8	14	1g
p_dis1y3_f	968	NUM	8	14	1g
p_dis1y4_f	1010	NUM	8	14	1g
p_dis1y4_n	1366	NUM	8	14	1g
p_dis1y4_s	1289	NUM	8	14	1g
p_dis1y4_u	1443	NUM	8	14	1g

p_dis2y1_f	885	NUM	8	14	1g
p_dis2y2_f	927	NUM	8	14	1g
p_dis2y3_f	969	NUM	8	14	1g
p_dis2y4_f	1011	NUM	8	14	1g
p_dis2y4_n	1367	NUM	8	14	1g
p_dis2y4_s	1290	NUM	8	14	1g
p_dis2y4_u	1444	NUM	8	14	1g
p_dis3y1_f	886	NUM	8	14	1g
p_dis3y2_f	928	NUM	8	14	1g
p_dis3y3_f	970	NUM	8	14	1g
p_dis3y4_f	1012	NUM	8	14	1g
p_dis3y4_n	1368	NUM	8	14	1g
p_dis3y4_s	1291	NUM	8	14	1g
p_dis3y4_u	1445	NUM	8	14	1g
p_dis4y1_f	887	NUM	8	14	1g
p_dis4y2_f	929	NUM	8	14	1g
p_dis4y3_f	971	NUM	8	14	1g
p_dis4y4_f	1013	NUM	8	14	1g
p_dis4y4_n	1369	NUM	8	14	1g
p_dis4y4_s	1292	NUM	8	14	1g
p_dis4y4_u	1446	NUM	8	14	1g
p_dis5y1_f	888	NUM	8	14	1g
p_dis5y2_f	930	NUM	8	14	1g
p_dis5y3_f	972	NUM	8	14	1g
p_dis5y4_f	1014	NUM	8	14	1g
p_dis5y4_n	1370	NUM	8	14	1g
p_dis5y4_s	1293	NUM	8	14	1g
p_dis5y4_u	1447	NUM	8	14	1g
p_dis6y1_f	889	NUM	8	14	1g
p_dis6y2_f	931	NUM	8	14	1g
p_dis6y3_f	973	NUM	8	14	1g
p_dis6y4_f	1015	NUM	8	14	1g
p_dis6y4_n	1371	NUM	8	14	1g
p_dis6y4_s	1294	NUM	8	14	1g
p_dis6y4_u	1448	NUM	8	14	1g
p_dis7y1_f	890	NUM	8	14	1g
p_dis7y2_f	932	NUM	8	14	1g
p_dis7y3_f	974	NUM	8	14	1g
p_dis7y4_f	1016	NUM	8	14	1g
p_dis7y4_n	1372	NUM	8	14	1g
p_dis7y4_s	1295	NUM	8	14	1g
p_dis7y4_u	1449	NUM	8	14	1g
p_dis8y1_f	891	NUM	8	14	1g
p_dis8y2_f	933	NUM	8	14	1g

p_dis8y3_f	975	NUM	8	14	1g
p_dis8y4_f	1017	NUM	8	14	1g
p_dis8y4_n	1373	NUM	8	14	1g
p_dis8y4_s	1296	NUM	8	14	1g
p_dis8y4_u	1450	NUM	8	14	1g
p_dyy1_f	871	NUM	8	14	3b
p_dyy2_f	913	NUM	8	14	3b
p_dyy3_f	955	NUM	8	14	3b
p_dyy4_f	997	NUM	8	14	3b
p_eth1y1_f	897	NUM	8	14	1f
p_eth1y2_f	939	NUM	8	14	1f
p_eth1y3_f	981	NUM	8	14	1f
p_eth1y4_f	1023	NUM	8	14	1f
p_eth1y4_n	1384	NUM	8	14	1f
p_eth1y4_s	1307	NUM	8	14	1f
p_eth1y4_u	1461	NUM	8	14	1f
p_eth2y1_f	898	NUM	8	14	1f
p_eth2y2_f	940	NUM	8	14	1f
p_eth2y3_f	982	NUM	8	14	1f
p_eth2y4_f	1024	NUM	8	14	1f
p_eth2y4_n	1385	NUM	8	14	1f
p_eth2y4_s	1308	NUM	8	14	1f
p_eth2y4_u	1462	NUM	8	14	1f
p_eth3y1_f	899	NUM	8	14	1f
p_eth3y2_f	941	NUM	8	14	1f
p_eth3y3_f	983	NUM	8	14	1f
p_eth3y4_f	1025	NUM	8	14	1f
p_eth3y4_n	1386	NUM	8	14	1f
p_eth3y4_s	1309	NUM	8	14	1f
p_eth3y4_u	1463	NUM	8	14	1f
p_hdy1_f	875	NUM	8	14	4c
p_hdy2_f	917	NUM	8	14	4c
p_hdy3_f	959	NUM	8	14	4c
p_hdy4_f	1001	NUM	8	14	4c
p_hdyy1_f	874	NUM	8	14	4b
p_hdyy2_f	916	NUM	8	14	4b
p_hdyy3_f	958	NUM	8	14	4b
p_hdyy4_f	1000	NUM	8	14	4b
p_hemomy1_f	1052	NUM	8	14	2k
p_hemomy2_f	1069	NUM	8	14	2k
p_hemomy3_f	1086	NUM	8	14	2k
p_hemomy4_f	1103	NUM	8	14	2k
p_htay1_f	873	NUM	8	14	4i
p_htay2_f	915	NUM	8	14	4i

p_htay3_f	957	NUM	8	14	4i
p_htay4_f	999	NUM	8	14	4i
p_insempmy1_f	1039	NUM	8	14	2g
p_insempmy2_f	1056	NUM	8	14	2g
p_insempmy3_f	1073	NUM	8	14	2g
p_insempmy4_f	1090	NUM	8	14	2g
p_insempmy4_n	1395	NUM	8	14	2g
p_insempmy4_s	1318	NUM	8	14	2g
p_insempmy4_u	1472	NUM	8	14	2g
p_insmcdmy1_f	1038	NUM	8	14	2g
p_insmcdmy2_f	1055	NUM	8	14	2g
p_insmcdmy3_f	1072	NUM	8	14	2g
p_insmcdmy4_f	1089	NUM	8	14	2g
p_insmcdmy4_n	1394	NUM	8	14	2g
p_insmcdmy4_s	1317	NUM	8	14	2g
p_insmcdmy4_u	1471	NUM	8	14	2g
p_insnonthmy1_f	1040	NUM	8	14	2g
p_insnonthmy2_f	1057	NUM	8	14	2g
p_insnonthmy3_f	1074	NUM	8	14	2g
p_insnonthmy4_f	1091	NUM	8	14	2g
p_insnonthmy4_n	1396	NUM	8	14	2g
p_insnonthmy4_s	1319	NUM	8	14	2g
p_insnonthmy4_u	1473	NUM	8	14	2g
p_ltcy1_f	1108	NUM	8	14	11g
p_ltcy2_f	1112	NUM	8	14	11g
p_ltcy3_f	1116	NUM	8	14	11g
p_ltcy4_f	1120	NUM	8	14	11g
p_ltcy4_n	1409	NUM	8	14	11g
p_ltcy4_s	1332	NUM	8	14	11g
p_ltcy4_u	1486	NUM	8	14	11g
p_mefavfmy1_f	1047	NUM	8	14	2l
p_mefavfmy2_f	1064	NUM	8	14	2l
p_mefavfmy3_f	1081	NUM	8	14	2l
p_mefavfmy4_f	1098	NUM	8	14	2l
p_mefavfmy4_n	1403	NUM	8	14	2l
p_mefavfmy4_s	1326	NUM	8	14	2l
p_mefavfmy4_u	1480	NUM	8	14	2l
p_mefcathmy1_f	1049	NUM	8	14	2l
p_mefcathmy2_f	1066	NUM	8	14	2l
p_mefcathmy3_f	1083	NUM	8	14	2l
p_mefcathmy4_f	1100	NUM	8	14	2l
p_mefcathmy4_n	1405	NUM	8	14	2l
p_mefcathmy4_s	1328	NUM	8	14	2l
p_mefcathmy4_u	1482	NUM	8	14	2l

p_mefgraftmy1_f	1048	NUM	8	14	2l
p_mefgraftmy2_f	1065	NUM	8	14	2l
p_mefgraftmy3_f	1082	NUM	8	14	2l
p_mefgraftmy4_f	1099	NUM	8	14	2l
p_mefgraftmy4_n	1404	NUM	8	14	2l
p_mefgraftmy4_s	1327	NUM	8	14	2l
p_mefgraftmy4_u	1481	NUM	8	14	2l
p_mefoumaccessmy1_f	1050	NUM	8	14	2l
p_mefoumaccessmy2_f	1067	NUM	8	14	2l
p_mefoumaccessmy3_f	1084	NUM	8	14	2l
p_mefoumaccessmy4_f	1101	NUM	8	14	2l
p_mefoumaccessmy4_n	1406	NUM	8	14	2l
p_mefoumaccessmy4_s	1329	NUM	8	14	2l
p_mefoumaccessmy4_u	1483	NUM	8	14	2l
p_modcapdy1_f	908	NUM	8	14	1k
p_modcapdy2_f	950	NUM	8	14	1k
p_modcapdy3_f	992	NUM	8	14	1k
p_modcapdy4_f	1034	NUM	8	14	1k
p_modcapdy4_n	1390	NUM	8	14	1k
p_modcapdy4_s	1313	NUM	8	14	1k
p_modcapdy4_u	1467	NUM	8	14	1k
p_modccpdy1_f	909	NUM	8	14	1k
p_modccpdy2_f	951	NUM	8	14	1k
p_modccpdy3_f	993	NUM	8	14	1k
p_modccpdy4_f	1035	NUM	8	14	1k
p_modccpdy4_n	1391	NUM	8	14	1k
p_modccpdy4_s	1314	NUM	8	14	1k
p_modccpdy4_u	1468	NUM	8	14	1k
p_modhdy1_f	906	NUM	8	14	1k
p_modhdy2_f	948	NUM	8	14	1k
p_modhdy3_f	990	NUM	8	14	1k
p_modhdy4_f	1032	NUM	8	14	1k
p_modhdy4_n	1388	NUM	8	14	1k
p_modhdy4_s	1311	NUM	8	14	1k
p_modhdy4_u	1465	NUM	8	14	1k
p_modhhdy1_f	907	NUM	8	14	1k
p_modhhdy2_f	949	NUM	8	14	1k
p_modhhdy3_f	991	NUM	8	14	1k
p_modhhdy4_f	1033	NUM	8	14	1k
p_modhhdy4_n	1389	NUM	8	14	1k
p_modhhdy4_s	1312	NUM	8	14	1k
p_modhhdy4_u	1466	NUM	8	14	1k
p_modothy1_f	910	NUM	8	14	1k
p_modothy2_f	952	NUM	8	14	1k

p_modothy3_f	994	NUM	8	14	1k
p_modothy4_f	1036	NUM	8	14	1k
p_modothy4_n	1392	NUM	8	14	1k
p_modothy4_s	1315	NUM	8	14	1k
p_modothy4_u	1469	NUM	8	14	1k
p_nepnomy1_f	1041	NUM	8	14	2s
p_nepnomy2_f	1058	NUM	8	14	2s
p_nepnomy3_f	1075	NUM	8	14	2s
p_nepnomy4_f	1092	NUM	8	14	2s
p_nepnomy4_n	1397	NUM	8	14	2s
p_nepnomy4_s	1320	NUM	8	14	2s
p_nepnomy4_u	1474	NUM	8	14	2s
p_nephunkmissmy1_f	1045	NUM	8	14	2s
p_nephunkmissmy2_f	1062	NUM	8	14	2s
p_nephunkmissmy3_f	1079	NUM	8	14	2s
p_nephunkmissmy4_f	1096	NUM	8	14	2s
p_nephunkmissmy4_n	1401	NUM	8	14	2s
p_nephunkmissmy4_s	1324	NUM	8	14	2s
p_nephunkmissmy4_u	1478	NUM	8	14	2s
p_nephy12my1_f	1044	NUM	8	14	2s
p_nephy12my2_f	1061	NUM	8	14	2s
p_nephy12my3_f	1078	NUM	8	14	2s
p_nephy12my4_f	1095	NUM	8	14	2s
p_nephy12my4_n	1400	NUM	8	14	2s
p_nephy12my4_s	1323	NUM	8	14	2s
p_nephy12my4_u	1477	NUM	8	14	2s
p_nephy612my1_f	1043	NUM	8	14	2s
p_nephy612my2_f	1060	NUM	8	14	2s
p_nephy612my3_f	1077	NUM	8	14	2s
p_nephy612my4_f	1094	NUM	8	14	2s
p_nephy612my4_n	1399	NUM	8	14	2s
p_nephy612my4_s	1322	NUM	8	14	2s
p_nephy612my4_u	1476	NUM	8	14	2s
p_nephy6my1_f	1042	NUM	8	14	2s
p_nephy6my2_f	1059	NUM	8	14	2s
p_nephy6my3_f	1076	NUM	8	14	2s
p_nephy6my4_f	1093	NUM	8	14	2s
p_nephy6my4_n	1398	NUM	8	14	2s
p_nephy6my4_s	1321	NUM	8	14	2s
p_nephy6my4_u	1475	NUM	8	14	2s
p_nmy1_f	1053	NUM	8	14	2a
p_nmy2_f	1070	NUM	8	14	2a
p_nmy3_f	1087	NUM	8	14	2a
p_nmy4_f	1104	NUM	8	14	2a



p_pahy1_f	879	NUM	8	14	1a
p_pahy2_f	921	NUM	8	14	1a
p_pahy3_f	963	NUM	8	14	1a
p_pahy4_f	1005	NUM	8	14	1a
p_phdvapty1_f	1105	NUM	8	14	11a
p_phdvapty2_f	1109	NUM	8	14	11a
p_phdvapty3_f	1113	NUM	8	14	11a
p_phdvapty4_f	1117	NUM	8	14	11a
p_phdy1_f	1106	NUM	8	14	11b
p_phdy2_f	1110	NUM	8	14	11b
p_phdy3_f	1114	NUM	8	14	11b
p_phdy4_f	1118	NUM	8	14	11b
p_ppavfy1_f	1107	NUM	8	14	11c
p_ppavfy2_f	1111	NUM	8	14	11c
p_ppavfy3_f	1115	NUM	8	14	11c
p_ppavfy4_f	1119	NUM	8	14	11c
p_ppavfy4_n	1408	NUM	8	14	11c
p_ppavfy4_s	1331	NUM	8	14	11c
p_ppavfy4_u	1485	NUM	8	14	11c
p_pppwpmly1_f	1121	NUM	8	14	6b
p_pppwpmly2_f	1126	NUM	8	14	6b
p_pppwpmly3_f	1131	NUM	8	14	6b
p_pppwpmly4_f	1136	NUM	8	14	6b
p_pppwpty1_f	1122	NUM	8	14	6a
p_pppwpty2_f	1127	NUM	8	14	6a
p_pppwpty3_f	1132	NUM	8	14	6a
p_pppwpty4_f	1137	NUM	8	14	6a
p_ptinfymy1_f	1046	NUM	8	14	2t
p_ptinfymy2_f	1063	NUM	8	14	2t
p_ptinfymy3_f	1080	NUM	8	14	2t
p_ptinfymy4_f	1097	NUM	8	14	2t
p_ptinfymy4_n	1402	NUM	8	14	2t
p_ptinfymy4_s	1325	NUM	8	14	2t
p_ptinfymy4_u	1479	NUM	8	14	2t
p_rac1y1_f	892	NUM	8	14	1e
p_rac1y2_f	934	NUM	8	14	1e
p_rac1y3_f	976	NUM	8	14	1e
p_rac1y4_f	1018	NUM	8	14	1e
p_rac1y4_n	1379	NUM	8	14	1e
p_rac1y4_s	1302	NUM	8	14	1e
p_rac1y4_u	1456	NUM	8	14	1e
p_rac2y1_f	893	NUM	8	14	1e
p_rac2y2_f	935	NUM	8	14	1e
p_rac2y3_f	977	NUM	8	14	1e

p_rac2y4_f	1019	NUM	8	14	1e
p_rac2y4_n	1380	NUM	8	14	1e
p_rac2y4_s	1303	NUM	8	14	1e
p_rac2y4_u	1457	NUM	8	14	1e
p_rac3y1_f	894	NUM	8	14	1e
p_rac3y2_f	936	NUM	8	14	1e
p_rac3y3_f	978	NUM	8	14	1e
p_rac3y4_f	1020	NUM	8	14	1e
p_rac3y4_n	1381	NUM	8	14	1e
p_rac3y4_s	1304	NUM	8	14	1e
p_rac3y4_u	1458	NUM	8	14	1e
p_rac4y1_f	895	NUM	8	14	1e
p_rac4y2_f	937	NUM	8	14	1e
p_rac4y3_f	979	NUM	8	14	1e
p_rac4y4_f	1021	NUM	8	14	1e
p_rac4y4_n	1382	NUM	8	14	1e
p_rac4y4_s	1305	NUM	8	14	1e
p_rac4y4_u	1459	NUM	8	14	1e
p_rac5y1_f	896	NUM	8	14	1e
p_rac5y2_f	938	NUM	8	14	1e
p_rac5y3_f	980	NUM	8	14	1e
p_rac5y4_f	1022	NUM	8	14	1e
p_rac5y4_n	1383	NUM	8	14	1e
p_rac5y4_s	1306	NUM	8	14	1e
p_rac5y4_u	1460	NUM	8	14	1e
p_rdshy1_f	869	NUM	8	14	4a
p_rdshy2_f	911	NUM	8	14	4a
p_rdshy3_f	953	NUM	8	14	4a
p_rdshy4_f	995	NUM	8	14	4a
p_rdsmy1_f	870	NUM	8	14	3a
p_rdsmy2_f	912	NUM	8	14	3a
p_rdsmy3_f	954	NUM	8	14	3a
p_rdsmy4_f	996	NUM	8	14	3a
p_rdsty1_f	876	NUM	8	14	5d
p_rdsty2_f	918	NUM	8	14	5d
p_rdsty3_f	960	NUM	8	14	5d
p_rdsty4_f	1002	NUM	8	14	5d
p_sexy1_f	905	NUM	8	14	1d
p_sexy2_f	947	NUM	8	14	1d
p_sexy3_f	989	NUM	8	14	1d
p_sexy4_f	1031	NUM	8	14	1d
p_sexy4_n	1387	NUM	8	14	1d
p_sexy4_s	1310	NUM	8	14	1d
p_sexy4_u	1464	NUM	8	14	1d

p_txy1_f	877	NUM	8	14	5f
p_txy2_f	919	NUM	8	14	5f
p_txy3_f	961	NUM	8	14	5f
p_txy4_f	1003	NUM	8	14	5f
p_txyy1_f	878	NUM	8	14	5e
p_txyy2_f	920	NUM	8	14	5e
p_txyy3_f	962	NUM	8	14	5e
p_txyy4_f	1004	NUM	8	14	5e
p_vin1y1_f	900	NUM	8	14	1i
p_vin1y2_f	942	NUM	8	14	1i
p_vin1y3_f	984	NUM	8	14	1i
p_vin1y4_f	1026	NUM	8	14	1i
p_vin1y4_n	1374	NUM	8	14	1i
p_vin1y4_s	1297	NUM	8	14	1i
p_vin1y4_u	1451	NUM	8	14	1i
p_vin2y1_f	901	NUM	8	14	1i
p_vin2y2_f	943	NUM	8	14	1i
p_vin2y3_f	985	NUM	8	14	1i
p_vin2y4_f	1027	NUM	8	14	1i
p_vin2y4_n	1375	NUM	8	14	1i
p_vin2y4_s	1298	NUM	8	14	1i
p_vin2y4_u	1452	NUM	8	14	1i
p_vin3y1_f	902	NUM	8	14	1i
p_vin3y2_f	944	NUM	8	14	1i
p_vin3y3_f	986	NUM	8	14	1i
p_vin3y4_f	1028	NUM	8	14	1i
p_vin3y4_n	1376	NUM	8	14	1i
p_vin3y4_s	1299	NUM	8	14	1i
p_vin3y4_u	1453	NUM	8	14	1i
p_vin4y1_f	903	NUM	8	14	1i
p_vin4y2_f	945	NUM	8	14	1i
p_vin4y3_f	987	NUM	8	14	1i
p_vin4y4_f	1029	NUM	8	14	1i
p_vin4y4_n	1377	NUM	8	14	1i
p_vin4y4_s	1300	NUM	8	14	1i
p_vin4y4_u	1454	NUM	8	14	1i
p_vin5y1_f	904	NUM	8	14	1i
p_vin5y2_f	946	NUM	8	14	1i
p_vin5y3_f	988	NUM	8	14	1i
p_vin5y4_f	1030	NUM	8	14	1i
p_vin5y4_n	1378	NUM	8	14	1i
p_vin5y4_s	1301	NUM	8	14	1i
p_vin5y4_u	1455	NUM	8	14	1i
p_WL1017y1_f	1125	NUM	8	14	6d

p_WL1017y2_f	1130	NUM	8	14	6d
p_WL1017y3_f	1135	NUM	8	14	6d
p_WL1017y4_f	1140	NUM	8	14	6d
p_WL1017y4_n	1412	NUM	8	14	6d
p_WL1017y4_s	1335	NUM	8	14	6d
p_WL1017y4_u	1489	NUM	8	14	6d
p_WLlt10y1_f	1124	NUM	8	14	6d
p_WLlt10y2_f	1129	NUM	8	14	6d
p_WLlt10y3_f	1134	NUM	8	14	6d
p_WLlt10y4_f	1139	NUM	8	14	6d
p_WLlt10y4_n	1411	NUM	8	14	6d
p_WLlt10y4_s	1334	NUM	8	14	6d
p_WLlt10y4_u	1488	NUM	8	14	6d
p_WLy1_f	1123	NUM	8	14	6c
p_WLy2_f	1128	NUM	8	14	6c
p_WLy3_f	1133	NUM	8	14	6c
p_WLy4_f	1138	NUM	8	14	6c
p_WLy4_n	1410	NUM	8	14	6c
p_WLy4_s	1333	NUM	8	14	6c
p_WLy4_u	1487	NUM	8	14	6c
pahdy1_f	1522	NUM	8	DATA	
pahdy2_f	1531	NUM	8	DATA	
pahdy3_f	1540	NUM	8	DATA	
pahdy4_f	1549	NUM	8	DATA	
pahdy4_n	1713	NUM	8	DATA	
pahdy4_s	1679	NUM	8	DATA	
pahdy4_u	1747	NUM	8	DATA	
pahy1_f	140	NUM	8	1	a
pahy2_f	171	NUM	8	1	a
pahy3_f	202	NUM	8	1	a
pahy4_f	233	NUM	8	1	a
pahy4m_n	325	NUM	8	1	a
pahy4m_s	294	NUM	8	1	a
pahy4m_u	356	NUM	8	1	a
paody1_f	1523	NUM	8	DATA	
paody2_f	1532	NUM	8	DATA	
paody3_f	1541	NUM	8	DATA	
paody4_f	1550	NUM	8	DATA	
paody4_n	1714	NUM	8	DATA	
paody4_s	1680	NUM	8	DATA	
paody4_u	1748	NUM	8	DATA	
pchdy1_f	3143	NUM	8	4	f
pchdy2_f	3146	NUM	8	4	f
pchdy3_f	3149	NUM	8	4	f

pchdy4_f	3152	NUM	8	4	f
pchdz_f	3155	NUM	8	4	f
pchedy1_f	3183	NUM	8	4	v
pchedy2_f	3186	NUM	8	4	v
pchedy3_f	3189	NUM	8	4	v
pchedy4_f	3192	NUM	8	4	v
pchedz_f	3195	NUM	8	4	v
pchtay1_f	3128	NUM	8	4	l
pchtay2_f	3131	NUM	8	4	l
pchtay3_f	3134	NUM	8	4	l
pchtay4_f	3137	NUM	8	4	l
pchtaz_f	3140	NUM	8	4	l
pd2inf100moy1_f	574	NUM	8	11	m
pd2inf100moy1_u	638	NUM	8	11	Foot
pd2inf100moy2_f	577	NUM	8	11	m
pd2inf100moy2_u	639	NUM	8	11	Foot
pd2inf100moy3_f	580	NUM	8	11	m
pd2inf100moy3_u	640	NUM	8	11	Foot
pd2inf100moy4_f	583	NUM	8	11	m
pd2inf100moy4_n	621	NUM	8	11	m
pd2inf100moy4_s	604	NUM	8	11	m
pd2inf100moy4_u	641	NUM	8	11	m
pdhdy1_f	1519	NUM	8	DATA	
pdhdy2_f	1528	NUM	8	DATA	
pdhdy3_f	1537	NUM	8	DATA	
pdhdy4_f	1546	NUM	8	DATA	
pdhdy4_n	1710	NUM	8	DATA	
pdhdy4_s	1676	NUM	8	DATA	
pdhdy4_u	1744	NUM	8	DATA	
pdmodMEFHDmy1_f	2422	NUM	8	2	j
pdmodMEFHDmy2_f	2488	NUM	8	2	j
pdmodMEFHDmy3_f	2554	NUM	8	2	j
pdmodMEFHDmy4_f	2620	NUM	8	2	j
pdmodMEFHDmy4_n	2752	NUM	8	2	j
pdmodMEFHDmy4_s	2686	NUM	8	2	j
pdmodMEFHDmy4_u	2818	NUM	8	2	j
pdmodMEFOTHUNKmy1_f	2424	NUM	8	2	j
pdmodMEFOTHUNKmy2_f	2490	NUM	8	2	j
pdmodMEFOTHUNKmy3_f	2556	NUM	8	2	j
pdmodMEFOTHUNKmy4_f	2622	NUM	8	2	j
pdmodMEFOTHUNKmy4_n	2754	NUM	8	2	j
pdmodMEFOTHUNKmy4_s	2688	NUM	8	2	j
pdmodMEFOTHUNKmy4_u	2820	NUM	8	2	j
pdmodMEFPDmy1_f	2423	NUM	8	2	j

pdmodMEFPDmy2_f	2489	NUM	8	2	j
pdmodMEFPDmy3_f	2555	NUM	8	2	j
pdmodMEFPDmy4_f	2621	NUM	8	2	j
pdmodMEFPDmy4_n	2753	NUM	8	2	j
pdmodMEFPDmy4_s	2687	NUM	8	2	j
pdmodMEFPDmy4_u	2819	NUM	8	2	j
pdody1_f	1520	NUM	8	DATA	
pdody2_f	1529	NUM	8	DATA	
pdody3_f	1538	NUM	8	DATA	
pdody4_f	1547	NUM	8	DATA	
pdody4_n	1711	NUM	8	DATA	
pdody4_s	1677	NUM	8	DATA	
pdody4_u	1745	NUM	8	DATA	
pdpaty1_f	572	NUM	8	11	k
pdpaty2_f	575	NUM	8	11	k
pdpaty3_f	578	NUM	8	11	k
pdpaty4_f	581	NUM	8	11	k
pdpaty4m_n	619	NUM	8	11	k
pdpaty4m_s	602	NUM	8	11	k
pdpaty4m_u	636	NUM	8	11	k
pdptmoy1_f	573	NUM	8	11	l
pdptmoy2_f	576	NUM	8	11	l
pdptmoy3_f	579	NUM	8	11	l
pdptmoy4_f	582	NUM	8	11	l
pdptmoy4m_n	620	NUM	8	11	l
pdptmoy4m_s	603	NUM	8	11	l
pdptmoy4m_u	637	NUM	8	11	l
pempmy1_f	2410	NUM	8	2	i
pempmy2_f	2476	NUM	8	2	i
pempmy3_f	2542	NUM	8	2	i
pempmy4_f	2608	NUM	8	2	i
pempmy4_n	2740	NUM	8	2	i
pempmy4_s	2674	NUM	8	2	i
pempmy4_u	2806	NUM	8	2	i
pFVfy1_f	3763	NUM	8	7	d
pFVfy2_f	3764	NUM	8	7	d
pFVfy3_f	3765	NUM	8	7	d
pFVhy1_f	3759	NUM	8	7	g
pFVhy2_f	3760	NUM	8	7	g
pFVhy3_f	3761	NUM	8	7	g
pFVhy4_f	3762	NUM	8	7	g
phdvapty1_f	504	NUM	8	11	a
phdvapty2_f	517	NUM	8	11	a
phdvapty3_f	530	NUM	8	11	a

phdvapty4_f	543	NUM	8	11	a
phdvapty4m_n	615	NUM	8	11	a
phdvapty4m_s	598	NUM	8	11	a
phdvapty4m_u	632	NUM	8	11	a
phdy1_f	505	NUM	8	11	b
phdy2_f	518	NUM	8	11	b
phdy3_f	531	NUM	8	11	b
phdy4_f	544	NUM	8	11	b
phdy4m_n	616	NUM	8	11	b
phdy4m_s	599	NUM	8	11	b
phdy4m_u	633	NUM	8	11	b
piavfy1_f	512	NUM	8	11	i
piavfy2_f	525	NUM	8	11	i
piavfy3_f	538	NUM	8	11	i
piavfy4_f	551	NUM	8	11	i
piavfy4_n	610	NUM	8	11	i
piavfy4_s	593	NUM	8	11	i
piavfy4_u	627	NUM	8	11	i
piavgy1_f	513	NUM	8	11	i
piavgy2_f	526	NUM	8	11	i
piavgy3_f	539	NUM	8	11	i
piavgy4_f	552	NUM	8	11	i
piavgy4_n	611	NUM	8	11	i
piavgy4_s	594	NUM	8	11	i
piavgy4_u	628	NUM	8	11	i
picathy1_f	514	NUM	8	11	i
picathy2_f	527	NUM	8	11	i
picathy3_f	540	NUM	8	11	i
picathy4_f	553	NUM	8	11	i
picathy4_n	612	NUM	8	11	i
picathy4_s	595	NUM	8	11	i
picathy4_u	629	NUM	8	11	i
pifisty1_f	516	NUM	8	11	j
pifisty2_f	529	NUM	8	11	j
pifisty3_f	542	NUM	8	11	j
pifisty4_f	555	NUM	8	11	j
pifisty4_n	614	NUM	8	11	j
pifisty4_s	597	NUM	8	11	j
pifisty4_u	631	NUM	8	11	j
piomy1_f	515	NUM	8	11	i
piomy2_f	528	NUM	8	11	i
piomy3_f	541	NUM	8	11	i
piomy4_f	554	NUM	8	11	i
piomy4_n	613	NUM	8	11	i

piomy4_s	596	NUM	8	11	i
piomy4_u	630	NUM	8	11	i
pmy1_f	2901	NUM	8	3	i
pmy2_f	2904	NUM	8	3	i
pmy3_f	2907	NUM	8	3	i
pmy4_f	2910	NUM	8	3	i
pmz_f	2913	NUM	8	3	i
potdy1_f	1524	NUM	8	DATA	
potdy2_f	1533	NUM	8	DATA	
potdy3_f	1542	NUM	8	DATA	
potdy4_f	1551	NUM	8	DATA	
potdy4_n	1715	NUM	8	DATA	
potdy4_s	1681	NUM	8	DATA	
potdy4_u	1749	NUM	8	DATA	
ppavfy1_f	506	NUM	8	11	c
ppavfy2_f	519	NUM	8	11	c
ppavfy3_f	532	NUM	8	11	c
ppavfy4_f	545	NUM	8	11	c
ppavfy4_n	605	NUM	8	11	c
ppavfy4_s	588	NUM	8	11	c
ppavfy4_u	622	NUM	8	11	c
ppavgy1_f	507	NUM	8	11	c
ppavgy2_f	520	NUM	8	11	c
ppavgy3_f	533	NUM	8	11	c
ppavgy4_f	546	NUM	8	11	c
ppavgy4_n	606	NUM	8	11	c
ppavgy4_s	589	NUM	8	11	c
ppavgy4_u	623	NUM	8	11	c
ppcathy1_f	508	NUM	8	11	c
ppcathy2_f	521	NUM	8	11	c
ppcathy3_f	534	NUM	8	11	c
ppcathy4_f	547	NUM	8	11	c
ppcathy4_n	607	NUM	8	11	c
ppcathy4_s	590	NUM	8	11	c
ppcathy4_u	624	NUM	8	11	c
ppcdy1_f	1517	NUM	8	DATA	
ppcdy2_f	1526	NUM	8	DATA	
ppcdy3_f	1535	NUM	8	DATA	
ppcdy4_f	1544	NUM	8	DATA	
ppcdy4_n	1708	NUM	8	DATA	
ppcdy4_s	1674	NUM	8	DATA	
ppcdy4_u	1742	NUM	8	DATA	
ppidy1_f	1516	NUM	8	DATA	
ppidy2_f	1525	NUM	8	DATA	



ppidy3_f	1534	NUM	8	DATA	
ppidy4_f	1543	NUM	8	DATA	
ppidy4_n	1707	NUM	8	DATA	
ppidy4_s	1673	NUM	8	DATA	
ppidy4_u	1741	NUM	8	DATA	
ppomy1_f	509	NUM	8	11	c
ppomy2_f	522	NUM	8	11	c
ppomy3_f	535	NUM	8	11	c
ppomy4_f	548	NUM	8	11	c
ppomy4_n	608	NUM	8	11	c
ppomy4_s	591	NUM	8	11	c
ppomy4_u	625	NUM	8	11	c
PPPWchiy1_f	3460	NUM	8	6	g
PPPWchiy2_f	3464	NUM	8	6	g
PPPWchiy3_f	3468	NUM	8	6	g
PPPWchiy4_f	3472	NUM	8	6	g
PPPWcloy1_f	3459	NUM	8	6	g
PPPWcloy2_f	3463	NUM	8	6	g
PPPWcloy3_f	3467	NUM	8	6	g
PPPWcloy4_f	3471	NUM	8	6	g
pppwpm1_f	3473	NUM	8	6	b
pppwpm2_f	3493	NUM	8	6	b
pppwpm3_f	3513	NUM	8	6	b
pppwpm4_f	3533	NUM	8	6	b
pppwpm4m_n	3618	NUM	8	6	b
pppwpm4m_s	3592	NUM	8	6	b
pppwpm4m_u	3644	NUM	8	6	b
pppwpty1_f	3474	NUM	8	6	a
pppwpty2_f	3494	NUM	8	6	a
pppwpty3_f	3514	NUM	8	6	a
pppwpty4_f	3534	NUM	8	6	a
pppwpty4m_n	3599	NUM	8	6	a
pppwpty4m_s	3573	NUM	8	6	a
pppwpty4m_u	3625	NUM	8	6	a
PPPWpvaluey1_f	3458	NUM	8	6	f
PPPWpvaluey2_f	3462	NUM	8	6	f
PPPWpvaluey3_f	3466	NUM	8	6	f
PPPWpvaluey4_f	3470	NUM	8	6	f
pppwy1_f	3457	NUM	8	6	e
pppwy2_f	3461	NUM	8	6	e
pppwy3_f	3465	NUM	8	6	e
pppwy4_f	3469	NUM	8	6	e
pppwy4_n	3619	NUM	8	6	e
pppwy4_s	3593	NUM	8	6	e

pppwy4_u	3645	NUM	8	6	e
pptdy1_f	1518	NUM	8	DATA	
pptdy2_f	1527	NUM	8	DATA	
pptdy3_f	1536	NUM	8	DATA	
pptdy4_f	1545	NUM	8	DATA	
pptdy4_n	1709	NUM	8	DATA	
pptdy4_s	1675	NUM	8	DATA	
pptdy4_u	1743	NUM	8	DATA	
preepomy1_f	2432	NUM	8	2	r
preepomy2_f	2498	NUM	8	2	r
preepomy3_f	2564	NUM	8	2	r
preepomy4_f	2630	NUM	8	2	r
preepomy4_n	2762	NUM	8	2	r
preepomy4_s	2696	NUM	8	2	r
preepomy4_u	2828	NUM	8	2	r
PROV1	833	CHAR	6	13	h
PROV2	834	CHAR	6	13	h
PROV3	835	CHAR	6	13	h
PROVCITY	3	CHAR	20	ID	
provfs	1	CHAR	10	ID	
ptcareFTy1_f	1572	NUM	8	DATA	
ptcareFTy2_f	1604	NUM	8	DATA	
ptcareFTy3_f	1636	NUM	8	DATA	
ptcareFTy4_f	1663	NUM	8	DATA	
ptcareFTy4m_n	1730	NUM	8	DATA	
ptcareFTy4m_s	1696	NUM	8	DATA	
ptcareFTy4m_u	1764	NUM	8	DATA	
ptcarePTy1_f	1573	NUM	8	DATA	
ptcarePTy2_f	1605	NUM	8	DATA	
ptcarePTy3_f	1637	NUM	8	DATA	
ptcarePTy4_f	1664	NUM	8	DATA	
ptcarePTy4m_n	1734	NUM	8	DATA	
ptcarePTy4m_s	1700	NUM	8	DATA	
ptcarePTy4m_u	1768	NUM	8	DATA	
ptfy1_f	3954	NUM	8	8	p
ptfy2_f	3957	NUM	8	8	p
ptfy3_f	3960	NUM	8	8	p
ptfy4_f	3963	NUM	8	8	p
ptinfnmy1_f	2449	NUM	8	2	u
ptinfnmy2_f	2515	NUM	8	2	u
ptinfnmy3_f	2581	NUM	8	2	u
ptinfnmy4_f	2647	NUM	8	2	u
ptinfnmy4m_n	2781	NUM	8	2	u
ptinfnmy4m_s	2715	NUM	8	2	u

ptinfnmy4m_u	2848	NUM	8	2	u
ptinfy1_f	2438	NUM	8	2	t
ptinfy2_f	2504	NUM	8	2	t
ptinfy3_f	2570	NUM	8	2	t
ptinfy4_f	2636	NUM	8	2	t
ptinfy4_n	2768	NUM	8	2	t
ptinfy4_s	2702	NUM	8	2	t
ptinfy4_u	2835	NUM	8	2	t
ptxagedmy1_f	2440	NUM	8	2	v
ptxagedmy2_f	2506	NUM	8	2	v
ptxagedmy3_f	2572	NUM	8	2	v
ptxagedmy4_f	2638	NUM	8	2	v
ptxagedmy4_n	2770	NUM	8	2	v
ptxagedmy4_s	2704	NUM	8	2	v
ptxagedmy4_u	2837	NUM	8	2	v
ptxdeclinemy1_f	2442	NUM	8	2	v
ptxdeclinemy2_f	2508	NUM	8	2	v
ptxdeclinemy3_f	2574	NUM	8	2	v
ptxdeclinemy4_f	2640	NUM	8	2	v
ptxdeclinemy4_n	2772	NUM	8	2	v
ptxdeclinemy4_s	2706	NUM	8	2	v
ptxdeclinemy4_u	2839	NUM	8	2	v
ptxdy1_f	1521	NUM	8	DATA	
ptxdy2_f	1530	NUM	8	DATA	
ptxdy3_f	1539	NUM	8	DATA	
ptxdy4_f	1548	NUM	8	DATA	
ptxdy4_n	1712	NUM	8	DATA	
ptxdy4_s	1678	NUM	8	DATA	
ptxdy4_u	1746	NUM	8	DATA	
ptxmedunfitmy1_f	2439	NUM	8	2	v
ptxmedunfitmy2_f	2505	NUM	8	2	v
ptxmedunfitmy3_f	2571	NUM	8	2	v
ptxmedunfitmy4_f	2637	NUM	8	2	v
ptxmedunfitmy4_n	2769	NUM	8	2	v
ptxmedunfitmy4_s	2703	NUM	8	2	v
ptxmedunfitmy4_u	2836	NUM	8	2	v
ptxnotassessmy1_f	2443	NUM	8	2	v
ptxnotassessmy2_f	2509	NUM	8	2	v
ptxnotassessmy3_f	2575	NUM	8	2	v
ptxnotassessmy4_f	2641	NUM	8	2	v
ptxnotassessmy4_n	2773	NUM	8	2	v
ptxnotassessmy4_s	2707	NUM	8	2	v
ptxnotassessmy4_u	2840	NUM	8	2	v
ptxpsyunfitmy1_f	2441	NUM	8	2	v

ptxpsyunfitmy2_f	2507	NUM	8	2	v
ptxpsyunfitmy3_f	2573	NUM	8	2	v
ptxpsyunfitmy4_f	2639	NUM	8	2	v
ptxpsyunfitmy4_n	2771	NUM	8	2	v
ptxpsyunfitmy4_s	2705	NUM	8	2	v
ptxpsyunfitmy4_u	2838	NUM	8	2	v
ptz_f	3422	NUM	8	5	i
pv_pd2infy1_f	584	NUM	8	12	n
pv_pd2infy2_f	585	NUM	8	12	n
pv_pd2infy3_f	586	NUM	8	12	n
pv_pd2infy4_f	587	NUM	8	12	n
pvdmy1_f	2401	NUM	8	2	w
pvdmy2_f	2467	NUM	8	2	w
pvdmy3_f	2533	NUM	8	2	w
pvdmy4_f	2599	NUM	8	2	w
pvdmy4_n	2731	NUM	8	2	w
pvdmy4_s	2665	NUM	8	2	w
pvdmy4_u	2797	NUM	8	2	w
rac1y1_f	151	NUM	8	1	e
rac1y2_f	182	NUM	8	1	e
rac1y3_f	213	NUM	8	1	e
rac1y4_f	244	NUM	8	1	e
rac1y4_n	309	NUM	8	1	e
rac1y4_s	278	NUM	8	1	e
rac1y4_u	340	NUM	8	1	e
rac2y1_f	152	NUM	8	1	e
rac2y2_f	183	NUM	8	1	e
rac2y3_f	214	NUM	8	1	e
rac2y4_f	245	NUM	8	1	e
rac2y4_n	310	NUM	8	1	e
rac2y4_s	279	NUM	8	1	e
rac2y4_u	341	NUM	8	1	e
rac3y1_f	153	NUM	8	1	e
rac3y2_f	184	NUM	8	1	e
rac3y3_f	215	NUM	8	1	e
rac3y4_f	246	NUM	8	1	e
rac3y4_n	311	NUM	8	1	e
rac3y4_s	280	NUM	8	1	e
rac3y4_u	342	NUM	8	1	e
rac4y1_f	154	NUM	8	1	e
rac4y2_f	185	NUM	8	1	e
rac4y3_f	216	NUM	8	1	e
rac4y4_f	247	NUM	8	1	e
rac4y4_n	312	NUM	8	1	e

rac4y4_s	281	NUM	8	1	e
rac4y4_u	343	NUM	8	1	e
rac5y1_f	155	NUM	8	1	e
rac5y2_f	186	NUM	8	1	e
rac5y3_f	217	NUM	8	1	e
rac5y4_f	248	NUM	8	1	e
rac5y4_n	313	NUM	8	1	e
rac5y4_s	282	NUM	8	1	e
rac5y4_u	344	NUM	8	1	e
racoummy1_f	2408	NUM	8	2	d
racoummy2_f	2474	NUM	8	2	d
racoummy3_f	2540	NUM	8	2	d
racoummy4_f	2606	NUM	8	2	d
racoummy4_n	2738	NUM	8	2	d
racoummy4_s	2672	NUM	8	2	d
racoummy4_u	2804	NUM	8	2	d
rdsallty1_f	3391	NUM	8	5	a
rdsallty2_f	3399	NUM	8	5	a
rdsallty3_f	3407	NUM	8	5	a
rdsallty4_f	3415	NUM	8	5	a
rdsalltz_f	3385	NUM	8	5	a
rdsalltzm_n	3438	NUM	8	5	a
rdsalltzm_s	3429	NUM	8	5	a
rdsalltzm_u	3447	NUM	8	5	a
rdsey1_f	3165	NUM	8	DATA	
rdsey2_f	3170	NUM	8	DATA	
rdsey3_f	3175	NUM	8	DATA	
rdsey4_f	3180	NUM	8	DATA	
rdsez_f	3161	NUM	8	DATA	
rdsezm_n	3345	NUM	8	DATA	
rdsezm_s	3315	NUM	8	DATA	
rdsezm_u	3375	NUM	8	DATA	
rdshy1_f	3064	NUM	8	4	a
rdshy2_f	3080	NUM	8	4	a
rdshy3_f	3096	NUM	8	4	a
rdshy4_f	3112	NUM	8	4	a
rdshz_f	3048	NUM	8	4	a
rdshzm_n	3321	NUM	8	4	a
rdshzm_s	3291	NUM	8	4	a
rdshzm_u	3351	NUM	8	4	a
rdsmy1_f	2861	NUM	8	3	a
rdsmy2_f	2871	NUM	8	3	a
rdsmy3_f	2881	NUM	8	3	a
rdsmy4_f	2891	NUM	8	3	a

rdsmz_f	2851	NUM	8	3	a
rdsmzm_n	3010	NUM	8	3	a
rdsmzm_s	2991	NUM	8	3	a
rdsmzm_u	3029	NUM	8	3	a
rdstfy1_f	3934	NUM	8	8	k
rdstfy2_f	3939	NUM	8	8	k
rdstfy3_f	3944	NUM	8	8	k
rdstfy4_f	3949	NUM	8	8	k
rdstfy4m_n	4007	NUM	8	8	k
rdstfy4m_s	3984	NUM	8	8	k
rdstfy4m_u	4030	NUM	8	8	k
rdsty1_f	3390	NUM	8	5	d
rdsty2_f	3398	NUM	8	5	d
rdsty3_f	3406	NUM	8	5	d
rdsty4_f	3414	NUM	8	5	d
rdstz_f	3381	NUM	8	5	d
rdstzm_n	3437	NUM	8	5	d
rdstzm_s	3428	NUM	8	5	d
rdstzm_u	3446	NUM	8	5	d
readmmy4_n	3343	NUM	8	4	ae
readmmy4_s	3313	NUM	8	4	ae
readmmy4_u	3373	NUM	8	4	ae
readmy1_f	3234	NUM	8	4	ae
readmy2_f	3241	NUM	8	4	ae
readmy3_f	3248	NUM	8	4	ae
readmy4_f	3255	NUM	8	4	ae
rkfymny1_f	2978	NUM	8	3	u
rkfymny2_f	2979	NUM	8	3	u
rkfymny3_f	2980	NUM	8	3	u
rkfymnz_f	2981	NUM	8	3	u
rkfymsy1_f	2969	NUM	8	3	u
rkfymsy2_f	2970	NUM	8	3	u
rkfymsy3_f	2971	NUM	8	3	u
rkfymsz_f	2972	NUM	8	3	u
rkfymuy1_f	2987	NUM	8	3	u
rkfymuy2_f	2988	NUM	8	3	u
rkfymuy3_f	2989	NUM	8	3	u
rkfymuz_f	2990	NUM	8	3	u
rkmny1_f	2973	NUM	8	3	k
rkmny2_f	2974	NUM	8	3	k
rkmny3_f	2975	NUM	8	3	k
rkmny4_f	2976	NUM	8	3	k
rkmnz_f	2977	NUM	8	3	k
rkmsy1_f	2964	NUM	8	3	k

rkmsy2_f	2965	NUM	8	3	k
rkmsy3_f	2966	NUM	8	3	k
rkmsy4_f	2967	NUM	8	3	k
rkmsz_f	2968	NUM	8	3	k
rkmuy1_f	2982	NUM	8	3	k
rkmuy2_f	2983	NUM	8	3	k
rkmuy3_f	2984	NUM	8	3	k
rkmuy4_f	2985	NUM	8	3	k
rkmuz_f	2986	NUM	8	3	k
rkshrdny1_f	3276	NUM	8	4	h
rkshrdny2_f	3277	NUM	8	4	h
rkshrdny3_f	3278	NUM	8	4	h
rkshrdny4_f	3279	NUM	8	4	h
rkshrdnz_f	3280	NUM	8	4	h
rkshrdsy1_f	3266	NUM	8	4	h
rkshrdsy2_f	3267	NUM	8	4	h
rkshrdsy3_f	3268	NUM	8	4	h
rkshrdsy4_f	3269	NUM	8	4	h
rkshrdsz_f	3270	NUM	8	4	h
rkshrduy1_f	3286	NUM	8	4	h
rkshrduy2_f	3287	NUM	8	4	h
rkshrduy3_f	3288	NUM	8	4	h
rkshrduy4_f	3289	NUM	8	4	h
rkshrduz_f	3290	NUM	8	4	h
rkshrtny1_f	3271	NUM	8	4	n
rkshrtny2_f	3272	NUM	8	4	n
rkshrtny3_f	3273	NUM	8	4	n
rkshrtny4_f	3274	NUM	8	4	n
rkshrtnz_f	3275	NUM	8	4	n
rkshrtsy1_f	3261	NUM	8	4	n
rkshrtsy2_f	3262	NUM	8	4	n
rkshrtsy3_f	3263	NUM	8	4	n
rkshrtsy4_f	3264	NUM	8	4	n
rkshrtsz_f	3265	NUM	8	4	n
rkshrtuy1_f	3281	NUM	8	4	n
rkshrtuy2_f	3282	NUM	8	4	n
rkshrtuy3_f	3283	NUM	8	4	n
rkshrtuy4_f	3284	NUM	8	4	n
rkshrtuz_f	3285	NUM	8	4	n
rktnz_f	3426	NUM	8	5	k
rktz_f	3425	NUM	8	5	k
rktuz_f	3427	NUM	8	5	k
salbmy1_f	2417	NUM	8	2	o
salbmy2_f	2483	NUM	8	2	o

salbmy3_f	2549	NUM	8	2	o
salbmy4_f	2615	NUM	8	2	o
salbmy4_n	2747	NUM	8	2	o
salbmy4_s	2681	NUM	8	2	o
salbmy4_u	2813	NUM	8	2	o
schooly1_f	1583	NUM	8	DATA	
schooly2_f	1615	NUM	8	DATA	
schooly3_f	1647	NUM	8	DATA	
schooly4_f	1672	NUM	8	DATA	
schooly4_n	1740	NUM	8	DATA	
schooly4_s	1706	NUM	8	DATA	
schooly4_u	1774	NUM	8	DATA	
sedry1_f	3167	NUM	8	4	u
sedry2_f	3172	NUM	8	4	u
sedry3_f	3177	NUM	8	4	u
sedry4_f	3182	NUM	8	4	u
sedrz_f	3162	NUM	8	4	u
sedrz_n	3350	NUM	8	4	u
sedrz_s	3320	NUM	8	4	u
sedrz_u	3380	NUM	8	4	u
sepiy1_f	3071	NUM	8	4	o
sepiy2_f	3087	NUM	8	4	o
sepiy3_f	3103	NUM	8	4	o
sepiy4_f	3119	NUM	8	4	o
sepiz_f	3059	NUM	8	4	o
sepiz_n	3332	NUM	8	4	o
sepiz_s	3302	NUM	8	4	o
sepiz_u	3362	NUM	8	4	o
serumphospatsy1_f	365	NUM	8	DATA	
serumphospatsy2_f	386	NUM	8	DATA	
serumphospatsy3_f	407	NUM	8	DATA	
serumphospatsy4_f	428	NUM	8	DATA	
serumphospatsy4m_n	479	NUM	8	DATA	
serumphospatsy4m_s	458	NUM	8	DATA	
serumphospatsy4m_u	500	NUM	8	DATA	
serumphospmy1_f	366	NUM	8	DATA	
serumphospmy2_f	387	NUM	8	DATA	
serumphospmy3_f	408	NUM	8	DATA	
serumphospmy4_f	429	NUM	8	DATA	
serumphospmy4m_n	480	NUM	8	DATA	
serumphospmy4m_s	459	NUM	8	DATA	
serumphospmy4m_u	501	NUM	8	DATA	
sexy1_f	164	NUM	8	1	d
sexy2_f	195	NUM	8	1	d



sexy3_f	226	NUM	8	1	d
sexy4_f	257	NUM	8	1	d
sexy4_n	317	NUM	8	1	d
sexy4_s	286	NUM	8	1	d
sexy4_u	348	NUM	8	1	d
sfrlcly1_f	559	NUM	8	11	f
sfrlcly2_f	563	NUM	8	11	f
sfrlcly3_f	567	NUM	8	11	f
sfrlcly4_f	571	NUM	8	11	f
sfrpy1_f	557	NUM	8	11	e
sfrpy2_f	561	NUM	8	11	e
sfrpy3_f	565	NUM	8	11	e
sfrpy4_f	569	NUM	8	11	e
sfrucly1_f	558	NUM	8	11	f
sfrucly2_f	562	NUM	8	11	f
sfrucly3_f	566	NUM	8	11	f
sfrucly4_f	570	NUM	8	11	f
sfrly1_f	556	NUM	8	11	d
sfrly2_f	560	NUM	8	11	d
sfrly3_f	564	NUM	8	11	d
sfrly4_f	568	NUM	8	11	d
sfrly4_n	618	NUM	8	11	d
sfrly4_s	601	NUM	8	11	d
sfrly4_u	635	NUM	8	11	d
shrdy1_f	3076	NUM	8	4	e
shrdy2_f	3092	NUM	8	4	e
shrdy3_f	3108	NUM	8	4	e
shrdy4_f	3124	NUM	8	4	e
shrdz_f	3055	NUM	8	4	e
shrdz_n	3328	NUM	8	4	e
shrdz_s	3298	NUM	8	4	e
shrdz_u	3358	NUM	8	4	e
shrty1_f	3075	NUM	8	4	k
shrty2_f	3091	NUM	8	4	k
shrty3_f	3107	NUM	8	4	k
shrty4_f	3123	NUM	8	4	k
shrtz_f	3054	NUM	8	4	k
shrtz_n	3327	NUM	8	4	k
shrtz_s	3297	NUM	8	4	k
shrtz_u	3357	NUM	8	4	k
smokmy1_f	2402	NUM	8	2	w
smokmy2_f	2468	NUM	8	2	w
smokmy3_f	2534	NUM	8	2	w
smokmy4_f	2600	NUM	8	2	w

smokmy4_n	2732	NUM	8	2	w
smokmy4_s	2666	NUM	8	2	w
smokmy4_u	2798	NUM	8	2	w
smry1_f	2870	NUM	8	3	h
smry2_f	2880	NUM	8	3	h
smry3_f	2890	NUM	8	3	h
smry4_f	2900	NUM	8	3	h
smrz_f	2856	NUM	8	3	h
smrz_n	3015	NUM	8	3	h
smrz_s	2996	NUM	8	3	h
smrz_u	3034	NUM	8	3	h
socwkFTy1_f	1576	NUM	8	DATA	
socwkFTy2_f	1608	NUM	8	DATA	
socwkFTy3_f	1640	NUM	8	DATA	
socwkFTy4_f	1667	NUM	8	DATA	
socwkFTy4m_n	1732	NUM	8	DATA	
socwkFTy4m_s	1698	NUM	8	DATA	
socwkFTy4m_u	1766	NUM	8	DATA	
socwkPTy1_f	1577	NUM	8	DATA	
socwkPTy2_f	1609	NUM	8	DATA	
socwkPTy3_f	1641	NUM	8	DATA	
socwkPTy4_f	1668	NUM	8	DATA	
socwkPTy4m_n	1736	NUM	8	DATA	
socwkPTy4m_s	1702	NUM	8	DATA	
socwkPTy4m_u	1770	NUM	8	DATA	
srrexpmy4_n	3344	NUM	8	4	af
srrexpmy4_s	3314	NUM	8	4	af
srrexpmy4_u	3374	NUM	8	4	af
srrepxy1_f	3239	NUM	8	4	af
srrepxy2_f	3246	NUM	8	4	af
srrepxy3_f	3253	NUM	8	4	af
srrepxy4_f	3260	NUM	8	4	af
srrlclly1_f	3236	NUM	8	4	ai
srrlclly2_f	3243	NUM	8	4	ai
srrlclly3_f	3250	NUM	8	4	ai
srrlclly4_f	3257	NUM	8	4	ai
srrpy1_f	3238	NUM	8	4	ah
srrpy2_f	3245	NUM	8	4	ah
srrpy3_f	3252	NUM	8	4	ah
srrpy4_f	3259	NUM	8	4	ah
srruclly1_f	3237	NUM	8	4	ai
srruclly2_f	3244	NUM	8	4	ai
srruclly3_f	3251	NUM	8	4	ai
srruclly4_f	3258	NUM	8	4	ai

srry1_f	3235	NUM	8	4	ag
srry2_f	3242	NUM	8	4	ag
srry3_f	3249	NUM	8	4	ag
srry4_f	3256	NUM	8	4	ag
srry4_n	3341	NUM	8	4	ag
srry4_s	3311	NUM	8	4	ag
srry4_u	3371	NUM	8	4	ag
srvy_prpse_cd	825	CHAR	8	13	r
staffy1_f	1569	NUM	8	DATA	
staffy2_f	1601	NUM	8	DATA	
staffy3_f	1633	NUM	8	DATA	
staffy4_f	1660	NUM	8	DATA	
staffy4m_n	1728	NUM	8	DATA	
staffy4m_s	1694	NUM	8	DATA	
staffy4m_u	1762	NUM	8	DATA	
STATE	4	CHAR	2	ID	
std_f	828	NUM	8	13	u
std_N	856	NUM	8	13	u
std_S	847	NUM	8	13	u
std_U	865	NUM	8	13	u
stry1_f	3938	NUM	8	8	o
stry2_f	3943	NUM	8	8	o
stry3_f	3948	NUM	8	8	o
stry4_f	3953	NUM	8	8	o
stry4_n	4011	NUM	8	8	o
stry4_s	3988	NUM	8	8	o
stry4_u	4034	NUM	8	8	o
strz_f	3389	NUM	8	5	h
strz_n	3445	NUM	8	5	h
strz_s	3436	NUM	8	5	h
strz_u	3454	NUM	8	5	h
survey_dt	824	NUM	8	13	q
SV_DIALYZER_REUSE	836	CHAR	1	13	g
SV_SHIFT_START_AFTER_5_PM	837	CHAR	1	13	f
swrchiz_f	3571	NUM	8	6	n
swrcloz_f	3572	NUM	8	6	n
swrexwly1_f	3558	NUM	8	6	k
swrexwly2_f	3562	NUM	8	6	k
swrexwly3_f	3566	NUM	8	6	k
swrexwlz_f	3554	NUM	8	6	k
swrexwlzm_n	3623	NUM	8	6	k
swrexwlzm_s	3597	NUM	8	6	k
swrexwlzm_u	3649	NUM	8	6	k
swrpty1_f	3561	NUM	8	6	h

swrpty2_f	3565	NUM	8	6	h
swrpty3_f	3569	NUM	8	6	h
swrptz_f	3556	NUM	8	6	h
swrptzm_n	3620	NUM	8	6	h
swrptzm_s	3594	NUM	8	6	h
swrptzm_u	3646	NUM	8	6	h
swrpvaluez_f	3570	NUM	8	6	m
swrppy1_f	3560	NUM	8	6	i
swrppy2_f	3564	NUM	8	6	i
swrppy3_f	3568	NUM	8	6	i
swrpyz_f	3555	NUM	8	6	i
swrpyzm_n	3621	NUM	8	6	i
swrpyzm_s	3595	NUM	8	6	i
swrpyzm_u	3647	NUM	8	6	i
swrwly1_f	3559	NUM	8	6	j
swrwly2_f	3563	NUM	8	6	j
swrwly3_f	3567	NUM	8	6	j
swrwlz_f	3553	NUM	8	6	j
swrwlm_n	3622	NUM	8	6	j
swrwlm_s	3596	NUM	8	6	j
swrwlm_u	3648	NUM	8	6	j
swrz_f	3557	NUM	8	6	l
swrz_n	3624	NUM	8	6	l
swrz_s	3598	NUM	8	6	l
swrz_u	3650	NUM	8	6	l
tfy1_f	3935	NUM	8	8	m
tfy2_f	3940	NUM	8	8	m
tfy3_f	3945	NUM	8	8	m
tfy4_f	3950	NUM	8	8	m
tfy4m_n	4009	NUM	8	8	m
tfy4m_s	3986	NUM	8	8	m
tfy4m_u	4032	NUM	8	8	m
tfyy1_f	3936	NUM	8	8	l
tfyy2_f	3941	NUM	8	8	l
tfyy3_f	3946	NUM	8	8	l
tfyy4_f	3951	NUM	8	8	l
tfyy4m_n	4008	NUM	8	8	l
tfyy4m_s	3985	NUM	8	8	l
tfyy4m_u	4031	NUM	8	8	l
transiny1_f	1580	NUM	8	DATA	
transiny2_f	1612	NUM	8	DATA	
transiny3_f	1644	NUM	8	DATA	
transiny4_f	822	NUM	8	13	m
transiny4_n	850	NUM	8	13	m

transiny4_s	841	NUM	8	13	m
transiny4_u	859	NUM	8	13	m
transmy1_f	2399	NUM	8	2	w
transmy2_f	2465	NUM	8	2	w
transmy3_f	2531	NUM	8	2	w
transmy4_f	2597	NUM	8	2	w
transmy4_n	2729	NUM	8	2	w
transmy4_s	2663	NUM	8	2	w
transmy4_u	2795	NUM	8	2	w
transouty1_f	1581	NUM	8	DATA	
transouty2_f	1613	NUM	8	DATA	
transouty3_f	1645	NUM	8	DATA	
transouty4_f	823	NUM	8	13	n
transouty4_n	851	NUM	8	13	n
transouty4_s	842	NUM	8	13	n
transouty4_u	860	NUM	8	13	n
txally1_f	3394	NUM	8	5	b
txally2_f	3402	NUM	8	5	b
txally3_f	3410	NUM	8	5	b
txally4_f	3418	NUM	8	5	b
txallz_f	3386	NUM	8	5	b
txallzm_n	3440	NUM	8	5	b
txallzm_s	3431	NUM	8	5	b
txallzm_u	3449	NUM	8	5	b
txp_lt_90d	3455	NUM	8	5	Foot
txp_not_asgnd	3456	NUM	8	5	Foot
txy1_f	3395	NUM	8	5	f
txy2_f	3403	NUM	8	5	f
txy3_f	3411	NUM	8	5	f
txy4_f	3419	NUM	8	5	f
txyy1_f	3396	NUM	8	5	e
txyy2_f	3404	NUM	8	5	e
txyy3_f	3412	NUM	8	5	e
txyy4_f	3420	NUM	8	5	e
txyz_f	3384	NUM	8	5	e
txyzm_n	3441	NUM	8	5	e
txyzm_s	3432	NUM	8	5	e
txyzm_u	3450	NUM	8	5	e
txz_f	3382	NUM	8	5	f
txzm_n	3439	NUM	8	5	f
txzm_s	3430	NUM	8	5	f
txzm_u	3448	NUM	8	5	f
US	4280	NUM	8	ID	
vin1y1_f	159	NUM	8	1	i

vin1y2_f	190	NUM	8	1	i
vin1y3_f	221	NUM	8	1	i
vin1y4_f	252	NUM	8	1	i
vin1y4_n	304	NUM	8	1	i
vin1y4_s	273	NUM	8	1	i
vin1y4_u	335	NUM	8	1	i
vin2y1_f	160	NUM	8	1	i
vin2y2_f	191	NUM	8	1	i
vin2y3_f	222	NUM	8	1	i
vin2y4_f	253	NUM	8	1	i
vin2y4_n	305	NUM	8	1	i
vin2y4_s	274	NUM	8	1	i
vin2y4_u	336	NUM	8	1	i
vin3y1_f	161	NUM	8	1	i
vin3y2_f	192	NUM	8	1	i
vin3y3_f	223	NUM	8	1	i
vin3y4_f	254	NUM	8	1	i
vin3y4_n	306	NUM	8	1	i
vin3y4_s	275	NUM	8	1	i
vin3y4_u	337	NUM	8	1	i
vin4y1_f	162	NUM	8	1	i
vin4y2_f	193	NUM	8	1	i
vin4y3_f	224	NUM	8	1	i
vin4y4_f	255	NUM	8	1	i
vin4y4_n	307	NUM	8	1	i
vin4y4_s	276	NUM	8	1	i
vin4y4_u	338	NUM	8	1	i
vin5y1_f	163	NUM	8	1	i
vin5y2_f	194	NUM	8	1	i
vin5y3_f	225	NUM	8	1	i
vin5y4_f	256	NUM	8	1	i
vin5y4_n	308	NUM	8	1	i
vin5y4_s	277	NUM	8	1	i
vin5y4_u	339	NUM	8	1	i
viny1_f	142	NUM	8	1	h
viny2_f	173	NUM	8	1	h
viny3_f	204	NUM	8	1	h
viny4_f	235	NUM	8	1	h
viny4_n	319	NUM	8	1	h
viny4_s	288	NUM	8	1	h
viny4_u	350	NUM	8	1	h
vocrehaby1_f	1578	NUM	8	DATA	
vocrehaby2_f	1610	NUM	8	DATA	
vocrehaby3_f	1642	NUM	8	DATA	

vocrehab4_f	1669	NUM	8	DATA	
vocrehab4m_n	1737	NUM	8	DATA	
vocrehab4m_s	1703	NUM	8	DATA	
vocrehab4m_u	1771	NUM	8	DATA	
whitemy1_f	2404	NUM	8	2	d
whitemy2_f	2470	NUM	8	2	d
whitemy3_f	2536	NUM	8	2	d
whitemy4_f	2602	NUM	8	2	d
whitemy4_n	2734	NUM	8	2	d
whitemy4_s	2668	NUM	8	2	d
whitemy4_u	2800	NUM	8	2	d
wity1_f	2866	NUM	8	3	e
wity2_f	2876	NUM	8	3	e
wity3_f	2886	NUM	8	3	e
wity4_f	2896	NUM	8	3	e
witz_f	2857	NUM	8	3	e
witz_n	3016	NUM	8	3	e
witz_s	2997	NUM	8	3	e
witz_u	3035	NUM	8	3	e
WL4074y1_f	3477	NUM	8	6	d
WL4074y2_f	3497	NUM	8	6	d
WL4074y3_f	3517	NUM	8	6	d
WL4074y4_f	3537	NUM	8	6	d
WL4074y4_n	3602	NUM	8	6	d
WL4074y4_s	3576	NUM	8	6	d
WL4074y4_u	3628	NUM	8	6	d
WLasy1_f	3483	NUM	8	6	d
WLasy2_f	3503	NUM	8	6	d
WLasy3_f	3523	NUM	8	6	d
WLasy4_f	3543	NUM	8	6	d
WLasy4_n	3608	NUM	8	6	d
WLasy4_s	3582	NUM	8	6	d
WLasy4_u	3634	NUM	8	6	d
WLbly1_f	3482	NUM	8	6	d
WLbly2_f	3502	NUM	8	6	d
WLbly3_f	3522	NUM	8	6	d
WLbly4_f	3542	NUM	8	6	d
WLbly4_n	3607	NUM	8	6	d
WLbly4_s	3581	NUM	8	6	d
WLbly4_u	3633	NUM	8	6	d
WLDMy1_f	3486	NUM	8	6	d
WLDMy2_f	3506	NUM	8	6	d
WLDMy3_f	3526	NUM	8	6	d
WLDMy4_f	3546	NUM	8	6	d

WLDMy4_n	3611	NUM	8	6	d
WLDMy4_s	3585	NUM	8	6	d
WLDMy4_u	3637	NUM	8	6	d
Wlfemy1_f	3479	NUM	8	6	d
Wlfemy2_f	3499	NUM	8	6	d
Wlfemy3_f	3519	NUM	8	6	d
Wlfemy4_f	3539	NUM	8	6	d
Wlfemy4_n	3604	NUM	8	6	d
Wlfemy4_s	3578	NUM	8	6	d
Wlfemy4_u	3630	NUM	8	6	d
Wlit40y1_f	3476	NUM	8	6	d
Wlit40y2_f	3496	NUM	8	6	d
Wlit40y3_f	3516	NUM	8	6	d
Wlit40y4_f	3536	NUM	8	6	d
Wlit40y4_n	3601	NUM	8	6	d
Wlit40y4_s	3575	NUM	8	6	d
Wlit40y4_u	3627	NUM	8	6	d
Wlmaley1_f	3478	NUM	8	6	d
Wlmaley2_f	3498	NUM	8	6	d
Wlmaley3_f	3518	NUM	8	6	d
Wlmaley4_f	3538	NUM	8	6	d
Wlmaley4_n	3603	NUM	8	6	d
Wlmaley4_s	3577	NUM	8	6	d
Wlmaley4_u	3629	NUM	8	6	d
Wlnay1_f	3484	NUM	8	6	d
Wlnay2_f	3504	NUM	8	6	d
Wlnay3_f	3524	NUM	8	6	d
Wlnay4_f	3544	NUM	8	6	d
Wlnay4_n	3609	NUM	8	6	d
Wlnay4_s	3583	NUM	8	6	d
Wlnay4_u	3635	NUM	8	6	d
Wlnodmy1_f	3487	NUM	8	6	d
Wlnodmy2_f	3507	NUM	8	6	d
Wlnodmy3_f	3527	NUM	8	6	d
Wlnodmy4_f	3547	NUM	8	6	d
Wlnodmy4_n	3612	NUM	8	6	d
Wlnodmy4_s	3586	NUM	8	6	d
Wlnodmy4_u	3638	NUM	8	6	d
Wlnotxy1_f	3488	NUM	8	6	d
Wlnotxy2_f	3508	NUM	8	6	d
Wlnotxy3_f	3528	NUM	8	6	d
Wlnotxy4_f	3548	NUM	8	6	d
Wlnotxy4_n	3613	NUM	8	6	d
Wlnotxy4_s	3587	NUM	8	6	d



WLnotxy4_u	3639	NUM	8	6	d
WLothy1_f	3485	NUM	8	6	d
WLothy2_f	3505	NUM	8	6	d
WLothy3_f	3525	NUM	8	6	d
WLothy4_f	3545	NUM	8	6	d
WLothy4_n	3610	NUM	8	6	d
WLothy4_s	3584	NUM	8	6	d
WLothy4_u	3636	NUM	8	6	d
WLtxy1_f	3489	NUM	8	6	d
WLtxy2_f	3509	NUM	8	6	d
WLtxy3_f	3529	NUM	8	6	d
WLtxy4_f	3549	NUM	8	6	d
WLtxy4_n	3614	NUM	8	6	d
WLtxy4_s	3588	NUM	8	6	d
WLtxy4_u	3640	NUM	8	6	d
WLVCat1y1_f	3490	NUM	8	6	d
WLVCat1y2_f	3510	NUM	8	6	d
WLVCat1y3_f	3530	NUM	8	6	d
WLVCat1y4_f	3550	NUM	8	6	d
WLVCat1y4_n	3615	NUM	8	6	d
WLVCat1y4_s	3589	NUM	8	6	d
WLVCat1y4_u	3641	NUM	8	6	d
WLVCat2y1_f	3491	NUM	8	6	d
WLVCat2y2_f	3511	NUM	8	6	d
WLVCat2y3_f	3531	NUM	8	6	d
WLVCat2y4_f	3551	NUM	8	6	d
WLVCat2y4_n	3616	NUM	8	6	d
WLVCat2y4_s	3590	NUM	8	6	d
WLVCat2y4_u	3642	NUM	8	6	d
WLVCat3y1_f	3492	NUM	8	6	d
WLVCat3y2_f	3512	NUM	8	6	d
WLVCat3y3_f	3532	NUM	8	6	d
WLVCat3y4_f	3552	NUM	8	6	d
WLVCat3y4_n	3617	NUM	8	6	d
WLVCat3y4_s	3591	NUM	8	6	d
WLVCat3y4_u	3643	NUM	8	6	d
WLwhhy1_f	3480	NUM	8	6	d
WLwhhy2_f	3500	NUM	8	6	d
WLwhhy3_f	3520	NUM	8	6	d
WLwhhy4_f	3540	NUM	8	6	d
WLwhhy4_n	3605	NUM	8	6	d
WLwhhy4_s	3579	NUM	8	6	d
WLwhhy4_u	3631	NUM	8	6	d
WLwhnhy1_f	3481	NUM	8	6	d

WLwhnhy2_f	3501	NUM	8	6	d
WLwhnhy3_f	3521	NUM	8	6	d
WLwhnhy4_f	3541	NUM	8	6	d
WLwhnhy4_n	3606	NUM	8	6	d
WLwhnhy4_s	3580	NUM	8	6	d
WLwhnhy4_u	3632	NUM	8	6	d
WLy1_f	3475	NUM	8	6	c
WLy2_f	3495	NUM	8	6	c
WLy3_f	3515	NUM	8	6	c
WLy4_f	3535	NUM	8	6	c
WLy4_n	3600	NUM	8	6	c
WLy4_s	3574	NUM	8	6	c
WLy4_u	3626	NUM	8	6	c

## Label

---

F: Hospitalization - Diagnosis: % with Cardiac Arrest, 2019  
F: Hospitalization - Diagnosis: % with Cardiac Arrest, 2020  
F: Hospitalization - Diagnosis: % with Cardiac Arrest, 2021  
F: Hospitalization - Diagnosis: % with Cardiac Arrest, 2022  
F: Hospitalization - Diagnosis: % with Cardiac Arrest, 2019-2022  
N: Hospitalization - Diagnosis: Average % with Cardiac Arrest (per year in average facility), 2019-2022  
S: Hospitalization - Diagnosis: Average % with Cardiac Arrest (per year in average facility), 2019-2022  
US: Hospitalization - Diagnosis: Average % with Cardiac Arrest (per year in average facility), 2019-2022  
F: Hospitalization - Diagnosis: % with Cardiac Dysrhythmia, 2019  
F: Hospitalization - Diagnosis: % with Cardiac Dysrhythmia, 2020  
F: Hospitalization - Diagnosis: % with Cardiac Dysrhythmia, 2021  
F: Hospitalization - Diagnosis: % with Cardiac Dysrhythmia, 2022  
F: Hospitalization - Diagnosis: % with Cardiac Dysrhythmia, 2019-2022  
N: Hospitalization - Diagnosis: Average % with Cardiac Dysrhythmia (per year in average facility), 2019-2022  
S: Hospitalization - Diagnosis: Average % with Cardiac Dysrhythmia (per year in average facility), 2019-2022  
US: Hospitalization - Diagnosis: Average % with Cardiac Dysrhythmia (per year in average facility), 2019-2022  
F: Hospitalization - Diagnosis: % with Congestive Heart Failure, 2019  
F: Hospitalization - Diagnosis: % with Congestive Heart Failure, 2020  
F: Hospitalization - Diagnosis: % with Congestive Heart Failure, 2021  
F: Hospitalization - Diagnosis: % with Congestive Heart Failure, 2022  
F: Hospitalization - Diagnosis: % with Congestive Heart Failure, 2019-2022  
N: Hospitalization - Diagnosis: Average % with Congestive Heart Failure (per year in average facility), 2019-2022  
S: Hospitalization - Diagnosis: Average % with Congestive Heart Failure (per year in average facility), 2019-2022  
US: Hospitalization - Diagnosis: Average % with Congestive Heart Failure (per year in average facility), 2019-2022  
F: Prevalent Patients - Age: % Less than 18 years, 12/31/2019  
F: Prevalent Patients - Age: % Less than 18 years, 12/31/2020  
F: Prevalent Patients - Age: % Less than 18 years, 12/31/2021  
F: Prevalent Patients - Age: % Less than 18 years, 12/31/2022  
N: Prevalent Patients - Age: % Less than 18 years, 12/31/2022  
S: Prevalent Patients - Age: % Less than 18 years, 12/31/2022  
US: Prevalent Patients - Age: % Less than 18 years, 12/31/2022  
F: Prevalent Patients - Age: % Between 18-64 years, 12/31/2019  
F: Prevalent Patients - Age: % Between 18-64 years, 12/31/2020  
F: Prevalent Patients - Age: % Between 18-64 years, 12/31/2021  
F: Prevalent Patients - Age: % Between 18-64 years, 12/31/2022  
N: Prevalent Patients - Age: % Between 18-64 years, 12/31/2022  
S: Prevalent Patients - Age: % Between 18-64 years, 12/31/2022  
US: Prevalent Patients - Age: % Between 18-64 years, 12/31/2022  
F: Prevalent Patients - Age: % Greater than or equal to 65 years, 12/31/2019  
F: Prevalent Patients - Age: % Greater than or equal to 65 years, 12/31/2020  
F: Prevalent Patients - Age: % Greater than or equal to 65 years, 12/31/2021  
F: Prevalent Patients - Age: % Greater than or equal to 65 years, 12/31/2022  
N: Prevalent Patients - Age: % Greater than or equal to 65 years, 12/31/2022

S: Prevalent Patients - Age: % Greater than or equal to 65 years, 12/31/2022  
US: Prevalent Patients - Age: % Greater than or equal to 65 years, 12/31/2022  
F (2728): Incident Patients - Average age, 2019  
F (2728): Incident Patients - Average age, 2020  
F (2728): Incident Patients - Average age, 2021  
F (2728): Incident Patients - Average age, 2022  
N (2728): Incident Patients - Average age, 2022  
S (2728): Incident Patients - Average age, 2022  
US (2728): Incident Patients - Average age, 2022  
F: Prevalent Patients - Age: Average patient age, 12/31/2019  
F: Prevalent Patients - Age: Average patient age, 12/31/2020  
F: Prevalent Patients - Age: Average patient age, 12/31/2021  
F: Prevalent Patients - Age: Average patient age, 12/31/2022  
N: Prevalent Patients - Age: Average patient age, 12/31/2022  
S: Prevalent Patients - Age: Average patient age, 12/31/2022  
US: Prevalent Patients - Age: Average patient age, 12/31/2022  
F (2728): Incident Patients - Percent alcohol dependent, 2019  
F (2728): Incident Patients - Percent alcohol dependent, 2020  
F (2728): Incident Patients - Percent alcohol dependent, 2021  
F (2728): Incident Patients - Percent alcohol dependent, 2022  
N (2728): Incident Patients - Percent alcohol dependent, 2022  
S (2728): Incident Patients - Percent alcohol dependent, 2022  
US (2728): Incident Patients - Percent alcohol dependent, 2022  
F (AFS): Facility Information - Facility Information - Number of patients, 2019  
F (AFS): Facility Information - Facility Information - Number of patients, 2020  
F (AFS): Facility Information - Facility Information - Number of patients, 2021  
F (AFS): Facility Information - Facility Information - Number of patients, 2022  
N (AFS): Facility Information - Average number of patients, 2022  
S (AFS): Facility Information - Average number of patients, 2022  
US (AFS): Facility Information - Average number of patients, 2022  
F: COVID - Number of deaths among Medicare dialysis patients, 2022-Q1  
F: COVID - Number of deaths among Medicare dialysis patients, 2022-Q2  
F: COVID - Number of deaths among Medicare dialysis patients, 2022-Q3  
F: COVID - Number of deaths among Medicare dialysis patients, 2022-Q4  
F: COVID - Number of deaths among Medicare dialysis patients, 2021  
F: COVID - % of deaths with patients ever infected with COVID, 2022-Q1  
F: COVID - % of deaths with patients ever infected with COVID, 2022-Q2  
F: COVID - % of deaths with patients ever infected with COVID, 2022-Q3  
F: COVID - % of deaths with patients ever infected with COVID, 2022-Q4  
NETWORK: COVID - % of deaths with patients ever infected with COVID, 2022-Q4  
STATE: COVID - % of deaths with patients ever infected with COVID, 2022-Q4  
US: COVID - % of deaths with patients ever infected with COVID, 2022-Q4  
F: COVID - % of deaths with patients ever infected with COVID, 2021  
F: COVID - Number of deaths among patients ever infected with COVID, 2022-Q1

F: COVID - Number of deaths among patients ever infected with COVID, 2022-Q2  
F: COVID - Number of deaths among patients ever infected with COVID, 2022-Q3  
F: COVID - Number of deaths among patients ever infected with COVID, 2022-Q4  
F: COVID - Number of deaths among patients ever infected with COVID, 2021  
F: COVID - % of hospitalizations with patients ever infected with COVID, 2022-Q1  
F: COVID - % of hospitalizations with patients ever infected with COVID, 2022-Q2  
F: COVID - % of hospitalizations with patients ever infected with COVID, 2022-Q3  
F: COVID - % of hospitalizations with patients ever infected with COVID, 2022-Q4  
NETWORK: COVID - % of hospitalizations with patients ever infected with COVID, 2022-Q4  
STATE: COVID - % of hospitalizations with patients ever infected with COVID, 2022-Q4  
US: COVID - % of hospitalizations with patients ever infected with COVID, 2022-Q4  
F: COVID - % of hospitalizations with patients ever infected with COVID, 2021  
F: COVID - Number of hospitalizations among patients ever infected with COVID, 2022-Q1  
F: COVID - Number of hospitalizations among patients ever infected with COVID, 2022-Q2  
F: COVID - Number of hospitalizations among patients ever infected with COVID, 2022-Q3  
F: COVID - Number of hospitalizations among patients ever infected with COVID, 2022-Q4  
F: COVID - Number of hospitalizations among patients ever infected with COVID, 2021  
F: COVID - % of Medicare patients ever infected with COVID, 2022-Q1  
F: COVID - % of Medicare patients ever infected with COVID, 2022-Q2  
F: COVID - % of Medicare patients ever infected with COVID, 2022-Q3  
F: COVID - % of Medicare patients ever infected with COVID, 2022-Q4  
NETWORK: COVID - % of Medicare patients ever infected with COVID, 2022-Q4  
STATE: COVID - % of Medicare patients ever infected with COVID, 2022-Q4  
US: COVID - % of Medicare patients ever infected with COVID, 2022-Q4  
F: COVID - % of Medicare patients ever infected with COVID, 2021  
F: COVID - Number of patients ever infected with COVID (prior to or during current quarter), 2022-Q1  
F: COVID - Number of patients ever infected with COVID (prior to or during current quarter), 2022-Q2  
F: COVID - Number of patients ever infected with COVID (prior to or during current quarter), 2022-Q3  
F: COVID - Number of patients ever infected with COVID (prior to or during current quarter), 2022-Q4  
F: COVID - Number of patients ever infected with COVID (prior to or during current quarter), 2021  
F: COVID - % of Medicare patients initially infected with COVID, 2022-Q1  
F: COVID - % of Medicare patients initially infected with COVID, 2022-Q2  
F: COVID - % of Medicare patients initially infected with COVID, 2022-Q3  
F: COVID - % of Medicare patients initially infected with COVID, 2022-Q4  
NETWORK: COVID - % of Medicare patients initially infected with COVID, 2022-Q4  
STATE: COVID - % of Medicare patients initially infected with COVID, 2022-Q4  
US: COVID - % of Medicare patients initially infected with COVID, 2022-Q4  
F: COVID - % of Medicare patients initially infected with COVID, 2021  
F: COVID - Number of patients initially infected with COVID, 2022-Q1  
F: COVID - Number of patients initially infected with COVID, 2022-Q2  
F: COVID - Number of patients initially infected with COVID, 2022-Q3  
F: COVID - Number of patients initially infected with COVID, 2022-Q4  
F: COVID - Number of patients initially infected with COVID, 2021  
F: COVID - Number of hospitalizations among Medicare dialysis patients, 2022-Q1

F: COVID - Number of hospitalizations among Medicare dialysis patients, 2022-Q2  
F: COVID - Number of hospitalizations among Medicare dialysis patients, 2022-Q3  
F: COVID - Number of hospitalizations among Medicare dialysis patients, 2022-Q4  
F: COVID - Number of hospitalizations among Medicare dialysis patients, 2021  
F: COVID - Number of Medicare dialysis patients, 2022-Q1  
F: COVID - Number of Medicare dialysis patients, 2022-Q2  
F: COVID - Number of Medicare dialysis patients, 2022-Q3  
F: COVID - Number of Medicare dialysis patients, 2022-Q4  
F: COVID - Number of Medicare dialysis patients, 2021  
F (2728): Incident Patients - Percent inability to ambulate, 2019  
F (2728): Incident Patients - Percent inability to ambulate, 2020  
F (2728): Incident Patients - Percent inability to ambulate, 2021  
F (2728): Incident Patients - Percent inability to ambulate, 2022  
N (2728): Incident Patients - Percent inability to ambulate, 2022  
S (2728): Incident Patients - Percent inability to ambulate, 2022  
US (2728): Incident Patients - Percent inability to ambulate, 2022  
F (2728): Incident Patients - Percent with atherosclerotic heart disease, 2019  
F (2728): Incident Patients - Percent with atherosclerotic heart disease, 2020  
F (2728): Incident Patients - Percent with atherosclerotic heart disease, 2021  
F (2728): Incident Patients - Percent with atherosclerotic heart disease, 2022  
N (2728): Incident Patients - Percent with atherosclerotic heart disease, 2022  
S (2728): Incident Patients - Percent with atherosclerotic heart disease, 2022  
US (2728): Incident Patients - Percent with atherosclerotic heart disease, 2022  
F (2728): Incident Patients - Percent Asian/Pacific Islander, 2019  
F (2728): Incident Patients - Percent Asian/Pacific Islander, 2020  
F (2728): Incident Patients - Percent Asian/Pacific Islander, 2021  
F (2728): Incident Patients - Percent Asian/Pacific Islander, 2022  
N (2728): Incident Patients - Percent Asian/Pacific Islander, 2022  
S (2728): Incident Patients - Percent Asian/Pacific Islander, 2022  
US (2728): Incident Patients - Percent Asian/Pacific Islander, 2022  
F (2728): Incident Patients - Percent of patients with Arteriovenous fistulae placed, 2019  
F (2728): Incident Patients - Percent of patients with Arteriovenous fistulae placed, 2020  
F (2728): Incident Patients - Percent of patients with Arteriovenous fistulae placed, 2021  
F (2728): Incident Patients - Percent of patients with Arteriovenous fistulae placed, 2022  
N (2728): Incident Patients - Percent of Incident Patients with Arteriovenous fistulae placed, 2022  
S (2728): Incident Patients - Percent of Incident Patients with Arteriovenous fistulae placed, 2022  
US (2728): Incident Patients - Percent of Incident Patients with Arteriovenous fistulae placed, 2022  
F (2728): Incident Patients - Percent African American, 2019  
F (2728): Incident Patients - Percent African American, 2020  
F (2728): Incident Patients - Percent African American, 2021  
F (2728): Incident Patients - Percent African American, 2022  
N (2728): Incident Patients - Percent African American, 2022  
S (2728): Incident Patients - Percent African American, 2022  
US (2728): Incident Patients - Percent African American, 2022

F (2728): Incident Patients - Median BMI for females  $\geq$  20 yrs, 2019  
F (2728): Incident Patients - Median BMI for females  $\geq$  20 yrs, 2020  
F (2728): Incident Patients - Median BMI for females  $\geq$  20 yrs, 2021  
F (2728): Incident Patients - Median BMI for females  $\geq$  20 yrs, 2022  
N (2728): Incident Patients - Median BMI for females  $\geq$  20 yrs, 2022  
S (2728): Incident Patients - Median BMI for females  $\geq$  20 yrs, 2022  
US (2728): Incident Patients - Median BMI for females  $\geq$  20 yrs, 2022  
F (2728): Incident Patients - Median BMI for males  $\geq$  20 yrs, 2019  
F (2728): Incident Patients - Median BMI for males  $\geq$  20 yrs, 2020  
F (2728): Incident Patients - Median BMI for males  $\geq$  20 yrs, 2021  
F (2728): Incident Patients - Median BMI for males  $\geq$  20 yrs, 2022  
N (2728): Incident Patients - Median BMI for males  $\geq$  20 yrs, 2022  
S (2728): Incident Patients - Median BMI for males  $\geq$  20 yrs, 2022  
US (2728): Incident Patients - Median BMI for males  $\geq$  20 yrs, 2022  
F: STR - Number of deceased donor transplants, 2019  
F: STR - Number of deceased donor transplants, 2020  
F: STR - Number of deceased donor transplants, 2021  
F: STR - Number of deceased donor transplants, 2022  
F: STR - Number of deceased donor transplants, 2019-2022  
N: STR - Average number of deceased donor transplant (per year in average facility), 2019-2022  
S: STR - Average number of deceased donor transplant (per year in average facility), 2019-2022  
US: STR - Average number of deceased donor transplant (per year in average facility), 2019-2022  
F (2728): Incident Patients - Percent with cancer, 2019  
F (2728): Incident Patients - Percent with cancer, 2020  
F (2728): Incident Patients - Percent with cancer, 2021  
F (2728): Incident Patients - Percent with cancer, 2022  
N (2728): Incident Patients - Percent with cancer, 2022  
S (2728): Incident Patients - Percent with cancer, 2022  
US (2728): Incident Patients - Percent with cancer, 2022  
F: All Patient Mortality - % of deaths from cardiac causes, 2019  
F: All Patient Mortality - % of deaths from cardiac causes, 2020  
F: All Patient Mortality - % of deaths from cardiac causes, 2021  
F: All Patient Mortality - % of deaths from cardiac causes, 2022  
F: All Patient Mortality - % of deaths from cardiac causes, 2019-2022  
N: All Patient Mortality - % of deaths from cardiac causes, 2019-2022  
S: All Patient Mortality - % of deaths from cardiac causes, 2019-2022  
US: All Patient Mortality - % of deaths from cardiac causes, 2019-2022  
F (2728): Incident Patients - Percent currently employed FT/PT/student, 2019  
F (2728): Incident Patients - Percent currently employed FT/PT/student, 2020  
F (2728): Incident Patients - Percent currently employed FT/PT/student, 2021  
F (2728): Incident Patients - Percent currently employed FT/PT/student, 2022  
N (2728): Incident Patients - Percent currently employed FT/PT/student, 2022  
S (2728): Incident Patients - Percent currently employed FT/PT/student, 2022  
US (2728): Incident Patients - Percent currently employed FT/PT/student, 2022

F (QIES): Facility Information – Total number of CfCs Cited  
N (QIES): Facility Information – Average number of Condition-Level Citations/Survey  
S (QIES): Facility Information – Average number of Condition-Level Citations/Survey  
U (QIES): Facility Information – Average number of Condition-Level Citations/Survey  
DFR: Dialysis Organization name  
F (2728): Incident Patients - Percent with congestive heart failure, 2019  
F (2728): Incident Patients - Percent with congestive heart failure, 2020  
F (2728): Incident Patients - Percent with congestive heart failure, 2021  
F (2728): Incident Patients - Percent with congestive heart failure, 2022  
N (2728): Incident Patients - Percent with congestive heart failure, 2022  
S (2728): Incident Patients - Percent with congestive heart failure, 2022  
US (2728): Incident Patients - Percent with congestive heart failure, 2022  
F: SHR (Days) - 97.5% Upper Confidence Limit, 2019  
F: SHR (Days) - 97.5% Upper Confidence Limit, 2020  
F: SHR (Days) - 97.5% Upper Confidence Limit, 2021  
F: SHR (Days) - 97.5% Upper Confidence Limit, 2022  
F: SHR (Days)- 97.5% Upper Confidence Limit, 2019-2022  
F: SEDR - 97.5% Upper Confidence Limit, 2019  
F: SEDR - 97.5% Upper Confidence Limit, 2020  
F: SEDR - 97.5% Upper Confidence Limit, 2021  
F: SEDR - 97.5% Upper Confidence Limit, 2022  
F: SEDR - 97.5% Upper Confidence Limit, 2019-2022  
F: SHR (Admissions) - 97.5% Upper Confidence Limit, 2019  
F: SHR (Admissions) - 97.5% Upper Confidence Limit, 2020  
F: SHR (Admissions) - 97.5% Upper Confidence Limit, 2021  
F: SHR (Admissions) - 97.5% Upper Confidence Limit, 2022  
F: SHR (Admissions)- 97.5% Upper Confidence Limit, 2019-2022  
F: All Patient Mortality - 97.5% Upper Confidence Limit, 2019  
F: All Patient Mortality - 97.5% Upper Confidence Limit, 2020  
F: All Patient Mortality - 97.5% Upper Confidence Limit, 2021  
F: All Patient Mortality - 97.5% Upper Confidence Limit, 2022  
F: All Patient Mortality - 97.5% Upper Confidence Limit, 2019-2022  
F: STrR (Adult) - 97.5% Upper Confidence Limit, 2019  
F: STrR (Adult) - 97.5% Upper Confidence Limit, 2020  
F: STrR (Adult) - 97.5% Upper Confidence Limit, 2021  
F: STrR (Adult) - 97.5% Upper Confidence Limit, 2022  
F: STR - 97.5% Upper Confidence Limit, 2019-2022  
F: Prevalent Comorbidities - % with Alcohol Dependence, 2019  
F: Prevalent Comorbidities - % with Alcohol Dependence, 2020  
F: Prevalent Comorbidities - % with Alcohol Dependence, 2021  
F: Prevalent Comorbidities - % with Alcohol Dependence, 2022  
N: Prevalent Comorbidities - Average % with Alcohol Dependence, 2022  
S: Prevalent Comorbidities - Average % with Alcohol Dependence, 2022  
US: Prevalent Comorbidities - Average % with Alcohol Dependence, 2022



F: Prevalent Comorbidities - % with Anemia, 2019  
F: Prevalent Comorbidities - % with Anemia, 2020  
F: Prevalent Comorbidities - % with Anemia, 2021  
F: Prevalent Comorbidities - % with Anemia, 2022  
N: Prevalent Comorbidities - Average % with Anemia, 2022  
S: Prevalent Comorbidities - Average % with Anemia, 2022  
US: Prevalent Comorbidities - Average % with Anemia, 2022  
F: Prevalent Comorbidities - % with Cardiac Arrest, 2019  
F: Prevalent Comorbidities - % with Cardiac Arrest, 2020  
F: Prevalent Comorbidities - % with Cardiac Arrest, 2021  
F: Prevalent Comorbidities - % with Cardiac Arrest, 2022  
N: Prevalent Comorbidities - Average % with Cardiac Arrest, 2022  
S: Prevalent Comorbidities - Average % with Cardiac Arrest, 2022  
US: Prevalent Comorbidities - Average % with Cardiac Arrest, 2022  
F: Prevalent Comorbidities - % with Cancer, 2019  
F: Prevalent Comorbidities - % with Cancer, 2020  
F: Prevalent Comorbidities - % with Cancer, 2021  
F: Prevalent Comorbidities - % with Cancer, 2022  
N: Prevalent Comorbidities - Average % with Cancer, 2022  
S: Prevalent Comorbidities - Average % with Cancer, 2022  
US: Prevalent Comorbidities - Average % with Cancer, 2022  
F: Prevalent Comorbidities - % with Cardiac Dysrhythmias, 2019  
F: Prevalent Comorbidities - % with Cardiac Dysrhythmias, 2020  
F: Prevalent Comorbidities - % with Cardiac Dysrhythmias, 2021  
F: Prevalent Comorbidities - % with Cardiac Dysrhythmias, 2022  
N: Prevalent Comorbidities - Average % with Cardiac Dysrhythmias, 2022  
S: Prevalent Comorbidities - Average % with Cardiac Dysrhythmias, 2022  
US: Prevalent Comorbidities - Average % with Cardiac Dysrhythmias, 2022  
F: Prevalent Comorbidities - % with Congestive Heart Failure, 2019  
F: Prevalent Comorbidities - % with Congestive Heart Failure, 2020  
F: Prevalent Comorbidities - % with Congestive Heart Failure, 2021  
F: Prevalent Comorbidities - % with Congestive Heart Failure, 2022  
N: Prevalent Comorbidities - Average % with Congestive Heart Failure, 2022  
S: Prevalent Comorbidities - Average % with Congestive Heart Failure, 2022  
US: Prevalent Comorbidities - Average % with Congestive Heart Failure, 2022  
F: Prevalent Comorbidities - Average Number of Comorbid Conditions, 2019  
F: Prevalent Comorbidities - Average Number of Comorbid Conditions, 2020  
F: Prevalent Comorbidities - Average Number of Comorbid Conditions, 2021  
F: Prevalent Comorbidities - Average Number of Comorbid Conditions, 2022  
N: Prevalent Comorbidities - Average Number of Comorbid Conditions, 2022  
S: Prevalent Comorbidities - Average Number of Comorbid Conditions, 2022  
US: Prevalent Comorbidities - Average Number of Comorbid Conditions, 2022  
F: Prevalent Comorbidities - % with Chronic Obstructive Pulmonary Disease, 2019  
F: Prevalent Comorbidities - % with Chronic Obstructive Pulmonary Disease, 2020

F: Prevalent Comorbidities - % with Chronic Obstructive Pulmonary Disease, 2021  
F: Prevalent Comorbidities - % with Chronic Obstructive Pulmonary Disease, 2022  
N: Prevalent Comorbidities - Average % with Chronic Observedtructive Pulmonary Disease, 2022  
S: Prevalent Comorbidities - Average % with Chronic Observedtructive Pulmonary Disease, 2022  
US: Prevalent Comorbidities - Average % with Chronic Observedtructive Pulmonary Disease, 2022  
F: Prevalent Comorbidities - % with Cerebrovascular Disease, 2019  
F: Prevalent Comorbidities - % with Cerebrovascular Disease, 2020  
F: Prevalent Comorbidities - % with Cerebrovascular Disease, 2021  
F: Prevalent Comorbidities - % with Cerebrovascular Disease, 2022  
N: Prevalent Comorbidities - Average % with Cerebrovascular Disease, 2022  
S: Prevalent Comorbidities - Average % with Cerebrovascular Disease, 2022  
US: Prevalent Comorbidities - Average % with Cerebrovascular Disease, 2022  
F: Prevalent Comorbidities - % with Diabetes, 2019  
F: Prevalent Comorbidities - % with Diabetes, 2020  
F: Prevalent Comorbidities - % with Diabetes, 2021  
F: Prevalent Comorbidities - % with Diabetes, 2022  
N: Prevalent Comorbidities - Average % with Diabetes, 2022  
S: Prevalent Comorbidities - Average % with Diabetes, 2022  
US: Prevalent Comorbidities - Average % with Diabetes, 2022  
F: Prevalent Comorbidities - % with Drug Dependence, 2019  
F: Prevalent Comorbidities - % with Drug Dependence, 2020  
F: Prevalent Comorbidities - % with Drug Dependence, 2021  
F: Prevalent Comorbidities - % with Drug Dependence, 2022  
N: Prevalent Comorbidities - Average % with Drug Dependence, 2022  
S: Prevalent Comorbidities - Average % with Drug Dependence, 2022  
US: Prevalent Comorbidities - Average % with Drug Dependence, 2022  
F: Prevalent Comorbidities - % with Gastro-Intestinal Tract Bleeding, 2019  
F: Prevalent Comorbidities - % with Gastro-Intestinal Tract Bleeding, 2020  
F: Prevalent Comorbidities - % with Gastro-Intestinal Tract Bleeding, 2021  
F: Prevalent Comorbidities - % with Gastro-Intestinal Tract Bleeding, 2022  
N: Prevalent Comorbidities - Average % with Gastro-Intestinal Tract Bleeding, 2022  
S: Prevalent Comorbidities - Average % with Gastro-Intestinal Tract Bleeding, 2022  
US: Prevalent Comorbidities - Average % with Gastro-Intestinal Tract Bleeding, 2022  
F: Prevalent Comorbidities - % with Hepatitis B, 2019  
F: Prevalent Comorbidities - % with Hepatitis B, 2020  
F: Prevalent Comorbidities - % with Hepatitis B, 2021  
F: Prevalent Comorbidities - % with Hepatitis B, 2022  
N: Prevalent Comorbidities - Average % with Hepatitis B, 2022  
S: Prevalent Comorbidities - Average % with Hepatitis B, 2022  
US: Prevalent Comorbidities - Average % with Hepatitis B, 2022  
F: Prevalent Comorbidities - % with Hepatitis Other, 2019  
F: Prevalent Comorbidities - % with Hepatitis Other, 2020  
F: Prevalent Comorbidities - % with Hepatitis Other, 2021  
F: Prevalent Comorbidities - % with Hepatitis Other, 2022

N: Prevalent Comorbidities - Average % with Hepatitis Other, 2022  
S: Prevalent Comorbidities - Average % with Hepatitis Other, 2022  
US: Prevalent Comorbidities - Average % with Hepatitis Other, 2022  
F: Prevalent Comorbidities - % with AIDS, 2019  
F: Prevalent Comorbidities - % with AIDS, 2020  
F: Prevalent Comorbidities - % with AIDS, 2021  
F: Prevalent Comorbidities - % with AIDS, 2022  
N: Prevalent Comorbidities - Average % with AIDS, 2022  
S: Prevalent Comorbidities - Average % with AIDS, 2022  
US: Prevalent Comorbidities - Average % with AIDS, 2022  
F: Prevalent Comorbidities - % with Hyperparathyroidism, 2019  
F: Prevalent Comorbidities - % with Hyperparathyroidism, 2020  
F: Prevalent Comorbidities - % with Hyperparathyroidism, 2021  
F: Prevalent Comorbidities - % with Hyperparathyroidism, 2022  
N: Prevalent Comorbidities - Average % with Hyperparathyroidism, 2022  
S: Prevalent Comorbidities - Average % with Hyperparathyroidism, 2022  
US: Prevalent Comorbidities - Average % with Hyperparathyroidism, 2022  
F: Prevalent Comorbidities - % with Ischemic Heart Disease, 2019  
F: Prevalent Comorbidities - % with Ischemic Heart Disease, 2020  
F: Prevalent Comorbidities - % with Ischemic Heart Disease, 2021  
F: Prevalent Comorbidities - % with Ischemic Heart Disease, 2022  
N: Prevalent Comorbidities - Average % with Ischemic Heart Disease, 2022  
S: Prevalent Comorbidities - Average % with Ischemic Heart Disease, 2022  
US: Prevalent Comorbidities - Average % with Ischemic Heart Disease, 2022  
F: Prevalent Comorbidities - % with Non-Vascular Access-Related Infection, 2019  
F: Prevalent Comorbidities - % with Non-Vascular Access-Related Infection, 2020  
F: Prevalent Comorbidities - % with Non-Vascular Access-Related Infection, 2021  
F: Prevalent Comorbidities - % with Non-Vascular Access-Related Infection, 2022  
N: Prevalent Comorbidities - Average % with Non-Vascular Access-Related Infection, 2022  
S: Prevalent Comorbidities - Average % with Non-Vascular Access-Related Infection, 2022  
US: Prevalent Comorbidities - Average % with Non-Vascular Access-Related Infection, 2022  
F: Prevalent Comorbidities - % with Vascular Access-Related Infection, 2019  
F: Prevalent Comorbidities - % with Vascular Access-Related Infection, 2020  
F: Prevalent Comorbidities - % with Vascular Access-Related Infection, 2021  
F: Prevalent Comorbidities - % with Vascular Access-Related Infection, 2022  
N: Prevalent Comorbidities - Average % with Vascular Access-Related Infection, 2022  
S: Prevalent Comorbidities - Average % with Vascular Access-Related Infection, 2022  
US: Prevalent Comorbidities - Average % with Vascular Access-Related Infection, 2022  
F: Prevalent Comorbidities - % with Myocardial Infarction, 2019  
F: Prevalent Comorbidities - % with Myocardial Infarction, 2020  
F: Prevalent Comorbidities - % with Myocardial Infarction, 2021  
F: Prevalent Comorbidities - % with Myocardial Infarction, 2022  
N: Prevalent Comorbidities - Average % with Myocardial Infarction, 2022  
S: Prevalent Comorbidities - Average % with Myocardial Infarction, 2022

US: Prevalent Comorbidities - Average % with Myocardial Infarction, 2022  
F: Prevalent Comorbidities - % with Metastatic Infection, 2019  
F: Prevalent Comorbidities - % with Metastatic Infection, 2020  
F: Prevalent Comorbidities - % with Metastatic Infection, 2021  
F: Prevalent Comorbidities - % with Metastatic Infection, 2022  
N: Prevalent Comorbidities - Average % with Metastatic Infection, 2022  
S: Prevalent Comorbidities - Average % with Metastatic Infection, 2022  
US: Prevalent Comorbidities - Average % with Metastatic Infection, 2022  
F: Prevalent Comorbidities - % with Pneumonia, 2019  
F: Prevalent Comorbidities - % with Pneumonia, 2020  
F: Prevalent Comorbidities - % with Pneumonia, 2021  
F: Prevalent Comorbidities - % with Pneumonia, 2022  
N: Prevalent Comorbidities - Average % with Pneumonia, 2022  
S: Prevalent Comorbidities - Average % with Pneumonia, 2022  
US: Prevalent Comorbidities - Average % with Pneumonia, 2022  
F: Prevalent Comorbidities - % with Peripheral Vascular Disease, 2019  
F: Prevalent Comorbidities - % with Peripheral Vascular Disease, 2020  
F: Prevalent Comorbidities - % with Peripheral Vascular Disease, 2021  
F: Prevalent Comorbidities - % with Peripheral Vascular Disease, 2022  
N: Prevalent Comorbidities - Average % with Peripheral Vascular Disease, 2022  
S: Prevalent Comorbidities - Average % with Peripheral Vascular Disease, 2022  
US: Prevalent Comorbidities - Average % with Peripheral Vascular Disease, 2022  
F: Prevalent Comorbidities - % with Tuberculosis, 2019  
F: Prevalent Comorbidities - % with Tuberculosis, 2020  
F: Prevalent Comorbidities - % with Tuberculosis, 2021  
F: Prevalent Comorbidities - % with Tuberculosis, 2022  
N: Prevalent Comorbidities - Average % with Tuberculosis, 2022  
S: Prevalent Comorbidities - Average % with Tuberculosis, 2022  
US: Prevalent Comorbidities - Average % with Tuberculosis, 2022  
F: SHR (Days) - 2.5% Lower Confidence Limit, 2019  
F: SHR (Days) - 2.5% Lower Confidence Limit, 2020  
F: SHR (Days) - 2.5% Lower Confidence Limit, 2021  
F: SHR (Days) - 2.5% Lower Confidence Limit, 2022  
F: SHR (Days)- 2.5% Lower Confidence Limit, 2019-2022  
F: SEDR- 2.5% Lower Confidence Limit, 2019  
F: SEDR- 2.5% Lower Confidence Limit, 2020  
F: SEDR- 2.5% Lower Confidence Limit, 2021  
F: SEDR- 2.5% Lower Confidence Limit, 2022  
F: SEDR- 2.5% Lower Confidence Limit, 2019-2022  
F: SHR (Admissions)- 2.5% Lower Confidence Limit, 2019  
F: SHR (Admissions)- 2.5% Lower Confidence Limit, 2020  
F: SHR (Admissions)- 2.5% Lower Confidence Limit, 2021  
F: SHR (Admissions)- 2.5% Lower Confidence Limit, 2022  
F: SHR (Admissions)- 2.5% Lower Confidence Limit, 2019-2022

F: All Patient Mortality - 2.5% Lower Confidence Limit, 2019  
F: All Patient Mortality - 2.5% Lower Confidence Limit, 2020  
F: All Patient Mortality - 2.5% Lower Confidence Limit, 2021  
F: All Patient Mortality - 2.5% Lower Confidence Limit, 2022  
F: All Patient Mortality - 2.5% Lower Confidence Limit, 2019-2022  
F: STrR (Adult) - 2.5% Lower Confidence Limit, 2019  
F: STrR (Adult) - 2.5% Lower Confidence Limit, 2020  
F: STrR (Adult) - 2.5% Lower Confidence Limit, 2021  
F: STrR (Adult) - 2.5% Lower Confidence Limit, 2022  
F: STR - 2.5% Lower Confidence Limit, 2019-2022  
F (2728): Incident Patients - Average count of comorbidities, 2019  
F (2728): Incident Patients - Average count of comorbidities, 2020  
F (2728): Incident Patients - Average count of comorbidities, 2021  
F (2728): Incident Patients - Average count of comorbidities, 2022  
N (2728): Incident Patients - Average count of comorbidities, 2022  
S (2728): Incident Patients - Average count of comorbidities, 2022  
US (2728): Incident Patients - Average count of comorbidities, 2022  
F(QIES): Compliance Status  
F (2728): Incident Patients - Percent with chronic obstructive pulmonary disease, 2019  
F (2728): Incident Patients - Percent with chronic obstructive pulmonary disease, 2020  
F (2728): Incident Patients - Percent with chronic obstructive pulmonary disease, 2021  
F (2728): Incident Patients - Percent with chronic obstructive pulmonary disease, 2022  
N (2728): Incident Patients - Percent with chronic obstructive pulmonary disease, 2022  
S (2728): Incident Patients - Percent with chronic obstructive pulmonary disease, 2022  
US (2728): Incident Patients - Percent with chronic obstructive pulmonary disease, 2022  
F (2728): Incident Patients - Average creatinine, 2019  
F (2728): Incident Patients - Average creatinine, 2020  
F (2728): Incident Patients - Average creatinine, 2021  
F (2728): Incident Patients - Average creatinine, 2022  
N (2728): Incident Patients - Average creatinine, 2022  
S (2728): Incident Patients - Average creatinine, 2022  
US (2728): Incident Patients - Average creatinine, 2022  
F (2728): Incident Patients - Percent with cardiovascular disease, cerebral vascular incident, and transient ischemic attack, 2019  
F (2728): Incident Patients - Percent with cardiovascular disease, cerebral vascular incident, and transient ischemic attack, 2020  
F (2728): Incident Patients - Percent with cardiovascular disease, cerebral vascular incident, and transient ischemic attack, 2021  
F (2728): Incident Patients - Percent with cardiovascular disease, cerebral vascular incident, and transient ischemic attack, 2022  
N (2728): Incident Patients - Percent with cardiovascular disease, cerebral vascular incident, and transient ischemic attack, 2022  
S (2728): Incident Patients - Percent with cardiovascular disease, cerebral vascular incident, and transient ischemic attack, 2022  
US (2728): Incident Patients - Percent with cardiovascular disease, cerebral vascular incident, and transient ischemic attack, 2022  
CWFacDir: Number of Hemodialysis Stations  
DFR: Profit Status from CROWNWeb  
F: Phosphorus (Adult) - Average serum phosphorus in mg/dL, out of valid in range patient-months, 2019  
F: Phosphorus (Adult) - Average serum phosphorus in mg/dL, out of valid in range patient-months, 2020  
F: Phosphorus (Adult) - Average serum phosphorus in mg/dL, out of valid in range patient-months, 2021

F: Phosphorus (Adult) - Average serum phosphorus in mg/dL, out of valid in range patient-months, 2022  
N: Phosphorus (Adult) - Average serum phosphorus in mg/dL, out of valid in range patient-months, 2022  
S: Phosphorus (Adult) - Average serum phosphorus in mg/dL, out of valid in range patient-months, 2022  
US: Phosphorus (Adult) - Average serum phosphorus in mg/dL, out of valid in range patient-months, 2022  
F: Calcium (Adult) - Average uncorrected calcium in mg/dL, out of valid in range patient-months, 2019  
F: Calcium (Adult) - Average uncorrected calcium in mg/dL, out of valid in range patient-months, 2020  
F: Calcium (Adult) - Average uncorrected calcium in mg/dL, out of valid in range patient-months, 2021  
F: Calcium (Adult) - Average uncorrected calcium in mg/dL, out of valid in range patient-months, 2022  
N: Calcium (Adult) - Average uncorrected calcium in mg/dL, out of valid in range patient-months, 2022  
S: Calcium (Adult) - Average uncorrected calcium in mg/dL, out of valid in range patient-months, 2022  
US: Calcium (Adult) - Average uncorrected calcium in mg/dL, out of valid in range patient-months, 2022  
F: Hypercalcemia (Adult) - Total Number of Eligible Dialysis Patients, 2019  
F: Hypercalcemia (Adult) - Total Number of Eligible Dialysis Patients, 2020  
F: Hypercalcemia (Adult) - Total Number of Eligible Dialysis Patients, 2021  
F: Hypercalcemia (Adult) - Total Number of Eligible Dialysis Patients, 2022  
N: Hypercalcemia (Adult) - Average Number of Eligible Dialysis Patients, 2022  
S: Hypercalcemia (Adult) - Average Number of Eligible Dialysis Patients, 2022  
US: Hypercalcemia (Adult) - Average Number of Eligible Dialysis Patients, 2022  
F: Hypercalcemia (Adult) - Total Number of Eligible Dialysis Patient-months, 2019  
F: Hypercalcemia (Adult) - Total Number of Eligible Dialysis Patient-months, 2020  
F: Hypercalcemia (Adult) - Total Number of Eligible Dialysis Patient-months, 2021  
F: Hypercalcemia (Adult) - Total Number of Eligible Dialysis Patient-months, 2022  
N: Hypercalcemia (Adult) - Average Number of Eligible Dialysis Patient-months, 2022  
S: Hypercalcemia (Adult) - Average Number of Eligible Dialysis Patient-months, 2022  
US: Hypercalcemia (Adult) - Average Number of Eligible Dialysis Patient-months, 2022  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin < 3 g/dL, 2019  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin < 3 g/dL, 2020  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin < 3 g/dL, 2021  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin < 3 g/dL, 2022  
N: Albumin (Adult) - % of HD patient-months with serum albumin < 3 g/dL, 2022  
S: Albumin (Adult) - % of HD patient-months with serum albumin < 3 g/dL, 2022  
U: Albumin (Adult) - % of HD patient-months with serum albumin < 3 g/dL, 2022  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2019  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2020  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2021  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2022  
N: Albumin (Adult) - % of HD patient-months with serum albumin 3 - < 3.5 g/dL, 2022  
S: Albumin (Adult) - % of HD patient-months with serum albumin 3 - < 3.5 g/dL, 2022  
U: Albumin (Adult) - % of HD patient-months with serum albumin 3 - < 3.5 g/dL, 2022  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2019  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2020  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2021  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2022  
N: Albumin (Adult) - % of HD patient-months with serum albumin 3.5 - < 4 g/dL, 2022

S: Albumin (Adult) - % of HD patient-months with serum albumin 3.5 - < 4 g/dL, 2022  
U: Albumin (Adult) - % of HD patient-months with serum albumin 3.5 - < 4 g/dL, 2022  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin >= 4 g/dL, 2019  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin >= 4 g/dL, 2020  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin >= 4 g/dL, 2021  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin >= 4 g/dL, 2022  
N: Albumin (Adult) - % of HD patient-months with serum albumin >= 4 g/dL, 2022  
S: Albumin (Adult) - % of HD patient-months with serum albumin >= 4 g/dL, 2022  
U: Albumin (Adult) - % of HD patient-months with serum albumin >= 4 g/dL, 2022  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin Missing, 2019  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin Missing, 2020  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin Missing, 2021  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin Missing, 2022  
N: Albumin (Adult) - % of HD patient-months with serum albumin Missing, 2022  
S: Albumin (Adult) - % of HD patient-months with serum albumin Missing, 2022  
U: Albumin (Adult) - % of HD patient-months with serum albumin Missing, 2022  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin < 4.0 g/dL, 2019  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin < 4.0 g/dL, 2020  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin < 4.0 g/dL, 2021  
F: Albumin (Adult) - % of HD patient-months with Serum Albumin < 4.0 g/dL, 2022  
N: Albumin (Adult) - % of HD patient-months with Serum Albumin < 4.0 g/dL, 2022  
S: Albumin (Adult) - % of HD patient-months with Serum Albumin < 4.0 g/dL, 2022  
U: Albumin (Adult) - % of HD patient-months with Serum Albumin < 4.0 g/dL, 2022  
F: Albumin (Adult) - Average Serum Albumin, of valid in range HD patient-months, 2019  
F: Albumin (Adult) - Average Serum Albumin, of valid in range HD patient-months, 2020  
F: Albumin (Adult) - Average Serum Albumin, of valid in range HD patient-months, 2021  
F: Albumin (Adult) - Average Serum Albumin, of valid in range HD patient-months, 2022  
N: Albumin (Adult) - Average Serum Albumin, of valid in range HD patient-months, 2022  
S: Albumin (Adult) - Average Serum Albumin, of valid in range HD patient-months, 2022  
U: Albumin (Adult) - Average Serum Albumin, of valid in range HD patient-months, 2022  
F: HD HGB (Adult) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2019  
F: HD HGB (Adult) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2020  
F: HD HGB (Adult) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2021  
F: HD HGB (Adult) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
N: HD HGB (Adult) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
S: HD HGB (Adult) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
US: HD HGB (Adult) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
F: HD Kt/V (Adult)- Average Kt/V, of valid in-range values, 2019  
F: HD Kt/V (Adult)- Average Kt/V, of valid in-range values, 2020  
F: HD Kt/V (Adult)- Average Kt/V, of valid in-range values, 2021  
F: HD Kt/V (Adult)- Average Kt/V, of valid in-range values, 2022  
N: HD Kt/V (Adult)- Average Kt/V, of valid in-range values, 2022  
S: HD Kt/V (Adult)- Average Kt/V, of valid in-range values, 2022  
U: HD Kt/V (Adult)- Average Kt/V, of valid in-range values, 2022

F: UFR (Adult) - Average UFR, of valid in range HD patient-months, 2019  
F: UFR (Adult) - Average UFR, of valid in range HD patient-months, 2020  
F: UFR (Adult) - Average UFR, of valid in range HD patient-months, 2021  
F: UFR (Adult) - Average UFR, of valid in range HD patient-months, 2022  
N: UFR (Adult) - Average UFR, of valid in range HD patient-months, 2022  
S: UFR (Adult) - Average UFR, of valid in range HD patient-months, 2022  
U: UFR (Adult) - Average UFR, of valid in range HD patient-months, 2022  
F: HD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patients, 2019  
F: HD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patients, 2020  
F: HD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patients, 2021  
F: HD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patients, 2022  
N: HD Dialysis Adequacy (Adult)- Average number of eligible patients, 2022  
S: HD Dialysis Adequacy (Adult)- Average number of eligible patients, 2022  
U: HD Dialysis Adequacy (Adult)- Average number of eligible patients, 2022  
F: HD HGB (Adult) - % of patient-months with ESA prescribed, 2019  
F: HD HGB (Adult) - % of patient-months with ESA prescribed, 2020  
F: HD HGB (Adult) - % of patient-months with ESA prescribed, 2021  
F: HD HGB (Adult) - % of patient-months with ESA prescribed, 2022  
N: HD HGB (Adult) - % of patient-months with ESA prescribed, 2022  
S: HD HGB (Adult) - % of patient-months with ESA prescribed, 2022  
US: HD HGB (Adult) - % of patient-months with ESA prescribed, 2022  
F: HD HGB (Adult) - % of patient-months with hemoglobin < 10 g/dL, 2019  
F: HD HGB (Adult) - % of patient-months with hemoglobin < 10 g/dL, 2020  
F: HD HGB (Adult) - % of patient-months with hemoglobin < 10 g/dL, 2021  
F: HD HGB (Adult) - % of patient-months with hemoglobin < 10 g/dL, 2022  
N: HD HGB (Adult) - % of patient-months with hemoglobin < 10 g/dL, 2022  
S: HD HGB (Adult) - % of patient-months with hemoglobin < 10 g/dL, 2022  
US: HD HGB (Adult) - % of patient-months with hemoglobin < 10 g/dL, 2022  
F: HD HGB (Adult) - % of patient-months with hemoglobin 10 - <11 g/dL, 2019  
F: HD HGB (Adult) - % of patient-months with hemoglobin 10 - <11 g/dL, 2020  
F: HD HGB (Adult) - % of patient-months with hemoglobin 10 - <11 g/dL, 2021  
F: HD HGB (Adult) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
N: HD HGB (Adult) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
S: HD HGB (Adult) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
US: HD HGB (Adult) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
F: HD HGB (Adult) - % of patient-months with hemoglobin 11 - 12 g/dL, 2019  
F: HD HGB (Adult) - % of patient-months with hemoglobin 11 - 12 g/dL, 2020  
F: HD HGB (Adult) - % of patient-months with hemoglobin 11 - 12 g/dL, 2021  
F: HD HGB (Adult) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022  
N: HD HGB (Adult) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022  
S: HD HGB (Adult) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022  
US: HD HGB (Adult) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022  
F: HD HGB (Adult) - % of patient-months with hemoglobin > 12 g/dL, 2019  
F: HD HGB (Adult) - % of patient-months with hemoglobin > 12 g/dL, 2020



F: HD HGB (Adult) - % of patient-months with hemoglobin > 12 g/dL, 2021  
F: HD HGB (Adult) - % of patient-months with hemoglobin > 12 g/dL, 2022  
N: HD HGB (Adult) - % of patient-months with hemoglobin > 12 g/dL, 2022  
S: HD HGB (Adult) - % of patient-months with hemoglobin > 12 g/dL, 2022  
US: HD HGB (Adult) - % of patient-months with hemoglobin > 12 g/dL, 2022  
F: HD HGB (Adult) - % of patient-months with hemoglobin Missing or Out of Range, 2019  
F: HD HGB (Adult) - % of patient-months with hemoglobin Missing or Out of Range, 2020  
F: HD HGB (Adult) - % of patient-months with hemoglobin Missing or Out of Range, 2021  
F: HD HGB (Adult) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
N: HD HGB (Adult) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
S: HD HGB (Adult) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
US: HD HGB (Adult) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
F: HD Kt/V (Adult)- % of patient-months with Kt/V < 1.2, 2019  
F: HD Kt/V (Adult)- % of patient-months with Kt/V < 1.2, 2020  
F: HD Kt/V (Adult)- % of patient-months with Kt/V < 1.2, 2021  
F: HD Kt/V (Adult)- % of patient-months with Kt/V < 1.2, 2022  
N: HD Kt/V (Adult)- % of patient-months with Kt/V < 1.2, 2022  
S: HD Kt/V (Adult)- % of patient-months with Kt/V < 1.2, 2022  
U: HD Kt/V (Adult)- % of patient-months with Kt/V < 1.2, 2022  
F: HD Kt/V (Adult)- % of patient-months with Kt/V 1.2-<1.8, 2019  
F: HD Kt/V (Adult)- % of patient-months with Kt/V 1.2-<1.8, 2020  
F: HD Kt/V (Adult)- % of patient-months with Kt/V 1.2-<1.8, 2021  
F: HD Kt/V (Adult)- % of patient-months with Kt/V 1.2-<1.8, 2022  
N: HD Kt/V (Adult)- % of patient-months with Kt/V 1.2-<1.8, 2022  
S: HD Kt/V (Adult)- % of patient-months with Kt/V 1.2-<1.8, 2022  
U: HD Kt/V (Adult)- % of patient-months with Kt/V 1.2-<1.8, 2022  
F: HD Kt/V (Adult)- % of patient-months with Kt/V >= 1.8, 2019  
F: HD Kt/V (Adult)- % of patient-months with Kt/V >= 1.8, 2020  
F: HD Kt/V (Adult)- % of patient-months with Kt/V >= 1.8, 2021  
F: HD Kt/V (Adult)- % of patient-months with Kt/V >= 1.8, 2022  
N: HD Kt/V (Adult)- % of patient-months with Kt/V >= 1.8, 2022  
S: HD Kt/V (Adult)- % of patient-months with Kt/V >= 1.8, 2022  
U: HD Kt/V (Adult)- % of patient-months with Kt/V >= 1.8, 2022  
F: HD Kt/V (Adult)- % of patient-months with Kt/V missing or out of range, 2019  
F: HD Kt/V (Adult)- % of patient-months with Kt/V missing or out of range, 2020  
F: HD Kt/V (Adult)- % of patient-months with Kt/V missing or out of range, 2021  
F: HD Kt/V (Adult)- % of patient-months with Kt/V missing or out of range, 2022  
N: HD Kt/V (Adult)- % of patient-months with Kt/V missing or out of range, 2022  
S: HD Kt/V (Adult)- % of patient-months with Kt/V missing or out of range, 2022  
U: HD Kt/V (Adult)- % of patient-months with Kt/V missing or out of range, 2022  
F: HD Kt/V (Adult)- Total number of eligible patient-months, 2019  
F: HD Kt/V (Adult)- Total number of eligible patient-months, 2020  
F: HD Kt/V (Adult)- Total number of eligible patient-months, 2021  
F: HD Kt/V (Adult)- Total number of eligible patient-months, 2022

N: HD Kt/V (Adult)- Average number of eligible patient-months, 2022  
S: HD Kt/V (Adult)- Average number of eligible patient-months, 2022  
U: HD Kt/V (Adult)- Average number of eligible patient-months, 2022  
F: HD Kt/V (Adult)- Total number of eligible patients, 2019  
F: HD Kt/V (Adult)- Total number of eligible patients, 2020  
F: HD Kt/V (Adult)- Total number of eligible patients, 2021  
F: HD Kt/V (Adult)- Total number of eligible patients, 2022  
N: HD Kt/V (Adult)- Average number of eligible patients, 2022  
S: HD Kt/V (Adult)- Average number of eligible patients, 2022  
U: HD Kt/V (Adult)- Average number of eligible patients, 2022  
F: HD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patient-months, 2019  
F: HD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patient-months, 2020  
F: HD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patient-months, 2021  
F: HD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patient-months, 2022  
N: HD Dialysis Adequacy (Adult) - Average number of Eligible Dialysis Patient-months, 2022  
S: HD Dialysis Adequacy (Adult) - Average number of Eligible Dialysis Patient-months, 2022  
U: HD Dialysis Adequacy (Adult) - Average number of Eligible Dialysis Patient-months, 2022  
F: HD HGB (Adult) - Total number of eligible patients, 2019  
F: HD HGB (Adult) - Total number of eligible patients, 2020  
F: HD HGB (Adult) - Total number of eligible patients, 2021  
F: HD HGB (Adult) - Total number of eligible patients, 2022  
N: HD HGB (Adult) - Average number of eligible patients, 2022  
S: HD HGB (Adult) - Average number of eligible patients, 2022  
US: HD HGB (Adult) - Average number of eligible patients, 2022  
F: HD HGB (Adult) -Total number of eligible patient-months, 2019  
F: HD HGB (Adult) -Total number of eligible patient-months, 2020  
F: HD HGB (Adult) -Total number of eligible patient-months, 2021  
F: HD HGB (Adult) -Total number of eligible patient-months, 2022  
N: HD HGB (Adult) - Average number of eligible patient-months, 2022  
S: HD HGB (Adult) - Average number of eligible patient-months, 2022  
US: HD HGB (Adult) - Average number of eligible patient-months, 2022  
F: UFR (Adult) - % of HD patient-months with UFR <= 13 ml/kg/hr, 2019  
F: UFR (Adult) - % of HD patient-months with UFR <= 13 ml/kg/hr, 2020  
F: UFR (Adult) - % of HD patient-months with UFR <= 13 ml/kg/hr, 2021  
F: UFR (Adult) - % of HD patient-months with UFR <= 13 ml/kg/hr, 2022  
N: UFR (Adult) - % of HD patient-months with UFR <= 13 ml/kg/hr, 2022  
S: UFR (Adult) - % of HD patient-months with UFR <= 13 ml/kg/hr, 2022  
U: UFR (Adult) - % of HD patient-months with UFR <= 13 ml/kg/hr, 2022  
F: UFR (Adult) - % of HD patient-months with UFR > 13 ml/kg/hr, 2019  
F: UFR (Adult) - % of HD patient-months with UFR > 13 ml/kg/hr, 2020  
F: UFR (Adult) - % of HD patient-months with UFR > 13 ml/kg/hr, 2021  
F: UFR (Adult) - % of HD patient-months with UFR > 13 ml/kg/hr, 2022  
N: UFR (Adult) - % of HD patient-months with UFR > 13 ml/kg/hr, 2022  
S: UFR (Adult) - % of HD patient-months with UFR > 13 ml/kg/hr, 2022





F: Albumin (Adult) - % of PD patient-months with Serum Albumin < 4.0 g/dL, 2022  
N: Albumin (Adult) - % of PD patient-months with Serum Albumin < 4.0 g/dL, 2022  
S: Albumin (Adult) - % of PD patient-months with Serum Albumin < 4.0 g/dL, 2022  
U: Albumin (Adult) - % of PD patient-months with Serum Albumin < 4.0 g/dL, 2022  
F: Albumin (Adult) - Average Serum Albumin, of valid in range PD patient-months, 2019  
F: Albumin (Adult) - Average Serum Albumin, of valid in range PD patient-months, 2020  
F: Albumin (Adult) - Average Serum Albumin, of valid in range PD patient-months, 2021  
F: Albumin (Adult) - Average Serum Albumin, of valid in range PD patient-months, 2022  
N: Albumin (Adult) - Average Serum Albumin, of valid in range PD patient-months, 2022  
S: Albumin (Adult) - Average Serum Albumin, of valid in range PD patient-months, 2022  
U: Albumin (Adult) - Average Serum Albumin, of valid in range PD patient-months, 2022  
F: PD HGB (Adult) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2019  
F: PD HGB (Adult) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2020  
F: PD HGB (Adult) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2021  
F: PD HGB (Adult) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
N: PD HGB (Adult) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
S: PD HGB (Adult) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
US: PD HGB (Adult) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
F: PD Kt/V (Adult)- Average Kt/V, of valid in-range values, 2019  
F: PD Kt/V (Adult)- Average Kt/V, of valid in-range values, 2020  
F: PD Kt/V (Adult)- Average Kt/V, of valid in-range values, 2021  
F: PD Kt/V (Adult)- Average Kt/V, of valid in-range values, 2022  
N: PD Kt/V (Adult)- Average Kt/V, of valid in-range values, 2022  
S: PD Kt/V (Adult)- Average Kt/V, of valid in-range values, 2022  
U: PD Kt/V (Adult)- Average Kt/V, of valid in-range values, 2022  
F: PD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patients, 2019  
F: PD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patients, 2020  
F: PD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patients, 2021  
F: PD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patients, 2022  
N: PD Dialysis Adequacy (Adult)- Average number of eligible patients, 2022  
S: PD Dialysis Adequacy (Adult)- Average number of eligible patients, 2022  
U: PD Dialysis Adequacy (Adult)- Average number of eligible patients, 2022  
F: PD HGB (Adult) - % of patient-months with ESA prescribed, 2019  
F: PD HGB (Adult) - % of patient-months with ESA prescribed, 2020  
F: PD HGB (Adult) - % of patient-months with ESA prescribed, 2021  
F: PD HGB (Adult) - % of patient-months with ESA prescribed, 2022  
N: PD HGB (Adult) - % of patient-months with ESA prescribed, 2022  
S: PD HGB (Adult) - % of patient-months with ESA prescribed, 2022  
US: PD HGB (Adult) - % of patient-months with ESA prescribed, 2022  
F: PD HGB (Adult) - % of patient-months with hemoglobin < 10 g/dL, 2019  
F: PD HGB (Adult) - % of patient-months with hemoglobin < 10 g/dL, 2020  
F: PD HGB (Adult) - % of patient-months with hemoglobin < 10 g/dL, 2021  
F: PD HGB (Adult) - % of patient-months with hemoglobin < 10 g/dL, 2022  
N: PD HGB (Adult) - % of patient-months with hemoglobin < 10 g/dL, 2022

S: PD HGB (Adult) - % of patient-months with hemoglobin < 10 g/dL, 2022  
US: PD HGB (Adult) - % of patient-months with hemoglobin < 10 g/dL, 2022  
F: PD HGB (Adult) - % of patient-months with hemoglobin 10 - <11 g/dL, 2019  
F: PD HGB (Adult) - % of patient-months with hemoglobin 10 - <11 g/dL, 2020  
F: PD HGB (Adult) - % of patient-months with hemoglobin 10 - <11 g/dL, 2021  
F: PD HGB (Adult) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
N: PD HGB (Adult) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
S: PD HGB (Adult) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
US: PD HGB (Adult) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
F: PD HGB (Adult) - % of patient-months with hemoglobin 11 - 12 g/dL, 2019  
F: PD HGB (Adult) - % of patient-months with hemoglobin 11 - 12 g/dL, 2020  
F: PD HGB (Adult) - % of patient-months with hemoglobin 11 - 12 g/dL, 2021  
F: PD HGB (Adult) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022  
N: PD HGB (Adult) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022  
S: PD HGB (Adult) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022  
US: PD HGB (Adult) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022  
F: PD HGB (Adult) - % of patient-months with hemoglobin > 12 g/dL, 2019  
F: PD HGB (Adult) - % of patient-months with hemoglobin > 12 g/dL, 2020  
F: PD HGB (Adult) - % of patient-months with hemoglobin > 12 g/dL, 2021  
F: PD HGB (Adult) - % of patient-months with hemoglobin > 12 g/dL, 2022  
N: PD HGB (Adult) - % of patient-months with hemoglobin > 12 g/dL, 2022  
S: PD HGB (Adult) - % of patient-months with hemoglobin > 12 g/dL, 2022  
US: PD HGB (Adult) - % of patient-months with hemoglobin > 12 g/dL, 2022  
F: PD HGB (Adult) - % of patient-months with hemoglobin Missing or Out of Range, 2019  
F: PD HGB (Adult) - % of patient-months with hemoglobin Missing or Out of Range, 2020  
F: PD HGB (Adult) - % of patient-months with hemoglobin Missing or Out of Range, 2021  
F: PD HGB (Adult) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
N: PD HGB (Adult) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
S: PD HGB (Adult) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
US: PD HGB (Adult) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
F: PD Kt/V (Adult)- % of patient-months with Kt/V < 1.7, 2019  
F: PD Kt/V (Adult)- % of patient-months with Kt/V < 1.7, 2020  
F: PD Kt/V (Adult)- % of patient-months with Kt/V < 1.7, 2021  
F: PD Kt/V (Adult)- % of patient-months with Kt/V < 1.7, 2022  
N: PD Kt/V (Adult)- % of patient-months with Kt/V < 1.7, 2022  
S: PD Kt/V (Adult)- % of patient-months with Kt/V < 1.7, 2022  
U: PD Kt/V (Adult)- % of patient-months with Kt/V < 1.7, 2022  
F: PD Kt/V (Adult)- % of patient-months with Kt/V 1.7-<2.5, 2019  
F: PD Kt/V (Adult)- % of patient-months with Kt/V 1.7-<2.5, 2020  
F: PD Kt/V (Adult)- % of patient-months with Kt/V 1.7-<2.5, 2021  
F: PD Kt/V (Adult)- % of patient-months with Kt/V 1.7-<2.5, 2022  
N: PD Kt/V (Adult)- % of patient-months with Kt/V 1.7-<2.5, 2022  
S: PD Kt/V (Adult)- % of patient-months with Kt/V 1.7-<2.5, 2022  
U: PD Kt/V (Adult)- % of patient-months with Kt/V 1.7-<2.5, 2022

F: PD Kt/V (Adult)- % of patient-months with Kt/V  $\geq$  2.5, 2019  
F: PD Kt/V (Adult)- % of patient-months with Kt/V  $\geq$  2.5, 2020  
F: PD Kt/V (Adult)- % of patient-months with Kt/V  $\geq$  2.5, 2021  
F: PD Kt/V (Adult)- % of patient-months with Kt/V  $\geq$  2.5, 2022  
N: PD Kt/V (Adult)- % of patient-months with Kt/V  $\geq$  2.5, 2022  
S: PD Kt/V (Adult)- % of patient-months with Kt/V  $\geq$  2.5, 2022  
U: PD Kt/V (Adult)- % of patient-months with Kt/V  $\geq$  2.5, 2022  
F: PD Kt/V (Adult)- % of patient-months with Kt/V missing or out of range, 2019  
F: PD Kt/V (Adult)- % of patient-months with Kt/V missing or out of range, 2020  
F: PD Kt/V (Adult)- % of patient-months with Kt/V missing or out of range, 2021  
F: PD Kt/V (Adult)- % of patient-months with Kt/V missing or out of range, 2022  
N: PD Kt/V (Adult)- % of patient-months with Kt/V missing or out of range, 2022  
S: PD Kt/V (Adult)- % of patient-months with Kt/V missing or out of range, 2022  
U: PD Kt/V (Adult)- % of patient-months with Kt/V missing or out of range, 2022  
F: PD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patient-months, 2019  
F: PD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patient-months, 2020  
F: PD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patient-months, 2021  
F: PD Dialysis Adequacy (Adult) - Total Number of Eligible Dialysis Patient-months, 2022  
N: PD Dialysis Adequacy (Adult) - Average number of Eligible Dialysis Patient-months, 2022  
S: PD Dialysis Adequacy (Adult) - Average number of Eligible Dialysis Patient-months, 2022  
U: PD Dialysis Adequacy (Adult) - Average number of Eligible Dialysis Patient-months, 2022  
F: PD HGB (Adult) - Total number of eligible patients, 2019  
F: PD HGB (Adult) - Total number of eligible patients, 2020  
F: PD HGB (Adult) - Total number of eligible patients, 2021  
F: PD HGB (Adult) - Total number of eligible patients, 2022  
N: PD HGB (Adult) - Average number of eligible patients, 2022  
S: PD HGB (Adult) - Average number of eligible patients, 2022  
US: PD HGB (Adult) - Average number of eligible patients, 2022  
F: PD HGB (Adult) - Total number of eligible patient-months, 2019  
F: PD HGB (Adult) - Total number of eligible patient-months, 2020  
F: PD HGB (Adult) - Total number of eligible patient-months, 2021  
F: PD HGB (Adult) - Total number of eligible patient-months, 2022  
N: PD HGB (Adult) - Average number of eligible patient-months, 2022  
S: PD HGB (Adult) - Average number of eligible patient-months, 2022  
US: PD HGB (Adult) - Average number of eligible patient-months, 2022  
F: Phosphorus (Adult) - % of patient-months with serum phosphorus Missing, 2019  
F: Phosphorus (Adult) - % of patient-months with serum phosphorus Missing, 2020  
F: Phosphorus (Adult) - % of patient-months with serum phosphorus Missing, 2021  
F: Phosphorus (Adult) - % of patient-months with serum phosphorus Missing, 2022  
N: Phosphorus (Adult) - % of patient-months with serum phosphorus Missing, 2022  
S: Phosphorus (Adult) - % of patient-months with serum phosphorus Missing, 2022  
US: Phosphorus (Adult) - % of patient-months with serum phosphorus Missing, 2022  
F: Phosphorus (Adult) - % of patient-months with serum phosphorus Out of Range, 2019  
F: Phosphorus (Adult) - % of patient-months with serum phosphorus Out of Range, 2020

F: Phosphorus (Adult) - % of patient-months with serum phosphorus Out of Range, 2021  
F: Phosphorus (Adult) - % of patient-months with serum phosphorus Out of Range, 2022  
N: Phosphorus (Adult) - % of patient-months with serum phosphorus Out of Range, 2022  
S: Phosphorus (Adult) - % of patient-months with serum phosphorus Out of Range, 2022  
US: Phosphorus (Adult) - % of patient-months with serum phosphorus Out of Range, 2022  
F: Calcium (Adult) - Total Number of Eligible Dialysis Patients, 2019  
F: Calcium (Adult) - Total Number of Eligible Dialysis Patients, 2020  
F: Calcium (Adult) - Total Number of Eligible Dialysis Patients, 2021  
F: Calcium (Adult) - Total Number of Eligible Dialysis Patients, 2022  
N: Calcium (Adult) - Average Number of Eligible Dialysis Patients, 2022  
S: Calcium (Adult) - Average Number of Eligible Dialysis Patients, 2022  
US: Calcium (Adult) - Average Number of Eligible Dialysis Patients, 2022  
F: Calcium (Adult) - Total Number of Eligible Dialysis Patient-months, 2019  
F: Calcium (Adult) - Total Number of Eligible Dialysis Patient-months, 2020  
F: Calcium (Adult) - Total Number of Eligible Dialysis Patient-months, 2021  
F: Calcium (Adult) - Total Number of Eligible Dialysis Patient-months, 2022  
N: Calcium (Adult) - Average Number of Eligible Dialysis Patient-months, 2022  
S: Calcium (Adult) - Average Number of Eligible Dialysis Patient-months, 2022  
US: Calcium (Adult) - Average Number of Eligible Dialysis Patient-months, 2022  
F: Calcium (Adult) - % of patient-months with uncorrected calcium < 8.4 mg/dL, 2019  
F: Calcium (Adult) - % of patient-months with uncorrected calcium < 8.4 mg/dL, 2020  
F: Calcium (Adult) - % of patient-months with uncorrected calcium < 8.4 mg/dL, 2021  
F: Calcium (Adult) - % of patient-months with uncorrected calcium < 8.4 mg/dL, 2022  
N: Calcium (Adult) - % of patient-months with uncorrected calcium < 8.4 mg/dL, 2022  
S: Calcium (Adult) - % of patient-months with uncorrected calcium < 8.4 mg/dL, 2022  
US: Calcium (Adult) - % of patient-months with uncorrected calcium < 8.4 mg/dL, 2022  
F: Calcium (Adult) - % of patient-months with uncorrected calcium 8.4-10.2 mg/dL, 2019  
F: Calcium (Adult) - % of patient-months with uncorrected calcium 8.4-10.2 mg/dL, 2020  
F: Calcium (Adult) - % of patient-months with uncorrected calcium 8.4-10.2 mg/dL, 2021  
F: Calcium (Adult) - % of patient-months with uncorrected calcium 8.4-10.2 mg/dL, 2022  
N: Calcium (Adult) - % of patient-months with uncorrected calcium 8.4-10.2 mg/dL, 2022  
S: Calcium (Adult) - % of patient-months with uncorrected calcium 8.4-10.2 mg/dL, 2022  
US: Calcium (Adult) - % of patient-months with uncorrected calcium 8.4-10.2 mg/dL, 2022  
F: Calcium (Adult) - % of patient-months with uncorrected calcium > 10.2 mg/dL, 2019  
F: Calcium (Adult) - % of patient-months with uncorrected calcium > 10.2 mg/dL, 2020  
F: Calcium (Adult) - % of patient-months with uncorrected calcium > 10.2 mg/dL, 2021  
F: Calcium (Adult) - % of patient-months with uncorrected calcium > 10.2 mg/dL, 2022  
N: Calcium (Adult) - % of patient-months with uncorrected calcium > 10.2 mg/dL, 2022  
S: Calcium (Adult) - % of patient-months with uncorrected calcium > 10.2 mg/dL, 2022  
US: Calcium (Adult) - % of patient-months with uncorrected calcium > 10.2 mg/dL, 2022  
F: Hypercalcemia (Adult) - Average uncorrected calcium > 10.2 mg/dL, out of valid in range patient-months, 2019  
F: Hypercalcemia (Adult) - Average uncorrected calcium > 10.2 mg/dL, out of valid in range patient-months, 2020  
F: Hypercalcemia (Adult) - Average uncorrected calcium > 10.2 mg/dL, out of valid in range patient-months, 2021  
F: Hypercalcemia (Adult) - Average uncorrected calcium > 10.2 mg/dL, out of valid in range patient-months, 2022



N: Hypercalcemia (Adult) - Average uncorrected calcium > 10.2 mg/dL, out of valid in range patient-months, 2022  
S: Hypercalcemia (Adult) - Average uncorrected calcium > 10.2 mg/dL, out of valid in range patient-months, 2022  
US: Hypercalcemia (Adult) - Average uncorrected calcium > 10.2 mg/dL, out of valid in range patient-months, 2022  
F: Calcium (Adult) - % of patient-months with uncorrected calcium Missing, 2019  
F: Calcium (Adult) - % of patient-months with uncorrected calcium Missing, 2020  
F: Calcium (Adult) - % of patient-months with uncorrected calcium Missing, 2021  
F: Calcium (Adult) - % of patient-months with uncorrected calcium Missing, 2022  
N: Calcium (Adult) - % of patient-months with uncorrected calcium Missing, 2022  
S: Calcium (Adult) - % of patient-months with uncorrected calcium Missing, 2022  
US: Calcium (Adult) - % of patient-months with uncorrected calcium Missing, 2022  
F: Calcium (Adult) - % of patient-months with uncorrected calcium Out of Range, 2019  
F: Calcium (Adult) - % of patient-months with uncorrected calcium Out of Range, 2020  
F: Calcium (Adult) - % of patient-months with uncorrected calcium Out of Range, 2021  
F: Calcium (Adult) - % of patient-months with uncorrected calcium Out of Range, 2022  
N: Calcium (Adult) - % of patient-months with uncorrected calcium Out of Range, 2022  
S: Calcium (Adult) - % of patient-months with uncorrected calcium Out of Range, 2022  
US: Calcium (Adult) - % of patient-months with uncorrected calcium Out of Range, 2022  
F (2728): Incident Patients - Percent diabetes as primary cause ESRD, 2019  
F (2728): Incident Patients - Percent diabetes as primary cause ESRD, 2020  
F (2728): Incident Patients - Percent diabetes as primary cause ESRD, 2021  
F (2728): Incident Patients - Percent diabetes as primary cause ESRD, 2022  
N (2728): Incident Patients - Percent diabetes as primary cause ESRD, 2022  
S (2728): Incident Patients - Percent diabetes as primary cause ESRD, 2022  
US (2728): Incident Patients - Percent diabetes as primary cause ESRD, 2022  
F: All Patient Mortality - Number of patient deaths, 2019  
F: All Patient Mortality - Number of patient deaths, 2020  
F: All Patient Mortality - Number of patient deaths, 2021  
F: All Patient Mortality - Number of patient deaths, 2022  
F: All Patient Mortality - Number of patient deaths, 2019-2022  
N: All Patient Mortality - Average number of deaths (per year in average facility), 2019-2022  
S: All Patient Mortality - Average number of deaths (per year in average facility), 2019-2022  
US: All Patient Mortality - Average number of deaths (per year in average facility), 2019-2022  
F: Facility Information - Original Certification Date  
DFR: Facility name reported in the DFR  
F (2728): Incident Patients - Percent with diabetes on insulin, 2019  
F (2728): Incident Patients - Percent with diabetes on insulin, 2020  
F (2728): Incident Patients - Percent with diabetes on insulin, 2021  
F (2728): Incident Patients - Percent with diabetes on insulin, 2022  
N (2728): Incident Patients - Percent with diabetes on insulin, 2022  
S (2728): Incident Patients - Percent with diabetes on insulin, 2022  
US (2728): Incident Patients - Percent with diabetes on insulin, 2022  
F (2728): Incident Patients - Percent with diabetes, 2019  
F (2728): Incident Patients - Percent with diabetes, 2020  
F (2728): Incident Patients - Percent with diabetes, 2021

F (2728): Incident Patients - Percent with diabetes, 2022  
N (2728): Incident Patients - Percent with diabetes, 2022  
S (2728): Incident Patients - Percent with diabetes, 2022  
US (2728): Incident Patients - Percent with diabetes, 2022  
F (AFS): Facility Information - Number of full time renal dieticians on 12/31/2019  
F (AFS): Facility Information - Number of full time renal dieticians on 12/31/2020  
F (AFS): Facility Information - Number of full time renal dieticians on 12/31/2021  
F (AFS): Facility Information - Number of full time renal dieticians on 12/31/2022  
N (AFS): Facility Information - Average number of full time renal dieticians on 12/31/2022  
S (AFS): Facility Information - Average number of full time renal dieticians on 12/31/2022  
US (AFS): Facility Information - Average number of full time renal dieticians on 12/31/2022  
F (AFS): Facility Information - Number of part time renal dieticians on 12/31/2019  
F (AFS): Facility Information - Number of part time renal dieticians on 12/31/2020  
F (AFS): Facility Information - Number of part time renal dieticians on 12/31/2021  
F (AFS): Facility Information - Number of part time renal dieticians on 12/31/2022  
N (AFS): Facility Information - Average number of part time renal dieticians on 12/31/2022  
S (AFS): Facility Information - Average number of part time renal dieticians on 12/31/2022  
US (AFS): Facility Information - Average number of part time renal dieticians on 12/31/2022  
F: Prevalent Patients - Primary Cause of ESRD: % Diabetes, 12/31/2019  
F: Prevalent Patients - Primary Cause of ESRD: % Diabetes, 12/31/2020  
F: Prevalent Patients - Primary Cause of ESRD: % Diabetes, 12/31/2021  
F: Prevalent Patients - Primary Cause of ESRD: % Diabetes, 12/31/2022  
N: Prevalent Patients - Primary Cause of ESRD: % Diabetes, 12/31/2022  
S: Prevalent Patients - Primary Cause of ESRD: % Diabetes, 12/31/2022  
US: Prevalent Patients - Primary Cause of ESRD: % Diabetes, 12/31/2022  
F: Prevalent Patients - Primary Cause of ESRD: % Hypertension, 12/31/2019  
F: Prevalent Patients - Primary Cause of ESRD: % Hypertension, 12/31/2020  
F: Prevalent Patients - Primary Cause of ESRD: % Hypertension, 12/31/2021  
F: Prevalent Patients - Primary Cause of ESRD: % Hypertension, 12/31/2022  
N: Prevalent Patients - Primary Cause of ESRD: % Hypertension, 12/31/2022  
S: Prevalent Patients - Primary Cause of ESRD: % Hypertension, 12/31/2022  
US: Prevalent Patients - Primary Cause of ESRD: % Hypertension, 12/31/2022  
F: Prevalent Patients - Primary Cause of ESRD: % Glomerulonephritis, 12/31/2019  
F: Prevalent Patients - Primary Cause of ESRD: % Glomerulonephritis, 12/31/2020  
F: Prevalent Patients - Primary Cause of ESRD: % Glomerulonephritis, 12/31/2021  
F: Prevalent Patients - Primary Cause of ESRD: % Glomerulonephritis, 12/31/2022  
N: Prevalent Patients - Primary Cause of ESRD: % Glomerulonephritis, 12/31/2022  
S: Prevalent Patients - Primary Cause of ESRD: % Glomerulonephritis, 12/31/2022  
US: Prevalent Patients - Primary Cause of ESRD: % Glomerulonephritis, 12/31/2022  
F: Prevalent Patients - Primary Cause of ESRD: % Other/Unknown Cause, 12/31/2019  
F: Prevalent Patients - Primary Cause of ESRD: % Other/Unknown Cause, 12/31/2020  
F: Prevalent Patients - Primary Cause of ESRD: % Other/Unknown Cause, 12/31/2021  
F: Prevalent Patients - Primary Cause of ESRD: % Other/Unknown Cause, 12/31/2022  
N: Prevalent Patients - Primary Cause of ESRD: % Other/Unknown Cause, 12/31/2022

S: Prevalent Patients - Primary Cause of ESRD: % Other/Unknown Cause, 12/31/2022  
US: Prevalent Patients - Primary Cause of ESRD: % Other/Unknown Cause, 12/31/2022  
F: Prevalent Patients - Primary Cause of ESRD: % Missing Cause, 12/31/2019  
F: Prevalent Patients - Primary Cause of ESRD: % Missing Cause, 12/31/2020  
F: Prevalent Patients - Primary Cause of ESRD: % Missing Cause, 12/31/2021  
F: Prevalent Patients - Primary Cause of ESRD: % Missing Cause, 12/31/2022  
N: Prevalent Patients - Primary Cause of ESRD: % Missing Cause, 12/31/2022  
S: Prevalent Patients - Primary Cause of ESRD: % Missing Cause, 12/31/2022  
US: Prevalent Patients - Primary Cause of ESRD: % Missing Cause, 12/31/2022  
F (2728): Incident Patients - Percent drug dependent, 2019  
F (2728): Incident Patients - Percent drug dependent, 2020  
F (2728): Incident Patients - Percent drug dependent, 2021  
F (2728): Incident Patients - Percent drug dependent, 2022  
N (2728): Incident Patients - Percent drug dependent, 2022  
S (2728): Incident Patients - Percent drug dependent, 2022  
US (2728): Incident Patients - Percent drug dependent, 2022  
F: All Patient Mortality - Number of deaths from dialysis unrelated deaths, 2019  
F: All Patient Mortality - Number of deaths from dialysis unrelated deaths, 2020  
F: All Patient Mortality - Number of deaths from dialysis unrelated deaths, 2021  
F: All Patient Mortality - Number of deaths from dialysis unrelated deaths, 2022  
F: All Patient Mortality - Number of deaths from dialysis unrelated death, 2019-2022  
N: All Patient Mortality - Average number deaths from dialysis, unrelated deaths (per year in average facility), 20  
S: All Patient Mortality - Average number deaths from dialysis, unrelated deaths (per year in average facility), 20  
US: All Patient Mortality - Average number deaths from dialysis, unrelated deaths (per year in average facility), 20  
F: All Patient Mortality - Years at risk for mortality, 2019  
F: All Patient Mortality - Years at risk for mortality, 2020  
F: All Patient Mortality - Years at risk for mortality, 2021  
F: All Patient Mortality - Years at risk for mortality, 2022  
F: All Patient Mortality - Years at risk, 2019-2022  
N: All Patient Mortality - Average years at risk for mortality (per year in average facility), 2019-2022  
S: All Patient Mortality - Average years at risk for mortality (per year in average facility), 2019-2022  
US: All Patient Mortality - Average years at risk for mortality (per year in average facility), 2019-2022  
Expected total ED30, 2019  
Expected total ED30, 2020  
Expected total ED30, 2021  
Expected total ED30, 2022  
Expected total ED30, 2019-22  
N: ED30 - Average annual expected ED visits, 2019-22  
S: ED30 - Average annual expected ED visits, 2019-22  
U: ED30 - Average annual expected ED visits, 2019-22  
ED30: Index discharges, 2019  
ED30: Index discharges, 2020  
ED30: Index discharges, 2021  
ED30: Index discharges, 2022

ED30: Index discharges, 2019-22  
N: ED30 - Average annual index discharges, 2019-22  
S: ED30 - Average annual index discharges, 2019-22  
U: ED30 - Average annual index discharges, 2019-22  
ED30: Lower confidence limit, 2019  
ED30: Lower confidence limit, 2020  
ED30: Lower confidence limit, 2021  
ED30: Lower confidence limit, 2022  
ED30: Lower confidence limit, 2019-22  
Observed Total ED30, 2019  
Observed Total ED30, 2020  
Observed Total ED30, 2021  
Observed Total ED30, 2022  
Observed Total ED30, 2019-22  
N: ED30- Average annual number of ED visits, 2019-22  
S: ED30- Average annual number of ED visits, 2019-22  
U: ED30- Average annual number of ED visits, 2019-22  
ED30: P-value, 2019  
ED30: P-value, 2020  
ED30: P-value, 2021  
ED30: P-value, 2022  
ED30: P-value, 2019-22  
ED30: Upper confidence limit, 2019  
ED30: Upper confidence limit, 2020  
ED30: Upper confidence limit, 2021  
ED30: Upper confidence limit, 2022  
ED30: Upper confidence limit, 2019-22  
Standardized Ratio of ED30, 2019  
Standardized Ratio of ED30, 2020  
Standardized Ratio of ED30, 2021  
Standardized Ratio of ED30, 2022  
Standardized Ratio of ED30, 2019-22  
N: ED30: Standardized Ratio of ED30, 2019-22  
S: ED30: Standardized Ratio of ED30, 2019-22  
U: ED30: Standardized Ratio of ED30, 2019-22  
F: SEDR - Years at Risk, 2019  
F: SEDR - Years at Risk, 2020  
F: SEDR - Years at Risk, 2021  
F: SEDR - Years at Risk, 2022  
Years at risk for ED visit rate  
Years at risk for ED visit rate  
Years at risk for ED visit rate  
Years at risk for ED visit rate  
Years at risk for ED visit rate

Years at risk for ED visit rate

Years at risk for ED visit rate

F: Influenza - Total number of patients treated on 12/31, 2019

F: Influenza - Total number of patients treated on 12/31, 2020

F: Influenza - Total number of patients treated on 12/31, 2021

F: Influenza - Total number of patients treated on 12/31, 2022

N: Influenza - Average number of patients treated on 12/31, 2022

S: Influenza - Average number of patients treated on 12/31, 2022

U: Influenza - Average number of patients treated on 12/31, 2022

F (AFS): Facility Information - % Patients 18-54 who are employed on 12/31/2019

F (AFS): Facility Information - % Patients 18-54 who are employed on 12/31/2020

F (AFS): Facility Information - % Patients 18-54 who are employed on 12/31/2021

F (AFS): Facility Information - % Patients 18-54 who are employed on 12/31/2022

N (AFS): Facility Information - % Patients 18-54 who are employed on 12/31/2022

S (AFS): Facility Information - % Patients 18-54 who are employed on 12/31/2022

US (AFS): Facility Information - % Patients 18-54 who are employed on 12/31/2022

F (AFS): Facility Information - Number of all patients on 12/31/2019

F (AFS): Facility Information - Number of all patients on 12/31/2020

F (AFS): Facility Information - Number of all patients on 12/31/2021

F (AFS): Facility Information - Number of all patients on 12/31/2022

N (AFS): Facility Information - Average number of all patients on 12/31/2022

S (AFS): Facility Information - Average number of all patients on 12/31/2022

US (AFS): Facility Information - Average number of all patients on 12/31/2022

F: Prevalent Patients - Ethnicity: % Hispanic, 12/31/2019

F: Prevalent Patients - Ethnicity: % Hispanic, 12/31/2020

F: Prevalent Patients - Ethnicity: % Hispanic, 12/31/2021

F: Prevalent Patients - Ethnicity: % Hispanic, 12/31/2022

N: Prevalent Patients - Ethnicity: % Hispanic, 12/31/2022

S: Prevalent Patients - Ethnicity: % Hispanic, 12/31/2022

US: Prevalent Patients - Ethnicity: % Hispanic, 12/31/2022

F: Prevalent Patients - Ethnicity: % Non-Hispanic, 12/31/2019

F: Prevalent Patients - Ethnicity: % Non-Hispanic, 12/31/2020

F: Prevalent Patients - Ethnicity: % Non-Hispanic, 12/31/2021

F: Prevalent Patients - Ethnicity: % Non-Hispanic, 12/31/2022

N: Prevalent Patients - Ethnicity: % Non-Hispanic, 12/31/2022

S: Prevalent Patients - Ethnicity: % Non-Hispanic, 12/31/2022

US: Prevalent Patients - Ethnicity: % Non-Hispanic, 12/31/2022

F: Prevalent Patients - Ethnicity: % Unknown Ethnicity, 12/31/2019

F: Prevalent Patients - Ethnicity: % Unknown Ethnicity, 12/31/2020

F: Prevalent Patients - Ethnicity: % Unknown Ethnicity, 12/31/2021

F: Prevalent Patients - Ethnicity: % Unknown Ethnicity, 12/31/2022

N: Prevalent Patients - Ethnicity: % Unknown Ethnicity, 12/31/2022

S: Prevalent Patients - Ethnicity: % Unknown Ethnicity, 12/31/2022

US: Prevalent Patients - Ethnicity: % Unknown Ethnicity, 12/31/2022

F (2728): Incident Patients - Percent Hispanic, 2019  
F (2728): Incident Patients - Percent Hispanic, 2020  
F (2728): Incident Patients - Percent Hispanic, 2021  
F (2728): Incident Patients - Percent Hispanic, 2022  
N (2728): Incident Patients - Percent Hispanic, 2022  
S (2728): Incident Patients - Percent Hispanic, 2022  
US (2728): Incident Patients - Percent Hispanic, 2022  
F: All Patient Mortality - Expected number of patient deaths, 2019  
F: All Patient Mortality - Expected number of patient deaths, 2020  
F: All Patient Mortality - Expected number of patient deaths, 2021  
F: All Patient Mortality - Expected number of patient deaths, 2022  
F: All Patient Mortality - Expected number of patient deaths, 2019-2022  
N: All Patient Mortality - Average expected deaths (per year in average facility), 2019-2022  
S: All Patient Mortality - Average expected deaths (per year in average facility), 2019-2022  
US: All Patient Mortality - Average expected deaths (per year in average facility), 2019-2022  
F: SEDR - Expected Number of Emergency Department Events, 2019  
F: SEDR - Expected Number of Emergency Department Events, 2020  
F: SEDR - Expected Number of Emergency Department Events, 2021  
F: SEDR - Expected Number of Emergency Department Events, 2022  
F: SEDR - Expected Number of Emergency Department Events, 2019-2022  
Expected number of ED events  
Expected number of ED events  
Expected number of ED events  
F: SHR (Days) - Expected Days Hospitalized, 2019  
F: SHR (Days) - Expected Days Hospitalized, 2020  
F: SHR (Days) - Expected Days Hospitalized, 2021  
F: SHR (Days) - Expected Days Hospitalized, 2022  
F: SHR (Days) - Expected Days Hospitalized, 2019-2022  
N: SHR (Days) - Average Expected Days Hospitalized (per year in average facility), 2019-2022  
S: SHR (Days) - Average Expected Days Hospitalized (per year in average facility), 2019-2022  
US: SHR (Days) - Average Expected Days Hospitalized (per year in average facility), 2019-2022  
F: STRR (Adult) - Expected Total Number of Transfusions, 2019  
F: STRR (Adult) - Expected Total Number of Transfusions, 2020  
F: STRR (Adult) - Expected Total Number of Transfusions, 2021  
F: STRR (Adult) - Expected Total Number of Transfusions, 2022  
N: STRR (Adult) - Average Expected Total Number of Transfusions, 2022  
S: STRR (Adult) - Average Expected Total Number of Transfusions, 2022  
US: STRR (Adult) - Average Expected Total Number of Transfusions, 2022  
F: STR - Expected number of 1st transplants, 2019  
F: STR - Expected number of 1st transplants, 2020  
F: STR - Expected number of 1st transplants, 2021  
F: STR - Expected number of 1st transplants, 2022  
F: STR - Expected number of 1st transplants, 2019-2022  
N: STR - Average number of expected 1st transplant (per year in average facility), 2019-2022

S: STR - Average number of expected 1st transplant (per year in average facility), 2019-2022  
US: STR - Average number of expected 1st transplant (per year in average facility), 2019-2022  
F: SHR (Admissions) - Expected Number of Hospital Admissions, 2019  
F: SHR (Admissions) - Expected Number of Hospital Admissions, 2020  
F: SHR (Admissions) - Expected Number of Hospital Admissions, 2021  
F: SHR (Admissions) - Expected Number of Hospital Admissions, 2022  
F: SHR (Admissions)- Expected Number of Hospital Admissions, 2019-2022  
N: SHR (Admissions) - Average Expected Number of Hospital Admissions (per year in average facility), 2019-2022  
S: SHR (Admissions) - Average Expected Number of Hospital Admissions (per year in average facility), 2019-2022  
US: SHR (Admissions) - Average Expected Number of Hospital Admissions (per year in average facility), 2019-2022  
F (2728): Incident Patients - Percent female, 2019  
F (2728): Incident Patients - Percent female, 2020  
F (2728): Incident Patients - Percent female, 2021  
F (2728): Incident Patients - Percent female, 2022  
N (2728): Incident Patients - Percent female, 2022  
S (2728): Incident Patients - Percent female, 2022  
US (2728): Incident Patients - Percent female, 2022  
F: Influenza - % of dialysis patients 18-39 vaccinated, 8/1-12/31, 2019  
F: Influenza - % of dialysis patients 18-39 vaccinated, 8/1-12/31, 2020  
F: Influenza - % of dialysis patients 18-39 vaccinated, 8/1-12/31, 2021  
F: Influenza - % of dialysis patients 18-39 vaccinated, 8/1-12/31, 2022  
N: Influenza - % of dialysis patients 18-39 vaccinated, 8/1-12/31, 2022  
S: Influenza - % of dialysis patients 18-39 vaccinated, 8/1-12/31, 2022  
U: Influenza - % of dialysis patients 18-39 vaccinated, 8/1-12/31, 2022  
F: Influenza - % of dialysis patients 40-64 vaccinated, 8/1-12/31, 2019  
F: Influenza - % of dialysis patients 40-64 vaccinated, 8/1-12/31, 2020  
F: Influenza - % of dialysis patients 40-64 vaccinated, 8/1-12/31, 2021  
F: Influenza - % of dialysis patients 40-64 vaccinated, 8/1-12/31, 2022  
N: Influenza - % of dialysis patients 40-64 vaccinated, 8/1-12/31, 2022  
S: Influenza - % of dialysis patients 40-64 vaccinated, 8/1-12/31, 2022  
U: Influenza - % of dialysis patients 40-64 vaccinated, 8/1-12/31, 2022  
F: Influenza - % of dialysis patients 65-74 vaccinated, 8/1-12/31, 2019  
F: Influenza - % of dialysis patients 65-74 vaccinated, 8/1-12/31, 2020  
F: Influenza - % of dialysis patients 65-74 vaccinated, 8/1-12/31, 2021  
F: Influenza - % of dialysis patients 65-74 vaccinated, 8/1-12/31, 2022  
N: Influenza - % of dialysis patients 65-74 vaccinated, 8/1-12/31, 2022  
S: Influenza - % of dialysis patients 65-74 vaccinated, 8/1-12/31, 2022  
U: Influenza - % of dialysis patients 65-74 vaccinated, 8/1-12/31, 2022  
F: Influenza - % of dialysis patients 75+ vaccinated, 8/1-12/31, 2019  
F: Influenza - % of dialysis patients 75+ vaccinated, 8/1-12/31, 2020  
F: Influenza - % of dialysis patients 75+ vaccinated, 8/1-12/31, 2021  
F: Influenza - % of dialysis patients 75+ vaccinated, 8/1-12/31, 2022  
N: Influenza - % of dialysis patients 75+ vaccinated, 8/1-12/31, 2022  
S: Influenza - % of dialysis patients 75+ vaccinated, 8/1-12/31, 2022

U: Influenza - % of dialysis patients 75+ vaccinated, 8/1-12/31, 2022  
F: Influenza - % of Asian dialysis patients vaccinated, 8/1-12/31, 2019  
F: Influenza - % of Asian dialysis patients vaccinated, 8/1-12/31, 2020  
F: Influenza - % of Asian dialysis patients vaccinated, 8/1-12/31, 2021  
F: Influenza - % of Asian dialysis patients vaccinated, 8/1-12/31, 2022  
N: Influenza - % of Asian dialysis patients vaccinated, 8/1-12/31, 2022  
S: Influenza - % of Asian dialysis patients vaccinated, 8/1-12/31, 2022  
U: Influenza - % of Asian dialysis patients vaccinated, 8/1-12/31, 2022  
F: Influenza - % of black dialysis patients vaccinated, 8/1-12/31, 2019  
F: Influenza - % of black dialysis patients vaccinated, 8/1-12/31, 2020  
F: Influenza - % of black dialysis patients vaccinated, 8/1-12/31, 2021  
F: Influenza - % of black dialysis patients vaccinated, 8/1-12/31, 2022  
N: Influenza - % of black dialysis patients vaccinated, 8/1-12/31, 2022  
S: Influenza - % of black dialysis patients vaccinated, 8/1-12/31, 2022  
U: Influenza - % of black dialysis patients vaccinated, 8/1-12/31, 2022  
F: Influenza - % of patients that declined vaccination, 8/1-3/31, 2019  
F: Influenza - % of patients that declined vaccination, 8/1-3/31, 2020  
F: Influenza - % of patients that declined vaccination, 8/1-3/31, 2021  
N: Influenza - % of patients that declined vaccination, 8/1-3/31, 2021  
S: Influenza - % of patients that declined vaccination, 8/1-3/31, 2021  
U: Influenza - % of patients that declined vaccination, 8/1-3/31, 2021  
F: Influenza - % of dual Medicare/Medicaid eligible patients vaccinated, 8/1-12/31, 2019  
F: Influenza - % of dual Medicare/Medicaid eligible patients vaccinated, 8/1-12/31, 2020  
F: Influenza - % of dual Medicare/Medicaid eligible patients vaccinated, 8/1-12/31, 2021  
F: Influenza - % of dual Medicare/Medicaid eligible patients vaccinated, 8/1-12/31, 2022  
N: Influenza - % of dual Medicare/Medicaid eligible patients vaccinated, 8/1-12/31, 2022  
S: Influenza - % of dual Medicare/Medicaid eligible patients vaccinated, 8/1-12/31, 2022  
U: Influenza - % of dual Medicare/Medicaid eligible patients vaccinated, 8/1-12/31, 2022  
F: Influenza - % of female dialysis patients vaccinated, 8/1-12/31, 2019  
F: Influenza - % of female dialysis patients vaccinated, 8/1-12/31, 2020  
F: Influenza - % of female dialysis patients vaccinated, 8/1-12/31, 2021  
F: Influenza - % of female dialysis patients vaccinated, 8/1-12/31, 2022  
N: Influenza - % of female dialysis patients vaccinated, 8/1-12/31, 2022  
S: Influenza - % of female dialysis patients vaccinated, 8/1-12/31, 2022  
U: Influenza - % of female dialysis patients vaccinated, 8/1-12/31, 2022  
F: Influenza - % of patients vaccinated, 8/1-3/31, 2019  
U: Influenza - % of patients vaccinated, 8/1-3/31, 2019  
F: Influenza - % of patients vaccinated, 8/1-3/31, 2020  
U: Influenza - % of patients vaccinated, 8/1-3/31, 2020  
F: Influenza - % of patients vaccinated, 8/1-3/31, 2021  
N: Influenza - % of patients vaccinated, 8/1-3/31, 2021  
S: Influenza - % of patients vaccinated, 8/1-3/31, 2021  
U: Influenza - % of patients vaccinated, 8/1-3/31, 2021  
F: Influenza - % of Hispanic dialysis patients vaccinated, 8/1-12/31, 2019



F: Influenza - % of Hispanic dialysis patients vaccinated, 8/1-12/31, 2020  
F: Influenza - % of Hispanic dialysis patients vaccinated, 8/1-12/31, 2021  
F: Influenza - % of Hispanic dialysis patients vaccinated, 8/1-12/31, 2022  
N: Influenza - % of Hispanic dialysis patients vaccinated, 8/1-12/31, 2022  
S: Influenza - % of Hispanic dialysis patients vaccinated, 8/1-12/31, 2022  
U: Influenza - % of Hispanic dialysis patients vaccinated, 8/1-12/31, 2022  
F: Influenza - % of patients vaccinated, 8/1-12/31, 2019  
U: Influenza - % of patients vaccinated, 8/1-12/31, 2019  
F: Influenza - % of patients vaccinated, 8/1-12/31, 2020  
U: Influenza - % of patients vaccinated, 8/1-12/31, 2020  
F: Influenza - % of patients vaccinated, 8/1-12/31, 2021  
U: Influenza - % of patients vaccinated, 8/1-12/31, 2021  
F: Influenza - % of patients vaccinated, 8/1-12/31, 2022  
N: Influenza - % of patients vaccinated, 8/1-12/31, 2022  
S: Influenza - % of patients vaccinated, 8/1-12/31, 2022  
U: Influenza - % of patients vaccinated, 8/1-12/31, 2022  
F: Influenza - % of dialysis patients <18 vaccinated, 8/1-12/31, 2019  
F: Influenza - % of dialysis patients <18 vaccinated, 8/1-12/31, 2020  
F: Influenza - % of dialysis patients <18 vaccinated, 8/1-12/31, 2021  
F: Influenza - % of dialysis patients <18 vaccinated, 8/1-12/31, 2022  
N: Influenza - % of dialysis patients <18 vaccinated, 8/1-12/31, 2022  
S: Influenza - % of dialysis patients <18 vaccinated, 8/1-12/31, 2022  
U: Influenza - % of dialysis patients <18 vaccinated, 8/1-12/31, 2022  
F: Influenza - % of Medicare Advantage patients vaccinated, 8/1-12/31, 2019  
F: Influenza - % of Medicare Advantage patients vaccinated, 8/1-12/31, 2020  
F: Influenza - % of Medicare Advantage patients vaccinated, 8/1-12/31, 2021  
F: Influenza - % of Medicare Advantage patients vaccinated, 8/1-12/31, 2022  
N: Influenza - % of Medicare Advantage patients vaccinated, 8/1-12/31, 2022  
S: Influenza - % of Medicare Advantage patients vaccinated, 8/1-12/31, 2022  
U: Influenza - % of Medicare Advantage patients vaccinated, 8/1-12/31, 2022  
F: Influenza - % of male dialysis patients vaccinated, 8/1-12/31, 2019  
F: Influenza - % of male dialysis patients vaccinated, 8/1-12/31, 2020  
F: Influenza - % of male dialysis patients vaccinated, 8/1-12/31, 2021  
F: Influenza - % of male dialysis patients vaccinated, 8/1-12/31, 2022  
N: Influenza - % of male dialysis patients vaccinated, 8/1-12/31, 2022  
S: Influenza - % of male dialysis patients vaccinated, 8/1-12/31, 2022  
U: Influenza - % of male dialysis patients vaccinated, 8/1-12/31, 2022  
F: Influenza - % of Medicare patients vaccinated, 8/1-12/31, 2019  
F: Influenza - % of Medicare patients vaccinated, 8/1-12/31, 2020  
F: Influenza - % of Medicare patients vaccinated, 8/1-12/31, 2021  
F: Influenza - % of Medicare patients vaccinated, 8/1-12/31, 2022  
N: Influenza - % of Medicare patients vaccinated, 8/1-12/31, 2022  
S: Influenza - % of Medicare patients vaccinated, 8/1-12/31, 2022  
U: Influenza - % of Medicare patients vaccinated, 8/1-12/31, 2022

F: Influenza - % of patients with Medicare as primary insurer vaccinated, 8/1-12/31, 2019  
F: Influenza - % of patients with Medicare as primary insurer vaccinated, 8/1-12/31, 2020  
F: Influenza - % of patients with Medicare as primary insurer vaccinated, 8/1-12/31, 2021  
F: Influenza - % of patients with Medicare as primary insurer vaccinated, 8/1-12/31, 2022  
N: Influenza - % of patients with Medicare as primary insurer vaccinated, 8/1-12/31, 2022  
S: Influenza - % of patients with Medicare as primary insurer vaccinated, 8/1-12/31, 2022  
U: Influenza - % of patients with Medicare as primary insurer vaccinated, 8/1-12/31, 2022  
F: Influenza - % of patients with Medicare as secondary insurer vaccinated, 8/1-12/31, 2019  
F: Influenza - % of patients with Medicare as secondary insurer vaccinated, 8/1-12/31, 2020  
F: Influenza - % of patients with Medicare as secondary insurer vaccinated, 8/1-12/31, 2021  
F: Influenza - % of patients with Medicare as secondary insurer vaccinated, 8/1-12/31, 2022  
N: Influenza - % of patients with Medicare as secondary insurer vaccinated, 8/1-12/31, 2022  
S: Influenza - % of patients with Medicare as secondary insurer vaccinated, 8/1-12/31, 2022  
U: Influenza - % of patients with Medicare as secondary insurer vaccinated, 8/1-12/31, 2022  
F: Influenza - % of Native American dialysis patients vaccinated, 8/1-12/31, 2019  
F: Influenza - % of Native American dialysis patients vaccinated, 8/1-12/31, 2020  
F: Influenza - % of Native American dialysis patients vaccinated, 8/1-12/31, 2021  
F: Influenza - % of Native American dialysis patients vaccinated, 8/1-12/31, 2022  
N: Influenza - % of Native American dialysis patients vaccinated, 8/1-12/31, 2022  
S: Influenza - % of Native American dialysis patients vaccinated, 8/1-12/31, 2022  
U: Influenza - % of Native American dialysis patients vaccinated, 8/1-12/31, 2022  
F: Influenza - % of Non-Medicare patients vaccinated, 8/1-12/31, 2019  
F: Influenza - % of Non-Medicare patients vaccinated, 8/1-12/31, 2020  
F: Influenza - % of Non-Medicare patients vaccinated, 8/1-12/31, 2021  
F: Influenza - % of Non-Medicare patients vaccinated, 8/1-12/31, 2022  
N: Influenza - % of Non-Medicare patients vaccinated, 8/1-12/31, 2022  
S: Influenza - % of Non-Medicare patients vaccinated, 8/1-12/31, 2022  
U: Influenza - % of Non-Medicare patients vaccinated, 8/1-12/31, 2022  
F: Influenza - % of patients without vaccination due to other reason or vaccine data not available, 8/1-3/31, 2019  
F: Influenza - % of patients without vaccination due to other reason or vaccine data not available, 8/1-3/31, 2020  
F: Influenza - % of patients without vaccination due to other reason or vaccine data not available, 8/1-3/31, 2021  
N: Influenza - % of patients without vaccination due to other reason or vaccine data not available, 8/1-3/31, 2021  
S: Influenza - % of patients without vaccination due to other reason or vaccine data not available, 8/1-3/31, 2021  
U: Influenza - % of patients without vaccination due to other reason or vaccine data not available, 8/1-3/31, 2021  
F: Influenza - % of patients without vaccination due to outside vaccination reported but no documentation, 8/1-3  
F: Influenza - % of patients without vaccination due to outside vaccination reported but no documentation, 8/1-3  
F: Influenza - % of patients without vaccination due to outside vaccination reported but no documentation, 8/1-3  
N: Influenza - % of patients without vaccination due to outside vaccination reported but no documentation, 8/1-3  
S: Influenza - % of patients without vaccination due to outside vaccination reported but no documentation, 8/1-3  
U: Influenza - % of patients without vaccination due to outside vaccination reported but no documentation, 8/1-3  
F: Influenza - % of Other race dialysis patients vaccinated, 8/1-12/31, 2019  
F: Influenza - % of Other race dialysis patients vaccinated, 8/1-12/31, 2020  
F: Influenza - % of Other race dialysis patients vaccinated, 8/1-12/31, 2021  
F: Influenza - % of Other race dialysis patients vaccinated, 8/1-12/31, 2022

N: Influenza - % of Other race dialysis patients vaccinated, 8/1-12/31, 2022  
S: Influenza - % of Other race dialysis patients vaccinated, 8/1-12/31, 2022  
U: Influenza - % of Other race dialysis patients vaccinated, 8/1-12/31, 2022  
F: Influenza - % of dialysis patients with <1 year of prior ESRD therapy vaccinated, 8/1-12/31, 2019  
F: Influenza - % of dialysis patients with <1 year of prior ESRD therapy vaccinated, 8/1-12/31, 2020  
F: Influenza - % of dialysis patients with <1 year of prior ESRD therapy vaccinated, 8/1-12/31, 2021  
F: Influenza - % of dialysis patients with <1 year of prior ESRD therapy vaccinated, 8/1-12/31, 2022  
N: Influenza - % of dialysis patients with <1 year of prior ESRD therapy vaccinated, 8/1-12/31, 2022  
S: Influenza - % of dialysis patients with <1 year of prior ESRD therapy vaccinated, 8/1-12/31, 2022  
U: Influenza - % of dialysis patients with <1 year of prior ESRD therapy vaccinated, 8/1-12/31, 2022  
F: Influenza - % of dialysis patients with 1-2 years of prior ESRD therapy vaccinated, 8/1-12/31, 2019  
F: Influenza - % of dialysis patients with 1-2 years of prior ESRD therapy vaccinated, 8/1-12/31, 2020  
F: Influenza - % of dialysis patients with 1-2 years of prior ESRD therapy vaccinated, 8/1-12/31, 2021  
F: Influenza - % of dialysis patients with 1-2 years of prior ESRD therapy vaccinated, 8/1-12/31, 2022  
N: Influenza - % of dialysis patients with 1-2 years of prior ESRD therapy vaccinated, 8/1-12/31, 2022  
S: Influenza - % of dialysis patients with 1-2 years of prior ESRD therapy vaccinated, 8/1-12/31, 2022  
U: Influenza - % of dialysis patients with 1-2 years of prior ESRD therapy vaccinated, 8/1-12/31, 2022  
F: Influenza - % of dialysis patients with 3+ years of prior ESRD therapy vaccinated, 8/1-12/31, 2019  
F: Influenza - % of dialysis patients with 3+ years of prior ESRD therapy vaccinated, 8/1-12/31, 2020  
F: Influenza - % of dialysis patients with 3+ years of prior ESRD therapy vaccinated, 8/1-12/31, 2021  
F: Influenza - % of dialysis patients with 3+ years of prior ESRD therapy vaccinated, 8/1-12/31, 2022  
N: Influenza - % of dialysis patients with 3+ years of prior ESRD therapy vaccinated, 8/1-12/31, 2022  
S: Influenza - % of dialysis patients with 3+ years of prior ESRD therapy vaccinated, 8/1-12/31, 2022  
U: Influenza - % of dialysis patients with 3+ years of prior ESRD therapy vaccinated, 8/1-12/31, 2022  
F: Influenza - % of white dialysis patients vaccinated, 8/1-12/31, 2019  
F: Influenza - % of white dialysis patients vaccinated, 8/1-12/31, 2020  
F: Influenza - % of white dialysis patients vaccinated, 8/1-12/31, 2021  
F: Influenza - % of white dialysis patients vaccinated, 8/1-12/31, 2022  
N: Influenza - % of white dialysis patients vaccinated, 8/1-12/31, 2022  
S: Influenza - % of white dialysis patients vaccinated, 8/1-12/31, 2022  
U: Influenza - % of white dialysis patients vaccinated, 8/1-12/31, 2022  
F: First-Year Mortality - Percent of deaths from cardiac causes, 2019  
F: First-Year Mortality - Percent of deaths from cardiac causes, 2020  
F: First-Year Mortality - Percent of deaths from cardiac causes, 2021  
F: First-Year Mortality - Percent of deaths from cardiac causes, 2019 - 2021  
N: First-Year Mortality - Percent of deaths from cardiac causes, 2019 - 2021  
S: First-Year Mortality - Percent of deaths from cardiac causes, 2019 - 2021  
US: First-Year Mortality - Percent of deaths from cardiac causes, 2019 - 2021  
F: First-Year Mortality - 97.5% upper limit confidence interval for SMR, 2019  
F: First-Year Mortality - 97.5% upper limit confidence interval for SMR, 2020  
F: First-Year Mortality - 97.5% upper limit confidence interval for SMR, 2021  
F: First-Year Mortality - 97.5% upper limit confidence interval for SMR, 2019 - 2021  
F: First-Year Mortality - 2.5% lower limit confidence interval for SMR, 2019  
F: First-Year Mortality - 2.5% lower limit confidence interval for SMR, 2020

F: First-Year Mortality - 2.5% lower limit confidence interval for SMR, 2021  
F: First-Year Mortality - 2.5% lower limit confidence interval for SMR, 2019 - 2021  
F: First-Year Mortality - Patient deaths, 2019  
F: First-Year Mortality - Patient deaths, 2020  
F: First-Year Mortality - Patient deaths, 2021  
F: First-Year Mortality - Patient deaths, 2019 - 2021  
N: First-Year Mortality - Average number of deaths, 2019 - 2021  
S: First-Year Mortality - Average number of deaths, 2019 - 2021  
US: First-Year Mortality - Average number of deaths, 2019 - 2021  
F: First-Year Mortality - Years at risk, 2019  
F: First-Year Mortality - Years at risk, 2020  
F: First-Year Mortality - Years at risk, 2021  
F: First-Year Mortality - Years at risk, 2019 - 2021  
N: First-Year Mortality - Average Years at risk , 2019 - 2021  
S: First-Year Mortality - Average Years at risk , 2019 - 2021  
US: First-Year Mortality - Average Years at risk , 2019 - 2021  
F: First-Year Mortality - Expected deaths, 2019  
F: First-Year Mortality - Expected deaths, 2020  
F: First-Year Mortality - Expected deaths, 2021  
F: First-Year Mortality - Expected deaths, 2019 - 2021  
N: First-Year Mortality - Average number of expected deaths, 2019 - 2021  
S: First-Year Mortality - Average number of expected deaths, 2019 - 2021  
US: First-Year Mortality - Average number of expected deaths, 2019 - 2021  
F: First-Year Mortality - Percent of deaths from infection, 2019  
F: First-Year Mortality - Percent of deaths from infection, 2020  
F: First-Year Mortality - Percent of deaths from infection, 2021  
F: First-Year Mortality - Percent of deaths from infection, 2019 - 2021  
N: First-Year Mortality - Percent of deaths from infection, 2019 - 2021  
S: First-Year Mortality - Percent of deaths from infection, 2019 - 2021  
US: First-Year Mortality - Percent of deaths from infection, 2019 - 2021  
F: First-Year Mortality - Percent of deaths from liver disease, 2019  
F: First-Year Mortality - Percent of deaths from liver disease, 2020  
F: First-Year Mortality - Percent of deaths from liver disease, 2021  
F: First-Year Mortality - Percent of deaths from liver disease, 2019 - 2021  
N: First-Year Mortality - Percent of deaths from liver disease, 2019 - 2021  
S: First-Year Mortality - Percent of deaths from liver disease, 2019 - 2021  
US: First-Year Mortality - Percent of deaths from liver disease, 2019 - 2021  
F: First-Year Mortality - Number of new patients, 2019  
F: First-Year Mortality - Number of new patients, 2020  
F: First-Year Mortality - Number of new patients, 2021  
F: First-Year Mortality - Number of new patients, 2019 - 2021  
N: First-Year Mortality - Average number of new patients, 2019 - 2021  
S: First-Year Mortality - Average number of new patients, 2019 - 2021  
US: First-Year Mortality - Average number of new patients, 2019 - 2021

F: First-Year Mortality - P-value for facility SMR, 2019  
F: First-Year Mortality - P-value for facility SMR, 2020  
F: First-Year Mortality - P-value for facility SMR, 2021  
F: First-Year Mortality - P-value for facilitySMR, 2019 - 2021  
F: First-Year Mortality - Standardized Mortality Ratio, 2019  
F: First-Year Mortality - Standardized Mortality Ratio, 2020  
F: First-Year Mortality - Standardized Mortality Ratio, 2021  
F: First-Year Mortality - Standardized Mortality Ratio, 2019 - 2021  
N: First-Year Mortality - Standardized First-Year Mortality Ratio, 2019 - 2021  
S: First-Year Mortality - Standardized First-Year Mortality Ratio, 2019 - 2021  
US: First-Year Mortality - Standardized First-Year Mortality Ratio, 2019 - 2021  
F: First-Year Mortality - Percent of deaths from withdrawal, 2019  
F: First-Year Mortality - Percent of deaths from withdrawal, 2020  
F: First-Year Mortality - Percent of deaths from withdrawal, 2021  
F: First-Year Mortality - Percent of deaths from withdrawal, 2019 - 2021  
N: First-Year Mortality - Percent of deaths from withdrawal, 2019 - 2021  
S: First-Year Mortality - Percent of deaths from withdrawal, 2019 - 2021  
US: First-Year Mortality - Percent of deaths from withdrawal, 2019 - 2021  
F (2728): Incident Patients - GFR by MDRD formula, 2019  
F (2728): Incident Patients - GFR by MDRD formula, 2020  
F (2728): Incident Patients - GFR by MDRD formula, 2021  
F (2728): Incident Patients - GFR by MDRD formula, 2022  
N (2728): Incident Patients - GFR by MDRD formula, 2022  
S (2728): Incident Patients - GFR by MDRD formula, 2022  
US (2728): Incident Patients - GFR by MDRD formula, 2022  
F (2728): Incident Patients - Percent glomerulonephritis as primary cause of ESRD, 2019  
F (2728): Incident Patients - Percent glomerulonephritis as primary cause of ESRD, 2020  
F (2728): Incident Patients - Percent glomerulonephritis as primary cause of ESRD, 2021  
F (2728): Incident Patients - Percent glomerulonephritis as primary cause of ESRD, 2022  
N (2728): Incident Patients - Percent glomerulonephritis as primary cause of ESRD, 2022  
S (2728): Incident Patients - Percent glomerulonephritis as primary cause of ESRD, 2022  
US (2728): Incident Patients - Percent glomerulonephritis as primary cause of ESRD, 2022  
F: SHR (Days) - Days Hospitalized, 2019  
F: SHR (Days) - Days Hospitalized, 2020  
F: SHR (Days) - Days Hospitalized, 2021  
F: SHR (Days) - Days Hospitalized, 2022  
F: Hospitalization - Years at Risk, 2019  
F: Hospitalization - Years at Risk, 2020  
F: Hospitalization - Years at Risk, 2021  
F: Hospitalization - Years at Risk, 2022  
F: Hospitalization - Years at Risk, 2019-2022  
N: Hospitalization - Average Years at Risk (per year in average facility), 2019-2022  
S: Hospitalization - Average Years at Risk (per year in average facility), 2019-2022  
US: Hospitalization - Average Years at Risk (per year in average facility), 2019-2022

F: SHR (Days)- Days Hospitalized, 2019-2022  
N: SHR (Days) - Average Days Hospitalized (per year in average facility), 2019-2022  
S: SHR (Days) - Average Days Hospitalized (per year in average facility), 2019-2022  
US: SHR (Days) - Average Days Hospitalized (per year in average facility), 2019-2022  
F: SEDR - Number of Emergency Department Events, 2019  
F: SEDR - Number of Emergency Department Events, 2020  
F: SEDR - Number of Emergency Department Events, 2021  
F: SEDR - Number of Emergency Department Events, 2022  
Total number of ED Visits  
Total number of ED Visits  
Total number of ED Visits  
Total number of ED Visits  
F (2728): Incident Patients - Number of incident hemodialysis patients (n),2019  
F (2728): Incident Patients - Number of incident hemodialysis patients (n),2020  
F (2728): Incident Patients - Number of incident hemodialysis patients (n),2021  
F (2728): Incident Patients - Number of incident hemodialysis patients (n),2022  
N (2728): Incident Patients - Average Number of incident hemodialysis patients (n),2022  
S (2728): Incident Patients - Average Number of incident hemodialysis patients (n),2022  
US (2728): Incident Patients - Average Number of incident hemodialysis patients (n),2022  
F (2728): Incident Patients - Average hemoglobin, 2019  
F (2728): Incident Patients - Average hemoglobin, 2020  
F (2728): Incident Patients - Average hemoglobin, 2021  
F (2728): Incident Patients - Average hemoglobin, 2022  
N (2728): Incident Patients - Average hemoglobin, 2022  
S (2728): Incident Patients - Average hemoglobin, 2022  
US (2728): Incident Patients - Average hemoglobin, 2022  
F: SHR (Admissions) - Number of Hospital Admissions, 2019  
F: SHR (Admissions) - Number of Hospital Admissions, 2020  
F: SHR (Admissions) - Number of Hospital Admissions, 2021  
F: SHR (Admissions) - Number of Hospital Admissions, 2022  
F: SHR (Admissions)- Number Hospital Admissions, 2019-2022  
N: SHR (Admissions) - Average Number of Hospital Admissions (per year in average facility), 2019-2022  
S: SHR (Admissions) - Average Number of Hospital Admissions (per year in average facility), 2019-2022  
US: SHR (Admissions) - Average Number of Hospital Admissions (per year in average facility), 2019-2022  
F (2728): Incident Patients - Percent hypertension as primary cause ESRD, 2019  
F (2728): Incident Patients - Percent hypertension as primary cause ESRD, 2020  
F (2728): Incident Patients - Percent hypertension as primary cause ESRD, 2021  
F (2728): Incident Patients - Percent hypertension as primary cause ESRD, 2022  
N (2728): Incident Patients - Percent hypertension as primary cause ESRD, 2022  
S (2728): Incident Patients - Percent hypertension as primary cause ESRD, 2022  
US (2728): Incident Patients - Percent hypertension as primary cause ESRD, 2022  
F (2728): Incident Patients - Percent with history of hypertension, 2019  
F (2728): Incident Patients - Percent with history of hypertension, 2020  
F (2728): Incident Patients - Percent with history of hypertension, 2021

F (2728): Incident Patients - Percent with history of hypertension, 2022  
N (2728): Incident Patients - Percent with history of hypertension, 2022  
S (2728): Incident Patients - Percent with history of hypertension, 2022  
US (2728): Incident Patients - Percent with history of hypertension, 2022  
F (AFS): Facility Information - Number of home Continuous Ambulatory Peritoneal Dialysis patients on 12/31/2019  
F (AFS): Facility Information - Number of home Continuous Ambulatory Peritoneal Dialysis patients on 12/31/2020  
F (AFS): Facility Information - Number of home Continuous Ambulatory Peritoneal Dialysis patients on 12/31/2021  
F (AFS): Facility Information - Number of home Continuous Ambulatory Peritoneal Dialysis patients on 12/31/2022  
N (AFS): Facility Information - Average number of home Continuous Ambulatory Peritoneal Dialysis patients on 12/31/2022  
S (AFS): Facility Information - Average number of home Continuous Ambulatory Peritoneal Dialysis patients on 12/31/2022  
US (AFS): Facility Information - Average number of home Continuous Ambulatory Peritoneal Dialysis patients on 12/31/2022  
F (AFS): Facility Information - Number of home Continuous Cycling Peritoneal Dialysis patients on 12/31/2019  
F (AFS): Facility Information - Number of home Continuous Cycling Peritoneal Dialysis patients on 12/31/2020  
F (AFS): Facility Information - Number of home Continuous Cycling Peritoneal Dialysis patients on 12/31/2021  
F (AFS): Facility Information - Number of home Continuous Cycling Peritoneal Dialysis patients on 12/31/2022  
N (AFS): Facility Information - Average number of home Continuous Cycling Peritoneal Dialysis patients on 12/31/2022  
S (AFS): Facility Information - Average number of home Continuous Cycling Peritoneal Dialysis patients on 12/31/2022  
US (AFS): Facility Information - Average number of home Continuous Cycling Peritoneal Dialysis patients on 12/31/2022  
F: Incident VA Type (Adult) - Total number of HD patients, 2019  
F: Incident VA Type (Adult) - Total number of HD patients, 2020  
F: Incident VA Type (Adult) - Total number of HD patients, 2021  
F: Incident VA Type (Adult) - Total number of HD patients, 2022  
N: Incident VA Type (Adult) - Average number of HD patients, 2022  
S: Incident VA Type (Adult) - Average number of HD patients, 2022  
U: Incident VA Type (Adult) - Average number of HD patients, 2022  
F (AFS): Facility Information - Number of home frequent HD patients on 12/31/2019  
F (AFS): Facility Information - Number of home frequent HD patients on 12/31/2020  
F (AFS): Facility Information - Number of home frequent HD patients on 12/31/2021  
F (AFS): Facility Information - Number of home frequent HD patients on 12/31/2022  
N (AFS): Facility Information - Average number of home frequent HD patients on 12/31/2022  
S (AFS): Facility Information - Average number of home frequent HD patients on 12/31/2022  
US (AFS): Facility Information - Average number of home frequent HD patients on 12/31/2022  
F (AFS): Facility Information - Number of home HD patients on 12/31/2019  
F (AFS): Facility Information - Number of home HD patients on 12/31/2020  
F (AFS): Facility Information - Number of home HD patients on 12/31/2021  
F (AFS): Facility Information - Number of home HD patients on 12/31/2022  
N (AFS): Facility Information - Average number of home HD patients on 12/31/2022  
S (AFS): Facility Information - Average number of home HD patients on 12/31/2022  
US (AFS): Facility Information - Average number of home HD patients on 12/31/2022  
F (AFS): Facility Information - Number of home non-frequent HD patients on 12/31/2019  
F (AFS): Facility Information - Number of home non-frequent HD patients on 12/31/2020  
F (AFS): Facility Information - Number of home non-frequent HD patients on 12/31/2021  
F (AFS): Facility Information - Number of home non-frequent HD patients on 12/31/2022  
N (AFS): Facility Information - Average number of home non-frequent HD patients on 12/31/2022

S (AFS): Facility Information - Average number of home non-frequent HD patients on 12/31/2022  
US (AFS): Facility Information - Average number of home non-frequent HD patients on 12/31/2022  
F (AFS): Facility Information - Number of home patients with other modality on 12/31/2019  
F (AFS): Facility Information - Number of home patients with other modality on 12/31/2020  
F (AFS): Facility Information - Number of home patients with other modality on 12/31/2021  
F (AFS): Facility Information - Number of home patients with other modality on 12/31/2022  
N (AFS): Facility Information - Average number of home patients with other modality on 12/31/2022  
S (AFS): Facility Information - Average number of home patients with other modality on 12/31/2022  
US (AFS): Facility Information - Average number of home patients with other modality on 12/31/2022  
F (AFS): Facility Information - % incident patients, 2019  
F (AFS): Facility Information - % incident patients, 2020  
F (AFS): Facility Information - % incident patients, 2021  
F (AFS): Facility Information - % incident patients, 2022  
N (AFS): Facility Information - Average % incident patients, 2022  
S (AFS): Facility Information - Average % incident patients, 2022  
US (AFS): Facility Information - Average % incident patients, 2022  
N: SRR - Average index discharges, 2022  
S: SRR - Average index discharges, 2022  
U: SRR - Average index discharges, 2022  
F: SRR - Index discharges, 2019  
F: SRR - Index discharges, 2020  
F: SRR - Index discharges, 2021  
F: SRR - Index discharges, 2022  
F: All Patient Mortality - % of deaths from infection, 2019  
F: All Patient Mortality - % of deaths from infection, 2020  
F: All Patient Mortality - % of deaths from infection, 2021  
F: All Patient Mortality - % of deaths from infection, 2022  
F: All Patient Mortality - % of deaths from infection, 2019-2022  
N: All Patient Mortality - % of deaths from infection, 2019-2022  
S: All Patient Mortality - % of deaths from infection, 2019-2022  
US: All Patient Mortality - % of deaths from infection, 2019-2022  
F (2728): Incident Patients - Percent with employer group coverage only, 2019  
F (2728): Incident Patients - Percent with employer group coverage only, 2020  
F (2728): Incident Patients - Percent with employer group coverage only, 2021  
F (2728): Incident Patients - Percent with employer group coverage only, 2022  
N (2728): Incident Patients - Percent with employer group coverage only, 2022  
S (2728): Incident Patients - Percent with employer group coverage only, 2022  
US (2728): Incident Patients - Percent with employer group coverage only, 2022  
F (2728): Incident Patients - Percent with Medicaid coverage only, 2019  
F (2728): Incident Patients - Percent with Medicaid coverage only, 2020  
F (2728): Incident Patients - Percent with Medicaid coverage only, 2021  
F (2728): Incident Patients - Percent with Medicaid coverage only, 2022  
N (2728): Incident Patients - Percent with Medicaid coverage only, 2022  
S (2728): Incident Patients - Percent with Medicaid coverage only, 2022



US (2728): Incident Patients - Percent with Medicaid coverage only, 2022  
F (2728): Incident Patients - Percent with Medicare and Medicaid coverage only, 2019  
F (2728): Incident Patients - Percent with Medicare and Medicaid coverage only, 2020  
F (2728): Incident Patients - Percent with Medicare and Medicaid coverage only, 2021  
F (2728): Incident Patients - Percent with Medicare and Medicaid coverage only, 2022  
N (2728): Incident Patients - Percent with Medicare and Medicaid coverage only, 2022  
S (2728): Incident Patients - Percent with Medicare and Medicaid coverage only, 2022  
US (2728): Incident Patients - Percent with Medicare and Medicaid coverage only, 2022  
F (2728): Incident Patients - Percent with Medicare coverage only, 2019  
F (2728): Incident Patients - Percent with Medicare coverage only, 2020  
F (2728): Incident Patients - Percent with Medicare coverage only, 2021  
F (2728): Incident Patients - Percent with Medicare coverage only, 2022  
N (2728): Incident Patients - Percent with Medicare coverage only, 2022  
S (2728): Incident Patients - Percent with Medicare coverage only, 2022  
US (2728): Incident Patients - Percent with Medicare coverage only, 2022  
F (2728): Incident Patients - Percent with Medicare and other coverage, 2019  
F (2728): Incident Patients - Percent with Medicare and other coverage, 2020  
F (2728): Incident Patients - Percent with Medicare and other coverage, 2021  
F (2728): Incident Patients - Percent with Medicare and other coverage, 2022  
N (2728): Incident Patients - Percent with Medicare and other coverage, 2022  
S (2728): Incident Patients - Percent with Medicare and other coverage, 2022  
US (2728): Incident Patients - Percent with Medicare and other coverage, 2022  
F (2728): Incident Patients - Percent with other or unknown coverage, 2019  
F (2728): Incident Patients - Percent with other or unknown coverage, 2020  
F (2728): Incident Patients - Percent with other or unknown coverage, 2021  
F (2728): Incident Patients - Percent with other or unknown coverage, 2022  
N (2728): Incident Patients - Percent with other or unknown coverage, 2022  
S (2728): Incident Patients - Percent with other or unknown coverage, 2022  
US (2728): Incident Patients - Percent with other or unknown coverage, 2022  
F (2728): Incident Patients - Percent with no coverage, 2019  
F (2728): Incident Patients - Percent with no coverage, 2020  
F (2728): Incident Patients - Percent with no coverage, 2021  
F (2728): Incident Patients - Percent with no coverage, 2022  
N (2728): Incident Patients - Percent with no coverage, 2022  
S (2728): Incident Patients - Percent with no coverage, 2022  
US (2728): Incident Patients - Percent with no coverage, 2022  
F: SHR (Admissions) - % Inpatient Admissions Originating in ED, 2019  
F: SHR (Admissions) - % Inpatient Admissions Originating in ED, 2020  
F: SHR (Admissions) - % Inpatient Admissions Originating in ED, 2021  
F: SHR (Admissions) - % Inpatient Admissions Originating in ED, 2022  
F: SHR (Admissions)- % Inpatient Admissions Originating in ED, 2019-2022  
N: SHR (Admissions) -Average % Inpatient Admissions Originating in ED (per year in average facility), 2019-2022  
S: SHR (Admissions) -Average % Inpatient Admissions Originating in ED (per year in average facility), 2019-2022  
US: SHR (Admissions) -Average % Inpatient Admissions Originating in ED (per year in average facility), 2019-2022



F: SHR (Admissions) - Average Length of Stay (Days per Admission), 2021  
F: SHR (Admissions) - Average Length of Stay (Days per Admission), 2022  
F: SHR (Admissions)- Average Length of Stay (Days per Admission), 2019-2022  
N: SHR (Days) - Average Length of Stay (days per admission, per year in average facility), 2019-2022  
S: SHR (Days) - Average Length of Stay (days per admission, per year in average facility), 2019-2022  
US: SHR (Days) - Average Length of Stay (days per admission, per year in average facility), 2019-2022  
F: STR - Number of living donor transplants, 2019  
F: STR - Number of living donor transplants, 2020  
F: STR - Number of living donor transplants, 2021  
F: STR - Number of living donor transplants, 2022  
F: STR - Number of living donor transplants, 2019-2022  
N: STR - Average number of living donor transplant (per year in average facility), 2019-2022  
S: STR - Average number of living donor transplant (per year in average facility), 2019-2022  
US: STR - Average number of living donor transplant (per year in average facility), 2019-2022  
F: All Patient Mortality - % of deaths from liver disease, 2019  
F: All Patient Mortality - % of deaths from liver disease, 2020  
F: All Patient Mortality - % of deaths from liver disease, 2021  
F: All Patient Mortality - % of deaths from liver disease, 2022  
F: All Patient Mortality - % of deaths from liver disease, 2019-2022  
N: All Patient Mortality - % of deaths from liver disease, 2019-2022  
S: All Patient Mortality - % of deaths from liver disease, 2019-2022  
US: All Patient Mortality - % of deaths from liver disease, 2019-2022  
F (QIES): Facility Information - Dialysis facility located in a SNF/NF (LTC)  
F (QIES): Facility Information - Services offered in Long-Term Care Facility  
F: Prevalent VA Type (Adult) - Long-Term Catheter Rate, 2019  
F: Prevalent VA Type (Adult) - Long-Term Catheter Rate, 2020  
F: Prevalent VA Type (Adult) - Long-Term Catheter Rate, 2021  
F: Prevalent VA Type (Adult) - Long-Term Catheter Rate, 2022  
N: Prevalent VA Type (Adult) - Long-Term Catheter Rate, 2022  
S: Prevalent VA Type (Adult) - Long-Term Catheter Rate, 2022  
U: Prevalent VA Type (Adult) - Long-Term Catheter Rate, 2022  
F (AFS): Facility Information - % Medicare patients on 12/31/2019  
F (AFS): Facility Information - % Medicare patients on 12/31/2020  
F (AFS): Facility Information - % Medicare patients on 12/31/2021  
F (AFS): Facility Information - % Medicare patients on 12/31/2022  
N (AFS): Facility Information - Average % Medicare patients on 12/31/2022  
S (AFS): Facility Information - Average % Medicare patients on 12/31/2022  
US (AFS): Facility Information - Average % Medicare patients on 12/31/2022  
F (AFS): Facility Information - % Medicare pending on 12/31/2019  
F (AFS): Facility Information - % Medicare pending on 12/31/2020  
F (AFS): Facility Information - % Medicare pending on 12/31/2021  
F (AFS): Facility Information - % Medicare pending on 12/31/2022  
N (AFS): Facility Information - Average % Medicare pending on 12/31/2022  
S (AFS): Facility Information - Average % Medicare pending on 12/31/2022

US (AFS): Facility Information - Average % Medicare pending on 12/31/2022  
F: Influenza - Total number of patients not vaccinated due to medical contraindication, 8/1-3/31, 2019  
F: Influenza - Total number of patients not vaccinated due to medical contraindication, 8/1-3/31, 2020  
F: Influenza - Total number of patients not vaccinated due to medical contraindication, 8/1-3/31, 2021  
F: Influenza - Total number of patients not vaccinated due to medical contraindication, 8/1-3/31, 2022  
N: Influenza - Average number of patients not vaccinated due to medical contraindication, 8/1-3/31, 2022  
S: Influenza - Average number of patients not vaccinated due to medical contraindication, 8/1-3/31, 2022  
U: Influenza - Average number of patients not vaccinated due to medical contraindication, 8/1-3/31, 2022  
F (2728): Incident Patients - Percent of HD patients.: Arteriovenous Fistula, 2019  
F (2728): Incident Patients - Percent of HD patients.: Arteriovenous Fistula, 2020  
F (2728): Incident Patients - Percent of HD patients.: Arteriovenous Fistula, 2021  
F (2728): Incident Patients - Percent of HD patients.: Arteriovenous Fistula, 2022  
N (2728): Incident Patients - Percent of Incident HD Patients: Arteriovenous Fistula, 2022  
S (2728): Incident Patients - Percent of Incident HD Patients: Arteriovenous Fistula, 2022  
US (2728): Incident Patients - Percent of Incident HD Patients: Arteriovenous Fistula, 2022  
F (2728): Incident Patients - Percent of HD patients.: Catheter, 2019  
F (2728): Incident Patients - Percent of HD patients.: Catheter, 2020  
F (2728): Incident Patients - Percent of HD patients.: Catheter, 2021  
F (2728): Incident Patients - Percent of HD patients.: Catheter, 2022  
N (2728): Incident Patients - Percent of Incident HD Patients: Catheter, 2022  
S (2728): Incident Patients - Percent of Incident HD Patients: Catheter, 2022  
US (2728): Incident Patients - Percent of Incident HD Patients: Catheter, 2022  
F (2728): Incident Patients - Percent of HD patients.: Arteriovenous Graft, 2019  
F (2728): Incident Patients - Percent of HD patients.: Arteriovenous Graft, 2020  
F (2728): Incident Patients - Percent of HD patients.: Arteriovenous Graft, 2021  
F (2728): Incident Patients - Percent of HD patients.: Arteriovenous Graft, 2022  
N (2728): Incident Patients - Percent of Incident HD Patients: Arteriovenous Graft, 2022  
S (2728): Incident Patients - Percent of Incident HD Patients: Arteriovenous Graft, 2022  
US (2728): Incident Patients - Percent of Incident HD Patients: Arteriovenous Graft, 2022  
F (2728): Incident Patients - Percent of HD patients.: Other/Unknown/Missing Access, 2019  
F (2728): Incident Patients - Percent of HD patients.: Other/Unknown/Missing Access, 2020  
F (2728): Incident Patients - Percent of HD patients.: Other/Unknown/Missing Access, 2021  
F (2728): Incident Patients - Percent of HD patients.: Other/Unknown/Missing Access, 2022  
N (2728): Incident Patients - Percent of Incident HD Patients: Other/Unknown/Missing, 2022  
S (2728): Incident Patients - Percent of Incident HD Patients: Other/Unknown/Missing, 2022  
US (2728): Incident Patients - Percent of Incident HD Patients: Other/Unknown/Missing, 2022  
F: Hospitalization - Diagnosis: % with Acute Myocardial Infarction, 2019  
F: Hospitalization - Diagnosis: % with Acute Myocardial Infarction, 2020  
F: Hospitalization - Diagnosis: % with Acute Myocardial Infarction, 2021  
F: Hospitalization - Diagnosis: % with Acute Myocardial Infarction, 2022  
F: Hospitalization - Diagnosis: % with Acute Myocardial Infarction, 2019-2022  
N: Hospitalization - Diagnosis: Average % with Acute Myocardial Infarction (per year in average facility), 2019-20:  
S: Hospitalization - Diagnosis: Average % with Acute Myocardial Infarction (per year in average facility), 2019-202  
US: Hospitalization - Diagnosis: Average % with Acute Myocardial Infarction (per year in average facility), 2019-20

Modality(ies) treated at facility

F: Prevalent Patients - Modality: % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2019  
F: Prevalent Patients - Modality: % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2020  
F: Prevalent Patients - Modality: % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2021  
F: Prevalent Patients - Modality: % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2022  
N: Prevalent Patients - Modality: % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2022  
S: Prevalent Patients - Modality: % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2022  
US: Prevalent Patients - Modality: % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2022  
F: Prevalent Patients - Modality: % on Continuous Cycling Peritoneal Dialysis, 12/31/2019  
F: Prevalent Patients - Modality: % on Continuous Cycling Peritoneal Dialysis, 12/31/2020  
F: Prevalent Patients - Modality: % on Continuous Cycling Peritoneal Dialysis, 12/31/2021  
F: Prevalent Patients - Modality: % on Continuous Cycling Peritoneal Dialysis, 12/31/2022  
N: Prevalent Patients - Modality: % on Continuous Cycling Peritoneal Dialysis, 12/31/2022  
S: Prevalent Patients - Modality: % on Continuous Cycling Peritoneal Dialysis, 12/31/2022  
US: Prevalent Patients - Modality: % on Continuous Cycling Peritoneal Dialysis, 12/31/2022  
F: Prevalent Patients - Modality: % on Hemodialysis, 12/31/2019  
F: Prevalent Patients - Modality: % on Hemodialysis, 12/31/2020  
F: Prevalent Patients - Modality: % on Hemodialysis, 12/31/2021  
F: Prevalent Patients - Modality: % on Hemodialysis, 12/31/2022  
N: Prevalent Patients - Modality: % on Hemodialysis, 12/31/2022  
S: Prevalent Patients - Modality: % on Hemodialysis, 12/31/2022  
US: Prevalent Patients - Modality: % on Hemodialysis, 12/31/2022  
F: Prevalent Patients - Modality: % on Home Hemodialysis, 12/31/2019  
F: Prevalent Patients - Modality: % on Home Hemodialysis, 12/31/2020  
F: Prevalent Patients - Modality: % on Home Hemodialysis, 12/31/2021  
F: Prevalent Patients - Modality: % on Home Hemodialysis, 12/31/2022  
N: Prevalent Patients - Modality: % on Home Hemodialysis, 12/31/2022  
S: Prevalent Patients - Modality: % on Home Hemodialysis, 12/31/2022  
US: Prevalent Patients - Modality: % on Home Hemodialysis, 12/31/2022  
F: Prevalent Patients - Modality: % on Other Modality, 12/31/2019  
F: Prevalent Patients - Modality: % on Other Modality, 12/31/2020  
F: Prevalent Patients - Modality: % on Other Modality, 12/31/2021  
F: Prevalent Patients - Modality: % on Other Modality, 12/31/2022  
N: Prevalent Patients - Modality: % Other Modality, 12/31/2022  
S: Prevalent Patients - Modality: % Other Modality, 12/31/2022  
US: Prevalent Patients - Modality: % Other Modality, 12/31/2022  
F (2728): Incident Patients - Percent Native American, 2019  
F (2728): Incident Patients - Percent Native American, 2020  
F (2728): Incident Patients - Percent Native American, 2021  
F (2728): Incident Patients - Percent Native American, 2022  
N (2728): Incident Patients - Percent Native American, 2022  
S (2728): Incident Patients - Percent Native American, 2022  
US (2728): Incident Patients - Percent Native American, 2022  
F: Prevalent Comorbidities - Number of Medicare Dialysis Patients Alive on December 31, 2019

F: Prevalent Comorbidities - Number of Medicare Dialysis Patients Alive on December 31, 2020  
F: Prevalent Comorbidities - Number of Medicare Dialysis Patients Alive on December 31, 2021  
F: Prevalent Comorbidities - Number of Medicare Dialysis Patients Alive on December 31, 2022  
N: Prevalent Comorbidities - Average Number of Medicare Dialysis Patients Alive on December 31, 2022  
S: Prevalent Comorbidities - Average Number of Medicare Dialysis Patients Alive on December 31, 2022  
US: Prevalent Comorbidities - Average Number of Medicare Dialysis Patients Alive on December 31, 2022  
F (2728): Incident Patients - No Pre-ESRD Nephrologist Care, 2019  
F (2728): Incident Patients - No Pre-ESRD Nephrologist Care, 2020  
F (2728): Incident Patients - No Pre-ESRD Nephrologist Care, 2021  
F (2728): Incident Patients - No Pre-ESRD Nephrologist Care, 2022  
N (2728): Incident Patients - No Pre-ESRD Nephrologist Care, 2022  
S (2728): Incident Patients - No Pre-ESRD Nephrologist Care, 2022  
US (2728): Incident Patients - No Pre-ESRD Nephrologist Care, 2022  
F (2728): Incident Patients - Unknown Pre-ESRD Nephrologist Care, 2019  
F (2728): Incident Patients - Unknown Pre-ESRD Nephrologist Care, 2020  
F (2728): Incident Patients - Unknown Pre-ESRD Nephrologist Care, 2021  
F (2728): Incident Patients - Unknown Pre-ESRD Nephrologist Care, 2022  
N (2728): Incident Patients - Unknown Pre-ESRD Nephrologist Care, 2022  
S (2728): Incident Patients - Unknown Pre-ESRD Nephrologist Care, 2022  
US (2728): Incident Patients - Unknown Pre-ESRD Nephrologist Care, 2022  
F (2728): Incident Patients - Pre-ESRD Nephrologist Care Greater Than 12 months, 2019  
F (2728): Incident Patients - Pre-ESRD Nephrologist Care Greater Than 12 months, 2020  
F (2728): Incident Patients - Pre-ESRD Nephrologist Care Greater Than 12 months, 2021  
F (2728): Incident Patients - Pre-ESRD Nephrologist Care Greater Than 12 months, 2022  
N (2728): Incident Patients - Pre-ESRD Nephrologist Care Greater Than 12 months, 2022  
S (2728): Incident Patients - Pre-ESRD Nephrologist Care Greater Than 12 months, 2022  
US (2728): Incident Patients - Pre-ESRD Nephrologist Care Greater Than 12 months, 2022  
F (2728): Incident Patients - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2019  
F (2728): Incident Patients - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2020  
F (2728): Incident Patients - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2021  
F (2728): Incident Patients - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2022  
N (2728): Incident Patients - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2022  
S (2728): Incident Patients - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2022  
US (2728): Incident Patients - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2022  
F (2728): Incident Patients - Pre-ESRD Nephrologist Care Less Than 6 months, 2019  
F (2728): Incident Patients - Pre-ESRD Nephrologist Care Less Than 6 months, 2020  
F (2728): Incident Patients - Pre-ESRD Nephrologist Care Less Than 6 months, 2021  
F (2728): Incident Patients - Pre-ESRD Nephrologist Care Less Than 6 months, 2022  
N (2728): Incident Patients - Pre-ESRD Nephrologist Care Less Than 6 months, 2022  
S (2728): Incident Patients - Pre-ESRD Nephrologist Care Less Than 6 months, 2022  
US (2728): Incident Patients - Pre-ESRD Nephrologist Care Less Than 6 months, 2022  
US (2728): Incident Patients - Pre-ESRD Nephrologist Care Unknown, 2022  
CWFacDir: ESRD Network  
F: Hospitalization (Nursing Home) - Diagnosis: % with Cardiac Arrest, 2019

F: Hospitalization (Nursing Home) - Diagnosis: % with Cardiac Arrest, 2020  
F: Hospitalization (Nursing Home) - Diagnosis: % with Cardiac Arrest, 2021  
F: Hospitalization (Nursing Home) - Diagnosis: % with Cardiac Arrest, 2022  
N: Hospitalization (Nursing Home) - Diagnosis: % with Cardiac Arrest, 2022  
S: Hospitalization (Nursing Home) - Diagnosis: % with Cardiac Arrest, 2022  
US: Hospitalization (Nursing Home) - Diagnosis: % with Cardiac Arrest, 2022  
F: Hospitalization (Nursing Home) - Diagnosis: % with Cardiac Dysrhythmia, 2019  
F: Hospitalization (Nursing Home) - Diagnosis: % with Cardiac Dysrhythmia, 2020  
F: Hospitalization (Nursing Home) - Diagnosis: % with Cardiac Dysrhythmia, 2021  
F: Hospitalization (Nursing Home) - Diagnosis: % with Cardiac Dysrhythmia, 2022  
N: Hospitalization (Nursing Home) - Diagnosis: % with Cardiac Dysrhythmia, 2022  
S: Hospitalization (Nursing Home) - Diagnosis: % with Cardiac Dysrhythmia, 2022  
US: Hospitalization (Nursing Home) - Diagnosis: % with Cardiac Dysrhythmia, 2022  
F: Hospitalization (Nursing Home) - Diagnosis: % with Congestive Heart Failure, 2019  
F: Hospitalization (Nursing Home) - Diagnosis: % with Congestive Heart Failure, 2020  
F: Hospitalization (Nursing Home) - Diagnosis: % with Congestive Heart Failure, 2021  
F: Hospitalization (Nursing Home) - Diagnosis: % with Congestive Heart Failure, 2022  
N: Hospitalization (Nursing Home) - Diagnosis: % with Congestive Heart Failure, 2022  
S: Hospitalization (Nursing Home) - Diagnosis: % with Congestive Heart Failure, 2022  
US: Hospitalization (Nursing Home) - Diagnosis: % with Congestive Heart Failure, 2022  
F: Prevalent Patients (Nursing Home) - Age: % Less than 18 years, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Age: % Less than 18 years, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Age: % Less than 18 years, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Age: % Less than 18 years, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Age: % Less than 18 years, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Age: % Less than 18 years, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Age: % Less than 18 years, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Age: % Between 18-64 years, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Age: % Between 18-64 years, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Age: % Between 18-64 years, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Age: % Between 18-64 years, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Age: % Between 18-64 years, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Age: % Between 18-64 years, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Age: % Between 18-64 years, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Age: % Greater than or equal to 65 years, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Age: % Greater than or equal to 65 years, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Age: % Greater than or equal to 65 years, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Age: % Greater than or equal to 65 years, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Age: % Greater than or equal to 65 years, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Age: % Greater than or equal to 65 years, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Age: % Greater than or equal to 65 years, 12/31/2022  
F: Incident Patients (Nursing Home) - Percent with Medicare alone or with other insurance, 2019  
F: Incident Patients (Nursing Home) - Percent with Medicare alone or with other insurance, 2020  
F: Incident Patients (Nursing Home) - Percent with Medicare alone or with other insurance, 2021

F: Incident Patients (Nursing Home) - Percent with Medicare alone or with other insurance, 2022  
N: Incident Patients (Nursing Home) - Percent with Medicare alone or with other insurance, 2022  
S: Incident Patients (Nursing Home) - Percent with Medicare alone or with other insurance, 2022  
US: Incident Patients (Nursing Home) - Percent with Medicare alone or with other insurance, 2022  
F: Incident Patients (Nursing Home) - Percent of patients with Arteriovenous fistulae placed, 2019  
F: Incident Patients (Nursing Home) - Percent of patients with Arteriovenous fistulae placed, 2020  
F: Incident Patients (Nursing Home) - Percent of patients with Arteriovenous fistulae placed, 2021  
F: Incident Patients (Nursing Home) - Percent of patients with Arteriovenous fistulae placed, 2022  
N: Incident Patients (Nursing Home) - Percent of patients with Arteriovenous fistulae placed, 2022  
S: Incident Patients (Nursing Home) - Percent of patients with Arteriovenous fistulae placed, 2022  
US: Incident Patients (Nursing Home) - Percent of patients with Arteriovenous fistulae placed, 2022  
F: Prevalent Comorbidities (Nursing Home) - % with Cardiac Arrest, 2019  
F: Prevalent Comorbidities (Nursing Home) - % with Cardiac Arrest, 2020  
F: Prevalent Comorbidities (Nursing Home) - % with Cardiac Arrest, 2021  
F: Prevalent Comorbidities (Nursing Home) - % with Cardiac Arrest, 2022  
N: Prevalent Comorbidities (Nursing Home) - % with Cardiac Arrest, 2022  
S: Prevalent Comorbidities (Nursing Home) - % with Cardiac Arrest, 2022  
US: Prevalent Comorbidities (Nursing Home) - % with Cardiac Arrest, 2022  
F: Prevalent Comorbidities (Nursing Home) - % with Cardiac Dysrhythmias, 2019  
F: Prevalent Comorbidities (Nursing Home) - % with Cardiac Dysrhythmias, 2020  
F: Prevalent Comorbidities (Nursing Home) - % with Cardiac Dysrhythmias, 2021  
F: Prevalent Comorbidities (Nursing Home) - % with Cardiac Dysrhythmias, 2022  
N: Prevalent Comorbidities (Nursing Home) - % with Cardiac Dysrhythmias, 2022  
S: Prevalent Comorbidities (Nursing Home) - % with Cardiac Dysrhythmias, 2022  
US: Prevalent Comorbidities (Nursing Home) - % with Cardiac Dysrhythmias, 2022  
F: Prevalent Comorbidities (Nursing Home) - % with Congestive Heart Failure, 2019  
F: Prevalent Comorbidities (Nursing Home) - % with Congestive Heart Failure, 2020  
F: Prevalent Comorbidities (Nursing Home) - % with Congestive Heart Failure, 2021  
F: Prevalent Comorbidities (Nursing Home) - % with Congestive Heart Failure, 2022  
N: Prevalent Comorbidities (Nursing Home) - % with Congestive Heart Failure, 2022  
S: Prevalent Comorbidities (Nursing Home) - % with Congestive Heart Failure, 2022  
US: Prevalent Comorbidities (Nursing Home) - % with Congestive Heart Failure, 2022  
F: Prevalent Comorbidities (Nursing Home) - % with Cerebrovascular Disease, 2019  
F: Prevalent Comorbidities (Nursing Home) - % with Cerebrovascular Disease, 2020  
F: Prevalent Comorbidities (Nursing Home) - % with Cerebrovascular Disease, 2021  
F: Prevalent Comorbidities (Nursing Home) - % with Cerebrovascular Disease, 2022  
N: Prevalent Comorbidities (Nursing Home) - % with Cerebrovascular Disease, 2022  
S: Prevalent Comorbidities (Nursing Home) - % with Cerebrovascular Disease, 2022  
US: Prevalent Comorbidities (Nursing Home) - % with Cerebrovascular Disease, 2022  
F: Prevalent Comorbidities (Nursing Home) - % with Hepatitis B, 2019  
F: Prevalent Comorbidities (Nursing Home) - % with Hepatitis B, 2020  
F: Prevalent Comorbidities (Nursing Home) - % with Hepatitis B, 2021  
F: Prevalent Comorbidities (Nursing Home) - % with Hepatitis B, 2022  
N: Prevalent Comorbidities (Nursing Home) - % with Hepatitis B, 2022





F: Prevalent Comorbidities (Nursing Home) - % with Metastatic Infection, 2019  
F: Prevalent Comorbidities (Nursing Home) - % with Metastatic Infection, 2020  
F: Prevalent Comorbidities (Nursing Home) - % with Metastatic Infection, 2021  
F: Prevalent Comorbidities (Nursing Home) - % with Metastatic Infection, 2022  
N: Prevalent Comorbidities (Nursing Home) - % with Metastatic Infection, 2022  
S: Prevalent Comorbidities (Nursing Home) - % with Metastatic Infection, 2022  
US: Prevalent Comorbidities (Nursing Home) - % with Metastatic Infection, 2022  
F: Prevalent Comorbidities (Nursing Home) - % with Pneumonia, 2019  
F: Prevalent Comorbidities (Nursing Home) - % with Pneumonia, 2020  
F: Prevalent Comorbidities (Nursing Home) - % with Pneumonia, 2021  
F: Prevalent Comorbidities (Nursing Home) - % with Pneumonia, 2022  
N: Prevalent Comorbidities (Nursing Home) - % with Pneumonia, 2022  
S: Prevalent Comorbidities (Nursing Home) - % with Pneumonia, 2022  
US: Prevalent Comorbidities (Nursing Home) - % with Pneumonia, 2022  
F: Prevalent Comorbidities (Nursing Home) - % with Peripheral Vascular Disease, 2019  
F: Prevalent Comorbidities (Nursing Home) - % with Peripheral Vascular Disease, 2020  
F: Prevalent Comorbidities (Nursing Home) - % with Peripheral Vascular Disease, 2021  
F: Prevalent Comorbidities (Nursing Home) - % with Peripheral Vascular Disease, 2022  
N: Prevalent Comorbidities (Nursing Home) - % with Peripheral Vascular Disease, 2022  
S: Prevalent Comorbidities (Nursing Home) - % with Peripheral Vascular Disease, 2022  
US: Prevalent Comorbidities (Nursing Home) - % with Peripheral Vascular Disease, 2022  
F: Prevalent Comorbidities (Nursing Home) - % with Tuberculosis, 2019  
F: Prevalent Comorbidities (Nursing Home) - % with Tuberculosis, 2020  
F: Prevalent Comorbidities (Nursing Home) - % with Tuberculosis, 2021  
F: Prevalent Comorbidities (Nursing Home) - % with Tuberculosis, 2022  
N: Prevalent Comorbidities (Nursing Home) - % with Tuberculosis, 2022  
S: Prevalent Comorbidities (Nursing Home) - % with Tuberculosis, 2022  
US: Prevalent Comorbidities (Nursing Home) - % with Tuberculosis, 2022  
F: HD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patients, 2019  
F: HD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patients, 2020  
F: HD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patients, 2021  
F: HD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patients, 2022  
F: HD HGB (Nursing Home) - % of Patient-months with ESA Prescribed, 2019  
F: HD HGB (Nursing Home) - % of Patient-months with ESA Prescribed, 2020  
F: HD HGB (Nursing Home) - % of Patient-months with ESA Prescribed, 2021  
F: HD HGB (Nursing Home) - % of Patient-months with ESA Prescribed, 2022  
N: HD HGB (Nursing Home) - % of Patient-months with ESA Prescribed, 2022  
S: HD HGB (Nursing Home) - % of Patient-months with ESA Prescribed, 2022  
US: HD HGB (Nursing Home) - % of Patient-months with ESA Prescribed, 2022  
F: HD HGB (Nursing Home) - % of Patient-months with Hemoglobin < 10 g/dL, 2019  
F: HD HGB (Nursing Home) - % of Patient-months with Hemoglobin < 10 g/dL, 2020  
F: HD HGB (Nursing Home) - % of Patient-months with Hemoglobin < 10 g/dL, 2021  
F: HD HGB (Nursing Home) - % of Patient-months with Hemoglobin < 10 g/dL, 2022  
N: HD HGB (Nursing Home) - % of Patient-months with Hemoglobin < 10 g/dL, 2022

S: HD HGB (Nursing Home) - % of Patient-months with Hemoglobin < 10 g/dL, 2022  
US: HD HGB (Nursing Home) - % of Patient-months with Hemoglobin < 10 g/dL, 2022  
F: HD Kt/V (Nursing Home)- % of Patient-months with Kt/V < 1.2, 2019  
F: HD Kt/V (Nursing Home)- % of Patient-months with Kt/V < 1.2, 2020  
F: HD Kt/V (Nursing Home)- % of Patient-months with Kt/V < 1.2, 2021  
F: HD Kt/V (Nursing Home)- % of Patient-months with Kt/V < 1.2, 2022  
N: HD Kt/V (Nursing Home)- % of Patient-months with Kt/V < 1.2, 2022  
S: HD Kt/V (Nursing Home)- % of Patient-months with Kt/V < 1.2, 2022  
US: HD Kt/V (Nursing Home)- % of Patient-months with Kt/V < 1.2, 2022  
F: HD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patient-months, 2019  
F: HD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patient-months, 2020  
F: HD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patient-months, 2021  
F: HD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patient-months, 2022  
F: HD HGB (Nursing Home) - Total Eligible Patients, 2019  
F: HD HGB (Nursing Home) - Total Eligible Patients, 2020  
F: HD HGB (Nursing Home) - Total Eligible Patients, 2021  
F: HD HGB (Nursing Home) - Total Eligible Patients, 2022  
F: HD HGB (Nursing Home) - Total Eligible Patient-months, 2019  
F: HD HGB (Nursing Home) - Total Eligible Patient-months, 2020  
F: HD HGB (Nursing Home) - Total Eligible Patient-months, 2021  
F: HD HGB (Nursing Home) - Total Eligible Patient-months, 2022  
F: PD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patients, 2019  
F: PD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patients, 2020  
F: PD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patients, 2021  
F: PD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patients, 2022  
F: PD HGB (Nursing Home) - % of Patient-months with ESA Prescribed, 2019  
F: PD HGB (Nursing Home) - % of Patient-months with ESA Prescribed, 2020  
F: PD HGB (Nursing Home) - % of Patient-months with ESA Prescribed, 2021  
F: PD HGB (Nursing Home) - % of Patient-months with ESA Prescribed, 2022  
N: PD HGB (Nursing Home) - % of Patient-months with ESA Prescribed, 2022  
S: PD HGB (Nursing Home) - % of Patient-months with ESA Prescribed, 2022  
US: PD HGB (Nursing Home) - % of Patient-months with ESA Prescribed, 2022  
F: PD HGB (Nursing Home) - % of Patient-months with Hemoglobin < 10 g/dL, 2019  
F: PD HGB (Nursing Home) - % of Patient-months with Hemoglobin < 10 g/dL, 2020  
F: PD HGB (Nursing Home) - % of Patient-months with Hemoglobin < 10 g/dL, 2021  
F: PD HGB (Nursing Home) - % of Patient-months with Hemoglobin < 10 g/dL, 2022  
N: PD HGB (Nursing Home) - % of Patient-months with Hemoglobin < 10 g/dL, 2022  
S: PD HGB (Nursing Home) - % of Patient-months with Hemoglobin < 10 g/dL, 2022  
US: PD HGB (Nursing Home) - % of Patient-months with Hemoglobin < 10 g/dL, 2022  
F: PD Kt/V (Nursing Home) - % of Patient-months with with Kt/V < 1.7, 2019  
F: PD Kt/V (Nursing Home) - % of Patient-months with with Kt/V < 1.7, 2020  
F: PD Kt/V (Nursing Home) - % of Patient-months with with Kt/V < 1.7, 2021  
F: PD Kt/V (Nursing Home) - % of Patient-months with with Kt/V < 1.7, 2022  
N: PD Kt/V (Nursing Home) - % of Patient-months with with Kt/V < 1.7, 2022

S: PD Kt/V (Nursing Home) - % of Patient-months with with Kt/V < 1.7, 2022  
US: PD Kt/V (Nursing Home) - % of Patient-months with with Kt/V < 1.7, 2022  
F: PD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patient-months, 2019  
F: PD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patient-months, 2020  
F: PD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patient-months, 2021  
F: PD Dialysis Adequacy (Nursing Home) - Total Eligible Dialysis Patient-months, 2022  
F: PD HGB (Nursing Home) - Total Eligible Patients, 2019  
F: PD HGB (Nursing Home) - Total Eligible Patients, 2020  
F: PD HGB (Nursing Home) - Total Eligible Patients, 2021  
F: PD HGB (Nursing Home) - Total Eligible Patients, 2022  
F: PD HGB (Nursing Home) - Total Eligible Patient-months, 2019  
F: PD HGB (Nursing Home) - Total Eligible Patient-months, 2020  
F: PD HGB (Nursing Home) - Total Eligible Patient-months, 2021  
F: PD HGB (Nursing Home) - Total Eligible Patient-months, 2022  
F: All Patient Mortality (Nursing Home) - Number of deaths, 2019  
F: All Patient Mortality (Nursing Home) - Number of deaths, 2020  
F: All Patient Mortality (Nursing Home) - Number of deaths, 2021  
F: All Patient Mortality (Nursing Home) - Number of deaths, 2022  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Diabetes, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Diabetes, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Diabetes, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Diabetes, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Diabetes, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Diabetes, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Diabetes, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Hypertension, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Hypertension, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Hypertension, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Hypertension, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Hypertension, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Hypertension, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Hypertension, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Glomerulonephritis, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Glomerulonephritis, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Glomerulonephritis, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Glomerulonephritis, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Glomerulonephritis, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Glomerulonephritis, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Glomerulonephritis, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Other/Unknown Cause, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Other/Unknown Cause, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Other/Unknown Cause, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Other/Unknown Cause, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Other/Unknown Cause, 12/31/2022

S: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Other/Unknown Cause, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Other/Unknown Cause, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Missing Cause, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Missing Cause, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Missing Cause, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Missing Cause, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Missing Cause, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Missing Cause, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Primary Cause of ESRD: % Missing Cause, 12/31/2022  
F: All Patient Mortality (Nursing Home) - Years at risk for mortality, 2019  
F: All Patient Mortality (Nursing Home) - Years at risk for mortality, 2020  
F: All Patient Mortality (Nursing Home) - Years at risk for mortality, 2021  
F: All Patient Mortality (Nursing Home) - Years at risk for mortality, 2022  
F: Prevalent Patients (Nursing Home) - Ethnicity: % Hispanic, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Ethnicity: % Hispanic, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Ethnicity: % Hispanic, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Ethnicity: % Hispanic, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Ethnicity: % Hispanic, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Ethnicity: % Hispanic, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Ethnicity: % Hispanic, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Ethnicity: % Non-Hispanic, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Ethnicity: % Non-Hispanic, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Ethnicity: % Non-Hispanic, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Ethnicity: % Non-Hispanic, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Ethnicity: % Non-Hispanic, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Ethnicity: % Non-Hispanic, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Ethnicity: % Non-Hispanic, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Ethnicity: % Unknown Ethnicity, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Ethnicity: % Unknown Ethnicity, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Ethnicity: % Unknown Ethnicity, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Ethnicity: % Unknown Ethnicity, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Ethnicity: % Unknown Ethnicity, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Ethnicity: % Unknown Ethnicity, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Ethnicity: % Unknown Ethnicity, 12/31/2022  
F: All Patient Mortality (Nursing Home) - Expected deaths, 2019  
F: All Patient Mortality (Nursing Home) - Expected deaths, 2020  
F: All Patient Mortality (Nursing Home) - Expected deaths, 2021  
F: All Patient Mortality (Nursing Home) - Expected deaths, 2022  
F: SHR (Nursing Home Admissions) - Expected Number of Hospital Admissions, 2019  
F: SHR (Nursing Home Admissions) - Expected Number of Hospital Admissions, 2020  
F: SHR (Nursing Home Admissions) - Expected Number of Hospital Admissions, 2021  
F: SHR (Nursing Home Admissions) - Expected Number of Hospital Admissions, 2022  
F: Hospitalization (Nursing Home) - Years at Risk , 2019  
F: Hospitalization (Nursing Home) - Years at Risk , 2020

F: Hospitalization (Nursing Home) - Years at Risk , 2021  
F: Hospitalization (Nursing Home) - Years at Risk , 2022  
F: Incident Patients (Nursing Home) - Number of hemodialysis patients (n),2019  
F: Incident Patients (Nursing Home) - Number of hemodialysis patients (n),2020  
F: Incident Patients (Nursing Home) - Number of hemodialysis patients (n),2021  
F: Incident Patients (Nursing Home) - Number of hemodialysis patients (n),2022  
F: SHR (Nursing Home Admissions) - Number of Hospital Admissions, 2019  
F: SHR (Nursing Home Admissions) - Number of Hospital Admissions, 2020  
F: SHR (Nursing Home Admissions) - Number of Hospital Admissions, 2021  
F: SHR (Nursing Home Admissions) - Number of Hospital Admissions, 2022  
F: Incident Patients (Nursing Home) - Percent with employer group coverage only, 2019  
F: Incident Patients (Nursing Home) - Percent with employer group coverage only, 2020  
F: Incident Patients (Nursing Home) - Percent with employer group coverage only, 2021  
F: Incident Patients (Nursing Home) - Percent with employer group coverage only, 2022  
N: Incident Patients (Nursing Home) - Percent with employer group coverage only, 2022  
S: Incident Patients (Nursing Home) - Percent with employer group coverage only, 2022  
US: Incident Patients (Nursing Home) - Percent with employer group coverage only, 2022  
F: Incident Patients (Nursing Home) - Percent with Medicaid coverage only, 2019  
F: Incident Patients (Nursing Home) - Percent with Medicaid coverage only, 2020  
F: Incident Patients (Nursing Home) - Percent with Medicaid coverage only, 2021  
F: Incident Patients (Nursing Home) - Percent with Medicaid coverage only, 2022  
N: Incident Patients (Nursing Home) - Percent with Medicaid coverage only, 2022  
S: Incident Patients (Nursing Home) - Percent with Medicaid coverage only, 2022  
US: Incident Patients (Nursing Home) - Percent with Medicaid coverage only, 2022  
F: Incident Patients (Nursing Home) - Percent with Other/Unknown/No insurance, 2019  
F: Incident Patients (Nursing Home) - Percent with Other/Unknown/No insurance, 2020  
F: Incident Patients (Nursing Home) - Percent with Other/Unknown/No insurance, 2021  
F: Incident Patients (Nursing Home) - Percent with Other/Unknown/No insurance, 2022  
N: Incident Patients (Nursing Home) - Percent with Other/Unknown/No insurance, 2022  
S: Incident Patients (Nursing Home) - Percent with Other/Unknown/No insurance, 2022  
US: Incident Patients (Nursing Home) - Percent with Other/Unknown/No insurance, 2022  
F: Prevalent VA Type (Nursing Home) - Long-Term Catheter Rate, 2019  
F: Prevalent VA Type (Nursing Home) - Long-Term Catheter Rate, 2020  
F: Prevalent VA Type (Nursing Home) - Long-Term Catheter Rate, 2021  
F: Prevalent VA Type (Nursing Home) - Long-Term Catheter Rate, 2022  
N: Prevalent VA Type (Nursing Home) - Long-Term Catheter Rate, 2022  
S: Prevalent VA Type (Nursing Home) - Long-Term Catheter Rate, 2022  
US: Prevalent VA Type (Nursing Home) - Long-Term Catheter Rate, 2022  
F: COVID Nursing Home - Number of deaths among Medicare dialysis patients, 2022-Q1  
F: COVID Nursing Home - Number of deaths among Medicare dialysis patients, 2022-Q2  
F: COVID Nursing Home - Number of deaths among Medicare dialysis patients, 2022-Q3  
F: COVID Nursing Home - Number of deaths among Medicare dialysis patients, 2022-Q4  
F: COVID Nursing Home - Number of deaths among Medicare dialysis patients, 2021  
F: COVID Nursing Home - % of deaths with patients ever infected with COVID, 2022-Q1



US: COVID Nursing Home - % of Medicare patients initially infected with COVID, 2022-Q4  
F: COVID Nursing Home - % of Medicare patients initially infected with COVID, 2021  
F: COVID Nursing Home - Number of patients initially infected with COVID, 2022-Q1  
F: COVID Nursing Home - Number of patients initially infected with COVID, 2022-Q2  
F: COVID Nursing Home - Number of patients initially infected with COVID, 2022-Q3  
F: COVID Nursing Home - Number of patients initially infected with COVID, 2022-Q4  
F: COVID Nursing Home - Number of patients initially infected with COVID, 2021  
F: COVID Nursing Home - Number of hospitalizations among Medicare dialysis patients, 2022-Q1  
F: COVID Nursing Home - Number of hospitalizations among Medicare dialysis patients, 2022-Q2  
F: COVID Nursing Home - Number of hospitalizations among Medicare dialysis patients, 2022-Q3  
F: COVID Nursing Home - Number of hospitalizations among Medicare dialysis patients, 2022-Q4  
F: COVID Nursing Home - Number of hospitalizations among Medicare dialysis patients, 2021  
F: COVID Nursing Home - Number of Medicare dialysis patients, 2022-Q1  
F: COVID Nursing Home - Number of Medicare dialysis patients, 2022-Q2  
F: COVID Nursing Home - Number of Medicare dialysis patients, 2022-Q3  
F: COVID Nursing Home - Number of Medicare dialysis patients, 2022-Q4  
F: COVID Nursing Home - Number of Medicare dialysis patients, 2021  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Arteriovenous Fistula, 2019  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Arteriovenous Fistula, 2020  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Arteriovenous Fistula, 2021  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Arteriovenous Fistula, 2022  
N: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Arteriovenous Fistula, 2022  
S: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Arteriovenous Fistula, 2022  
US: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Arteriovenous Fistula, 2022  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Catheter, 2019  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Catheter, 2020  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Catheter, 2021  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Catheter, 2022  
N: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Catheter, 2022  
S: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Catheter, 2022  
US: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Catheter, 2022  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Arteriovenous Graft, 2019  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Arteriovenous Graft, 2020  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Arteriovenous Graft, 2021  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Arteriovenous Graft, 2022  
N: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Arteriovenous Graft, 2022  
S: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Arteriovenous Graft, 2022  
US: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Arteriovenous Graft, 2022  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Other/Unknown/Missing Access, 2019  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Other/Unknown/Missing Access, 2020  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Other/Unknown/Missing Access, 2021  
F: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Other/Unknown/Missing Access, 2022  
N: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Other/Unknown/Missing Access, 2022  
S: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Other/Unknown/Missing Access, 2022



US: Incident Patients (Nursing Home) - Percent of hemodialysis patients.: Other/Unknown/Missing Access, 2022  
F: Hospitalization (Nursing Home) - Diagnosis: % with Acute Myocardial Infarction, 2019  
F: Hospitalization (Nursing Home) - Diagnosis: % with Acute Myocardial Infarction, 2020  
F: Hospitalization (Nursing Home) - Diagnosis: % with Acute Myocardial Infarction, 2021  
F: Hospitalization (Nursing Home) - Diagnosis: % with Acute Myocardial Infarction, 2022  
N: Hospitalization (Nursing Home) - Diagnosis: % with Acute Myocardial Infarction, 2022  
S: Hospitalization (Nursing Home) - Diagnosis: % with Acute Myocardial Infarction, 2022  
US: Hospitalization (Nursing Home) - Diagnosis: % with Acute Myocardial Infarction, 2022  
F: Prevalent Patients (Nursing Home) - % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2019  
F: Prevalent Patients (Nursing Home) - % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2020  
F: Prevalent Patients (Nursing Home) - % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2021  
F: Prevalent Patients (Nursing Home) - % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2022  
N: Prevalent Patients (Nursing Home) - % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2022  
S: Prevalent Patients (Nursing Home) - % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2022  
US: Prevalent Patients (Nursing Home) - % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2022  
F: Prevalent Patients (Nursing Home) - % on Continuous Cycling Peritoneal Dialysis, 12/31/2019  
F: Prevalent Patients (Nursing Home) - % on Continuous Cycling Peritoneal Dialysis, 12/31/2020  
F: Prevalent Patients (Nursing Home) - % on Continuous Cycling Peritoneal Dialysis, 12/31/2021  
F: Prevalent Patients (Nursing Home) - % on Continuous Cycling Peritoneal Dialysis, 12/31/2022  
N: Prevalent Patients (Nursing Home) - % on Continuous Cycling Peritoneal Dialysis, 12/31/2022  
S: Prevalent Patients (Nursing Home) - % on Continuous Cycling Peritoneal Dialysis, 12/31/2022  
US: Prevalent Patients (Nursing Home) - % on Continuous Cycling Peritoneal Dialysis, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Modality: % on Hemodialysis, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Modality: % on Hemodialysis, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Modality: % on Hemodialysis, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Modality: % on Hemodialysis, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Modality: % on Hemodialysis, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Modality: % on Hemodialysis, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Modality: % on Hemodialysis, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Modality: % on Home Hemodialysis, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Modality: % on Home Hemodialysis, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Modality: % on Home Hemodialysis, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Modality: % on Home Hemodialysis, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Modality: % on Home Hemodialysis, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Modality: % on Home Hemodialysis, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Modality: % on Home Hemodialysis, 12/31/2022  
F: Prevalent Patients (Nursing Home) - % on Other Modality, 12/31/2019  
F: Prevalent Patients (Nursing Home) - % on Other Modality, 12/31/2020  
F: Prevalent Patients (Nursing Home) - % on Other Modality, 12/31/2021  
F: Prevalent Patients (Nursing Home) - % on Other Modality, 12/31/2022  
N: Prevalent Patients (Nursing Home) - % on Other Modality, 12/31/2022  
S: Prevalent Patients (Nursing Home) - % on Other Modality, 12/31/2022  
US: Prevalent Patients (Nursing Home) - % on Other Modality, 12/31/2022  
F: Prevalent Comorbidities (Nursing Home) - Number of Medicare Dialysis Patients Alive on December 31, 2019

F: Prevalent Comorbidities (Nursing Home) - Number of Medicare Dialysis Patients Alive on December 31, 2020  
F: Prevalent Comorbidities (Nursing Home) - Number of Medicare Dialysis Patients Alive on December 31, 2021  
F: Prevalent Comorbidities (Nursing Home) - Number of Medicare Dialysis Patients Alive on December 31, 2022  
F: Incident Patients (Nursing Home) - No Pre-ESRD Nephrologist Care, 2019  
F: Incident Patients (Nursing Home) - No Pre-ESRD Nephrologist Care, 2020  
F: Incident Patients (Nursing Home) - No Pre-ESRD Nephrologist Care, 2021  
F: Incident Patients (Nursing Home) - No Pre-ESRD Nephrologist Care, 2022  
N: Incident Patients (Nursing Home) - No Pre-ESRD Nephrologist Care, 2022  
S: Incident Patients (Nursing Home) - No Pre-ESRD Nephrologist Care, 2022  
US: Incident Patients (Nursing Home) - No Pre-ESRD Nephrologist Care, 2022  
F: Incident Patients (Nursing Home) - Unknown Pre-ESRD Nephrologist Care, 2019  
F: Incident Patients (Nursing Home) - Unknown Pre-ESRD Nephrologist Care, 2020  
F: Incident Patients (Nursing Home) - Unknown Pre-ESRD Nephrologist Care, 2021  
F: Incident Patients (Nursing Home) - Unknown Pre-ESRD Nephrologist Care, 2022  
N: Incident Patients (Nursing Home) - Unknown Pre-ESRD Nephrologist Care, 2022  
S: Incident Patients (Nursing Home) - Unknown Pre-ESRD Nephrologist Care, 2022  
US: Incident Patients (Nursing Home) - Unknown Pre-ESRD Nephrologist Care, 2022  
F: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Greater Than 12 months, 2019  
F: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Greater Than 12 months, 2020  
F: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Greater Than 12 months, 2021  
F: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Greater Than 12 months, 2022  
N: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Greater Than 12 months, 2022  
S: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Greater Than 12 months, 2022  
US: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Greater Than 12 months, 2022  
F: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2019  
F: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2020  
F: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2021  
F: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2022  
N: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2022  
S: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2022  
US: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2022  
F: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Less Than 6 months, 2019  
F: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Less Than 6 months, 2020  
F: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Less Than 6 months, 2021  
F: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Less Than 6 months, 2022  
N: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Less Than 6 months, 2022  
S: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Less Than 6 months, 2022  
US: Incident Patients (Nursing Home) - Pre-ESRD Nephrologist Care Less Than 6 months, 2022  
F: Incident Patients (Nursing Home) - Number of forms returned, 2019  
F: Incident Patients (Nursing Home) - Number of forms returned, 2020  
F: Incident Patients (Nursing Home) - Number of forms returned, 2021  
F: Incident Patients (Nursing Home) - Number of forms returned, 2022  
F: All Patient Mortality (Nursing Home) - Observed death rate (per 100 patient-years), 2019  
F: All Patient Mortality (Nursing Home) - Observed death rate (per 100 patient-years), 2020

F: All Patient Mortality (Nursing Home) - Observed death rate (per 100 patient-years), 2021  
F: All Patient Mortality (Nursing Home) - Observed death rate (per 100 patient-years), 2022  
N: All Patient Mortality (Nursing Home) - Observed death rate (per 100 patient-years), 2022  
S: All Patient Mortality (Nursing Home) - Observed death rate (per 100 patient-years), 2022  
US: All Patient Mortality (Nursing Home) - Observed death rate (per 100 patient-years), 2022  
F: SHR (Nursing Home Admissions) - Observed Admission Rate (per patient-year in average facility), 2019  
F: SHR (Nursing Home Admissions) - Observed Admission Rate (per patient-year in average facility), 2020  
F: SHR (Nursing Home Admissions) - Observed Admission Rate (per patient-year in average facility), 2021  
F: SHR (Nursing Home Admissions) - Observed Admission Rate (per patient-year in average facility), 2022  
N: SHR (Nursing Home Admissions) - Observed Admission Rate (per patient-year in average facility), 2022  
S: SHR (Nursing Home Admissions) - Observed Admission Rate (per patient-year in average facility), 2022  
US: SHR (Nursing Home Admissions) - Observed Admission Rate (per patient-year in average facility), 2022  
F: Prevalent Patients (Nursing Home) - End of Year Status: Number of patients alive in this facility, 2019  
F: Prevalent Patients (Nursing Home) - End of Year Status: Number of patients alive in this facility, 2020  
F: Prevalent Patients (Nursing Home) - End of Year Status: Number of patients alive in this facility, 2021  
F: Prevalent Patients (Nursing Home) - End of Year Status: Number of patients alive in this facility, 2022  
F: Prevalent VA Type (Nursing Home) - Total Number of HD Patients, 2019  
F: Prevalent VA Type (Nursing Home) - Total Number of HD Patients, 2020  
F: Prevalent VA Type (Nursing Home) - Total Number of HD Patients, 2021  
F: Prevalent VA Type (Nursing Home) - Total Number of HD Patients, 2022  
F: Prevalent VA Type (Nursing Home) - Total Number of HD Patient-months, 2019  
F: Prevalent VA Type (Nursing Home) - Total Number of HD Patient-months, 2020  
F: Prevalent VA Type (Nursing Home) - Total Number of HD Patient-months, 2021  
F: Prevalent VA Type (Nursing Home) - Total Number of HD Patient-months, 2022  
F: Prevalent VA Type (Nursing Home) - % of Patients Receiving Treatment with Fistulae, 2019  
F: Prevalent VA Type (Nursing Home) - % of Patients Receiving Treatment with Fistulae, 2020  
F: Prevalent VA Type (Nursing Home) - % of Patients Receiving Treatment with Fistulae, 2021  
F: Prevalent VA Type (Nursing Home) - % of Patients Receiving Treatment with Fistulae, 2022  
N: Prevalent VA Type (Nursing Home) - % of Patients Receiving Treatment with Fistulae, 2022  
S: Prevalent VA Type (Nursing Home) - % of Patients Receiving Treatment with Fistulae, 2022  
US: Prevalent VA Type (Nursing Home) - % of Patients Receiving Treatment with Fistulae, 2022  
F: Incident Patients (Nursing Home) - Percent of Patients Informed of Transplant Options, 2019  
F: Incident Patients (Nursing Home) - Percent of Patients Informed of Transplant Options, 2020  
F: Incident Patients (Nursing Home) - Percent of Patients Informed of Transplant Options, 2021  
F: Incident Patients (Nursing Home) - Percent of Patients Informed of Transplant Options, 2022  
N: Incident Patients (Nursing Home) - Percent of Patients Informed of Transplant Options, 2022  
S: Incident Patients (Nursing Home) - Percent of Patients Informed of Transplant Options, 2022  
US: Incident Patients (Nursing Home) - Percent of Patients Informed of Transplant Options, 2022  
F: Prevalent Patients (Nursing Home) - Race: % Asian/Pacific Islander, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Race: % Asian/Pacific Islander, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Race: % Asian/Pacific Islander, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Race: % Asian/Pacific Islander, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Race: % Asian/Pacific Islander, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Race: % Asian/Pacific Islander, 12/31/2022

US: Prevalent Patients (Nursing Home) - Race: % Asian/Pacific Islander, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Race: % African American, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Race: % African American, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Race: % African American, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Race: % African American, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Race: % African American, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Race: % African American, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Race: % African American, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Race: % Native American, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Race: % Native American, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Race: % Native American, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Race: % Native American, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Race: % Native American, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Race: % Native American, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Race: % Native American, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Race: % White, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Race: % White, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Race: % White, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Race: % White, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Race: % White, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Race: % White, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Race: % White, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Race: % Other/Unknown/Missing race, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Race: % Other/Unknown/Missing race, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Race: % Other/Unknown/Missing race, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Race: % Other/Unknown/Missing race, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Race: % Other/Unknown/Missing race, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Race: % Other/Unknown/Missing race, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Race: % Other/Unknown/Missing race, 12/31/2022  
F: Hospitalization (Nursing Home) - Number of Patients, 2019  
F: Hospitalization (Nursing Home) - Number of Patients, 2020  
F: Hospitalization (Nursing Home) - Number of Patients, 2021  
F: Hospitalization (Nursing Home) - Number of Patients, 2022  
F: All Patient Mortality (Nursing Home) - Number of patients, 2019  
F: All Patient Mortality (Nursing Home) - Number of patients, 2020  
F: All Patient Mortality (Nursing Home) - Number of patients, 2021  
F: All Patient Mortality (Nursing Home) - Number of patients, 2022  
F: Hospitalization (Nursing Home) - Diagnosis: % with Septicemia, 2019  
F: Hospitalization (Nursing Home) - Diagnosis: % with Septicemia, 2020  
F: Hospitalization (Nursing Home) - Diagnosis: % with Septicemia, 2021  
F: Hospitalization (Nursing Home) - Diagnosis: % with Septicemia, 2022  
N: Hospitalization (Nursing Home) - Diagnosis: % with Septicemia, 2022  
S: Hospitalization (Nursing Home) - Diagnosis: % with Septicemia, 2022  
US: Hospitalization (Nursing Home) - Diagnosis: % with Septicemia, 2022

F: Prevalent Patients (Nursing Home) - Sex: % Female, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Sex: % Female, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Sex: % Female, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Sex: % Female, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Sex: % Female, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Sex: % Female, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Sex: % Female, 12/31/2022  
F: SHR (Nursing Home Admissions) - Standardized Hospitalization Ratio for Admissions, 2019  
F: SHR (Nursing Home Admissions) - Standardized Hospitalization Ratio for Admissions, 2020  
F: SHR (Nursing Home Admissions) - Standardized Hospitalization Ratio for Admissions, 2021  
F: SHR (Nursing Home Admissions) - Standardized Hospitalization Ratio for Admissions, 2022  
N: SHR (Nursing Home Admissions) - Standardized Hospitalization Ratio for Admissions, 2022  
S: SHR (Nursing Home Admissions) - Standardized Hospitalization Ratio for Admissions, 2022  
US: SHR (Nursing Home Admissions) - Standardized Hospitalization Ratio for Admissions, 2022  
F: All Patient Mortality (Nursing Home) - Standardized Mortality Ratio (SMR), 2019  
F: All Patient Mortality (Nursing Home) - Standardized Mortality Ratio (SMR), 2020  
F: All Patient Mortality (Nursing Home) - Standardized Mortality Ratio (SMR), 2021  
F: All Patient Mortality (Nursing Home) - Standardized Mortality Ratio (SMR), 2022  
N: All Patient Mortality (Nursing Home) - Standardized Mortality Ratio (SMR), 2022  
S: All Patient Mortality (Nursing Home) - Standardized Mortality Ratio (SMR), 2022  
US: All Patient Mortality (Nursing Home) - Standardized Mortality Ratio (SMR), 2022  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy less than 1 year, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy less than 1 year, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy less than 1 year, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy less than 1 year, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy less than 1 year, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy less than 1 year, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy less than 1 year, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2020

F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2022  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for over 6 years, 12/31/2019  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for over 6 years, 12/31/2020  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for over 6 years, 12/31/2021  
F: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for over 6 years, 12/31/2022  
N: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for over 6 years, 12/31/2022  
S: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for over 6 years, 12/31/2022  
US: Prevalent Patients (Nursing Home) - Vintage: % on ESRD Therapy for over 6 years, 12/31/2022  
F: All Patient Mortality (Nursing Home) - % of deaths from withdrawal, 2019  
F: All Patient Mortality (Nursing Home) - % of deaths from withdrawal, 2020  
F: All Patient Mortality (Nursing Home) - % of deaths from withdrawal, 2021  
F: All Patient Mortality (Nursing Home) - % of deaths from withdrawal, 2022  
N: All Patient Mortality (Nursing Home) - % of deaths from withdrawal, 2022  
S: All Patient Mortality (Nursing Home) - % of deaths from withdrawal, 2022  
US: All Patient Mortality (Nursing Home) - % of deaths from withdrawal, 2022  
F (2728): Incident Patients - Number of forms returned, 2019  
F (2728): Incident Patients - Number of forms returned, 2020  
F (2728): Incident Patients - Number of forms returned, 2021  
F (2728): Incident Patients - Number of forms returned, 2022  
N (2728): Incident Patients - Average Number of forms returned, 2022  
S (2728): Incident Patients - Average Number of forms returned, 2022  
US (2728): Incident Patients - Average Number of forms returned, 2022  
F (AFS): Facility Information - % Non-Medicare on 12/31/2019  
F (AFS): Facility Information - % Non-Medicare on 12/31/2020  
F (AFS): Facility Information - % Non-Medicare on 12/31/2021  
F (AFS): Facility Information - % Non-Medicare on 12/31/2022  
N (AFS): Facility Information - Average % Non-Medicare on 12/31/2022  
S (AFS): Facility Information - Average % Non-Medicare on 12/31/2022  
US (AFS): Facility Information - Average % Non-Medicare on 12/31/2022  
National Provider Identifier  
F: Prevalent Patients - Nursing Home: % of Nursing Home Facility Patients During Year, 12/31/2019  
F: Prevalent Patients - Nursing Home: % of Nursing Home Facility Patients During Year, 12/31/2020  
F: Prevalent Patients - Nursing Home: % of Nursing Home Facility Patients During Year, 12/31/2021  
F: Prevalent Patients - Nursing Home: % of Nursing Home Facility Patients During Year, 12/31/2022  
N: Prevalent Patients - Nursing Home: % of Nursing Home Facility Patients During Year, 12/31/2022  
S: Prevalent Patients - Nursing Home: % of Nursing Home Facility Patients During Year, 12/31/2022  
US: Prevalent Patients - Nursing Home: % of Nursing Home Facility Patients During Year, 12/31/2022  
F (AFS): Facility Information - Number of full time nurses on 12/31/2019  
F (AFS): Facility Information - Number of full time nurses on 12/31/2020  
F (AFS): Facility Information - Number of full time nurses on 12/31/2021

F (AFS): Facility Information - Number of full time nurses on 12/31/2022  
N (AFS): Facility Information - Average number of full time nurses on 12/31/2022  
S (AFS): Facility Information - Average number of full time nurses on 12/31/2022  
US (AFS): Facility Information - Average number of full time nurses on 12/31/2022  
F (AFS): Facility Information - Number of part time nurses on 12/31/2019  
F (AFS): Facility Information - Number of part time nurses on 12/31/2020  
F (AFS): Facility Information - Number of part time nurses on 12/31/2021  
F (AFS): Facility Information - Number of part time nurses on 12/31/2022  
N (AFS): Facility Information - Average number of part time nurses on 12/31/2022  
S (AFS): Facility Information - Average number of part time nurses on 12/31/2022  
US (AFS): Facility Information - Average number of part time nurses on 12/31/2022  
F (2728): Incident Patients - Percent other/missing primary cause of ESRD, 2019  
F (2728): Incident Patients - Percent other/missing primary cause of ESRD, 2020  
F (2728): Incident Patients - Percent other/missing primary cause of ESRD, 2021  
F (2728): Incident Patients - Percent other/missing primary cause of ESRD, 2022  
N (2728): Incident Patients - Percent other/missing primary cause of ESRD, 2022  
S (2728): Incident Patients - Percent other/missing primary cause of ESRD, 2022  
US (2728): Incident Patients - Percent other/missing primary cause of ESRD, 2022  
F: SHR (Admissions) - % One Day Admissions, 2019  
F: SHR (Admissions) - % One Day Admissions, 2020  
F: SHR (Admissions) - % One Day Admissions, 2021  
F: SHR (Admissions) - % One Day Admissions, 2022  
F: SHR (Admissions)- % One Day Admissions, 2019-2022  
N: SHR (Admissions) - Average % One Day Admissions (per year in average facility), 2019-2022  
S: SHR (Admissions) - Average % One Day Admissions (per year in average facility), 2019-2022  
US: SHR (Admissions) - Average % One Day Admissions (per year in average facility), 2019-2022  
F (2728): Incident Patients - Percent with other cardiac disorder, 2019  
F (2728): Incident Patients - Percent with other cardiac disorder, 2020  
F (2728): Incident Patients - Percent with other cardiac disorder, 2021  
F (2728): Incident Patients - Percent with other cardiac disorder, 2022  
N (2728): Incident Patients - Percent with other cardiac disorder, 2022  
S (2728): Incident Patients - Percent with other cardiac disorder, 2022  
US (2728): Incident Patients - Percent with other cardiac disorder, 2022  
F: Prevalent Patients (Pediatric) - Age: % Less than 5 years, 12/31/2019  
F: Prevalent Patients (Pediatric) - Age: % Less than 5 years, 12/31/2020  
F: Prevalent Patients (Pediatric) - Age: % Less than 5 years, 12/31/2021  
F: Prevalent Patients (Pediatric) - Age: % Less than 5 years, 12/31/2022  
N: Prevalent Patients (Pediatric) - Age: % under 5 years, 12/31/2022  
S: Prevalent Patients (Pediatric) - Age: % under 5 years, 12/31/2022  
US: Prevalent Patients (Pediatric) - Age: % under 5 years, 12/31/2022  
F: Prevalent Patients (Pediatric) - Age: % Between 5-9 years, 12/31/2019  
F: Prevalent Patients (Pediatric) - Age: % Between 5-9 years, 12/31/2020  
F: Prevalent Patients (Pediatric) - Age: % Between 5-9 years, 12/31/2021  
F: Prevalent Patients (Pediatric) - Age: % Between 5-9 years, 12/31/2022

N: Prevalent Patients (Pediatric) - Age: % between 5-9 years, 12/31/2022  
S: Prevalent Patients (Pediatric) - Age: % between 5-9 years, 12/31/2022  
US: Prevalent Patients (Pediatric) - Age: % between 5-9 years, 12/31/2022  
F: Prevalent Patients (Pediatric) - Age: % Between 10-14 years, 12/31/2019  
F: Prevalent Patients (Pediatric) - Age: % Between 10-14 years, 12/31/2020  
F: Prevalent Patients (Pediatric) - Age: % Between 10-14 years, 12/31/2021  
F: Prevalent Patients (Pediatric) - Age: % Between 10-14 years, 12/31/2022  
N: Prevalent Patients (Pediatric) - Age: % between 10-14 years, 12/31/2022  
S: Prevalent Patients (Pediatric) - Age: % between 10-14 years, 12/31/2022  
US: Prevalent Patients (Pediatric) - Age: % between 10-14 years, 12/31/2022  
F: Prevalent Patients (Pediatric) - Age: % Between 15-17 years, 12/31/2019  
F: Prevalent Patients (Pediatric) - Age: % Between 15-17 years, 12/31/2020  
F: Prevalent Patients (Pediatric) - Age: % Between 15-17 years, 12/31/2021  
F: Prevalent Patients (Pediatric) - Age: % Between 15-17 years, 12/31/2022  
N: Prevalent Patients (Pediatric) - Age: % between 15-17 years, 12/31/2022  
S: Prevalent Patients (Pediatric) - Age: % between 15-17 years, 12/31/2022  
US: Prevalent Patients (Pediatric) - Age: % between 15-17 years, 12/31/2022  
F (2728): Incident Patients (Pediatric) - Percent with Medicare coverage only, 2019  
F (2728): Incident Patients (Pediatric) - Percent with Medicare coverage only, 2020  
F (2728): Incident Patients (Pediatric) - Percent with Medicare coverage only, 2021  
F (2728): Incident Patients (Pediatric) - Percent with Medicare coverage only, 2022  
N (2728): Incident Patients (Pediatric) - Percent with Medicare coverage, 2022  
S (2728): Incident Patients (Pediatric) - Percent with Medicare coverage, 2022  
US (2728): Incident Patients (Pediatric) - Percent with Medicare coverage, 2022  
F (2728): Incident Patients (Pediatric) - Percent of patients with Fistulae placed, 2019  
F (2728): Incident Patients (Pediatric) - Percent of patients with Fistulae placed, 2020  
F (2728): Incident Patients (Pediatric) - Percent of patients with Fistulae placed, 2021  
F (2728): Incident Patients (Pediatric) - Percent of patients with Fistulae placed, 2022  
N (2728): Incident Patients (Pediatric) - Percent of Incident Patients with Fistulae placed, 2022  
S (2728): Incident Patients (Pediatric) - Percent of Incident Patients with Fistulae placed, 2022  
US (2728): Incident Patients (Pediatric) - Percent of Incident Patients with Fistulae placed, 2022  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin < 3 g/dL, 2019  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin < 3 g/dL, 2020  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin < 3 g/dL, 2021  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin < 3 g/dL, 2022  
N: Albumin (Pediatric) - % of HD patient-months with Serum Albumin < 3 g/dL, 2022  
S: Albumin (Pediatric) - % of HD patient-months with Serum Albumin < 3 g/dL, 2022  
U: Albumin (Pediatric) - % of HD patient-months with Serum Albumin < 3 g/dL, 2022  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2019  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2020  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2021  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2022  
N: Albumin (Pediatric) - % of HD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2022  
S: Albumin (Pediatric) - % of HD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2022



U: Albumin (Pediatric) - % of HD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2022  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2019  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2020  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2021  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2022  
N: Albumin (Pediatric) - % of HD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2022  
S: Albumin (Pediatric) - % of HD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2022  
U: Albumin (Pediatric) - % of HD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2022  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin >= 4 g/dL, 2019  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin >= 4 g/dL, 2020  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin >= 4 g/dL, 2021  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin >= 4 g/dL, 2022  
N: Albumin (Pediatric) - % of HD patient-months with Serum Albumin >= 4 g/dL, 2022  
S: Albumin (Pediatric) - % of HD patient-months with Serum Albumin >= 4 g/dL, 2022  
U: Albumin (Pediatric) - % of HD patient-months with Serum Albumin >= 4 g/dL, 2022  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin Missing, 2019  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin Missing, 2020  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin Missing, 2021  
F: Albumin (Pediatric) - % of HD patient-months with Serum Albumin Missing, 2022  
N: Albumin (Pediatric) - % of HD patient-months with Serum Albumin Missing, 2022  
S: Albumin (Pediatric) - % of HD patient-months with Serum Albumin Missing, 2022  
U: Albumin (Pediatric) - % of HD patient-months with Serum Albumin Missing, 2022  
F: Albumin (Pediatric) - Average Serum Albumin, of valid in range HD patient-months, 2019  
F: Albumin (Pediatric) - Average Serum Albumin, of valid in range HD patient-months, 2020  
F: Albumin (Pediatric) - Average Serum Albumin, of valid in range HD patient-months, 2021  
F: Albumin (Pediatric) - Average Serum Albumin, of valid in range HD patient-months, 2022  
N: Albumin (Pediatric) - Average serum albumin (g/dL), of valid in range HD patient-months, 2022  
S: Albumin (Pediatric) - Average serum albumin (g/dL), of valid in range HD patient-months, 2022  
U: Albumin (Pediatric) - Average serum albumin (g/dL), of valid in range HD patient-months, 2022  
F: HD HGB (Pediatric) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2019  
F: HD HGB (Pediatric) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2020  
F: HD HGB (Pediatric) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2021  
F: HD HGB (Pediatric) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
N: HD HGB (Pediatric) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
S: HD HGB (Pediatric) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
US: HD HGB (Pediatric) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
F: HD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patients, 2019  
F: HD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patients, 2020  
F: HD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patients, 2021  
F: HD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patients, 2022  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin < 10 g/dL, 2019  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin < 10 g/dL, 2020  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin < 10 g/dL, 2021  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin < 10 g/dL, 2022

N: HD HGB (Pediatric) - % of patient-months with hemoglobin < 10 g/dL, 2022  
S: HD HGB (Pediatric) - % of patient-months with hemoglobin < 10 g/dL, 2022  
US: HD HGB (Pediatric) - % of patient-months with hemoglobin < 10 g/dL, 2022  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin 10 - <11 g/dL, 2019  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin 10 - <11 g/dL, 2020  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin 10 - <11 g/dL, 2021  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
N: HD HGB (Pediatric) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
S: HD HGB (Pediatric) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
US: HD HGB (Pediatric) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin 11 - 12 g/dL, 2019  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin 11 - 12 g/dL, 2020  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin 11 - 12 g/dL, 2021  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022  
N: HD HGB (Pediatric) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022  
S: HD HGB (Pediatric) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022  
US: HD HGB (Pediatric) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin > 12 g/dL, 2019  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin > 12 g/dL, 2020  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin > 12 g/dL, 2021  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin > 12 g/dL, 2022  
N: HD HGB (Pediatric) - % of patient-months with hemoglobin > 12 g/dL, 2022  
S: HD HGB (Pediatric) - % of patient-months with hemoglobin > 12 g/dL, 2022  
US: HD HGB (Pediatric) - % of patient-months with hemoglobin > 12 g/dL, 2022  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin Missing or Out of Range, 2019  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin Missing or Out of Range, 2020  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin Missing or Out of Range, 2021  
F: HD HGB (Pediatric) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
N: HD HGB (Pediatric) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
S: HD HGB (Pediatric) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
US: HD HGB (Pediatric) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
F: HD Kt/V (Pediatric)- % of patient-months with Kt/V >= 1.2, 2019  
F: HD Kt/V (Pediatric)- % of patient-months with Kt/V >= 1.2, 2020  
F: HD Kt/V (Pediatric)- % of patient-months with Kt/V >= 1.2, 2021  
F: HD Kt/V (Pediatric)- % of patient-months with Kt/V >= 1.2, 2022  
N: HD Kt/V (Pediatric)- % of patient-months with Kt/V >= 1.2, 2022  
S: HD Kt/V (Pediatric)- % of patient-months with Kt/V >= 1.2, 2022  
U: HD Kt/V (Pediatric)- % of patient-months with Kt/V >= 1.2, 2022  
F: HD Kt/V (Pediatric)- Total number of eligible patient-months, 2019  
F: HD Kt/V (Pediatric)- Total number of eligible patient-months, 2020  
F: HD Kt/V (Pediatric)- Total number of eligible patient-months, 2021  
F: HD Kt/V (Pediatric)- Total number of eligible patient-months, 2022  
F: HD Kt/V (Pediatric)- Total number of eligible patients, 2019  
F: HD Kt/V (Pediatric)- Total number of eligible patients, 2020

F: HD Kt/V (Pediatric)- Total number of eligible patients, 2021  
F: HD Kt/V (Pediatric)- Total number of eligible patients, 2022  
F: HD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patient-months, 2019  
F: HD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patient-months, 2020  
F: HD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patient-months, 2021  
F: HD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patient-months, 2022  
F: HD HGB (Pediatric) - Total number of eligible patients, 2019  
F: HD HGB (Pediatric) - Total number of eligible patients, 2020  
F: HD HGB (Pediatric) - Total number of eligible patients, 2021  
F: HD HGB (Pediatric) - Total number of eligible patients, 2022  
F: HD HGB (Pediatric) - Total number of eligible patient-months, 2019  
F: HD HGB (Pediatric) - Total number of eligible patient-months, 2020  
F: HD HGB (Pediatric) - Total number of eligible patient-months, 2021  
F: HD HGB (Pediatric) - Total number of eligible patient-months, 2022  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin < 3 g/dL, 2019  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin < 3 g/dL, 2020  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin < 3 g/dL, 2021  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin < 3 g/dL, 2022  
N: Albumin (Pediatric) - % of PD patient-months with Serum Albumin < 3 g/dL, 2022  
S: Albumin (Pediatric) - % of PD patient-months with Serum Albumin < 3 g/dL, 2022  
U: Albumin (Pediatric) - % of PD patient-months with Serum Albumin < 3 g/dL, 2022  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2019  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2020  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2021  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2022  
N: Albumin (Pediatric) - % of PD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2022  
S: Albumin (Pediatric) - % of PD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2022  
U: Albumin (Pediatric) - % of PD patient-months with Serum Albumin 3 - < 3.5 g/dL, 2022  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2019  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2020  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2021  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2022  
N: Albumin (Pediatric) - % of PD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2022  
S: Albumin (Pediatric) - % of PD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2022  
U: Albumin (Pediatric) - % of PD patient-months with Serum Albumin 3.5 - < 4 g/dL, 2022  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin >= 4 g/dL, 2019  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin >= 4 g/dL, 2020  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin >= 4 g/dL, 2021  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin >= 4 g/dL, 2022  
N: Albumin (Pediatric) - % of PD patient-months with Serum Albumin >= 4 g/dL, 2022  
S: Albumin (Pediatric) - % of PD patient-months with Serum Albumin >= 4 g/dL, 2022  
U: Albumin (Pediatric) - % of PD patient-months with Serum Albumin >= 4 g/dL, 2022  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin Missing, 2019  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin Missing, 2020

F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin Missing, 2021  
F: Albumin (Pediatric) - % of PD patient-months with Serum Albumin Missing, 2022  
N: Albumin (Pediatric) - % of PD patient-months with Serum Albumin Missing, 2022  
S: Albumin (Pediatric) - % of PD patient-months with Serum Albumin Missing, 2022  
U: Albumin (Pediatric) - % of PD patient-months with Serum Albumin Missing, 2022  
F: Albumin (Pediatric) - Average Serum Albumin, of valid in range PD patient-months, 2019  
F: Albumin (Pediatric) - Average Serum Albumin, of valid in range PD patient-months, 2020  
F: Albumin (Pediatric) - Average Serum Albumin, of valid in range PD patient-months, 2021  
F: Albumin (Pediatric) - Average Serum Albumin, of valid in range PD patient-months, 2022  
N: Albumin (Pediatric) - Average Serum Albumin, of valid in range PD patient-months, 2022  
S: Albumin (Pediatric) - Average Serum Albumin, of valid in range PD patient-months, 2022  
U: Albumin (Pediatric) - Average Serum Albumin, of valid in range PD patient-months, 2022  
F: PD HGB (Pediatric) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2019  
F: PD HGB (Pediatric) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2020  
F: PD HGB (Pediatric) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2021  
F: PD HGB (Pediatric) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
N: PD HGB (Pediatric) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
S: PD HGB (Pediatric) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
US: PD HGB (Pediatric) - Average hemoglobin levels (g/dL), of valid in-range patient-months, 2022  
F: PD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patients, 2019  
F: PD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patients, 2020  
F: PD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patients, 2021  
F: PD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patients, 2022  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin < 10 g/dL, 2019  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin < 10 g/dL, 2020  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin < 10 g/dL, 2021  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin < 10 g/dL, 2022  
N: PD HGB (Pediatric) - % of patient-months with hemoglobin < 10 g/dL, 2022  
S: PD HGB (Pediatric) - % of patient-months with hemoglobin < 10 g/dL, 2022  
US: PD HGB (Pediatric) - % of patient-months with hemoglobin < 10 g/dL, 2022  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin 10 - <11 g/dL, 2019  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin 10 - <11 g/dL, 2020  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin 10 - <11 g/dL, 2021  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
N: PD HGB (Pediatric) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
S: PD HGB (Pediatric) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
US: PD HGB (Pediatric) - % of patient-months with hemoglobin 10 - <11 g/dL, 2022  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin 11 - 12 g/dL, 2019  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin 11 - 12 g/dL, 2020  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin 11 - 12 g/dL, 2021  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022  
N: PD HGB (Pediatric) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022  
S: PD HGB (Pediatric) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022  
US: PD HGB (Pediatric) - % of patient-months with hemoglobin 11 - 12 g/dL, 2022

F: PD HGB (Pediatric) - % of patient-months with hemoglobin > 12 g/dL, 2019  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin > 12 g/dL, 2020  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin > 12 g/dL, 2021  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin > 12 g/dL, 2022  
N: PD HGB (Pediatric) - % of patient-months with hemoglobin > 12 g/dL, 2022  
S: PD HGB (Pediatric) - % of patient-months with hemoglobin > 12 g/dL, 2022  
US: PD HGB (Pediatric) - % of patient-months with hemoglobin > 12 g/dL, 2022  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin Missing or Out of Range, 2019  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin Missing or Out of Range, 2020  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin Missing or Out of Range, 2021  
F: PD HGB (Pediatric) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
N: PD HGB (Pediatric) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
S: PD HGB (Pediatric) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
US: PD HGB (Pediatric) - % of patient-months with hemoglobin Missing or Out of Range, 2022  
F: PD Kt/V (Pediatric)- % of patient-months with Kt/V >= 1.8, 2019  
F: PD Kt/V (Pediatric)- % of patient-months with Kt/V >= 1.8, 2020  
F: PD Kt/V (Pediatric)- % of patient-months with Kt/V >= 1.8, 2021  
F: PD Kt/V (Pediatric)- % of patient-months with Kt/V >= 1.8, 2022  
N: PD Kt/V (Pediatric)- % of patient-months with Kt/V >= 1.8, 2022  
S: PD Kt/V (Pediatric)- % of patient-months with Kt/V >= 1.8, 2022  
U: PD Kt/V (Pediatric)- % of patient-months with Kt/V >= 1.8, 2022  
F: PD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patient-months, 2019  
F: PD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patient-months, 2020  
F: PD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patient-months, 2021  
F: PD Dialysis Adequacy (Pediatric) - Total Number of Eligible Dialysis Patient-months, 2022  
F: PD HGB (Pediatric) - Total number of eligible patients, 2019  
F: PD HGB (Pediatric) - Total number of eligible patients, 2020  
F: PD HGB (Pediatric) - Total number of eligible patients, 2021  
F: PD HGB (Pediatric) - Total number of eligible patients, 2022  
F: PD HGB (Pediatric) - Total number of eligible patient-months, 2019  
F: PD HGB (Pediatric) - Total number of eligible patient-months, 2020  
F: PD HGB (Pediatric) - Total number of eligible patient-months, 2021  
F: PD HGB (Pediatric) - Total number of eligible patient-months, 2022  
F: All Patient Mortality (Pediatric) - Number of patient deaths, 2019  
F: All Patient Mortality (Pediatric) - Number of patient deaths, 2020  
F: All Patient Mortality (Pediatric) - Number of patient deaths, 2021  
F: All Patient Mortality (Pediatric) - Number of patient deaths, 2022  
F: Prevalent Patients (Pediatric) - Primary Cause of ESRD: % Diabetes, 12/31/2019  
F: Prevalent Patients (Pediatric) - Primary Cause of ESRD: % Diabetes, 12/31/2020  
F: Prevalent Patients (Pediatric) - Primary Cause of ESRD: % Diabetes, 12/31/2021  
F: Prevalent Patients (Pediatric) - Primary Cause of ESRD: % Diabetes, 12/31/2022  
N: Prevalent Patients (Pediatric) - Primary Cause of ESRD: % Diabetes, 12/31/2022  
S: Prevalent Patients (Pediatric) - Primary Cause of ESRD: % Diabetes, 12/31/2022  
US: Prevalent Patients (Pediatric) - Primary Cause of ESRD: % Diabetes, 12/31/2022



F: Prevalent Patients (Pediatric) - Primary Cause of ESRD: % Missing/Unknown Cause, 12/31/2021  
F: Prevalent Patients (Pediatric) - Primary Cause of ESRD: % Missing/Unknown Cause, 12/31/2022  
N: Prevalent Patients (Pediatric) - Primary Cause of ESRD: % Missing/Unknown Cause, 12/31/2022  
S: Prevalent Patients (Pediatric) - Primary Cause of ESRD: % Missing/Unknown Cause, 12/31/2022  
US: Prevalent Patients (Pediatric) - Primary Cause of ESRD: % Missing/Unknown Cause, 12/31/2022  
F: All Patient Mortality (Pediatric) - Years at risk for mortality, 2019  
F: All Patient Mortality (Pediatric) - Years at risk for mortality, 2020  
F: All Patient Mortality (Pediatric) - Years at risk for mortality, 2021  
F: All Patient Mortality (Pediatric) - Years at risk for mortality, 2022  
F: Prevalent Patients (Pediatric) - Ethnicity: % Hispanic, 12/31/2019  
F: Prevalent Patients (Pediatric) - Ethnicity: % Hispanic, 12/31/2020  
F: Prevalent Patients (Pediatric) - Ethnicity: % Hispanic, 12/31/2021  
F: Prevalent Patients (Pediatric) - Ethnicity: % Hispanic, 12/31/2022  
N: Prevalent Patients (Pediatric) - Ethnicity: % Hispanic, 12/31/2022  
S: Prevalent Patients (Pediatric) - Ethnicity: % Hispanic, 12/31/2022  
US: Prevalent Patients (Pediatric) - Ethnicity: % Hispanic, 12/31/2022  
F: Prevalent Patients (Pediatric) - Ethnicity: % Non-Hispanic, 12/31/2019  
F: Prevalent Patients (Pediatric) - Ethnicity: % Non-Hispanic, 12/31/2020  
F: Prevalent Patients (Pediatric) - Ethnicity: % Non-Hispanic, 12/31/2021  
F: Prevalent Patients (Pediatric) - Ethnicity: % Non-Hispanic, 12/31/2022  
N: Prevalent Patients (Pediatric) - Ethnicity: % Non-Hispanic, 12/31/2022  
S: Prevalent Patients (Pediatric) - Ethnicity: % Non-Hispanic, 12/31/2022  
US: Prevalent Patients (Pediatric) - Ethnicity: % Non-Hispanic, 12/31/2022  
F: Prevalent Patients (Pediatric) - Ethnicity: % Unknown Ethnicity, 12/31/2019  
F: Prevalent Patients (Pediatric) - Ethnicity: % Unknown Ethnicity, 12/31/2020  
F: Prevalent Patients (Pediatric) - Ethnicity: % Unknown Ethnicity, 12/31/2021  
F: Prevalent Patients (Pediatric) - Ethnicity: % Unknown Ethnicity, 12/31/2022  
N: Prevalent Patients (Pediatric) - Ethnicity: % Unknown Ethnicity, 12/31/2022  
S: Prevalent Patients (Pediatric) - Ethnicity: % Unknown Ethnicity, 12/31/2022  
US: Prevalent Patients (Pediatric) - Ethnicity: % Unknown Ethnicity, 12/31/2022  
F: SHR (Pediatric Days) - Number of Days Hospitalized, 2019  
F: SHR (Pediatric Days) - Number of Days Hospitalized, 2020  
F: SHR (Pediatric Days) - Number of Days Hospitalized, 2021  
F: SHR (Pediatric Days) - Number of Days Hospitalized, 2022  
F: Hospitalization (Pediatric)- Years at Risk, 2019  
F: Hospitalization (Pediatric)- Years at Risk, 2020  
F: Hospitalization (Pediatric)- Years at Risk, 2021  
F: Hospitalization (Pediatric)- Years at Risk, 2022  
F (2728): Incident Patients (Pediatric) - Number of hemodialysis patients (n),2019  
F (2728): Incident Patients (Pediatric) - Number of hemodialysis patients (n),2020  
F (2728): Incident Patients (Pediatric) - Number of hemodialysis patients (n),2021  
F (2728): Incident Patients (Pediatric) - Number of hemodialysis patients (n),2022  
F: SHR (Pediatric Admissions)- Number of Hospital Admissions, 2019  
F: SHR (Pediatric Admissions)- Number of Hospital Admissions, 2020

F: SHR (Pediatric Admissions)- Number of Hospital Admissions, 2021  
F: SHR (Pediatric Admissions)- Number of Hospital Admissions, 2022  
F (2728): Incident Patients (Pediatric) - Percent with employer group coverage only, 2019  
F (2728): Incident Patients (Pediatric) - Percent with employer group coverage only, 2020  
F (2728): Incident Patients (Pediatric) - Percent with employer group coverage only, 2021  
F (2728): Incident Patients (Pediatric) - Percent with employer group coverage only, 2022  
N (2728): Incident Patients (Pediatric) - Percent with employer group coverage only, 2022  
S (2728): Incident Patients (Pediatric) - Percent with employer group coverage only, 2022  
US (2728): Incident Patients (Pediatric) - Percent with employer group coverage only, 2022  
F (2728): Incident Patients (Pediatric) - Percent with Medicaid coverage only, 2019  
F (2728): Incident Patients (Pediatric) - Percent with Medicaid coverage only, 2020  
F (2728): Incident Patients (Pediatric) - Percent with Medicaid coverage only, 2021  
F (2728): Incident Patients (Pediatric) - Percent with Medicaid coverage only, 2022  
N (2728): Incident Patients (Pediatric) - Percent with Medicaid coverage only, 2022  
S (2728): Incident Patients (Pediatric) - Percent with Medicaid coverage only, 2022  
US (2728): Incident Patients (Pediatric) - Percent with Medicaid coverage only, 2022  
F (2728): Incident Patients (Pediatric) - Percent with other or unknown coverage, 2019  
F (2728): Incident Patients (Pediatric) - Percent with other or unknown coverage, 2020  
F (2728): Incident Patients (Pediatric) - Percent with other or unknown coverage, 2021  
F (2728): Incident Patients (Pediatric) - Percent with other or unknown coverage, 2022  
N (2728): Incident Patients (Pediatric) - Percent with None, other or unknown coverage only, 2022  
S (2728): Incident Patients (Pediatric) - Percent with None, other or unknown coverage only, 2022  
US (2728): Incident Patients (Pediatric) - Percent with None, other or unknown coverage only, 2022  
F: Prevalent VA Type (Pediatric) - Long-Term Catheter Rate, 2019  
F: Prevalent VA Type (Pediatric) - Long-Term Catheter Rate, 2020  
F: Prevalent VA Type (Pediatric) - Long-Term Catheter Rate, 2021  
F: Prevalent VA Type (Pediatric) - Long-Term Catheter Rate, 2022  
N: Prevalent VA Type (Pediatric) - Long-Term Catheter Rate, 2022  
S: Prevalent VA Type (Pediatric) - Long-Term Catheter Rate, 2022  
U: Prevalent VA Type (Pediatric) - Long-Term Catheter Rate, 2022  
F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Arteriovenous Fistula, 2019  
F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Arteriovenous Fistula, 2020  
F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Arteriovenous Fistula, 2021  
F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Arteriovenous Fistula, 2022  
N (2728): Incident Patients (Pediatric) - Percent of Incident HD Patients: AV Fistula, 2022  
S (2728): Incident Patients (Pediatric) - Percent of Incident HD Patients: AV Fistula, 2022  
US (2728): Incident Patients (Pediatric) - Percent of Incident HD Patients: AV Fistula, 2022  
F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Catheter, 2019  
F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Catheter, 2020  
F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Catheter, 2021  
F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Catheter, 2022  
N (2728): Incident Patients (Pediatric) - Percent of Incident HD Patients: Catheter, 2022  
S (2728): Incident Patients (Pediatric) - Percent of Incident HD Patients: Catheter, 2022  
US (2728): Incident Patients (Pediatric) - Percent of Incident HD Patients: Catheter, 2022



F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Arteriovenous Graft, 2019  
F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Arteriovenous Graft, 2020  
F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Arteriovenous Graft, 2021  
F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Arteriovenous Graft, 2022  
N (2728): Incident Patients (Pediatric) - Percent of Incident HD Patients: AV Graft, 2022  
S (2728): Incident Patients (Pediatric) - Percent of Incident HD Patients: AV Graft, 2022  
US (2728): Incident Patients (Pediatric) - Percent of Incident HD Patients: AV Graft, 2022  
F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Other/Unknown/Missing, 2019  
F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Other/Unknown/Missing, 2020  
F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Other/Unknown/Missing, 2021  
F (2728): Incident Patients (Pediatric) - Percent of HD patients.: Other/Unknown/Missing, 2022  
N (2728): Incident Patients (Pediatric) - Percent of Incident HD Patients: Other/Unknown/Missing, 2022  
S (2728): Incident Patients (Pediatric) - Percent of Incident HD Patients: Other/Unknown/Missing, 2022  
US (2728): Incident Patients (Pediatric) - Percent of Incident HD Patients: Other/Unknown/Missing, 2022  
F: Prevalent Patients (Pediatric) - Modality: % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2019  
F: Prevalent Patients (Pediatric) - Modality: % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2020  
F: Prevalent Patients (Pediatric) - Modality: % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2021  
F: Prevalent Patients (Pediatric) - Modality: % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2022  
N: Prevalent Patients (Pediatric) - Modality: % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2022  
S: Prevalent Patients (Pediatric) - Modality: % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2022  
US: Prevalent Patients (Pediatric) - Modality: % on Continuous Ambulatory Peritoneal Dialysis, 12/31/2022  
F: Prevalent Patients (Pediatric) - Modality: % on Continuous Cycling Peritoneal Dialysis, 12/31/2019  
F: Prevalent Patients (Pediatric) - Modality: % on Continuous Cycling Peritoneal Dialysis, 12/31/2020  
F: Prevalent Patients (Pediatric) - Modality: % on Continuous Cycling Peritoneal Dialysis, 12/31/2021  
F: Prevalent Patients (Pediatric) - Modality: % on Continuous Cycling Peritoneal Dialysis, 12/31/2022  
N: Prevalent Patients (Pediatric) - Modality: % on Continuous Cycling Peritoneal Dialysis, 12/31/2022  
S: Prevalent Patients (Pediatric) - Modality: % on Continuous Cycling Peritoneal Dialysis, 12/31/2022  
US: Prevalent Patients (Pediatric) - Modality: % on Continuous Cycling Peritoneal Dialysis, 12/31/2022  
F: Prevalent Patients (Pediatric) - Modality: % on Hemodialysis, 12/31/2019  
F: Prevalent Patients (Pediatric) - Modality: % on Hemodialysis, 12/31/2020  
F: Prevalent Patients (Pediatric) - Modality: % on Hemodialysis, 12/31/2021  
F: Prevalent Patients (Pediatric) - Modality: % on Hemodialysis, 12/31/2022  
N: Prevalent Patients (Pediatric) - Modality: % on Hemodialysis, 12/31/2022  
S: Prevalent Patients (Pediatric) - Modality: % on Hemodialysis, 12/31/2022  
US: Prevalent Patients (Pediatric) - Modality: % on Hemodialysis, 12/31/2022  
F: Prevalent Patients (Pediatric) - Modality: % on Home Hemodialysis, 12/31/2019  
F: Prevalent Patients (Pediatric) - Modality: % on Home Hemodialysis, 12/31/2020  
F: Prevalent Patients (Pediatric) - Modality: % on Home Hemodialysis, 12/31/2021  
F: Prevalent Patients (Pediatric) - Modality: % on Home Hemodialysis, 12/31/2022  
N: Prevalent Patients (Pediatric) - Modality: % on Home Hemodialysis, 12/31/2022  
S: Prevalent Patients (Pediatric) - Modality: % on Home Hemodialysis, 12/31/2022  
US: Prevalent Patients (Pediatric) - Modality: % on Home Hemodialysis, 12/31/2022  
F: Prevalent Patients (Pediatric) - Modality: % on Other Modality, 12/31/2019  
F: Prevalent Patients (Pediatric) - Modality: % on Other Modality, 12/31/2020

F: Prevalent Patients (Pediatric) - Modality: % on Other Modality, 12/31/2021  
F: Prevalent Patients (Pediatric) - Modality: % on Other Modality, 12/31/2022  
N: Prevalent Patients (Pediatric) - Modality: % on Other Modality, 12/31/2022  
S: Prevalent Patients (Pediatric) - Modality: % on Other Modality, 12/31/2022  
US: Prevalent Patients (Pediatric) - Modality: % on Other Modality, 12/31/2022  
F (2728): Incident Patients (Pediatric) - No Pre-ESRD Nephrologist Care, 2019  
F (2728): Incident Patients (Pediatric) - No Pre-ESRD Nephrologist Care, 2020  
F (2728): Incident Patients (Pediatric) - No Pre-ESRD Nephrologist Care, 2021  
F (2728): Incident Patients (Pediatric) - No Pre-ESRD Nephrologist Care, 2022  
N (2728): Incident Patients (Pediatric) - No Pre-ESRD Nephrologist Care, 2022  
S (2728): Incident Patients (Pediatric) - No Pre-ESRD Nephrologist Care, 2022  
US (2728): Incident Patients (Pediatric) - No Pre-ESRD Nephrologist Care, 2022  
F (2728): Incident Patients (Pediatric) - Unknown Pre-ESRD Nephrologist Care, 2019  
F (2728): Incident Patients (Pediatric) - Unknown Pre-ESRD Nephrologist Care, 2020  
F (2728): Incident Patients (Pediatric) - Unknown Pre-ESRD Nephrologist Care, 2021  
F (2728): Incident Patients (Pediatric) - Unknown Pre-ESRD Nephrologist Care, 2022  
N (2728): Incident Patients (Pediatric) - Unknown Pre-ESRD Nephrologist Care, 2022  
S (2728): Incident Patients (Pediatric) - Unknown Pre-ESRD Nephrologist Care, 2022  
US (2728): Incident Patients (Pediatric) - Unknown Pre-ESRD Nephrologist Care, 2022  
F (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Greater Than 12 months, 2019  
F (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Greater Than 12 months, 2020  
F (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Greater Than 12 months, 2021  
F (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Greater Than 12 months, 2022  
N (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Greater Than 12 months, 2022  
S (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Greater Than 12 months, 2022  
US (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Greater Than 12 months, 2022  
F (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2019  
F (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2020  
F (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2021  
F (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2022  
N (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2022  
S (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2022  
US (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Between 6 and 12 months, 2022  
F (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Less Than 6 months, 2019  
F (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Less Than 6 months, 2020  
F (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Less Than 6 months, 2021  
F (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Less Than 6 months, 2022  
N (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Less Than 6 months, 2022  
S (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Less Than 6 months, 2022  
US (2728): Incident Patients (Pediatric) - Pre-ESRD Nephrologist Care Less Than 6 months, 2022  
F (2728): Incident Patients (Pediatric) - Number of forms returned, 2019  
F (2728): Incident Patients (Pediatric) - Number of forms returned, 2020  
F (2728): Incident Patients (Pediatric) - Number of forms returned, 2021  
F (2728): Incident Patients (Pediatric) - Number of forms returned, 2022

F: Prevalent Patients (Pediatric) - End of Year Status: Number of pediatric patients live in this facility, 2019  
F: Prevalent Patients (Pediatric) - End of Year Status: Number of pediatric patients live in this facility, 2020  
F: Prevalent Patients (Pediatric) - End of Year Status: Number of pediatric patients live in this facility, 2021  
F: Prevalent Patients (Pediatric) - End of Year Status: Number of pediatric patients live in this facility, 2022  
F: Prevalent VA Type (Pediatric) - Total number of HD patients, 2019  
F: Prevalent VA Type (Pediatric) - Total number of HD patients, 2020  
F: Prevalent VA Type (Pediatric) - Total number of HD patients, 2021  
F: Prevalent VA Type (Pediatric) - Total number of HD patients, 2022  
F: Prevalent VA Type (Pediatric) - Total number of HD patient-months, 2019  
F: Prevalent VA Type (Pediatric) - Total number of HD patient-months, 2020  
F: Prevalent VA Type (Pediatric) - Total number of HD patient-months, 2021  
F: Prevalent VA Type (Pediatric) - Total number of HD patient-months, 2022  
F: Prevalent VA Type (Pediatric) - % of patients receiving treatment with fistulae, 2019  
F: Prevalent VA Type (Pediatric) - % of patients receiving treatment with fistulae, 2020  
F: Prevalent VA Type (Pediatric) - % of patients receiving treatment with fistulae, 2021  
F: Prevalent VA Type (Pediatric) - % of patients receiving treatment with fistulae, 2022  
N: Prevalent VA Type (Pediatric) - % of patients receiving treatment with fistulae, 2022  
S: Prevalent VA Type (Pediatric) - % of patients receiving treatment with fistulae, 2022  
U: Prevalent VA Type (Pediatric) - % of patients receiving treatment with fistulae, 2022  
F: (Pediatric) Prevalent Waitlist - Total number of patient-months (age<18) at risk, 2019  
F: (Pediatric) Prevalent Waitlist - Total number of patient-months (age<18) at risk, 2020  
F: (Pediatric) Prevalent Waitlist - Total number of patient-months (age<18) at risk, 2021  
F: (Pediatric) Prevalent Waitlist - Total number of patient-months (age<18) at risk, 2022  
F: (Pediatric) Prevalent Waitlist - Total number of eligible dialysis patients (age<18), 2019  
F: (Pediatric) Prevalent Waitlist - Total number of eligible dialysis patients (age<18), 2020  
F: (Pediatric) Prevalent Waitlist - Total number of eligible dialysis patients (age<18), 2021  
F: (Pediatric) Prevalent Waitlist - Total number of eligible dialysis patients (age<18), 2022  
F (2728): Incident Patients (Pediatric) - Percent of Patients Informed of Transplant Options, 2019  
F (2728): Incident Patients (Pediatric) - Percent of Patients Informed of Transplant Options, 2020  
F (2728): Incident Patients (Pediatric) - Percent of Patients Informed of Transplant Options, 2021  
F (2728): Incident Patients (Pediatric) - Percent of Patients Informed of Transplant Options, 2022  
N (2728): Incident Patients (Pediatric) - Percent of Patients Informed of Transplant Options, 2022  
S (2728): Incident Patients (Pediatric) - Percent of Patients Informed of Transplant Options, 2022  
US (2728): Incident Patients (Pediatric) - Percent of Patients Informed of Transplant Options, 2022  
F: Prevalent Patients (Pediatric) - Race: % Asian/Pacific Islander, 12/31/2019  
F: Prevalent Patients (Pediatric) - Race: % Asian/Pacific Islander, 12/31/2020  
F: Prevalent Patients (Pediatric) - Race: % Asian/Pacific Islander, 12/31/2021  
F: Prevalent Patients (Pediatric) - Race: % Asian/Pacific Islander, 12/31/2022  
N: Prevalent Patients (Pediatric) - Race: % Asian/Pacific Islander, 12/31/2022  
S: Prevalent Patients (Pediatric) - Race: % Asian/Pacific Islander, 12/31/2022  
US: Prevalent Patients (Pediatric) - Race: % Asian/Pacific Islander, 12/31/2022  
F: Prevalent Patients (Pediatric) - Race: % African American, 12/31/2019  
F: Prevalent Patients (Pediatric) - Race: % African American, 12/31/2020  
F: Prevalent Patients (Pediatric) - Race: % African American, 12/31/2021

F: Prevalent Patients (Pediatric) - Race: % African American, 12/31/2022  
N: Prevalent Patients (Pediatric) - Race: % African American, 12/31/2022  
S: Prevalent Patients (Pediatric) - Race: % African American, 12/31/2022  
US: Prevalent Patients (Pediatric) - Race: % African American, 12/31/2022  
F: Prevalent Patients (Pediatric) - Race: % Native American, 12/31/2019  
F: Prevalent Patients (Pediatric) - Race: % Native American, 12/31/2020  
F: Prevalent Patients (Pediatric) - Race: % Native American, 12/31/2021  
F: Prevalent Patients (Pediatric) - Race: % Native American, 12/31/2022  
N: Prevalent Patients (Pediatric) - Race: % Native American, 12/31/2022  
S: Prevalent Patients (Pediatric) - Race: % Native American, 12/31/2022  
US: Prevalent Patients (Pediatric) - Race: % Native American, 12/31/2022  
F: Prevalent Patients (Pediatric) - Race: % White, 12/31/2019  
F: Prevalent Patients (Pediatric) - Race: % White, 12/31/2020  
F: Prevalent Patients (Pediatric) - Race: % White, 12/31/2021  
F: Prevalent Patients (Pediatric) - Race: % White, 12/31/2022  
N: Prevalent Patients (Pediatric) - Race: % White, 12/31/2022  
S: Prevalent Patients (Pediatric) - Race: % White, 12/31/2022  
US: Prevalent Patients (Pediatric) - Race: % White, 12/31/2022  
F: Prevalent Patients (Pediatric) - Race: % Other/Unknown/Missing race, 12/31/2019  
F: Prevalent Patients (Pediatric) - Race: % Other/Unknown/Missing race, 12/31/2020  
F: Prevalent Patients (Pediatric) - Race: % Other/Unknown/Missing race, 12/31/2021  
F: Prevalent Patients (Pediatric) - Race: % Other/Unknown/Missing race, 12/31/2022  
N: Prevalent Patients (Pediatric) - Race: % Other/Unk/Missing race, 12/31/2022  
S: Prevalent Patients (Pediatric) - Race: % Other/Unk/Missing race, 12/31/2022  
US: Prevalent Patients (Pediatric) - Race: % Other/Unk/Missing race, 12/31/2022  
F: Hospitalization (Pediatric) - Number of Patients, 2019  
F: Hospitalization (Pediatric) - Number of Patients, 2020  
F: Hospitalization (Pediatric) - Number of Patients, 2021  
F: Hospitalization (Pediatric) - Number of Patients, 2022  
F: All Patient Mortality (Pediatric) - Number of patients, 2019  
F: All Patient Mortality (Pediatric) - Number of patients, 2020  
F: All Patient Mortality (Pediatric) - Number of patients, 2021  
F: All Patient Mortality (Pediatric) - Number of patients, 2022  
F: STR (Pediatric)- Number of patients, 1st transplant, 2019  
F: STR (Pediatric)- Number of patients, 1st transplant, 2020  
F: STR (Pediatric)- Number of patients, 1st transplant, 2021  
F: STR (Pediatric)- Number of patients, 1st transplant, 2022  
F: Prevalent Patients (Pediatric) - Sex: % Female, 12/31/2019  
F: Prevalent Patients (Pediatric) - Sex: % Female, 12/31/2020  
F: Prevalent Patients (Pediatric) - Sex: % Female, 12/31/2021  
F: Prevalent Patients (Pediatric) - Sex: % Female, 12/31/2022  
N: Prevalent Patients (Pediatric) - Sex: % Female, 12/31/2022  
S: Prevalent Patients (Pediatric) - Sex: % Female, 12/31/2022  
US: Prevalent Patients (Pediatric) - Sex: % Female, 12/31/2022

F: STR (Pediatric)- Number of 1st transplants, 2019  
F: STR (Pediatric)- Number of 1st transplants, 2020  
F: STR (Pediatric)- Number of 1st transplants, 2021  
F: STR (Pediatric)- Number of 1st transplants, 2022  
F: STR (Pediatric)- Years at risk of eligible 1st transplant patients, 2019  
F: STR (Pediatric)- Years at risk of eligible 1st transplant patients, 2020  
F: STR (Pediatric)- Years at risk of eligible 1st transplant patients, 2021  
F: STR (Pediatric)- Years at risk of eligible 1st transplant patients, 2022  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy less than 1 year, 12/31/2019  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy less than 1 year, 12/31/2020  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy less than 1 year, 12/31/2021  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy less than 1 year, 12/31/2022  
N: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy less than 1 year, 12/31/2022  
S: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy less than 1 year, 12/31/2022  
US: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy less than 1 year, 12/31/2022  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2019  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2020  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2021  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2022  
N: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2022  
S: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2022  
US: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2022  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2019  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2020  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2021  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2022  
N: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2022  
S: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2022  
US: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2022  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2019  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2020  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2021  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2022  
N: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2022  
S: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2022  
US: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2022  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for over 6 years, 12/31/2019  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for over 6 years, 12/31/2020  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for over 6 years, 12/31/2021  
F: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for over 6 years, 12/31/2022  
N: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for over 6 years, 12/31/2022  
S: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for over 6 years, 12/31/2022  
US: Prevalent Patients (Pediatric) - Vintage: % on ESRD Therapy for over 6 years, 12/31/2022  
F: (Pediatric) Prevalent Waitlist - % of patient-months aged 10-17 on waitlist, 2019

F: (Pediatric) Prevalent Waitlist - % of patient-months aged 10-17 on waitlist, 2020  
F: (Pediatric) Prevalent Waitlist - % of patient-months aged 10-17 on waitlist, 2021  
F: (Pediatric) Prevalent Waitlist - % of dialysis patient-months 10-17 on waitlist, 2022  
N: Prevalent Waitlist (Pediatric) - % of patient-months aged 10-17 on waitlist, 2022  
S: Prevalent Waitlist (Pediatric) - % of patient-months aged 10-17 on waitlist, 2022  
US: Prevalent Waitlist (Pediatric) - % of patient-months aged 10-17 on waitlist, 2022  
F: (Pediatric) Prevalent Waitlist - % of patient-months <10 years on waitlist, 2019  
F: (Pediatric) Prevalent Waitlist - % of patient-months <10 years on waitlist, 2020  
F: (Pediatric) Prevalent Waitlist - % of patient-months <10 years on waitlist, 2021  
F: (Pediatric) Prevalent Waitlist - % of patient-months <10 years on waitlist, 2022  
N: Prevalent Waitlist (Pediatric) - % of patient-months <10 years on waitlist, 2022  
S: Prevalent Waitlist (Pediatric) - % of patient-months <10 years on waitlist, 2022  
US: Prevalent Waitlist (Pediatric) - % of patient-months <10 years on waitlist, 2022  
F: (Pediatric) Prevalent Waitlist - % of patient-months (<18 only) on waitlist, 2019  
F: (Pediatric) Prevalent Waitlist - % of patient-months (<18 only) on waitlist, 2020  
F: (Pediatric) Prevalent Waitlist - % of patient-months (<18 only) on waitlist, 2021  
F: (Pediatric) Prevalent Waitlist - % of patient-months (<18 only) on waitlist, 2022  
N: Prevalent Waitlist (Pediatric) - % of patient-months (<18 only) on waitlist, 2022  
S: Prevalent Waitlist (Pediatric) - % of patient-months (<18 only) on waitlist, 2022  
US: Prevalent Waitlist (Pediatric) - % of patient-months (<18 only) on waitlist, 2022  
F: End of Year Status - % of patients alive in this facility, 2019  
F: End of Year Status - % of patients alive in this facility, 2020  
F: End of Year Status - % of patients alive in this facility, 2021  
F: End of Year Status - % of patients alive in this facility, 2022  
N: End of Year Status - % of patients alive in this facility, 2022  
S: End of Year Status - % of patients alive in this facility, 2022  
US: End of Year Status - % of patients alive in this facility, 2022  
F: Prevalent Patients - End of Year Status: Number of patients alive in this facility, 2019  
F: Prevalent Patients - End of Year Status: Number of patients alive in this facility, 2020  
F: Prevalent Patients - End of Year Status: Number of patients alive in this facility, 2021  
F: Prevalent Patients - End of Year Status: Number of patients alive in this facility, 2022  
N: Prevalent Patients - End of Year Status: Average number of patients alive in facility, 2022  
S: Prevalent Patients - End of Year Status: Average number of patients alive in facility, 2022  
US: Prevalent Patients - End of Year Status: Average number of patients alive in facility, 2022  
F: End of Year Status - % of patients alive in another facility, 2019  
F: End of Year Status - % of patients alive in another facility, 2020  
F: End of Year Status - % of patients alive in another facility, 2021  
F: End of Year Status - % of patients alive in another facility, 2022  
N: End of Year Status - % of patients alive in another facility, 2022  
S: End of Year Status - % of patients alive in another facility, 2022  
US: End of Year Status - % of patients alive in another facility, 2022  
F: SHR (Days) - P-value, 2019  
F: SHR (Days) - P-value, 2020  
F: SHR (Days) - P-value, 2021

F: SHR (Days) - P-value, 2022  
F: SHR (Days)- P-value, 2019-2022  
F: SEDR - P-value, 2019  
F: SEDR - P-value, 2020  
F: SEDR - P-value, 2021  
F: SEDR - P-value, 2022  
F: SEDR - P-value, 2019-2022  
F: SHR (Admissions) - P-value, 2019  
F: SHR (Admissions) - P-value, 2020  
F: SHR (Admissions) - P-value, 2021  
F: SHR (Admissions) - P-value, 2022  
F: SHR (Admissions)- P-value, 2019-2022  
F: VA infection - PD Catheter infection rate per 100 PD patient-months, 2019  
U: VA infection - PD catheter infection rate per 100 PD patient-months, 2019  
F: VA infection - PD Catheter infection rate per 100 PD patient-months, 2020  
U: VA infection - PD catheter infection rate per 100 PD patient-months, 2020  
F: VA infection - PD Catheter infection rate per 100 PD patient-months, 2021  
U: VA infection - PD catheter infection rate per 100 PD patient-months, 2021  
F: VA infection - PD Catheter infection rate per 100 PD patient-months, 2022  
N: VA infection - PD catheter infection rate per 100 PD patient-months, 2022  
S: VA infection - PD catheter infection rate per 100 PD patient-months, 2022  
U: VA infection - PD catheter infection rate per 100 PD patient-months, 2022  
F: End of Year Status - % of patient deaths attributed to this facility, 2019  
F: End of Year Status - % of patient deaths attributed to this facility, 2020  
F: End of Year Status - % of patient deaths attributed to this facility, 2021  
F: End of Year Status - % of patient deaths attributed to this facility, 2022  
N: End of Year Status - % of patients death attributed to this facility, 2022  
S: End of Year Status - % of patients death attributed to this facility, 2022  
US: End of Year Status - % of patients death attributed to this facility, 2022  
F (2728): Incident Patients - Primary Modality: Hemodialysis, 2019  
F (2728): Incident Patients - Primary Modality: Hemodialysis, 2020  
F (2728): Incident Patients - Primary Modality: Hemodialysis, 2021  
F (2728): Incident Patients - Primary Modality: Hemodialysis, 2022  
N (2728): Incident Patients - Primary Modality: Hemodialysis, 2022  
S (2728): Incident Patients - Primary Modality: Hemodialysis, 2022  
US (2728): Incident Patients - Primary Modality: Hemodialysis, 2022  
F (2728): Incident Patients -Primary Modality: Other/Unknown/Missing, 2019  
F (2728): Incident Patients -Primary Modality: Other/Unknown/Missing, 2020  
F (2728): Incident Patients -Primary Modality: Other/Unknown/Missing, 2021  
F (2728): Incident Patients -Primary Modality: Other/Unknown/Missing, 2022  
N (2728): Incident Patients -Primary Modality: Other/Unknown/Missing, 2022  
S (2728): Incident Patients -Primary Modality: Other/Unknown/Missing, 2022  
US (2728): Incident Patients -Primary Modality: Other/Unknown/Missing, 2022  
F (2728): Incident Patients - Primary Modality: Peritoneal Dialysis, 2019

F (2728): Incident Patients - Primary Modality: Peritoneal Dialysis, 2020  
F (2728): Incident Patients - Primary Modality: Peritoneal Dialysis, 2021  
F (2728): Incident Patients - Primary Modality: Peritoneal Dialysis, 2022  
N (2728): Incident Patients - Primary Modality: Peritoneal Dialysis, 2022  
S (2728): Incident Patients - Primary Modality: Peritoneal Dialysis, 2022  
US (2728): Incident Patients - Primary Modality: Peritoneal Dialysis, 2022  
F: End of Year Status - % of patient deaths attributed to another facility, 2019  
F: End of Year Status - % of patient deaths attributed to another facility, 2020  
F: End of Year Status - % of patient deaths attributed to another facility, 2021  
F: End of Year Status - % of patient deaths attributed to another facility, 2022  
N: End of Year Status - % of patients death attributed to another facility, 2022  
S: End of Year Status - % of patients death attributed to another facility, 2022  
US: End of Year Status - % of patients death attributed to another facility, 2022  
F: VA infection - Total number of eligible PD patients, 2019  
F: VA infection - Total number of eligible PD patients, 2020  
F: VA infection - Total number of eligible PD patients, 2021  
F: VA infection - Total number of eligible PD patients, 2022  
N: VA infection - Average number of eligible PD patients, 2022  
S: VA infection - Average number of eligible PD patients, 2022  
U: VA infection - Average number of eligible PD patients, 2022  
F: VA infection - Total number of eligible PD patient-months, 2019  
F: VA infection - Total number of eligible PD patient-months, 2020  
F: VA infection - Total number of eligible PD patient-months, 2021  
F: VA infection - Total number of eligible PD patient-months, 2022  
N: VA infection - Average number of eligible PD patient-months, 2022  
S: VA infection - Average number of eligible PD patient-months, 2022  
U: VA infection - Average number of eligible PD patient-months, 2022  
F (2728): Incident Patients - Percent previously employed FT/PT/student, 2019  
F (2728): Incident Patients - Percent previously employed FT/PT/student, 2020  
F (2728): Incident Patients - Percent previously employed FT/PT/student, 2021  
F (2728): Incident Patients - Percent previously employed FT/PT/student, 2022  
N (2728): Incident Patients - Percent previously employed FT/PT/student, 2022  
S (2728): Incident Patients - Percent previously employed FT/PT/student, 2022  
US (2728): Incident Patients - Percent previously employed FT/PT/student, 2022  
F: Influenza - p-value for % vaccinated different than US, 8/1-3/31, 2019  
F: Influenza - p-value for % vaccinated different than US, 8/1-3/31, 2020  
F: Influenza - p-value for % vaccinated different than US, 8/1-3/31, 2021  
F: Influenza - p-value for % vaccinated different than US, 8/1-12/31, 2019  
F: Influenza - p-value for % vaccinated different than US, 8/1-12/31, 2020  
F: Influenza - p-value for % vaccinated different than US, 8/1-12/31, 2021  
F: Influenza - p-value for % vaccinated different than US, 8/1-12/31, 2022  
F: Prevalent VA Type (Adult) - Total number of HD patients, 2019  
F: Prevalent VA Type (Adult) - Total number of HD patients, 2020  
F: Prevalent VA Type (Adult) - Total number of HD patients, 2021



F: Prevalent VA Type (Adult) - Total number of HD patients, 2022  
N: Prevalent VA Type (Adult) - Average number of HD patients, 2022  
S: Prevalent VA Type (Adult) - Average number of HD patients, 2022  
U: Prevalent VA Type (Adult) - Average number of HD patients, 2022  
F: Prevalent VA Type (Adult) - Total number of HD patient-months, 2019  
F: Prevalent VA Type (Adult) - Total number of HD patient-months, 2020  
F: Prevalent VA Type (Adult) - Total number of HD patient-months, 2021  
F: Prevalent VA Type (Adult) - Total number of HD patient-months, 2022  
N: Prevalent VA Type (Adult) - Average number of HD patient-months, 2022  
S: Prevalent VA Type (Adult) - Average number of HD patient-months, 2022  
U: Prevalent VA Type (Adult) - Average number of HD patient-months, 2022  
F: Incident VA Type (Adult) - % of patients receiving treatment with fistulae, 2019  
F: Incident VA Type (Adult) - % of patients receiving treatment with fistulae, 2020  
F: Incident VA Type (Adult) - % of patients receiving treatment with fistulae, 2021  
F: Incident VA Type (Adult) - % of patients receiving treatment with fistulae, 2022  
N: Incident VA Type (Adult) - % of patients receiving treatment with fistulae, 2022  
S: Incident VA Type (Adult) - % of patients receiving treatment with fistulae, 2022  
U: Incident VA Type (Adult) - % of patients receiving treatment with fistulae, 2022  
F: Incident VA Type (Adult) - % of patients receiving treatment with grafts, 2019  
F: Incident VA Type (Adult) - % of patients receiving treatment with grafts, 2020  
F: Incident VA Type (Adult) - % of patients receiving treatment with grafts, 2021  
F: Incident VA Type (Adult) - % of patients receiving treatment with grafts, 2022  
N: Incident VA Type (Adult) - % of patients receiving treatment with grafts, 2022  
S: Incident VA Type (Adult) - % of patients receiving treatment with grafts, 2022  
U: Incident VA Type (Adult) - % of patients receiving treatment with grafts, 2022  
F: Incident VA Type (Adult) - % of patients receiving treatment with catheters, 2019  
F: Incident VA Type (Adult) - % of patients receiving treatment with catheters, 2020  
F: Incident VA Type (Adult) - % of patients receiving treatment with catheters, 2021  
F: Incident VA Type (Adult) - % of patients receiving treatment with catheters, 2022  
N: Incident VA Type (Adult) - % of patients receiving treatment with catheters, 2022  
S: Incident VA Type (Adult) - % of patients receiving treatment with catheters, 2022  
U: Incident VA Type (Adult) - % of patients receiving treatment with catheters, 2022  
F: Incident VA Type (Adult) - % of patients with fistulae placed, 2019  
F: Incident VA Type (Adult) - % of patients with fistulae placed, 2020  
F: Incident VA Type (Adult) - % of patients with fistulae placed, 2021  
F: Incident VA Type (Adult) - % of patients with fistulae placed, 2022  
N: Incident VA Type (Adult) - % of patients with fistulae placed, 2022  
S: Incident VA Type (Adult) - % of patients with fistulae placed, 2022  
U: Incident VA Type (Adult) - % of patients with fistulae placed, 2022  
F: Incident VA Type (Adult) - % of patients receiving treatment with other or unknown access type, 2019  
F: Incident VA Type (Adult) - % of patients receiving treatment with other or unknown access type, 2020  
F: Incident VA Type (Adult) - % of patients receiving treatment with other or unknown access type, 2021  
F: Incident VA Type (Adult) - % of patients receiving treatment with other or unknown access type, 2022  
N: Incident VA Type (Adult) - % of patients receiving treatment with other or unknown access type., 2022

S: Incident VA Type (Adult) - % of patients receiving treatment with other or unknown access type., 2022  
U: Incident VA Type (Adult) - % of patients receiving treatment with other or unknown access type., 2022  
F: All Patient Mortality - P-value, 2019  
F: All Patient Mortality - P-value, 2020  
F: All Patient Mortality - P-value, 2021  
F: All Patient Mortality - P-value, 2022  
F: All Patient Mortality - P-value, 2019-2022  
F: End of Year Status - % of patients, other, 2019  
F: End of Year Status - % of patients, other, 2020  
F: End of Year Status - % of patients, other, 2021  
F: End of Year Status - % of patients, other, 2022  
N: End of Year Status - % of patients other, 2022  
S: End of Year Status - % of patients other, 2022  
US: End of Year Status - % of patients other, 2022  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with fistulae, 2019  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with fistulae, 2020  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with fistulae, 2021  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with fistulae, 2022  
N: Prevalent VA Type (Adult) - % of patients receiving treatment with fistulae, 2022  
S: Prevalent VA Type (Adult) - % of patients receiving treatment with fistulae, 2022  
U: Prevalent VA Type (Adult) - % of patients receiving treatment with fistulae, 2022  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with grafts, 2019  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with grafts, 2020  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with grafts, 2021  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with grafts, 2022  
N: Prevalent VA Type (Adult) - % of patients receiving treatment with grafts, 2022  
S: Prevalent VA Type (Adult) - % of patients receiving treatment with grafts, 2022  
U: Prevalent VA Type (Adult) - % of patients receiving treatment with grafts, 2022  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with catheters, 2019  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with catheters, 2020  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with catheters, 2021  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with catheters, 2022  
N: Prevalent VA Type (Adult) - % of patients receiving treatment with catheters, 2022  
S: Prevalent VA Type (Adult) - % of patients receiving treatment with catheters, 2022  
U: Prevalent VA Type (Adult) - % of patients receiving treatment with catheters, 2022  
F: Patient Placement - % of patients continuing at facility, 2019  
F: Patient Placement - % of patients continuing at facility, 2020  
F: Patient Placement - % of patients continuing at facility, 2021  
F: Patient Placement - % of patients continuing at facility, 2022  
N: Patient Placement - % of patients continuing at facility, 2022  
S: Patient Placement - % of patients continuing at facility, 2022  
US: Patient Placement - % of patients continuing at facility, 2022  
F: Patient Placement - % of incident patients, 2019  
F: Patient Placement - % of incident patients, 2020

F: Patient Placement - % of incident patients, 2021  
F: Patient Placement - % of incident patients, 2022  
N: Patient Placement - % of incident patients, 2022  
S: Patient Placement - % of incident patients, 2022  
US: Patient Placement - % of incident patients, 2022  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with other or unknown access type, 2019  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with other or unknown access type, 2020  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with other or unknown access type, 2021  
F: Prevalent VA Type (Adult) - % of patients receiving treatment with other or unknown access type, 2022  
N: Prevalent VA Type (Adult) - % of patients receiving treatment with other or unknown access type., 2022  
S: Prevalent VA Type (Adult) - % of patients receiving treatment with other or unknown access type., 2022  
U: Prevalent VA Type (Adult) - % of patients receiving treatment with other or unknown access type., 2022  
F: Prevalent Waitlist - 97.5% upper confidence limit for age-adjusted waitlist percentage, 2019  
F: Prevalent Waitlist - 97.5% upper confidence limit for age-adjusted waitlist percentage, 2020  
F: Prevalent Waitlist - 97.5% upper confidence limit for age-adjusted waitlist percentage, 2021  
F: Prevalent Waitlist - 97.5% upper confidence limit for age-adjusted waitlist percentage, 2022  
F: Prevalent Waitlist - 2.5% lower confidence limit for age-adjusted waitlist percentage, 2019  
F: Prevalent Waitlist - 2.5% lower confidence limit for age-adjusted waitlist percentage, 2020  
F: Prevalent Waitlist - 2.5% lower confidence limit for age-adjusted waitlist percentage, 2021  
F: Prevalent Waitlist - 2.5% lower confidence limit for age-adjusted waitlist percentage, 2022  
F: Prevalent Waitlist - Total number of patient-months (age<75) at risk, 2019  
F: Prevalent Waitlist - Total number of patient-months (age<75) at risk, 2020  
F: Prevalent Waitlist - Total number of patient-months (age<75) at risk, 2021  
F: Prevalent Waitlist - Total number of patient-months (age<75) at risk, 2022  
N: Prevalent Waitlist - Average number of patient-months (age<75) at risk, 2022  
S: Prevalent Waitlist - Average number of patient-months (age<75) at risk, 2022  
US: Prevalent Waitlist - Average number of patient-months (age<75) at risk, 2022  
F: Prevalent Waitlist - Total number of eligible dialysis patients (age<75), 2019  
F: Prevalent Waitlist - Total number of eligible dialysis patients (age<75), 2020  
F: Prevalent Waitlist - Total number of eligible dialysis patients (age<75), 2021  
F: Prevalent Waitlist - Total number of eligible dialysis patients (age<75), 2022  
N: Prevalent Waitlist - Average number of eligible dialysis patients (age<75), 2022  
S: Prevalent Waitlist - Average number of eligible dialysis patients (age<75), 2022  
US: Prevalent Waitlist - Average number of eligible dialysis patients (age<75), 2022  
F: Prevalent Waitlist - p-value for age-adjusted percentage of patient-months waitlisted, 2019  
F: Prevalent Waitlist - p-value for age-adjusted percentage of patient-months waitlisted, 2020  
F: Prevalent Waitlist - p-value for age-adjusted percentage of patient-months waitlisted, 2021  
F: Prevalent Waitlist - p-value for age-adjusted percentage of patient-months waitlisted, 2022  
F: Prevalent Waitlist - Age-adjusted percentage of patient-months waitlisted (age<75), 2019  
F: Prevalent Waitlist - Age-adjusted percentage of patient-months waitlisted (age<75), 2020  
F: Prevalent Waitlist - Age-adjusted percentage of patient-months waitlisted (age<75), 2021  
F: Prevalent Waitlist - Age-adjusted percentage of patient-months waitlisted (age<75), 2022  
N: Prevalent Waitlist - Age-adjusted percentage of patient-months waitlisted (age<75), 2022  
S: Prevalent Waitlist - Age-adjusted percentage of patient-months waitlisted (age<75), 2022

US: Prevalent Waitlist - Age-adjusted percentage of patient-months waitlisted (age<75), 2022  
F: Patient Placement - % of patients transfered into facility, 2019  
F: Patient Placement - % of patients transfered into facility, 2020  
F: Patient Placement - % of patients transfered into facility, 2021  
F: Patient Placement - % of patients transfered into facility, 2022  
N: Patient Placement - % of patients that transfered into facility, 2022  
S: Patient Placement - % of patients that transfered into facility, 2022  
US: Patient Placement - % of patients that transfered into facility, 2022  
F (2728): Incident Patients - Percent of patients. Received ESA prior to ESRD, 2019  
F (2728): Incident Patients - Percent of patients. Received ESA prior to ESRD, 2020  
F (2728): Incident Patients - Percent of patients. Received ESA prior to ESRD, 2021  
F (2728): Incident Patients - Percent of patients. Received ESA prior to ESRD, 2022  
N (2728): Incident Patients - Percent of Patients Received ESA prior to ESRD, 2022  
S (2728): Incident Patients - Percent of Patients Received ESA prior to ESRD, 2022  
US (2728): Incident Patients - Percent of Patients Received ESA prior to ESRD, 2022  
CMS Certification Number (CCN) included in this report  
CMS Certification Number (CCN) included in this report  
CMS Certification Number (CCN) included in this report  
CWFacDir: Facility Physical City  
CMS Certification Number (CCN)  
F (AFS): Facility Information - Number of full time patient care technicians on 12/31/2019  
F (AFS): Facility Information - Number of full time patient care technicians on 12/31/2020  
F (AFS): Facility Information - Number of full time patient care technicians on 12/31/2021  
F (AFS): Facility Information - Number of full time patient care technicians on 12/31/2022  
N (AFS): Facility Information - Average number of full time patient care technicians on 12/31/2022  
S (AFS): Facility Information - Average number of full time patient care technicians on 12/31/2022  
US (AFS): Facility Information - Average number of full time patient care technicians on 12/31/2022  
F (AFS): Facility Information - Number of part time patient care technicians on 12/31/2019  
F (AFS): Facility Information - Number of part time patient care technicians on 12/31/2020  
F (AFS): Facility Information - Number of part time patient care technicians on 12/31/2021  
F (AFS): Facility Information - Number of part time patient care technicians on 12/31/2022  
N (AFS): Facility Information - Average number of part time patient care technicians on 12/31/2022  
S (AFS): Facility Information - Average number of part time patient care technicians on 12/31/2022  
US (AFS): Facility Information - Average number of part time patient care technicians on 12/31/2022  
F: STrR (Adult) - P-value, 2019  
F: STrR (Adult) - P-value, 2020  
F: STrR (Adult) - P-value, 2021  
F: STrR (Adult) - P-value, 2022  
F (2728): Incident Patients - Patients Not Informed of Transplant Options, 2019  
F (2728): Incident Patients - Patients Not Informed of Transplant Options, 2020  
F (2728): Incident Patients - Patients Not Informed of Transplant Options, 2021  
F (2728): Incident Patients - Patients Not Informed of Transplant Options, 2022  
N (2728): Incident Patients - Average Patients Not Informed of Transplant Options, 2022  
S (2728): Incident Patients - Average Patients Not Informed of Transplant Options, 2022

US (2728): Incident Patients - Average Patients Not Informed of Transplant Options, 2022  
F (2728): Incident Patients - Percent of Patients Informed of Transplant Options, 2019  
F (2728): Incident Patients - Percent of Patients Informed of Transplant Options, 2020  
F (2728): Incident Patients - Percent of Patients Informed of Transplant Options, 2021  
F (2728): Incident Patients - Percent of Patients Informed of Transplant Options, 2022  
N (2728): Incident Patients - Percent of Patients Informed of Transplant Options, 2022  
S (2728): Incident Patients - Percent of Patients Informed of Transplant Options, 2022  
US (2728): Incident Patients - Percent of Patients Informed of Transplant Options, 2022  
F (2728): Incident Patients - Reason Not Informed: Unsuitable Due to Age, 2019  
F (2728): Incident Patients - Reason Not Informed: Unsuitable Due to Age, 2020  
F (2728): Incident Patients - Reason Not Informed: Unsuitable Due to Age, 2021  
F (2728): Incident Patients - Reason Not Informed: Unsuitable Due to Age, 2022  
N (2728): Incident Patients - Reason Not Informed: Unsuitable Due to Age, 2022  
S (2728): Incident Patients - Reason Not Informed: Unsuitable Due to Age, 2022  
US (2728): Incident Patients - Reason Not Informed: Unsuitable Due to Age, 2022  
F (2728): Incident Patients - Reason Not Informed: Patient Declined Information, 2019  
F (2728): Incident Patients - Reason Not Informed: Patient Declined Information, 2020  
F (2728): Incident Patients - Reason Not Informed: Patient Declined Information, 2021  
F (2728): Incident Patients - Reason Not Informed: Patient Declined Information, 2022  
N (2728): Incident Patients - Reason Not Informed: Patient Declined Information, 2022  
S (2728): Incident Patients - Reason Not Informed: Patient Declined Information, 2022  
US (2728): Incident Patients - Reason Not Informed: Patient Declined Information, 2022  
F: End of Year Status - % of patients that received a transplant, 2019  
F: End of Year Status - % of patients that received a transplant, 2020  
F: End of Year Status - % of patients that received a transplant, 2021  
F: End of Year Status - % of patients that received a transplant, 2022  
N: End of Year Status - % of patients that received a transplant, 2022  
S: End of Year Status - % of patients that received a transplant, 2022  
US: End of Year Status - % of patients that received a transplant, 2022  
F (2728): Incident Patients - Reason Not Informed: Patient Medically Unfit, 2019  
F (2728): Incident Patients - Reason Not Informed: Patient Medically Unfit, 2020  
F (2728): Incident Patients - Reason Not Informed: Patient Medically Unfit, 2021  
F (2728): Incident Patients - Reason Not Informed: Patient Medically Unfit, 2022  
N (2728): Incident Patients - Reason Not Informed: Patient Medically Unfit, 2022  
S (2728): Incident Patients - Reason Not Informed: Patient Medically Unfit, 2022  
US (2728): Incident Patients - Reason Not Informed: Patient Medically Unfit, 2022  
F (2728): Incident Patients - Reason Not Informed: Patient Has Not Been Assessed, 2019  
F (2728): Incident Patients - Reason Not Informed: Patient Has Not Been Assessed, 2020  
F (2728): Incident Patients - Reason Not Informed: Patient Has Not Been Assessed, 2021  
F (2728): Incident Patients - Reason Not Informed: Patient Has Not Been Assessed, 2022  
N (2728): Incident Patients - Reason Not Informed: Patient Has Not Been Assessed, 2022  
S (2728): Incident Patients - Reason Not Informed: Patient Has Not Been Assessed, 2022  
US (2728): Incident Patients - Reason Not Informed: Patient Has Not Been Assessed, 2022  
F (2728): Incident Patients - Reason Not Informed: Patient Psychologically Unfit, 2019

F (2728): Incident Patients - Reason Not Informed: Patient Psychologically Unfit, 2020  
F (2728): Incident Patients - Reason Not Informed: Patient Psychologically Unfit, 2021  
F (2728): Incident Patients - Reason Not Informed: Patient Psychologically Unfit, 2022  
N (2728): Incident Patients - Reason Not Informed: Patient Psychologically Unfit, 2022  
S (2728): Incident Patients - Reason Not Informed: Patient Psychologically Unfit, 2022  
US (2728): Incident Patients - Reason Not Informed: Patient Psychologically Unfit, 2022  
F: STR - P-value, 2019-2022  
F: VA infection - P-value of 11m (compared to U.S. value), 2019  
F: VA infection - P-value of 11m (compared to U.S. value), 2020  
F: VA infection - P-value of 11m (compared to U.S. value), 2021  
F: VA infection - P-value of 11m (compared to U.S. value), 2022 run  
F (2728): Incident Patients - Percent with PVD, 2019  
F (2728): Incident Patients - Percent with PVD, 2020  
F (2728): Incident Patients - Percent with PVD, 2021  
F (2728): Incident Patients - Percent with PVD, 2022  
N (2728): Incident Patients - Percent with PVD, 2022  
S (2728): Incident Patients - Percent with PVD, 2022  
US (2728): Incident Patients - Percent with PVD, 2022  
F: Prevalent Patients - Race: % Asian/Pacific Islander, 12/31/2019  
F: Prevalent Patients - Race: % Asian/Pacific Islander, 12/31/2020  
F: Prevalent Patients - Race: % Asian/Pacific Islander, 12/31/2021  
F: Prevalent Patients - Race: % Asian/Pacific Islander, 12/31/2022  
N: Prevalent Patients - Race: % Asian/Pacific Islander, 12/31/2022  
S: Prevalent Patients - Race: % Asian/Pacific Islander, 12/31/2022  
US: Prevalent Patients - Race: % Asian/Pacific Islander, 12/31/2022  
F: Prevalent Patients - Race: % African American, 12/31/2019  
F: Prevalent Patients - Race: % African American, 12/31/2020  
F: Prevalent Patients - Race: % African American, 12/31/2021  
F: Prevalent Patients - Race: % African American, 12/31/2022  
N: Prevalent Patients - Race: % African American, 12/31/2022  
S: Prevalent Patients - Race: % African American, 12/31/2022  
US: Prevalent Patients - Race: % African American, 12/31/2022  
F: Prevalent Patients - Race: % Native American, 12/31/2019  
F: Prevalent Patients - Race: % Native American, 12/31/2020  
F: Prevalent Patients - Race: % Native American, 12/31/2021  
F: Prevalent Patients - Race: % Native American, 12/31/2022  
N: Prevalent Patients - Race: % Native American, 12/31/2022  
S: Prevalent Patients - Race: % Native American, 12/31/2022  
US: Prevalent Patients - Race: % Native American, 12/31/2022  
F: Prevalent Patients - Race: % White, 12/31/2019  
F: Prevalent Patients - Race: % White, 12/31/2020  
F: Prevalent Patients - Race: % White, 12/31/2021  
F: Prevalent Patients - Race: % White, 12/31/2022  
N: Prevalent Patients - Race: % White, 12/31/2022

S: Prevalent Patients - Race: % White, 12/31/2022  
US: Prevalent Patients - Race: % White, 12/31/2022  
F: Prevalent Patients - Race: % Other/Unknown/Missing race, 12/31/2019  
F: Prevalent Patients - Race: % Other/Unknown/Missing race, 12/31/2020  
F: Prevalent Patients - Race: % Other/Unknown/Missing race, 12/31/2021  
F: Prevalent Patients - Race: % Other/Unknown/Missing race, 12/31/2022  
N: Prevalent Patients - Race: % Other/Unknown/Missing Race, 12/31/2022  
S: Prevalent Patients - Race: % Other/Unknown/Missing Race, 12/31/2022  
US: Prevalent Patients - Race: % Other/Unknown/Missing Race, 12/31/2022  
F (2728): Incident Patients - Percent other/unknown/missing race, 2019  
F (2728): Incident Patients - Percent other/unknown/missing race, 2020  
F (2728): Incident Patients - Percent other/unknown/missing race, 2021  
F (2728): Incident Patients - Percent other/unknown/missing race, 2022  
N (2728): Incident Patients - Percent other/unknown/missing race, 2022  
S (2728): Incident Patients - Percent other/unknown/missing race, 2022  
US (2728): Incident Patients - Percent other/unknown/missing race, 2022  
F: STR - Number of eligible patients, all transplants, 2019  
F: STR - Number of eligible patients, all transplants, 2020  
F: STR - Number of eligible patients, all transplants, 2021  
F: STR - Number of eligible patients, all transplants, 2022  
F: STR - Number of eligible patients, all transplants, 2019-2022  
N: STR - Average number of patients (per year in average facility), 2019-2022  
S: STR - Average number of patients (per year in average facility), 2019-2022  
US: STR - Average number of patients (per year in average facility), 2019-2022  
F: SEDR - Number of Patients, 2019  
F: SEDR - Number of Patients, 2020  
F: SEDR - Number of Patients, 2021  
F: SEDR - Number of Patients, 2022  
F: SEDR - Number of Patients, 2019-2022  
Pt included in SEDR analysis  
Pt included in SEDR analysis  
Pt included in SEDR analysis  
F: Hospitalization - Number of Patients, 2019  
F: Hospitalization - Number of Patients, 2020  
F: Hospitalization - Number of Patients, 2021  
F: Hospitalization - Number of Patients, 2022  
F: Hospitalization - Number of Medicare Dialysis Patients, 2019-2022  
N: Hospitalization - Average Number of Patients (per year in average facility), 2019-2022  
S: Hospitalization - Average Number of Patients (per year in average facility), 2019-2022  
US: Hospitalization - Average Number of Patients (per year in average facility), 2019-2022  
F: All Patient Mortality - Number of patients, 2019  
F: All Patient Mortality - Number of patients, 2020  
F: All Patient Mortality - Number of patients, 2021  
F: All Patient Mortality - Number of patients, 2022

F: All Patient Mortality - Number of patients, 2019-2022  
N: All Patient Mortality - Average number of patients (per year in average facility), 2019-2022  
S: All Patient Mortality - Average number of patients (per year in average facility), 2019-2022  
US: All Patient Mortality - Average number of patients (per year in average facility), 2019-2022  
F: STrR (Adult) - Number of Medicare Patients, 2019  
F: STrR (Adult) - Number of Medicare Patients, 2020  
F: STrR (Adult) - Number of Medicare Patients, 2021  
F: STrR (Adult) - Number of Medicare Patients, 2022  
N: STrR (Adult) - Average Number of Medicare Patients, 2022  
S: STrR (Adult) - Average Number of Medicare Patients, 2022  
US: STrR (Adult) - Average Number of Medicare Patients, 2022  
F: STR - Number of eligible patients (age<75) with no previous transplant, 2019  
F: STR - Number of eligible patients (age<75) with no previous transplant, 2020  
F: STR - Number of eligible patients (age<75) with no previous transplant, 2021  
F: STR - Number of eligible patients (age<75) with no previous transplant, 2022  
F: STR - Number of eligible patients, 1st transplant, 2019-2022  
N: STR - Average number of eligible patients (age<75) with no previous transplant (per year in average facility), 2019-2022  
S: STR - Average number of eligible patients (age<75) with no previous transplant (per year in average facility), 2019-2022  
US: STR - Average number of eligible patients (age<75) with no previous transplant (per year in average facility), 2019-2022  
N: SRR - Average number of readmissions, 2022  
S: SRR - Average number of readmissions, 2022  
U: SRR - Average number of readmissions, 2022  
F: SRR - Total readmissions, 2019  
F: SRR - Total readmissions, 2020  
F: SRR - Total readmissions, 2021  
F: SRR - Total readmissions, 2022  
F:First-Year Mortality - Percentile rank in Network, 2019  
F:First-Year Mortality - Percentile rank in Network, 2020  
F:First-Year Mortality - Percentile rank in Network, 2021  
F:First-Year Mortality - Percentile rank in Network, 2019-21  
F:First-Year Mortality - Percentile rank in State, 2019  
F:First-Year Mortality - Percentile rank in State, 2020  
F:First-Year Mortality - Percentile rank in State, 2021  
F:First-Year Mortality - Percentile rank in State, 2019-21  
F:First-Year Mortality - Percentile rank in US, 2019  
F:First-Year Mortality - Percentile rank in US, 2020  
F:First-Year Mortality - Percentile rank in US, 2021  
F:First-Year Mortality - Percentile rank in US, 2019-21  
F: All Patient Mortality - Percentile rank in Network, 2019  
F: All Patient Mortality - Percentile rank in Network, 2020  
F: All Patient Mortality - Percentile rank in Network, 2021  
F: All Patient Mortality - Percentile rank in Network, 2022  
F: All Patient Mortality - Percentile rank in Network, 2019-22  
F: All Patient Mortality - Percentile rank in State, 2019



F: All Patient Mortality - Percentile rank in State, 2020  
F: All Patient Mortality - Percentile rank in State, 2021  
F: All Patient Mortality - Percentile rank in State, 2022  
F: All Patient Mortality - Percentile rank in State, 2019-22  
F: All Patient Mortality - Percentile rank in US, 2019  
F: All Patient Mortality - Percentile rank in US, 2020  
F: All Patient Mortality - Percentile rank in US, 2021  
F: All Patient Mortality - Percentile rank in US, 2022  
F: All Patient Mortality - Percentile rank in US, 2019-22  
F: SHR (Days)-Percentile rank in Network, 2019  
F: SHR (Days)-Percentile rank in Network, 2020  
F: SHR (Days)-Percentile rank in Network, 2021  
F: SHR (Days)-Percentile rank in Network, 2022  
F: SHR (Days)-Percentile rank in Network, 2019-22  
F: SHR (Days)-Percentile rank in State, 2019  
F: SHR (Days)-Percentile rank in State, 2020  
F: SHR (Days)-Percentile rank in State, 2021  
F: SHR (Days)-Percentile rank in State, 2022  
F: SHR (Days)-Percentile rank in State, 2019-22  
F: SHR (Days)-Percentile rank in US, 2019  
F: SHR (Days)-Percentile rank in US, 2020  
F: SHR (Days)-Percentile rank in US, 2021  
F: SHR (Days)-Percentile rank in US, 2022  
F: SHR (Days)-Percentile rank in US, 2019-22  
F: SHR (Admissions)-Percentile rank in Network, 2019  
F: SHR (Admissions)-Percentile rank in Network, 2020  
F: SHR (Admissions)-Percentile rank in Network, 2021  
F: SHR (Admissions)-Percentile rank in Network, 2022  
F: SHR (Admissions)-Percentile rank in Network, 2019-22  
F: SHR (Admissions)-Percentile rank in State, 2019  
F: SHR (Admissions)-Percentile rank in State, 2020  
F: SHR (Admissions)-Percentile rank in State, 2021  
F: SHR (Admissions)-Percentile rank in State, 2022  
F: SHR (Admissions)-Percentile rank in State, 2019-22  
F: SHR (Admissions)-Percentile rank in US, 2019  
F: SHR (Admissions)-Percentile rank in US, 2020  
F: SHR (Admissions)-Percentile rank in US, 2021  
F: SHR (Admissions)-Percentile rank in US, 2022  
F: SHR (Admissions)-Percentile rank in US, 2019-22  
F: STR-Percentile rank in Network, 2019-22  
F: STR-Percentile rank in State, 2019-22  
F: STR-Percentile rank in US, 2019-22  
F (2728): Incident Patients - Average serum albumin, 2019  
F (2728): Incident Patients - Average serum albumin, 2020

F (2728): Incident Patients - Average serum albumin, 2021  
F (2728): Incident Patients - Average serum albumin, 2022  
N (2728): Incident Patients - Average serum albumin, 2022  
S (2728): Incident Patients - Average serum albumin, 2022  
US (2728): Incident Patients - Average serum albumin, 2022  
F (AFS): Facility Information - % Patients 18-54 who are in school on 12/31/2019  
F (AFS): Facility Information - % Patients 18-54 who are in school on 12/31/2020  
F (AFS): Facility Information - % Patients 18-54 who are in school on 12/31/2021  
F (AFS): Facility Information - % Patients 18-54 who are in school on 12/31/2022  
N (AFS): Facility Information - % Patients 18-54 who are school on 12/31/2022  
S (AFS): Facility Information - % Patients 18-54 who are school on 12/31/2022  
US (AFS): Facility Information - % Patients 18-54 who are school on 12/31/2022  
F: SEDR - Standardized Emergency Department Encounter Ratio, 2019  
F: SEDR - Standardized Emergency Department Encounter Ratio, 2020  
F: SEDR - Standardized Emergency Department Encounter Ratio, 2021  
F: SEDR - Standardized Emergency Department Encounter Ratio, 2022  
F: SEDR - Standardized Emergency Department Encounter Ratio, 2019-2022  
N: SEDR - Standardized Emergency Department Encounter Ratio, 2019-2022  
S: SEDR - Standardized Emergency Department Encounter Ratio, 2019-2022  
US: SEDR - Standardized Emergency Department Encounter Ratio, 2019-2022  
F: Hospitalization - Diagnosis: % with Septicemia, 2019  
F: Hospitalization - Diagnosis: % with Septicemia, 2020  
F: Hospitalization - Diagnosis: % with Septicemia, 2021  
F: Hospitalization - Diagnosis: % with Septicemia, 2022  
F: Hospitalization - Diagnosis: % with Septicemia, 2019-2022  
N: Hospitalization - Diagnosis: Average % with Septicemia (per year in average facility), 2019-2022  
S: Hospitalization - Diagnosis: Average % with Septicemia (per year in average facility), 2019-2022  
US: Hospitalization - Diagnosis: Average % with Septicemia (per year in average facility), 2019-2022  
F: Phosphorus (Adult) - Total Number of Eligible Dialysis Patients, 2019  
F: Phosphorus (Adult) - Total Number of Eligible Dialysis Patients, 2020  
F: Phosphorus (Adult) - Total Number of Eligible Dialysis Patients, 2021  
F: Phosphorus (Adult) - Total Number of Eligible Dialysis Patients, 2022  
N: Phosphorus (Adult) - Average Number of Eligible Dialysis Patients, 2022  
S: Phosphorus (Adult) - Average Number of Eligible Dialysis Patients, 2022  
US: Phosphorus (Adult) - Average Number of Eligible Dialysis Patients, 2022  
F: Phosphorus (Adult) - Total Number of Eligible Dialysis Patient-months, 2019  
F: Phosphorus (Adult) - Total Number of Eligible Dialysis Patient-months, 2020  
F: Phosphorus (Adult) - Total Number of Eligible Dialysis Patient-months, 2021  
F: Phosphorus (Adult) - Total Number of Eligible Dialysis Patient-months, 2022  
N: Phosphorus (Adult) - Average Number of Eligible Dialysis Patient-months, 2022  
S: Phosphorus (Adult) - Average Number of Eligible Dialysis Patient-months, 2022  
US: Phosphorus (Adult) - Average Number of Eligible Dialysis Patient-months, 2022  
F: Prevalent Patients - Sex: % Female, 12/31/2019  
F: Prevalent Patients - Sex: % Female, 12/31/2020

F: Prevalent Patients - Sex: % Female, 12/31/2021  
F: Prevalent Patients - Sex: % Female, 12/31/2022  
N: Prevalent Patients - Sex: % Female, 12/31/2022  
S: Prevalent Patients - Sex: % Female, 12/31/2022  
US: Prevalent Patients - Sex: % Female, 12/31/2022  
F: Prevalent VA Type (Adult) - Lower bound of 95% CI for SFR, 2019  
F: Prevalent VA Type (Adult) - Lower bound of 95% CI for SFR, 2020  
F: Prevalent VA Type (Adult) - Lower bound of 95% CI for SFR, 2021  
F: Prevalent VA Type (Adult) - Lower bound of 95% CI for SFR, 2022  
F: Prevalent VA Type (Adult) - P-value testing SFR different than national average, 2019  
F: Prevalent VA Type (Adult) - P-value testing SFR different than national average, 2020  
F: Prevalent VA Type (Adult) - P-value testing SFR different than national average, 2021  
F: Prevalent VA Type (Adult) - P-value testing SFR different than national average, 2022  
F: Prevalent VA Type (Adult) - Upper bound of 95% CI for SFR, 2019  
F: Prevalent VA Type (Adult) - Upper bound of 95% CI for SFR, 2020  
F: Prevalent VA Type (Adult) - Upper bound of 95% CI for SFR, 2021  
F: Prevalent VA Type (Adult) - Upper bound of 95% CI for SFR, 2022  
F: Prevalent VA Type (Adult) - Standardized Fistula Rate (SFR), 2019  
F: Prevalent VA Type (Adult) - Standardized Fistula Rate (SFR), 2020  
F: Prevalent VA Type (Adult) - Standardized Fistula Rate (SFR), 2021  
F: Prevalent VA Type (Adult) - Standardized Fistula Rate (SFR), 2022  
N: Prevalent VA Type (Adult) - Standardized Fistula Rate (SFR), 2022  
S: Prevalent VA Type (Adult) - Standardized Fistula Rate (SFR), 2022  
U: Prevalent VA Type (Adult) - Standardized Fistula Rate (SFR), 2022  
F: SHR (Days) - Standardized Hospitalization Ratio for Days, 2019  
F: SHR (Days) - Standardized Hospitalization Ratio for Days, 2020  
F: SHR (Days) - Standardized Hospitalization Ratio for Days, 2021  
F: SHR (Days) - Standardized Hospitalization Ratio for Days, 2022  
F: SHR (Days)- Standardized Total Days Hospitalized Ratio, 2019-2022  
N: SHR (Days) - Average Standardized Hospitalization Ratio for Days (per year in average facility), 2019-2022  
S: SHR (Days) - Average Standardized Hospitalization Ratio for Days (per year in average facility), 2019-2022  
US: SHR (Days) - Average Standardized Hospitalization Ratio for Days (per year in average facility), 2019-2022  
F: SHR (Admissions) - Standardized Hospitalization Ratio for Admissions, 2019  
F: SHR (Admissions) - Standardized Hospitalization Ratio for Admissions, 2020  
F: SHR (Admissions) - Standardized Hospitalization Ratio for Admissions, 2021  
F: SHR (Admissions) - Standardized Hospitalization Ratio for Admissions, 2022  
F: SHR (Admissions)- Standardized Hospitalization Ratio for Admissions, 2019-2022  
N: SHR (Admissions) - Average Standardized Hospitalization Ratio for Admissions (per year in average facility), 20  
S: SHR (Admissions) - Average Standardized Hospitalization Ratio for Admissions (per year in average facility), 20  
US: SHR (Admissions) - Average Standardized Hospitalization Ratio for Admissions (per year in average facility), 20  
F (2728): Incident Patients - Percent smoker, 2019  
F (2728): Incident Patients - Percent smoker, 2020  
F (2728): Incident Patients - Percent smoker, 2021  
F (2728): Incident Patients - Percent smoker, 2022

N (2728): Incident Patients - Percent smoker, 2022  
S (2728): Incident Patients - Percent smoker, 2022  
US (2728): Incident Patients - Percent smoker, 2022  
F: All Patient Mortality - Standardized Mortality Ratio, 2019  
F: All Patient Mortality - Standardized Mortality Ratio, 2020  
F: All Patient Mortality - Standardized Mortality Ratio, 2021  
F: All Patient Mortality - Standardized Mortality Ratio, 2022  
F: All Patient Mortality - Standardized Mortality Ratio, 2019-2022  
N: All Patient Mortality - Standardized Mortality Ratio (SMR), 2019-2022  
S: All Patient Mortality - Standardized Mortality Ratio (SMR), 2019-2022  
US: All Patient Mortality - Standardized Mortality Ratio (SMR), 2019-2022  
F (AFS): Facility Information - Number of full time social workers on 12/31/2019  
F (AFS): Facility Information - Number of full time social workers on 12/31/2020  
F (AFS): Facility Information - Number of full time social workers on 12/31/2021  
F (AFS): Facility Information - Number of full time social workers on 12/31/2022  
N (AFS): Facility Information - Average number of full time social workers on 12/31/2022  
S (AFS): Facility Information - Average number of full time social workers on 12/31/2022  
US (AFS): Facility Information - Average number of full time social workers on 12/31/2022  
F (AFS): Facility Information - Number of part time social workers on 12/31/2019  
F (AFS): Facility Information - Number of part time social workers on 12/31/2020  
F (AFS): Facility Information - Number of part time social workers on 12/31/2021  
F (AFS): Facility Information - Number of part time social workers on 12/31/2022  
N (AFS): Facility Information - Average number of part time social workers on 12/31/2022  
S (AFS): Facility Information - Average number of part time social workers on 12/31/2022  
US (AFS): Facility Information - Average number of part time social workers on 12/31/2022  
N: SRR - Average expected readmissions, 2022  
S: SRR - Average expected readmissions, 2022  
U: SRR - Average expected readmissions, 2022  
F: SRR - Expected total readmissions, 2019  
F: SRR - Expected total readmissions, 2020  
F: SRR - Expected total readmissions, 2021  
F: SRR - Expected total readmissions, 2022  
F: SRR - 2.5% Lower confidence limit, 2019  
F: SRR - 2.5% Lower confidence limit, 2020  
F: SRR - 2.5% Lower confidence limit, 2021  
F: SRR - 2.5% Lower confidence limit, 2022  
F: SRR - P-value, 2019  
F: SRR - P-value, 2020  
F: SRR - P-value, 2021  
F: SRR - P-value, 2022  
F: SRR - 97.5% Upper confidence limit, 2019  
F: SRR - 97.5% Upper confidence limit, 2020  
F: SRR - 97.5% Upper confidence limit, 2021  
F: SRR - 97.5% Upper confidence limit, 2022

F: SRR - Standardized Readmission Ratio, 2019  
F: SRR - Standardized Readmission Ratio, 2020  
F: SRR - Standardized Readmission Ratio, 2021  
F: SRR - Standardized Readmission Ratio, 2022  
N SRR - Standardized Readmission Ratio, 2022  
S SRR - Standardized Readmission Ratio, 2022  
U SRR - Standardized Readmission Ratio, 2022  
F(QIES): Type of Action Code  
F (AFS): Facility Information - Number of total staff positions on Dec 31 (full & part time), 2019  
F (AFS): Facility Information - Number of total staff positions on Dec 31 (full & part time), 2020  
F (AFS): Facility Information - Number of total staff positions on Dec 31 (full & part time), 2021  
F (AFS): Facility Information - Number of total staff positions on Dec 31 (full & part time), 2022  
N (AFS): Facility Information - Average number of total staff positions on Dec 31 (full & part time), 2022  
S (AFS): Facility Information - Average number of total staff positions on Dec 31 (full & part time), 2022  
US (AFS): Facility Information - Average number of total staff positions on Dec 31 (full & part time), 2022  
CWFacDir: Facility Physical State  
F (QIES): Facility Information – Total number of Standard Citations Cited  
N (QIES): Facility Information – Average number of Standard-Level Citations/Survey  
S (QIES): Facility Information – Average number of Standard-Level Citations/Survey  
U (QIES): Facility Information – Average number of Standard-Level Citations/Survey  
F: STR (Adult) - Standardized Transfusion Ratio, 2019  
F: STR (Adult) - Standardized Transfusion Ratio, 2020  
F: STR (Adult) - Standardized Transfusion Ratio, 2021  
F: STR (Adult) - Standardized Transfusion Ratio, 2022  
N: STR (Adult) - Standardized Transfusion Ratio, 2022  
S: STR (Adult) - Standardized Transfusion Ratio, 2022  
US: STR (Adult) - Standardized Transfusion Ratio, 2022  
F: STR - Standardized 1st Transplantation Ratio, 2019-2022  
N: STR - Standardized 1st Transplant Ratio, 2019-2022  
S: STR - Standardized 1st Transplant Ratio, 2019-2022  
US: STR - Standardized 1st Transplant Ratio, 2019-2022  
F(QIES): Survey Date  
Dialyzer Reuse  
Shifts after 5:00 pm  
F: Incident Waitlist - 97.5% upper confidence limit for SWR, 2019-2021  
F: Incident Waitlist - 2.5% lower confidence limit for SWR, 2019-2021  
F: Incident Waitlist - Number of expected waitlisting or receipt of a living-donor transplant, 2019  
F: Incident Waitlist - Number of expected waitlisting or receipt of a living-donor transplant, 2020  
F: Incident Waitlist - Number of expected waitlisting or receipt of a living-donor transplant, 2021  
F: Incident Waitlist - Number of expected waitlisting or receipt of a living-donor transplant, 2019-2021  
N: Incident Waitlist - Average number of expected transplant waitlisting or receipt of a living-donor transplant (p  
S: Incident Waitlist - Average number of expected transplant waitlisting or receipt of a living-donor transplant (pe  
U: Incident Waitlist - Average number of expected transplant waitlisting or receipt of a living-donor transplant (p  
F: Incident Waitlist - Number of patients in this facility for SWR, 2019

F: Incident Waitlist - Number of patients in this facility for SWR, 2020  
F: Incident Waitlist - Number of patients in this facility for SWR, 2021  
F: Incident Waitlist - Number of patients in this facility for SWR, 2019-2021  
N: Incident Waitlist - Average number of patients (per year in average facility), 2019-2021  
S: Incident Waitlist - Average number of patients (per year in average facility), 2019-2021  
U: Incident Waitlist - Average number of patients (per year in average facility), 2019-2021  
F: Incident Waitlist - p-value for facility SWR, 2019-2021  
F: Incident Waitlist - Patient-year at risk for SWR, 2019  
F: Incident Waitlist - Patient-year at risk for SWR, 2020  
F: Incident Waitlist - Patient-year at risk for SWR, 2021  
F: Incident Waitlist - Patient-year at risk for SWR, 2019-2021  
N: Incident Waitlist - Average number of of patient-years at risk (per year in average facility), 2019-2021  
S: Incident Waitlist - Average number of of patient-years at risk (per year in average facility), 2019-2021  
U: Incident Waitlist - Average number of of patient-years at risk (per year in average facility), 2019-2021  
F: Incident Waitlist - Number of waitlisting or receipt of a living-donor transplant, 2019  
F: Incident Waitlist - Number of waitlisting or receipt of a living-donor transplant, 2020  
F: Incident Waitlist - Number of waitlisting or receipt of a living-donor transplant, 2021  
F: Incident Waitlist - Number of waitlisting or receipt of a living-donor transplant, 2019-2021  
N: Incident Waitlist - Average number of waitlisting or receipt of a living-donor transplant for SWR (per year in av  
S: Incident Waitlist - Average number of waitlisting or receipt of a living-donor transplant for SWR (per year in av  
U: Incident Waitlist - Average number of waitlisting or receipt of a living-donor transplant for SWR (per year in av  
F: Incident Waitlist - Standardized Waitlist Ratio, 2019-2021  
N: Incident Waitlist - Standardized Waitlist Ratio, 2019 - 2021  
S: Incident Waitlist - Standardized Waitlist Ratio, 2019 - 2021  
U: Incident Waitlist - Standardized Waitlist Ratio, 2019 - 2021  
F: STrR (Adult) - Total Number of Transfusions, 2019  
F: STrR (Adult) - Total Number of Transfusions, 2020  
F: STrR (Adult) - Total Number of Transfusions, 2021  
F: STrR (Adult) - Total Number of Transfusions, 2022  
N: STrR (Adult) - Average Number of Transfusions, 2022  
S: STrR (Adult) - Average Number of Transfusions, 2022  
US: STrR (Adult) - Average Number of Transfusions, 2022  
F: STrR (Adult) - Patient Years at Risk, 2019  
F: STrR (Adult) - Patient Years at Risk, 2020  
F: STrR (Adult) - Patient Years at Risk, 2021  
F: STrR (Adult) - Patient Years at Risk, 2022  
N: STrR (Adult) - Average Patient Years at Risk, 2022  
S: STrR (Adult) - Average Patient Years at Risk, 2022  
US: STrR (Adult) - Average Patient Years at Risk, 2022  
F (AFS): Facility Information - % of patients transferred in, 2019  
F (AFS): Facility Information - % of patients transferred in, 2020  
F (AFS): Facility Information - % of patients transferred in, 2021  
F (AFS): Facility Information - % of patients transferred in, 2022  
N (AFS): Facility Information - Average % of patients transferred in, 2022

S (AFS): Facility Information - Average % of patients transferred in, 2022  
US (AFS): Facility Information - Average % of patients transferred in, 2022  
F (2728): Incident Patients - Percent inability to transfer, 2019  
F (2728): Incident Patients - Percent inability to transfer, 2020  
F (2728): Incident Patients - Percent inability to transfer, 2021  
F (2728): Incident Patients - Percent inability to transfer, 2022  
N (2728): Incident Patients - Percent inability to transfer, 2022  
S (2728): Incident Patients - Percent inability to transfer, 2022  
US (2728): Incident Patients - Percent inability to transfer, 2022  
F (AFS): Facility Information - % of patients transferred out, 2019  
F (AFS): Facility Information - % of patients transferred out, 2020  
F (AFS): Facility Information - % of patients transferred out, 2021  
F (AFS): Facility Information - % of patients transferred out, 2022  
N (AFS): Facility Information - Average % of patients transferred out, 2022  
S (AFS): Facility Information - Average % of patients transferred out, 2022  
US (AFS): Facility Information - Average % of patients transferred out, 2022  
F: STR - Number of transplants among eligible patients, 2019  
F: STR - Number of transplants among eligible patients, 2020  
F: STR - Number of transplants among eligible patients, 2021  
F: STR - Number of transplants among eligible patients, 2022  
F: STR - Number of transplants, 2019-2022  
N: Transplantation - Average number of transplants (per year in average facility), 2019-2022  
S: Transplantation - Average number of transplants (per year in average facility), 2019-2022  
US: Transplantation - Average number of transplants (per year in average facility), 2019-2022  
Transplantation - % of transplants that occurred < 91 days after start of ESRD  
Transplantation - % of transplants that occurred when patient was not assigned to a facility  
F: STR - Number of 1st transplants among eligible patients (age<75), 2019  
F: STR - Number of 1st transplants among eligible patients (age<75), 2020  
F: STR - Number of 1st transplants among eligible patients (age<75), 2021  
F: STR - Number of 1st transplants among eligible patients (age<75), 2022  
F: STR - Number of years at risk for eligible patients (age<75) with no previous transplant, 2019  
F: STR - Number of years at risk for eligible patients (age<75) with no previous transplant, 2020  
F: STR - Number of years at risk for eligible patients (age<75) with no previous transplant, 2021  
F: STR - Number of years at risk for eligible patients (age<75) with no previous transplant, 2022  
F: STR - Years at risk of eligible 1st transplant patients, 2019-2022  
N: STR - Average number of years at risk for eligible patients (age<75) with no previous transplant (per year in av  
S: STR - Average number of years at risk for eligible patients (age<75) with no previous transplant (per year in ave  
US: STR - Average number of years at risk for eligible patients (age<75) with no previous transplant (per year in a  
F: STR - Number of 1st transplants among eligible patients (age<75), 2019-2022  
N: STR - Average number of 1st transplant (per year in average facility), 2019-2022  
S: STR - Average number of 1st transplant (per year in average facility), 2019-2022  
US: STR - Average number of 1st transplant (per year in average facility), 2019-2022  
Facility located in the United States  
F: Prevalent Patients - Vintage: % on ESRD Therapy less than 1 year, 12/31/2019

F: Prevalent Patients - Vintage: % on ESRD Therapy less than 1 year, 12/31/2020  
F: Prevalent Patients - Vintage: % on ESRD Therapy less than 1 year, 12/31/2021  
F: Prevalent Patients - Vintage: % on ESRD Therapy less than 1 year, 12/31/2022  
N: Prevalent Patients - Vintage: % on ESRD Therapy less than 1 year, 12/31/2022  
S: Prevalent Patients - Vintage: % on ESRD Therapy less than 1 year, 12/31/2022  
US: Prevalent Patients - Vintage: % on ESRD Therapy less than 1 year, 12/31/2022  
F: Prevalent Patients - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2019  
F: Prevalent Patients - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2020  
F: Prevalent Patients - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2021  
F: Prevalent Patients - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2022  
N: Prevalent Patients - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2022  
S: Prevalent Patients - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2022  
US: Prevalent Patients - Vintage: % on ESRD Therapy for 1-2 years, 12/31/2022  
F: Prevalent Patients - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2019  
F: Prevalent Patients - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2020  
F: Prevalent Patients - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2021  
F: Prevalent Patients - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2022  
N: Prevalent Patients - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2022  
S: Prevalent Patients - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2022  
US: Prevalent Patients - Vintage: % on ESRD Therapy for 2-3 years, 12/31/2022  
F: Prevalent Patients - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2019  
F: Prevalent Patients - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2020  
F: Prevalent Patients - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2021  
F: Prevalent Patients - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2022  
N: Prevalent Patients - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2022  
S: Prevalent Patients - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2022  
US: Prevalent Patients - Vintage: % on ESRD Therapy for 3-6 years, 12/31/2022  
F: Prevalent Patients - Vintage: % on ESRD Therapy for over 6 years, 12/31/2019  
F: Prevalent Patients - Vintage: % on ESRD Therapy for over 6 years, 12/31/2020  
F: Prevalent Patients - Vintage: % on ESRD Therapy for over 6 years, 12/31/2021  
F: Prevalent Patients - Vintage: % on ESRD Therapy for over 6 years, 12/31/2022  
N: Prevalent Patients - Vintage: % on ESRD Therapy for over 6 years, 12/31/2022  
S: Prevalent Patients - Vintage: % on ESRD Therapy for over 6 years, 12/31/2022  
US: Prevalent Patients - Vintage: % on ESRD Therapy for over 6 years, 12/31/2022  
F: Prevalent Patients - Vintage: Average Years of Prior ESRD Therapy, 12/31/2019  
F: Prevalent Patients - Vintage: Average Years of Prior ESRD Therapy, 12/31/2020  
F: Prevalent Patients - Vintage: Average Years of Prior ESRD Therapy, 12/31/2021  
F: Prevalent Patients - Vintage: Average Years of Prior ESRD Therapy, 12/31/2022  
N: Prevalent Patients - Vintage: Average Years of Prior ESRD Therapy, 12/31/2022  
S: Prevalent Patients - Vintage: Average Years of Prior ESRD Therapy, 12/31/2022  
US: Prevalent Patients - Vintage: Average Years of Prior ESRD Therapy, 12/31/2022  
F (AFS): Facility Information - Vocational Rehab number of Patients 18-54 on 12/31/2019  
F (AFS): Facility Information - Vocational Rehab number of Patients 18-54 on 12/31/2020  
F (AFS): Facility Information - Vocational Rehab number of Patients 18-54 on 12/31/2021



F (AFS): Facility Information - Vocational Rehab number of Patients 18-54 on 12/31/2022  
F (AFS): Facility Information - Vocational Rehab number of Patients 18-54 on 12/31/2022  
F (AFS): Facility Information - Vocational Rehab number of Patients 18-54 on 12/31/2022  
F (AFS): Facility Information - Vocational Rehab number of Patients 18-54 on 12/31/2022  
F (2728): Incident Patients - Percent White, 2019  
F (2728): Incident Patients - Percent White, 2020  
F (2728): Incident Patients - Percent White, 2021  
F (2728): Incident Patients - Percent White, 2022  
N (2728): Incident Patients - Percent White, 2022  
S (2728): Incident Patients - Percent White, 2022  
US (2728): Incident Patients - Percent White, 2022  
F: All Patient Mortality - % of deaths from withdrawal, 2019  
F: All Patient Mortality - % of deaths from withdrawal, 2020  
F: All Patient Mortality - % of deaths from withdrawal, 2021  
F: All Patient Mortality - % of deaths from withdrawal, 2022  
F: All Patient Mortality - % of deaths from withdrawal, 2019-2022  
N: All Patient Mortality - % of deaths from withdrawal, 2019-2022  
S: All Patient Mortality - % of deaths from withdrawal, 2019-2022  
US: All Patient Mortality - % of deaths from withdrawal, 2019-2022  
F: Prevalent Waitlist - % of patient-months aged 40-74 on waitlist, 2019  
F: Prevalent Waitlist - % of patient-months aged 40-74 on waitlist, 2020  
F: Prevalent Waitlist - % of patient-months aged 40-74 on waitlist, 2021  
F: Prevalent Waitlist - % of patient-months aged 40-74 on waitlist, 2022  
N: Prevalent Waitlist - % of patient-months aged 40-74 on waitlist, 2022  
S: Prevalent Waitlist - % of patient-months aged 40-74 on waitlist, 2022  
US: Prevalent Waitlist - % of patient-months aged 40-74 on waitlist, 2022  
F: Prevalent Waitlist - % of Asian patient-months (age<75) on waitlist, 2019  
F: Prevalent Waitlist - % of Asian patient-months (age<75) on waitlist, 2020  
F: Prevalent Waitlist - % of Asian patient-months (age<75) on waitlist, 2021  
F: Prevalent Waitlist - % of Asian patient-months (age<75) on waitlist, 2022  
N: Prevalent Waitlist - % of Asian patient-months (age<75) on waitlist, 2022  
S: Prevalent Waitlist - % of Asian patient-months (age<75) on waitlist, 2022  
US: Prevalent Waitlist - % of Asian patient-months (age<75) on waitlist, 2022  
F: Prevalent Waitlist - % of African American patient-months (age<75) on waitlist, 2019  
F: Prevalent Waitlist - % of African American patient-months (age<75) on waitlist, 2020  
F: Prevalent Waitlist - % of African American patient-months (age<75) on waitlist, 2021  
F: Prevalent Waitlist - % of African American patient-months (age<75) on waitlist, 2022  
N: Prevalent Waitlist - % of African American patient-months (age<75) on waitlist, 2022  
S: Prevalent Waitlist - % of African American patient-months (age<75) on waitlist, 2022  
US: Prevalent Waitlist - % of African American patient-months (age<75) on waitlist, 2022  
F: Prevalent Waitlist - % of diabetic patient-months (age<75) on waitlist, 2019  
F: Prevalent Waitlist - % of diabetic patient-months (age<75) on waitlist, 2020  
F: Prevalent Waitlist - % of diabetic patient-months (age<75) on waitlist, 2021  
F: Prevalent Waitlist - % of diabetic patient-months (age<75) on waitlist, 2022





F: Prevalent Waitlist - % Non-Hispanic White patient-months (age<75) on waitlist, 2020  
F: Prevalent Waitlist - % Non-Hispanic White patient-months (age<75) on waitlist, 2021  
F: Prevalent Waitlist - % Non-Hispanic White patient-months (age<75) on waitlist, 2022  
N: Prevalent Waitlist - % Non-Hispanic White patient-months (age<75) on waitlist, 2022  
S: Prevalent Waitlist - % Non-Hispanic White patient-months (age<75) on waitlist, 2022  
US: Prevalent Waitlist - % Non-Hispanic White patient-months (age<75) on waitlist, 2022  
F: Prevalent Waitlist - % of patient-months (age<75) on waitlist, 2019  
F: Prevalent Waitlist - % of patient-months (age<75) on waitlist, 2020  
F: Prevalent Waitlist - % of patient-months (age<75) on waitlist, 2021  
F: Prevalent Waitlist - % of patient-months (age<75) on waitlist, 2022  
N: Prevalent Waitlist - % of patient-months (age<75) on waitlist, 2022  
S: Prevalent Waitlist - % of patient-months (age<75) on waitlist, 2022  
US: Prevalent Waitlist - % of patient-months (age<75) on waitlist, 2022























nic attack, 2019  
nic attack, 2020  
nic attack, 2021  
nic attack, 2022  
nic attack, 2022  
nic attack, 2022  
mic attack, 2022



























2

12



19-2022  
19-2022  
019-2022















/31, 2019  
/31, 2020  
/31, 2021  
3/31, 2021  
/31, 2021  
3/31, 2021











.9

!0

!1

!2

2/31/2022

2/31/2022

12/31/2022

/2022

'2022

1/2022





2019

2020

2021

2022

n 12/31/2022

n 12/31/2022

on 12/31/2022

|

|

|

|

|

/31/2022

'31/2022

2/31/2022





























-Q1  
-Q2  
-Q3  
-Q4









































































019-2022  
119-2022  
2019-2022





19-2022  
19-2022  
019-2022



er year in average facility), 2019-2021  
er year in average facility), 2019-2021  
er year in average facility), 2019-2021

verage facility), 2019-2021  
verage facility), 2019-2021  
verage facility), 2019-2021



verage facility), 2019-2022  
verage facility), 2019-2022  
verage facility), 2019-2022